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Summary
Human African trypanosomiasis (HAT), also known as sleeping sickness, is prevalent in 
sub-Saliai'an Africa. The illness results from infection with the protozoan parasites 
Trypanosoma brucei (T.b.) gambiense in West and Central Africa and T.b.rhodesiense in 
East and Central Africa and is spread tlnough the bite of the insect vector of the parasite, 
the tsetse fly. Both forms of the disease are invariably fatal if not diagnosed and drug 
treated.
During the acute-stage of the infection the trypanosomes spread from the site of the tsetse 
fly bite, via the lymphatics and bloodstream to invade most of the organs and tissues of the 
body. As the disease progresses the parasites enter the brain tissue and become established 
within the CNS and a neuroinflammatory reaction develops. Treatment of the infection 
once it has reached the CNS-stage is problematic since few trypanocidal drugs can cross 
the blood-brain barrier (BBB) to clear the parasites that are sequestered in the brain. The 
only drug commonly available to treat this stage of the disease is the arsenical derivative 
melarsoprol but its use is associated with the development of a post-treatment reactive 
encephalopathy (PTRE) that can in itself prove fatal. The PTRE is characterised by a 
severe meningoencephalitic reaction with the presence of reactive astrocytes, 
macrophages, T-cells, B-cells and plasma cells. The pathogenesis of this adverse reaction 
remains unclear.
Since brain tissue can only be obtained flom post-mortem cases of PI AT, there is a paucity 
of information regarding the early changes that occur within the CNS following infection 
and during the development of the PTRE. Therefore, a well-established and highly 
reproducible murine model, which closely mimics the human disease, was used in the 
current investigation to elucidate the kinetics of cellular reactivity and the expression of 
cytokines and chemokines following trypanosome-infection and induction of the PTRE. 
The mode of action of the ornithine decarboxylase inhibitor, eflornithine, a typanostatic 
drug used in the treatment of trypanosome infections, was also examined in the possible 
prevention and amelioration of the severe meningoencephalitic reaction. In addition, the 
role of the neuropeptide Substance P (SP) in the modulation of the inflammatory response 
associated with the disease was investigated.
The study of the kinetics of cellular reactivity within the CNS found that the astrocyte 
activation could be detected by 14-days post-infection. This initial cellular activation was
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associated with an influx CD4*^  and CD8^ cells. These cells were first detected in the 
meninges and ventricles but spread throughout the brain tissue as the disease progressed.
1+ |-| 1 J.1CD4 cells were consistently detected in higher numbers than CD8 cells and in general 
preceded the appearance of CD8^ cells. Macrophages were also detected in rising numbers 
as the severity of the CNS reaction increased and B-cells were identified in the later stages. 
Following the induction of the PTRE, the population of both T-cell subsets increased 
significantly although CD4^ cells remained predominant. An expansion in the B-cell 
population was also found and numerous plasma cells were identified. No further increase 
in the macrophage population was detected.
The investigation of cytokine and chemokine transcription clearly demonstrated variations 
in the expression levels of IL-la, IL-6, TNF-a, MCP-1, M IP-la and RANTES within the 
CNS. Elevated levels of IL-6, TNF-a, MCP-1, M IP-la and RANTES were found 7-days 
following trypanosome infection and, with the exception of RANTES, continued to rise as 
the reaction progressed. Initially, IL -la  transcription was reduced after infection but this 
too increased with time. IL-la, IL-6, TNF-a and M IP-la transcription dropped while 
RANTES expression increased in the late-stage of the CNS reaction. Immediately 
following the induction of the PTRE a further rise in the transcription of IL-la, IL-6, TNF- 
a , MCP-1 and M IP-la was detected and RANTES levels were reduced at this stage. IL- 
l a  and IL-6 expression continued to rise as the PTRE developed but TNF-a, MCP-1 and 
M IP-la levels dropped. This was accompanied by a rise in RANTES expression.
In the current study, the ability of SP to influence the development of the CNS 
inflammatory reaction, associated with trypanosome infection, was demonstrated in 
experiments blocking the NKl, NK2 and NK3 receptors, with specific antagonists, in 
normal and NKl receptor knockout mice. When the action of SP was inliibited by 
administration of the NKl receptor a less severe neuroinflammatory response was found. 
Therefore, SP was shown to exert a pro-inflammatory effect, via interaction with the NKl 
receptor, within the CNS following trypanosome infection and induction of the PTRE,
The elucidation of the kinetics of cellular reactivity and cytokine and chemokine 
expression patterns, taken together with a role for the neuropeptide SP, has allowed the 
following hypothesis regarding the pathogenesis of the CNS reaction to be developed. The 
CNS inflammatory response begins to generate very quickly after the initial infection and 
before trypanosomes can be detected within the brain. Astrocytes are the primary cell type 
to display signs of cellular reactivity. The factor that instigates this response remains
Vunclear and could be either parasite derived or a mediator synthesised in the periphery in 
response to the infection out-’with the CNS. Once activated the astrocytes could be 
responsible for the production of an array of cytokines and chemokines including IL-6, 
TNF-a, MCP-1 and RANTES. The presence of these inflammatory mediators augments 
the neuroinflammatory reaction, leading to the recruitment of inflammatory cells, including 
CD4^ cells, CD8^ cells and macrophages, to the CNS, and stimulates further cellular 
activation. The neuropeptide Substance P may also be integrally involved in the 
generation of the reaction acting in a pro-inflammatory manner through signalling via the 
NKl receptor. This receptor is expressed on many of the cell types present in the reaction. 
Once the trypanosomes enter the CNS all of the constituents required to propagate the 
immune response are present within the brain and could initiate clonal expansion and 
further activation of the T-cell population. As the inflammation progresses the CD4^ cells 
become the predominant cell type in the reaction and may supersede the astrocytes in 
controlling the generation of the response. B-cells enter the brain in increasing numbers as 
the reaction matures and the population expands following the induction of the PTRE. The 
B-cells entering the brain proliferate, probably in response to parasite antigen, and may be 
induced to differentiate into antibody-producing plasma cells under the direction of the 
CD4^ cells and the cytokines, such as IL-6, that are present in the local environment. 
Ultimately, this cascade of events would result in the development of the extremely severe 
meningoencephalitis that is characteristic of the PTRE.
The investigation of action of eflornithine in the prevention and amelioration of the CNS 
inflammatory reaction confirmed that eflornithine treatment could reduced the severity of 
the neuroinflammatory reaction when administered prior to the development of the CNS 
response, and resulted in a dramatic reduction in the degree in inflammation when given to 
mice exhibiting an established PTRE. In both cases a reduction in the level of astrocyte 
activation was also found. When eflornithine was used to prevent the development of the 
CNS reaction a significant reduction in the transcription of IL -la  and IL-6 was detected 
together with lowered expression of M IP-la and RANTES. No alterations in the levels of 
TNF-a or MCP-1 were apparent. No changes were found in the expression of the 
cytokines and chemokines studied when eflornithine was used to resolve an established 
PTRE. Therefore the mechanisms employed by the drug, in the prevention and 
amelioration of the CNS inflammation, are divergent. The pathway used by eflornithine to 
prevent the development of the inflammatory reaction would appear to involve inhibition 
of the expression of the pro-inflammatory cytokines IL -la  and IL-6. The mechanism 
resulting in the resolution of the meningoencephalitis remains a matter of conjecture. In
vi
this study eflornithine resistant trypanosomes were used in the infections to isolate the anti­
inflammatory effects of the drug treatment from those that arise due to the clearance of the 
parasites. Therefore, the value of eflornithine treatment as an anti-inflammatory agent, 
even in cases where trypanosome resistance to the drug is suspected was demonstrated.
The identification of the key cellular and functional events resulting in the 
neuroinflammatory reaction associated with trypanosome infection have allowed a further 
degree of understanding regarding the mechanisms involved in the development of the 
CNS inflammation in human disease. Without the existence of the murine model the 
above conclusions could not have been reached. Furthermore, it is now possible to 
consider application of the potential novel therapeutic approaches indicated by this study, 
to prevent and ameliorate the development of the CNS inflammatory reaction, in the 
management of this devastating disease condition in man.
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“If we knew what we were doing, it would not be called research, would it?’
Albert Einstein
C h a p t e r  1
In t r o d u c t io n
1.1. Aetiology of African trypanosomiasis
Tsetse-transmitted trypanosomiasis affects both man and animals in Africa. The organisms 
responsible for causing the disease are protozoan parasites belonging to the genus 
Trypanosoma. Although there are numerous individual species of trypanosome that can 
affect many different hosts, species including. Trypanosoma brucei, T.congolense, T.vivax 
and Tsimiae are responsible for the bulk of the disease. Two sub-species of T. brucei 
namely Tbrucei gambiense and T.b.rhodesiense are the causative agents of sleeping 
sickness in man while T.congolense, T.vivax, Tsimiae and T.b.brucei result in infections in 
domestic ruminants and wild-life (Minray and Njogu, 1989). The main pathogenic species 
together with their hosts aie listed in Table 1.1 (Hoare, 1970; Molyneux, Pentreath, and 
Doua, 1996).
The occurrence of trypanosomiasis is episodic and during the first decade of the last 
century sleeping sickness outbreaks devastated Central and East Africa resulting in the 
death of 750,000 people and in the depopulation of several trypanosome endemic ai'eas. At 
the same time the presence of trypanosomes in Africa has precluded livestock rearing over 
vast areas of the continent and epidemics of the disease remain common to date (Kuzoe, 
1993). Trypanosome infection of African wild-life, as well as certain breeds of cattle and 
small ruminants, by and large, produces a protracted infection with long periods where the 
animals appear aparasitaemic and remain in generally good health. This endurance of the 
infection is Imown as trypanotolerance. In contrast, trypanosomiasis in most domestic 
livestock generally results in a high degree of morbidity and mortality and in some 
instances death can occur within 2-3 weeks of infections (Morrison, Murray, and McIntyre, 
1981; Murray, Trail, Davis, and Black, 1984; Murray and Njogu, 1989). This suggests that 
wild animals are the original and natural hosts for these pathogenic trypanosomes and as 
such may act as the reservoirs of infection from which man and domestic livestock acquire 
the disease (Hoare, 1972a; Murray and Trail, 1987). In a recent study by Welburn and 
colleagues 18% of the domestic cattle in the Tororo district of Uganda were found to be 
infected with T.b.rhodesiense indicating that domestic animals present a significant public 
health risk by providing a livestock reservoir of human infective trypanosomes (Welburn, 
Picozzi, Fevre, Coleman et a l, 2001). Furthermore, large scale restocking of domestic 
live-stock in the previously disease-free Soroti district of Uganda, with animals purchased 
from trypanosomiasis endemic areas, has resulted in the introduction and establishment of 
trypanosomiaisis in this region (Fevre, Coleman, Odiit, Magona e/a/., 2001). These
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4findings indicate the central role of live-stock farming in the spread and maintenance of 
human trypanosome infections.
1.1.1. History of the disease
The genus Trypanosoma was named over 150 years ago by Gruby, in 1843 following the 
isolation of Trypanosoma sanguinis parasites from frogs. Very little progress was made in 
the field dining the ensuing years until Griffith Evans, a veterinarian working in India in 
1880, showed that Surra, a disease of cattle and horses, was associated with the presence of 
trypanosomes in the blood of the infected animals. The parasite responsible for these 
infections came to bear Evans’ name and is now Imown as Trypanosoma evansi (Hoare, 
1972c; Vickerman, 1997). The discovery that trypanosomes could be serious pathogens 
proved pivotal in the elucidation of further conditions affecting both man and animals that 
result from trypanosome infection.
Sleeping sickness in man and nagana in cattle and horses had been recognised in Africa for 
many centuries but it was not until 1895 that David Bruce and his wife Mary, while 
investigating the deaths of numerous cattle in Zululand, identified a trypanosome as the 
causative agent of nagana. They also demonstrated that the infection was transmitted by 
the bite of the tsetse fly and that wild animals could act as reservoir hosts for the parasites 
(Bruce, 1895; Bruce, 1897). Following this Plimmer and Bradford isolated a trypanosome 
from the blood of a dog experimentally infected with Tiagana’ and sent to England, and 
named the parasite Trypanosoma brucei in Bruce’s honour (Plimmer and Bradford, 1895). 
Acknowledgement for identification of trypanosomes as the aetiological agents of sleeping 
sickness however cannot be so easily credited. The subject remains controversial as 
trypanosomes were isolated from the blood of sleeping sickness patients by both Aldo 
Castellani and David Bruce in 1903. Whether Castellani made the comiection between the 
presence of the parasites and the disease condition in man before Bruce produced his 
findings remains a subject of debate.
These discoveries began a cascade of events leading to the detection of many of the 
important trypanosome species that cause disease in man and animals (Table 1.1). In 1902 
Dutton isolated trypanosomes from humans in West Africa and named them T.gambiense. 
These were similar parasites to those isolated by Bruce, in 1903, who deemed them the 
infectious agent responsible for the development of sleeping sickness. Although it is now 
recognised that these parasites ai'e two different subspecies of T. brucei, the teclmology
5available to Dutton and Bruce at this time did not allow this distinction to be made. To 
reconcile the differences between the disease patterns resulting from infection with the 
individual trypanosomes it was believed that T.b.gambiense infection represented the early 
stages of the disease, known as Trypanosome fever’, while the acute disease resulting from 
T.b.rhodesiense infection was the late stage of the condition and called ‘sleeping sickness’. 
A few years later in 1910 the causative agent of the acute form of the disease was ‘re­
discovered’ by Stephens and Fantham who erroneously described a morphological 
difference between this parasite and T.gambiense. This ‘new’ species was named 
T.rhodesiense (Hoare, 1972c). Since this time T.gambiense and T.rhodesiense have been 
shown to be morphologically indistinguishable from the T.brucei parasite originally 
isolated from cattle suffering from nagana. These three trypanosomes have therefore 
become classified as sub-species of T.brucei and are now termed Trypanosoma brucei 
gambiense, T.b.rhodesiense and T.b.brucei. Trypanosomes infecting domestic animals and 
livestock were also discovered during the early 20^ *^  century. These include; T. equiperdum 
in 1901, T. congolense in 1904, T. vivax and T. suis in 1905 and T. simiae in 1911 (Hoare, 
1972c).
1.1.2. Trypanosome taxonomy
Trypanosomes are protozoan parasites (Fig. 1.1) belonging to the phylum 
Sarcomastigophora, subphylum Mastigophora, class Zoomastigophora, order 
Kinetoplastida, suborder Trypanosomatina and family Trypanosomatidae. This family 
divides into eight genera with trypanosome pai'asites belonging to the Trypanosoma genus. 
The genus has two sections, the Stercoraria and the Salivaiia. This division indicates the 
media, faecal or salivary respectively, in which the parasites complete their developmental 
cycle in their insect vector. The Stercoraria is formed by three sub genera; Megatrypanum, 
Herpetosoma and Schizotrypanum. Most African trypanosomes of any economic 
importance, with the exception of Trypanosoma (Megatrypanum) theileri which is 
Stercorarian, belong to the SaUvaria which further divides into four subgenera; the 
Duttonella group which includes Trypanosoma (Duttonella) vivax and Trypanosoma 
(Dutonella) uniforme, the Nannomonas group which includes Trypanosoma (Nannomonas) 
congolense and Trypanosoma (Nannomonas) simiae. The Trypanozoon group is the largest 
of the subgenera and includes tliree separate species of trypanosome; Trypanosoma 
(Trypanozoon) equiperdum. Trypanosoma (Trypanozoon) evansi and Trypanosoma 
(Trypanozoon) brucei. The species Trypanosoma brucei consists of three individual 
subspecies; Trypanosoma brucei brucei (T.b.brucei), T.b.rhodesiense and T.b.gambiense.
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7T.b.rhodesiense and T.b.gambiense are pathogenic to man and result in East African and 
West African trypanosomiasis respectively. The forth subgenus is the Pycomonas group 
which includes just one species, Trypanosoma (Pycomonas) suis. The trypanosome 
taxonomy as described here was detailed in a doctoral thesis by de Atouguia (de Atouguia,
1998).
1.1.3. Transmission of infection
In 1909 the tsetse fly was confirmed as the biological vector of the trypanosomes by 
Kleine who demonstrated that the parasites undergo a cyclical developmental process 
within the fly (Kleine, 1909). Before this time the transmission of the disease by the fly 
was widely thought to be purely mechanical in nature with the insect playing no role in the 
life cycle of the pai'asite.
Blood-sucking flies of the genus Glossina are responsible for the transmission of the 
disease. There are at least 23 species of tsetse fly and a number of sub-species. However, 
only a few are of importance in the transmission of sleeping sickness (Molyneux et al, 
1996). The different species of fly have different ecological requirements and therefore 
separate species are responsible for the transmission of East and West Afiican sleeping 
sickness. In general, Glossina morsitans, G. pallipides, and G. swynnertoni transmit East 
African disease whereas G. palpalis, G. tachinoides and G. fuscipes are responsible for the 
transmission of West African disease.
Under normal circumstances, in a trypanosomiasis endemic area, between 2 and 10% of 
tsetse flies are infected with trypanosomes. Flies become infected, by ingesting the 
trypomastigote form of the parasite, during a blood meal (Fig. 1.2). Once the fly has 
become infected with the parasite it remains infective for life. Following ingestion the 
trypomastigotes travel to the anterior mid-gut of the fly where they undergo morphological 
and physiological changes. The pai'asites change their energy source from glucose to 
proline and switch from aerobic to anaerobic respiration. In the mid-gut of the fly the 
parasites loose their variant surface antigenic coat and begin to multiply. The newly 
produced parasites have a long slender shape and move quickly to the salivai'y glands. 
Once in the glands they differentiate first into epimastigotes and then after further division 
they develop into the short and stumpy infective metacyclic form of the parasite. 
Transmission occurs during the infected tsetse fly’s next feed when the metacyclics are
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Figure 1.2. Life-cycle of trypanosome parasites in man and its 
vector the tsetse fly
9introduced directly into the host in the saliva of the fly (de Atouguia and Kennedy, 2000; 
Wakelin, 1996).
1.1.4. Scale and economic considerations of 
trypanosomiasis
Trypanosomiasis of man and both wild and domestic animals remains a major socio­
economic problem in sub-Saharan Africa. The disease is prevalent between the latitudes 
14° North and 29° South, an area covering some 10 million square kilometres and 
including 36 African countries. This sector corresponds with the region infested by the 
tsetse fly and current estimates suggest that approximately 60 million people are at risk of 
infection. Although the disease is often regarded as a problem of the past there has been an 
upsurgence in the number of diagnosed infections with around 300,000 new cases each 
year (WHO, 1998). In recent years over 100,000 new cases have been detected in the 
Democratic Republic of Congo with one quarter of these infections presenting in 1997 
alone (Welburn, Fevre, and Coleman, 1999). Of the 60 million people at risk, WHO 
estimates that less than 4 million are under medical sui'veillance and only 10% of new 
infections are actually diagnosed (WHO, 1998). The problem is being exacerbated by war, 
civil unrest, population and livestock movements together with a deteriorating 
infrastructure all of which result in the breakdown of systematic medical surveillance and 
lead to increased mortality rates.
In human terms trypanosomiasis is a significant contributor to the global burden of 
parasitic diseases. This is calculated as the disability of adjusted life years lost (DALY’S) 
as a result of the infection. DALY’S combine the healthy life years lost through premature 
mortality and those lost due to disability, Wlien expressed in these terms the most 
bm'densome parasitic disease is malaria which results in 315.1 x 10  ^DALY’S followed by 
schistosomiasis which results in 34.9 x 10^  DALY’s. Trypanosomiasis is responsible for 
17.8 x 10^  DALY’S and is the third most important parasitic disease adversely effecting 
human health (Molyneux et al, 1996).
In financial terms, trypanosomiasis results in the loss of millions of dollars amiually 
tlnough the death of livestock, reduction in milk and meat production as well as lowering 
fertility rates. Using geographic information systems to spatially link a biophysical herd 
simulation model with an economic surplus model, the financial costs of trypanosomiasis 
in livestock has recently been estimated to be in the region of $1340 million dollars
1 0
annually. This figure does not include the losses sustained though indirect livestock 
benefits such as manure and traction (Kiistjanson, Swallow, Rowlands, Ki'uska et a l,
1999). In the same study the potential benefits of improved trypanosomiasis control were 
estimated to be around $700 million per annum in terms of meat and milk production 
alone.
1.1.5. Parasite biology
Trypanosoma brucei spp. are unicellular, eukaryotic, protozoan parasites (Fig. 1.3). They 
form elongated, spindle shaped cells that vary in length from 12-42 pm with tapering 
anterior and blunt posterior ends. A characteristic feature of African trypanosomes is the 
presence of a free flagellum. The flagellum arises from the basal body, near the flagellar 
pocket, at the posterior end of the cell, and is attached along the entire length of the 
parasite. In the epimastigote form of the parasite (Fig. 1.2) the kinetoplast and flagellum 
are situated anterior to the nucleus. When the flagellum beats it draws up the cell 
membrane or pellicle to form an undulating membrane. This combination of flagellum and 
undulating membrane facilitates the parasite’s motility (Hoare, 1972b). The flagellar 
pocket is secluded from the environment to help prevent exposure of its antigenic sites to 
the host immime system. It is however a critical structure in the endo- and exocytosis of 
macromolecules and contains specialised receptors for the absorption of host-derived 
growth factors and nutrients (Hill, Hutchings, Russell, and Donelson, 1999).
The parasite has a single mitochondrion that contains a specialised organelle called the 
kinetoplast. The kinetoplast consists of a network of approximately 10,000 interlinked 
minicircles and around 50 maxicircles of DNA. The maxicircles are highly conserved and 
encode components of the mitochondrial respiratory chain and mitochondrial ribosomal 
RNAs. The RNA transcribed from the maxicircle genes is edited during its maturation 
with the help of small guide RNAs that are transcribed from the minicircles. These small 
RNA molecules serve as a template for editing the maxicircle transcripts by guiding the 
insertion and deletion of uridine nucleotides (Simpson and Shaw, 1989).
The trypanosome nucleus is located centrally in the cell. The parasites are regarded as 
diploid with a haploid DNA content of around 4x10"^ base pairs that probably encodes not 
more than 8000 genes. The nuclear organisation differs from that of higher eukaryotes in 
that the clnomatin does not condense during metaphase of mitosis hence an accurate 
definition of ploidy is difficult to assess. However, by employing pulse-field gel electro-
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phoresis it appeal's that the nucleus of African trypanosomes contains at least 120 
cliromosomal associated DNA molecules that can be divided into two groups depending on 
their size. There are around 20 DNA molecules that range from 200 kilobases (kb) to 
5700kb and at least 100 ‘miniclnomosomar DNAs of 50-150kb. With the exception of 
one report on the tyrosine transfer RNA gene no other introns have been demonstrated in 
the trypanosome genome (Schneider, McNally, and Agabian, 1993).
An electron dense coat covers the outer surface of the trypanosome in the mammalian host. 
This layer is approximately 15mn thick and is composed of variable surface glycoprotein 
(VSG) molecules and invariant surface glycoprotein (ISG) molecules. A 
glycophosphoinositol (GPI) anchor attaches the VSG molecules to the surface of the 
plasma membrane whereas the ISG molecules are fixed via a transmembrane helix and a 
short intracellular' domain. Approximately 10 million copies of a single VSG species cover 
the surface of the parasite. These VSG molecules out number the ISG molecules by about 
100 fold. Although the trypanosome can express over a thousand different VSG genes 
only one form of the molecule is present on the coat at any one time. This conservative 
method of antigenic variation allows the parasite to evade the immune system of the host 
by continually altering its major sui'face antigen. As parasites expressing one form of VSG 
are destroyed by the host a small proportion of the sui'viving trypanosomes, expressing a 
different VSG, continue to multiple producing successive waves of parasitaemia. If the 
parasites expressed more than one VSG at a time they would ultimately reduce the length 
of time that they could escape from the hosf s defences. Each trypanosome has around 
1000 different VSG genes located on the minicliromosomal DNA elements.
Approximately 6% of the total parasite genome is devoted to antigenic variation via the 
production of VSG molecules. Each VSG molecule is about 65kDa in size and consists of 
a polypeptide chain of around 500 amino acids. The molecule can be divided into specihc 
regions. The N-terminal domain contains a short signal sequence as well as a highly 
variable region where the amino acid sequence shows little homology with other VSG 
molecules. The C-terminal of the molecule shows considerable sequence homology 
between VSGs, however, as the molecules are densely packed only the variable N-terminal 
of the molecule is exposed to the host and the constant regions are effectively concealed. 
The complete molecules form cylindrical structures that are attached to the cell surface at a 
90° angle by the GPI anchor. Both the polypeptide back bone of the molecule and the GPI 
anchor carry carbohydrate side chains, however, as with the constant C-terminal portion of 
the VSG these molecules are effectively shielded from exposure to the environment and 
are not readily accessible for interaction with the host antibodies (Wakelin, 1996).
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1.2. Trypanosomiasis in man
1.2.1. Clinical picture
Human African trypanosomiasis (HAT) results from infection with either T.b.gambiense in 
West and Central Africa or T.b.rhodesiense in East and Central Africa. West African 
sleeping sickness is a chronic disease with a duration of months to years whereas East 
African sleeping sickness follows an acute course with a duration of 3 to 9 months before 
death ensues. Both forms of trypanosomiasis are invariably fatal without 
chemotherapeutic intervention. Clinical manifestations of sleeping sickness are not 
pathognomic and can vary greatly from one individual to another. After initial infection 
the trypanosomes are localised to a non-suppurative lesion or chancre that develops at the 
site of the infected tsetse bite. The chancre disappears spontaneously 2 to 3 weeks after 
infection. This is followed by a systemic phase when the parasites invade the lymph and 
blood. Clinically the patient experiences febrile episodes with headaches and enlarged 
lymph nodes may be present at this stage. An erythomatous skin rash may also appear. 
From here the parasites invade a variety of tissues including spleen, liver and heart and 
ultimately enter the central nervous system (CNS). In Rhodesian sleeping sickness CNS 
involvement occui’s early after infection, usually within 3 to 4 weeks of the tsetse bite, and 
there is no clear distinction between eai'ly and late stage disease. In Gambian sleeping 
sickness, CNS invasion can be delayed until years after infection and asymptomatic 
carriers occur frequently. Early signs of neurological involvement include, irritability, lack 
of concentration, personality changes and alterations in sleep patterns. However, these 
symptoms are not diagnostic of CNS involvement as they are occasionally found before 
any changes can be detected in the cerebrospinal fluid (CSF). As the disease progresses, 
further neurological symptoms become apparent including seizures and muscle 
fasciculations. There is a general wasting and increased sleep disturbance with the patient 
becoming more difficult to rouse. This leads to coma and death in untreated patients (de 
Atouguia and Keimedy, 2000).
1.2.2. Pathogenesis
Although the clinical and pathological features of HAT are well documented the 
pathogenesis of the disease remains to be fully elucidated and much of the information 
with regard to this topic has been extrapolated from animal models and experimental
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animal infections. Trypanosome infection in man results in numerous progressive 
pathological changes that encompass most of the organs and the systems of the body. 
After initial restriction to the chancre, the trypanosomes spread tlnoughout the haemo- 
lymphatic system and alterations in haematology and immunology are frequently 
encountered. Widespread dissemination of the parasites tlnoughout the body tissues then 
occurs with trypanosomes invading the major organs including the heart, liver, spleen and 
CNS where they evoke inflammatory reactions and tissue damage.
1.2.2.1. Haemo-lymphatic manifestations
Following infection many changes are found in the haeniatological constituents of the 
affected individual including anaemia, tlnomobocytopenia, fluctuations in leucocyte 
numbers, macroglobulinaemia and lipaemia (Molyneux et al, 1996). The anaemia 
associated with HAT is more severe in cases of the Rhodesian form of the disease and may 
be absent or only mild in Gambian sleeping sickness (Greenwood and Whittle, 1980). The 
anaemia results from a combination of factors such as impaired erytliropoesis and 
haemodilution. However, the major cause of the severe anaemia appears to be 
erythrophagocytosis. During infection, many of the red blood cells become coated in 
immune complexes. These erythrocytes are subsequently phagocytosed by macrophages 
in the spleen, liver and lymph-nodes leading to a reduction in the pool of circulating red 
cells (de Atouguia and Kemiedy, 2000; Jenkins and Facer, 1985; Molyneux et al, 1996; 
Murray and Dexter, 1988). In animals, the spleen has been shown to be the site of red cell 
phagocytosis during mild anaemia while the liver plays the major role in cases of severe 
anaemia (Jenkins and Facer, 1985). Haemolytic factors liberated directly by the 
trypanosomes may also contribute to the destruction of red blood cells (Jenkins and Facer, 
1985; Molyneux et al, 1996; Murray and Dexter, 1988). Furthermore, as the disease 
advances the production of new erythrocytes by the bone marrow is significantly reduced 
due to a lack of incorporation of iron into the red cell precursors (Jenkins and Facer, 1985; 
Murray and Dexter, 1988). In addition, the plasma volume increases as the disease 
progresses producing a haemodilution effect (Jenkins and Facer, 1985). The body 
therefore fails to compensate for this decrease in red cell number and increase in total 
plasma volume and a severe anaemia develops.
Thrombocytopenia commonly develops in both forms of sleeping sickness. Again this 
may be mild in the Gambian form of the disease and probably results from an enliancement 
of the reticuloendothelial system. In Rhodesian sleeping sickness the thi ombocytopenia is
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often more pronounced and can be associated with disseminated intravascular coagulation 
(Greenwood and Whittle, 1980). The coagulopathy consists of thrombosis, haemorrhage, 
multiple petechiae, and tissue necrosis. This is accompanied by fibrinolysis and fibrinogen 
and fibrin degradation products are elevated. In addition decreases in platelet cell numbers 
are found in patients with either form of sleeping sickness (Greenwood and Whittle, 1980; 
Molyneux 1996).
Pronounced immunological changes also occur following trypanosome infection resulting 
in fluctuations in the numbers of circulating leucocytes and antibody levels. In the acute 
stage of the disease there is a dramatic plasma cell response in the lymph-nodes and spleen. 
This plasma cell response is accompanied by a rise in the levels of circulating 
immunoglobins and produces a marked alteration in the ratio of plasma albumin to 
globulin levels. This macroglobulinaemia is common to both T.b.rhodesiense and 
T.b.gambiense infections and reflects the non-specific polyclonal B-cell activation that 
occurs at this stage of the infection. During the initial parasitaemia, IgM is the major 
immunoglobin produced but as the disease progresses this switches to IgG although IgM 
levels remain elevated. However, it appears that little of the IgM produced by sleeping 
sickness patients is specific for trypanosome antigens. Moreover, affinity for autoantigens 
such as aggregated IgG and double stranded DNA, as well as other tissue components has 
been reported (de Atouguia and Kemiedy, 2000; Greenwood and Whittle, 1980; Hunter 
and Kennedy, 1992). During the polyclonal response the splenic B-cells become 
unresponsive to mitogens such as LPS, later in infection this immunosuppressive 
interference extends to the T-cell population (Bancroft and Askonas, 1985; Murray, 1974). 
The mechanisms involved in this depletion of T-cell and B-cell responses remain unclear. 
Several hypotheses have been suggested including; saturation of the leucocyte cell surface 
receptors due to the continual changing of the parasite antigenic coat, or the transformation 
of the B-cells by a mitogenic effect of the trypanosome leaving the population unable to 
respond to alternative antigens (Murray, 1974).
1.2.2.2. Specific organ damage
Cellular degradation occurs in most of the organs of patients affected by sleeping sickness 
(Murray, 1974). However, as post-mortem information is only available from patients who 
have died of the advanced stage of the disease many of the details regarding the progress of 
the infection have been obtained from animal models. In early infections, 
lymphadenopathy is commonly found and the glands show lymphocyte, plasma cell and
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macrophage production (Ormerod, 1970). In some instances, especially those involving 
Gambian disease, the cervical lymph nodes in the neck can become easily visible. This is 
referred to as ‘Winterbottom’s sign’ (Apted, 1970). In advanced cases, fibrosis of the 
lymph nodes occurs and they become small and hard and morular or Mott cells can be 
detected in the glands at this stage. Mott cells are large plasma cells with a 
characteristically vacuolated cytoplasm and pycnotic nucleus. The cytoplasmic vacuoles, 
or Russell bodies, are dilated cisternae of the endoplasmic reticulum and are filled with 
non-secreted, mutated immunoglobin that cannot be degraded from the endoplasmic 
reticulum (Maggioni, Carelli, Cabibbo, Fagioli et a l, 1998).
Following trypanosome infection the spleen also increases in size and develops a firm 
texture. This organ shows few indications of fibrosis until the advanced stages of the 
disease are reached. Changes similar to those initiated in the lymph nodes are seen in the 
Malpighian corpuscles and numerous plasma cells can be found (Ormerod, 1970).
The inflammatory processes triggered by trypanosome infection result in a general increase 
in perivascular cellularity, characterised by the presence of monocytes, lymphocytes and 
plasma cells. However, it appears that polymorphonuclear lymphocytes have little input in 
the immune response generated in sleeping sickness (Ormerod, 1970). In contrast large 
numbers of polymorphonuclear lymphocytes have been found associated with the sites of 
tissue lesions in dogs experimentally infected with T.b.brucei (Morrison, Murray, and 
Sayer, 1997). The perivascular reaction is associated with tissue oedema and haemorrhage 
(Molyneux et al, 1996). In T.b.rhodesiense infections cardiac reactions are prominent and 
a myocarditis develops rapidly which quickly spreads to all layers of the heart including 
the valves and conduction pathways (Molyneux et al, 1996). Numerous plasma cells are 
present in the inflammatory infiltrate amongst which are Mott cells. Fibrosis and 
myocytolysis can also be seen in the cardiac tissue lesions as the disease advances.
1.2.2.2.1. Central nervous system manifestations
The data regarding the progressive changes that occur in the brain following trypanosome 
infeetion are limited to material obtained from patients that have died during the advanced 
stages of the disease. Therefore a substantial portion of the neuropathogenesis information 
has been gained from experimental animal models of the infection. The CNS is affected in 
both forms of sleeping sickness, although the changes become more apparent in the 
chi'onic Gambian form of the disease since infection with T.b.rhodesiense can cause fatal 
cardiac involvement before the CNS reaction becomes pronounced. It is likely that
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changes to the meninges and brain begin early in the infection and it has been suggested 
that the severe headaches that accompany the early stages of the diseases result from this 
CNS involvement (Ormerod, 1970).
The mechanisms employed by the parasites to enter the CNS and the kinetics of this 
invasion have yet to be fully elucidated. However since the choroid plexus shows injury 
fairly quickly after infection this seems a feasible route to allow the parasite to gain access 
to the CNS. From here the parasites can enter the cerebrospinal fluid (CSF) and 
subsequently penetrate the brain via the subaraclmoid and Virchow-Robin spaces 
(Molyneux et al, 1996; Pentreath, Baugh, and Lavin, 1994). Further evidence to 
substantiate this hypothesis is available since large numbers of trypanosomes have been 
found, soon after infection, in the choroid plexus of dogs experimentally infected with 
T.t.brucei (Morrison, Murray, Whitelaw, and Sayer, 1983). Moreover, in experimental 
rodent infections the parasites localise to areas of the CNS where the BBB is weak sueh as 
the choroid plexus, the trigeminal and dorsal root ganglia and the circumventricular organs 
including the pineal gland and median eminence (Bentivoglio, Grassi-Zucconi, Olsson, and 
Kristensson, 1994). However, human studies have shown only a minor involvement of the 
choroid plexus in the overall inflammatory reaction (Adams, Haller, Boa, Doua et a l, 
1986). Investigations in a rodent model employing T.b.brucei have suggested that 
progressive damage to the BBB occurs as the disease advances (Pentreath et al, 1994; 
Philip, Dascombe, Fraser, and Pentreath, 1994). Therefore the route of entry of 
trypanosomes to the CNS remains to be elucidated definitively.
Pathologically the neuroinflannnatory changes resulting from trypanosome infection are 
characterised by an influx of inflammatory cells including macrophages, T-cell, B-cells 
and many plasma cells eventually progressing to a severe meningoencephalitis. In many 
cases the inflammation results in a thickening of the leptomeninges which become 
adherent to the dura mater (Ormerod, 1970). This phenomenon has been reported in both 
the ventral and basal regions of the brain (Cegielski and Duiack, 1997). The meningitis is 
accompanied by severe perivascular cuffing of the blood vessels with inflannnatory cells 
infiltrating the parenchyma (Adams and Graham, 1998). The inflammatory infiltrate is 
composed of lymphocytes, macrophages and plasma cells. In addition, Mott cells are 
frequently encountered. A pronounced astrocytosis and diffuse microglial hyperplasia are 
also significant features of the neuroinflammatory reaction (Adams et al, 1986). In some 
cases the lesion can take the form of a severe haemorrhagic leukencephalopathy (Adams et 
al, 1986). Despite the severity of this reaction there appears to be little damage to the 
neuronal elements of the brain and these ai'c, in general, spared from harm. However in
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some fatal cases of sleeping sickness, perivascular demyelination has been reported in the 
subcortical white matter (Cegielski and Durack, 1997).
1.2.3. Diagnosis
Clinical diagnosis of early stage human African trypanosomiasis (HAT) is difficult since 
many of the initial symptoms are commonly found in a plethora of other infectious 
diseases endemic to the area. Due to the intermittent bouts of fever interspersed with 
periods when the patient feels well, it is not unusual for malaria or bacterial infections to 
be diagnosed and anti-malarial or antibiotic drugs administered. This treatment regimen 
reduces the fever and frequently results in the delay of an accurate diagnosis until the 
trypanosomiasis has progressed and signs of CNS involvement become appai’ent.
As there are no pathognomic clinical manifestations in HAT laboratory confirmation of 
infection is essential. Definitive diagnosis is dependent on the direct demonstration of 
trypanosome parasites in the chancre, blood smears, lymph node aspirates or CSF. This is 
usually carried out by examination of either wet smears or Giemsa-stained thick or thin 
peripheral blood smears. However, direct demonstration of the parasite can be difficult as 
the parasitaemia is cyclical and often extremely low therefore time consuming repeated 
examinations aie often required. If the parasites are detected, a lumbar puncture is 
essential. Since there is a high probability of CNS involvement if the CSF shows increased 
IgM levels or a raised leucocyte count, this test allows the clinician to determine the stage 
of the infection and prescribe the appropriate form of chemotherapy.
Several trypanosome concentration techniques are available such as the micro-haematocrit 
centrifugation teclmique (Woo, 1970), the quantitative huffy coat method (Bailey and 
Smith, 1992; Bailey and Smith, 1994), the miniature anion exchange teclmique and the 
double centrifugation technique. Although these methods improve the detection rates 
many infections remain undiagnosed. Indirect methods, such as the subimioculation of 
blood into susceptible laboratory animals or the kit for in vitro isolation (KIVI), can be 
more sensitive than microscopic examination of samples. However these tests are 
expensive and there is a significant time delay before they yield results (McNamara, 
Bailey, Smith, Wakliooli et a l, 1995; Truc, Bailey, Doua, Laveissiere et a l, 1994).
Alternative approaches, based on the detection of host antibody responses to the 
trypanosome antigens have emerged. The most useful aie the immunofluorescent antibody 
test (IFAT) (WHO, 1976), the enzyme linlced immunosorbant assay (ELISA) (Lejon,
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Buscher, Magnus, Moons et a l, 1998; WHO, 1976) and the card agglutination 
trypanosomiasis test (GATT) (Truc et al, 1994). However major problems still remain 
since the presence of anti-trypanosomal antibodies does not distinguish between past and 
active infections. Assays for the detection of circulating trypanosome antigens have been 
developed to circumvent these problems. Sandwich antibody antigen capture ELISA based 
tests are the most common format and their use in both human (Liu, Cattand, Gar diner, and 
Pearson, 1989; Nantulya, Doua, and Molisho, 1992) and animal (Liu, Pearson, Sayer, 
Gould et a l, 1988; Nantulya, Lindqvist, Stevenson, and Mwangi, 1992) diagnostics has 
been described. Unfortunately, generation of false positive and false negative results is not 
uncommon when trypanosome antigen based tests are employed.
1.2.4. Current treatment strategies
The successful chemotherapy of HAT is precarious due to dwindling supplies of an 
extremely limited array of useful drugs and further hampered by the development of drug 
resistance by the parasite (Ross and Sutherland, 1997). Whereas new compounds that can 
be delivered orally have been developed for the treatment of many parasitic diseases, the 
treatment of HAT still relies on highly toxic drugs, developed before 1950, that must be 
administered pai’enterally in repeated doses.
1.2.4.1. Chemotherapy of early-stage infections
Trypanosomiasis is considered to be in the early-stage when parasites can be detected in 
the blood and no trypanosomes or high leucocyte or protein levels are present in the 
cerebrospinal fluid (CSF). The current treatment regimens employed for early-stage 
chemotherapy are as follows: only two drugs are recommended for the treatment of 
trypanosomiasis if the disease is diagnosed during the early stage, before the parasites have 
progressed into the central nervous system. These drugs are pentamidine and suramin. 
Pentamidine (Pentacarinate®) is only used in the treatment of T.b.gambiense infections as 
T.b.rhodesiense has shown primary resistance to pentamidine therapy. It is administered 
as a course of 7 to 10 intramuscular injections, given once daily or every second day 
(WHO, 1998).
Suramin is effective against both T.b.gambiense and T.b.rhodesiense. However its use, for 
the time being, is generally restricted to the treatment of east African trypanosomiasis. 
Suramin is administered as an intravenous injection. The course usually comprises a test
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dose, to check the patient’s tolerance of the drug, followed by a series of 5 injections given 
at 5 to 7 day intervals.
Treatment of early-stage infections with the above regimens is usually successful although 
the patient may experience adverse reactions to the drugs that can occasionally be fatal 
(WHO, 1998).
1.2.4.2. Chemotherapy of CNS-stage infections
If the infection has progressed to the CNS, as indicated by the presence of trypanosomes or 
elevated leucocyte or protein levels in the CSF, the only commonly available drug of use is 
the trivalent arsenical melarsoprol (Mel B®). This drug is not soluble in water and is 
therefore produced as a 3.6% solution in propylene glycol. Treatment schedules for 
melarsoprol differ but generally consist of a series of daily intravenous injections 
administered over a 3 to 4 day period followed by a 7-day interval. This regimen is 
repeated 3 to 4 times using increasing doses of melarsoprol on each successive round of 
treatment. Melai'soprol treatment is generally preceded by two injections of either 
pentamidine or suramin to clear the trypanosomes from the bloodstream (WHO, 1998).
1.2.4.3. Adverse reactions to melarsoprol treatment
Unfortunately, melarsoprol therapy can result in several serious side effects. Myocardial 
damage and polyneuropathies occasionally appear. Due to the noxious nature of the 
propylene glycol solvent, severe venous damage occurs frequently in melarsoprol 
regimens. This tissue damage can be so severe that it necessitates amputation of the 
affected limbs. Great skill is therefore required to administer the drug whilst causing the 
least tissue damage over the protracted course of the therapy.
The most serious adverse reaction to melarsoprol therapy is the development of the post­
treatment reactive encephalopathy (PTRE). This occurs in 5-10% of melarsoprol treated 
individuals. In up to 50% of affected patients the condition deteriorates to a deep coma 
followed by death (Adams et al, 1986). The basis of this adverse reaction is unknown, 
although several hypotheses exist. These include; parasite persistence as a consequence of 
subcurative drug treatment (Hunter and Kemiedy, 1992; Jemiings, McNeil, Ndung'u, and 
Murray, 1989), the release of parasite antigen within the CNS as a result of chemotherapy 
(Pepin and Milord, 1991), the toxic nature of the arsenical drug (Hurst, 1959), immune
2 1
complex deposition (Lambert, Berney, and Kazyumba, 1981) and autoinimimity (Poltera, 
1980).
The onset of the PTRE is shown clinically by fever, tremors, slurring of speech and 
convulsions. Pathologically, the PTRE is characterised by a severe meningoencephalitis 
with the influx of lymphocytes, macrophages and plasma cells and an intense astrocytosis. 
Occasionally the PTRE can take the form of an acute haemorrhagic leucoencephalopathy 
(Adams et al, 1986). The kinetics of the inflammatory cell infiltration into the CNS and 
the breakdown of the proportions of individual cell types involved in the development and 
control of the meningoencephalitis have yet to be fully determined.
1.2.5. Alternative chemotherapeutic approaches
At present, up to 20% of diagnosed patients are failing to respond to melarsoprol therapy 
as a consequence of parasite resistance to the drug (Barrett, 1999). Hence, the search for 
an alternative therapeutic regimen for the treatment of this disease is of paramount 
importance.
1.2.5.1. Efiornithine
Since the introduction of melarsoprol in 1949, the only new drug registered for the 
treatment of late-stage HAT is efiornithine also known as DL-a-difluoromethylornithine 
(DFMO). Efiornithine is a potent irreversible inhibitor of ornithine decarboxylase (ODC), 
the key enzyme in the production of the polyamines putrescine, spermine and spermidine 
which are required by all dividing cells. Since the concentration of ODC is elevated in 
most tumours and pre-malignant lesions, efiornithine was originally developed as an anti­
cancer drug. It was first used, although unregistered, to treat HAT by van Nieuwenlrove in 
1981 (Van Nieuwenlrove, Schechter, Declercq, Bone et a l, 1985). Since efiornithine 
crosses the blood-brain barrier it can be used to treat late-stage disease. In fact the positive 
effects produced by efiornithine treatment of comatose sleeping sicloiess patients were so 
dramatic that it was nicknamed ‘the resurrection drug’. In addition, it was shown that 
efiornithine therapy could also produce a dramatic clinical improvement in late-stage 
sleeping sickness patients even when the patient’s immune system had become damaged 
by the disease and remained only partially functional. In these patients the treatment failed 
to resolve the infection however, the general sense of well being of the individual was 
nevertheless improved. These findings led to speculation that efiornithine has previously
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uni'ecognised pharmacological actions within the inflamed brain over and above the 
inliibition of ODC.
Senior scientists employed by the Merrell Dow Research Institute, the initial producers of 
efiornithine, pursued extensive clinical trials on efiornithine therapy of trypanosomiasis 
and efiornithine was registered by the US Food and Drug Administration (FDA) for the 
treatment of T.b.gambiense sleeping sickness in 1990 (Sjoerdsma and Schechter, 1999). 
There is limited information available on efiornithine monotherapy of East African 
sleeping sickness, although the existing data indicate that T.b.rhodesiense is not susceptible 
to the action of efiornithine (Iten, Matovu, Brun, and Kaminsky, 1995). On the other hand 
there is some evidence to suggest that efiornithine therapy, in combination with other 
trypanocidal drugs, may be effective in the treatment of late-stage T.b.rhodesiense- 
infections (Taelman, Clerinx, Bogaerts, and Vervoort, 1996) and in T.b.gambiense- 
infections where the parasites are refractory to melarsoprol therapy (Simarro and Asumu, 
1996; Van Nieuwenhove et al, 1985).
After dissolution of Menell Dow, efiornithine production was discontinued and the drug 
became virtually unavailable. Recently WHO and Hoechst Marion Roussel inc. signed a 
new Licensing Agreement that grants WHO reference right to the license to produce 
efiornithine. This will allow the necessary technology to be transferred to a third party 
within the private sector who will manufacture the drug. Although this third party has not 
yet been identified it is envisaged that funds will be secured to guarantee the production of 
efiornithine until 2005 (WHO, 2000).
1.2.5.2. Nifurtimox
Since the mid-1970’s nifuitimox (Lampit®) has been used to treat Chagas’ disease, the 
Latin American form of trypanosomiasis caused by infection with Trypanosoma cruzi. 
The drug is not well tolerated and can produce serious side effects ranging from gastro­
intestinal upset to neurological reactions. However, a few clinical trials have been carried 
out in patients with melarsoprol refractory T.b.gambiense-mTeoXions. The efficacy of the 
treatment varied substantially in these trials. A relapse rate of 63% was seen in patients 
given 12-17 mg/kg nifiutimox daily for a period of 60 days (Pepin, Milord, Mpia, Meurice 
et a l,  1989). This high failure rate was reduced to 36% by raising the dosage of 
nifurtimox to between 24-37 mg/kg daily for a 30 day period, but this higher dose rate 
produced significant toxicity in the patients and severe neurological reactions were not 
uncommon (Pepin, Milord, Meurice, Ethier et a l, 1992).
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The possibility of nifurtimox treatment has not been abandoned completely as more 
promising results were seen recently in the Democratic Republic of Congo. Here a 
regimen comprising a combination of melarsoprol and nifurtimox was employed and 
further trials are planned using this composite approach (WHO, 2001a)
1.2.5.3. Megazol
Megazol is a 5-nitroimidazole derivative that has shown in vitro trypanocidal activity 
against T. brucei (de Atouguia, 1998) although the mode of action remains unclear. The 
drug is absorbed into the cells mainly by passive difflision through the cell membrane 
however use of the P2 transporter has also been suggested as the drug possess the 
prerequisite motif for binding to the molecule (Denise and Barrett, 2001). In mouse 
models, megazol monotherapy is only effective against early-stage trypanosome infections 
and does not cuie CNS-stage disease. However, if megazol is administered in combination 
with sui'amin or melarsoprol CNS-stage infections can be successfully resolved (Enanga, 
Keita, Chauviere, Dumas et a l, 1998; Jennings, Chauviere, Viode, and Murray, 1996).
Despite the promising results with combination therapy the use of megazol to treat human 
African trypanosomiasis has been lar gely abandoned due to the fact that the drug produces 
a positive result in the Ames’ test and its use could therefore produce mutagenic effects. 
However, given the serious nature of the disease and the lack of effective drugs to treat the 
condition, flexibility in the licensing of ‘new’ drugs for use in the treatment of late-stage 
trypanosomiasis seems to be required.
1.3. Aims and objectives
In view of the possible therapeutic implications for trypanosomiasis and other CNS 
inflammatory conditions such as multiple sclerosis (MS), Alzheimer’s disease, AIDS 
dementia complex and cerebral malaria inter alia, an investigation of the key events 
leading to the CNS inflammatory lesion will be pursued in this thesis. In addition, the 
mechanisms of action of efiornithine and the role of the neuropeptide substance P in the 
control of the immune response within the CNS will be elucidated. This will significantly 
enhance our knowledge of CNS inflammatory responses and may prove important in the 
search for more efficacious treatment regimens for a variety of immune-mediated CNS 
conditions.
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The investigation has four main objectives:
• To define the kinetics of cytokine production in the central nervous system 
(CNS) during a meningitis and subsequent encephalitis.
• To detemine the temporal and spatial transmigration of leucocytes into the 
CNS following trypanosome infection and the development of the PTRE.
• To investigate the modulatory effects of the drug efiornithine on cytokine 
production and inflammatory cell recruitment into the CNS.
• To study the role of the neuropeptide Substance P in the generation of the 
neuroinflammatory reaction induced by sub curative drug treatment of 
trypanosome-infected mice.
1.4. Rationale
1.4.1. Neuropathogenesis and the mouse modei
During late-stage human African trypanosomiasis (HAT), pai’asites invade the CNS 
leading to the development of neurological disease. Following chemotherapy there is often 
a post-treatment inflammatory reaction in the CNS that augments the ongoing pathology 
and can be fatal. Pathologically the CNS lesions are characterised by a meningitis and 
subsequent encephalitis, with lymphocytes, plasma cells and macrophages infiltrating the 
meninges and perivasculai' spaces, and a reactive astrocytosis. A mouse model that 
simulates all phases of the CNS pathology, in particular the severe meningoencephalitis 
found in patients that exhibit the post-treatment reactive encephalopathy (PTRE) will be 
used to elucidate the mechanisms culminating in this inflammatory reaction. This model is 
described in greater detail in Chapter 2 of this thesis.
1.4.2. Migration of leucocytes across the blood- 
brain barrier
Leucocytes interact with and traverse the blood-brain barrier to enter the parenchyma in a 
multi-step process occmiing in an ordered sequential fashion. The release of mediators
25
controls the expression of an ensemble of adhesion molecules that are reciprocally 
expressed on endothelial cells and leucocytes. The local release of chemoattractant 
cytokines, termed chemokines, is also thought to be a prerequisite for leucocyte 
recruitment into the CNS. Most data have been derived from studies on non-CNS derived 
tissue and do not, therefore, address the unique situation within the brain. The time course 
of cytokine and chemokine expression within the CNS will therefore be investigated in this 
study.
1.4.3. Modulation of CNS pathology
Efiornithine, a specific inhibitor of ornithine decai’boxylase, the main regulatory enzyme 
for the de novo synthesis of polyamines, has been used effectively in the treatment of both 
human and animal trypanosomiasis. An intriguing aspect associated with the use of this 
drug is the rapid clinical improvement that it induces in comatose patients, even when it 
has failed to eliminate the infection prompting investigators to call it the ‘resurrection 
drug’. This led to speculation that efiornithine may have important pharmacological 
effects besides its trypanostatic action. Using an eflornithine-resistant trypanosome 
stabilate, we have demonstrated previously that treatment of infected animals with 
efiornithine both prevents and ameliorates the meningoencephalitis associated with the 
PTRE (Jermings, Gichuki, Kennedy, Rodgers et al., 1997). These findings indicate an 
important previously umecognised action of efiornithine in controlling the CNS pathology 
of the disease. It is possible that efiornithine is achieving this anti-inflammatory effect by 
inhibition of cytokine production within the CNS. This could block the cascade of events 
that lead to the formation of the inflammatory lesion and the ultimate transmigration of 
leucocytes across the blood-brain barrier. These possibilities will be investigated in this 
thesis.
1.4.4. The role of substance P
The neurotransmitter substance P (SP) is an 11 amino-acid neuropeptide that is widely 
distributed in the central nervous system and peripheral tissues. Recent evidence shows 
that SP may also be involved in a wide range of inflammatory reactions from rheumatoid 
artliritis (Anichini, Lepori, Maddali Bongi, Maresca et al., 1997) to multiple sclerosis 
(Barker and Earner, 1992). A role for SP in the pathogenesis of cerebral malaria has also 
been suggested as sera from Plasmodium falciparum-inÎQCted patients has been shown to 
induce the production of SP by human brain micro-vascular endothelial cells in vitro
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(Chiwakata, Hort, Hemmer, and Dietrich, 1996). The development of potent, highly 
specific, non-peptide SP antagonists provides a new opportunity to investigate the possible 
involvement of SP in sleeping sickness. The mechanism by which SP may modulate 
inflammation and its site of action in the inflamed brain remain to be elucidated. This will 
be investigated tlnough the use of NKl, NK2 and NK3 receptor antagonists, to block the 
action of SP by inliibiting receptor stimulation. In addition, NKl receptor knockout mice 
will be employed. These animals are phenotypically normal but express no NKl receptors 
at any sites throughout the body effectively blocking the action of SP.
1.5. Brief methodology
Our Trypanosoma brucei brucei mouse model will be used to induce meningoencephalitic 
responses with vai'ying degrees of severity. Long-term experience of this model within the 
Department provides familiarity in handling and maintaining trypanosome infections and 
in the consistent induction of the desired degrees of inflammation. The techniques of 
immunocytochemistry and in-situ reverse transcriptase polymerase chain reaction will be 
employed to determine which cell types express cytokines and chemokines within the 
inflamed brain. Also, using these techniques, we will discover when the expression of 
these molecules is up-regulated during the infection. The reverse transcriptase polymerase 
chain reaction (RT-PCR) teclmique will be used to elucidate the kinetics of cytokine 
production in relation to the developing inflammatory reaction. Inunimocytochemistry, 
using antibodies against CD4^ and CDS"" lymphocytes, B-cells and macrophages will be 
employed to follow the transmigration of these cells into the CNS. This will allow a 
comparison between the production of cytokines and chemokines and the appearance of 
leucocytes within the CNS. These parameters will also be investigated in infected animals 
treated with eflornithine in an effort to elucidate its mechanism of action. In addition, the 
CNS inflammatory response in mice treated with specific SP receptor antagonists and the 
neuroinflammatory reaction in transgenic mice that have no functional NKl receptors will 
be examined.
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C h a p t e r  2
G e n e r a l  m a t e r ia l s  a n d  m e t h o d s
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2.1. Introduction
In this Chapter the teclmiques that are used repeatedly throughout this thesis will be 
described. Any modification made to these methods for their application in specific 
situations, or procedures that are only employed for investigations in a single area of study 
will be detailed in the Materials and Methods section of the relevant Chapter.
2.2. Murine model of human African 
trypanosomiasis
The experimental animal model described below provides a valuable resource to 
investigate each stage analogous with trypanosome-infection in human patients, from the 
initial acute period to the development of the post-treatment reactive encephalopathy 
(PTRE) that can occur following melarsoprol administration. The use of this murine 
model to study the neuropathogenesis associated with trypanosome infections and to 
develop alternative drug strategies for the treatment of the disease is now well documented 
(Atouguia, Jennings, and Murray, 1995; Gichuki, Jennings, Kemiedy, Sommer et a l, 1997; 
Jeimings, 1993; Jemiings et al, 1997; Kennedy, 1999; Kemiedy, Rodgers, Jennings, 
Murray et a l, 1997). This experimental muiine model will be used thioughout the 
following investigations as a means to further analyse the CNS inflammatory reaction and 
to elucidate the mode of action of the trypanostatic drug, efiornithine.
2.2. f. Trypanosomes
The trypanosome stabilates used in this study were developed in the Department of 
Veterinary Parasitology, University of Glasgow, under the auspices of Dr. Frank Jemiings.
2.2.1.1. Trypanosoma brucei brucei GVR 35/01.6
In 1966 T.h.brucei parasites were isolated from an infected wildebeest in the Serengeti 
National Park (Serengeti/66/SVRP/lO) and subsequently transferred to the London School 
of Tropical Medicine and Hygiene. In 1977, a clone of this T.b.brucei stabilate {T.brucei 
LUMP 1001) was obtained by Dr. Franlc Jeimings, at Glasgow University. A new clone 
was grown from this stabilate by passage through sub-lethally irradiated mice. The
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resulting parasites were designated GVR 35/Cl and maintained in liquid nitrogen. New 
working clones were prepared from this reserve stabilate as necessary. The current study 
employs parasites of the Tb. brucei stabilate GVR 35/C 1.6.
2.2.2. Animals and infection regimens
Female CDl mice weighing 28-35g were purchased from Charles River Breeding 
Laboratories. These mice were allowed to acclimatise to the animal house facilities at 
Garscube Parasitology Animal Unit for a period lasting at least two weeks before any 
experimental procedures were carried out. Throughout all treatment regimens the animals 
were housed in standard caging and provided with food pellets and water ad libitum.
2.2.2.1. Donor animals
To generate the quantity of parasites required to infect the number of mice necessary for 
each experiment, a small group of donor animals was inoculated with Trypanosoma brucei 
brucei GVR35/C1.6 prepared directly from the fi'ozen stabilate. Each mouse was injected 
intraperitoneally (i.p.) with a total volume of 0.1ml phosphate buffered glucose saline 
(PBGS) pH8.0 containing 4x10^  ^trypanosomes. The level of parasitaemia in these mice 
was monitored by microscopic examination of fresh blood smears prepared from tail snips. 
When the parasitaemia reached the first parasitaemic peak (antilog 8.1) (Herbert & 
Lumsden, 1976) the mice were terminally anaesthetised and the blood collected by cardiac 
puncture. This blood was diluted in PBGS until an infective dose of approximately 2x10^  ^
trypanosomes was contained in a volume of 0.1ml. This concentration equates to 
approximately two trypanosomes per microscopy field when examined at a magnification 
of 400 fold. The resulting solution was subsequently used to infect the experimental 
animals.
2.2.2.2. Mouse model experimental design
The standard experimental regimens that comprise the mouse model of HAT are outlined 
in Figuie 2.1. The model is made up of tluee separate treatment schedules that allow us to 
simulate closely each of the four different stages of infection found in the human patient 
namely; acute infection, early CNS-stage, late CNS-stage and the PTRE.
The formulation for this solution is described in Appendix 1
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Treatment Schedule 1
m > K K K K
Acute-stage
14 21 28
Transition-stage Early CNS-stage
Treatment Schedule 2
CD > [ d
1 21
K K
28 35
Late CNS-stage
Treatment Schedule 3
[ D > C 3
1 21
D
56
K K
63 72
Post-treatment reactive encephalopathy
Figure 2.1. Schematic representation of the treatment regimens 
comprising the murine model of human African trypanosomiasis. In this 
model all mice will be infected (I) with 2x10"^  T.b.brucei parasites of the cloned stabilate 
GVR35/C1.6. Animals will be administered diminazene aceturate (D) as indicated. The 
number of days post-infection and the stage of HAT simulated are detailed below the 
treatment regimens and the mice were killed (K) on the days indicated.
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In all investigations control groups of uninfected mice that receive drug regimens identical 
to those given to the infected animals are included in the experimental design.
2.2.2.2.f, Acute infection
To mirror the acute-stage of trypanosome infection animals are injected with 0.1ml PBGS 
containing an infective dose of 2x10"^  trypanosomes prepai'ed and administered as 
described above. Following infection the parasites remain confined to the peripheral 
systems for approximately 14 days with no CNS involvement. Therefore animals killed at 
7 and 14 days post-infection simulate the acute stage of HAT and show no obvious signs of 
CNS inflammation.
2.2.2.2 2. Early CNS-stage
If the disease is allowed to progress naturally the parasites invade the CNS between day 14 
and day 21 after infection and the mice can survive for a period of approximately 30-days. 
Day 21 tlu'ough to day 28 after infection mirror the early CNS stage of the disease and 
animals killed at these time points show only a very mild CNS-inflammatory reaction. 
This is characterised by a slight rise in the level of astrocyte activation and the presence of 
a few inflammatory cells in the meninges.
2.2.2.2.J. Late CNS-stage
The late-stage CNS condition can be induced in the mice by treating infected animals at 
day 21 post-infection, or later, with the trypanocidal drug diminazene aceturate. 
Diminazene acetuiate is available as a commercial preparation from Hoechst AG under the 
trade name Berenil®. The compound is dissolved at a concentration of 9mg/ml in pyrogen 
free water and administered to the mice at a dose rate of 0.1 ml/1 Og bodyweight i.p. As 
there is 445mg of diminazene aceturate per gram of Berenil® this results in a final dose of 
40mg/kg bodyweight of the active principle. Although this is approximately ten times the 
recommended dose, the treatment is subcurative when it is administered on or after day 21 
post-infection. Since the diminazene aceturate does not cross the blood-brain barrier 
(BBB) efficiently the trypanosomes out-with the CNS are killed and the mice become 
aparasitaemic, however, the parasites established within the CNS remain viable and the 
animals relapse to parasitaemia approximately 4 to 6 weeks after the initial drug treatment. 
If the mice are killed at 7 or 14 days following the trypanocidal therapy the neuropathology 
resembles that found in human patients that have died during late-stage CNS disease. The
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neuroinflammatory response in these animals shows a moderate meningitis with 
lymphocytes and macrophages infiltrating the meninges and perivascular spaces. The 
inflammatory cell infiltration is accompanied by a diffuse astrocytosis. It is possible to 
manipulate the severity of the CNS inflammation in these animals by altering the timing of 
the trypanocidal treatment. When the diminazene aceturate treatment is delayed beyond 
day 21 post-infection a corresponding increase the degree of the inflammatory reaction is 
seen in the CNS of the infected mice. In addition to meningitis and astrocytosis, animals 
given diminazene aceturate at a delayed date exhibit a mild encephalitis with inflammatory 
cells present in the parenchyma.
2.2.2 2.4. Post-treatment reactive encephalopathy
The inflammatory pattern found in cases of the post-treatment reactive encephalopathy 
(PTRE) can be simulated by subcuratively treating the T.b.brucei-infectQd mice with 
diminazene aceturate on day 21 post-infection as before. This treatment clears the 
peripheral systems of trypanosomes, however the aparasiteamia is transitory and the 
animals eventually relapse. When relapse occurs, usually between 4 and 6 weeks 
following the initial diminazene acetmute treatment, the mice are given a second 
trypanocidal treatment. This exacerbates the CNS pathology and animals killed 7 and 14- 
days after the second diminazene aceturate treatment exhibit an extremely severe 
inflammatory response within the CNS that closely resembles the pathology found in 
human patients who have died of the PTRE. The meningoencephalitis generated in these 
mice is distinguished by the presence of numerous lymphocytes, plasma cells and 
macrophages in the brain parenchyma, meninges and perivascular spaces. A marked 
astrocytosis is also associated with this neuroinflammatory reaction.
2.2.3. Tissue Harvesting
At the scheduled termination points of the experiment the mice were killed and the brains 
extracted for subsequent analysis. Tissue was prepai'ed for histological assessment, 
including both grading of the severity of the neuroinflammatory reaction and 
immunocytochemistry. In addition material was extracted for RT-PCR analyses, to assess 
the levels of cytokine transcription. To cairy out this procedure the mice were deeply 
anaesthetised with fluorothane and exsanguinated by cardiac puncture. To remove any 
residual blood from the brain tissue the animals were perflised via the left ventricle of the 
heart with approximately 150ml of physiological saline. Following perfusion the brains
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were carefully removed from the skull and prepared for further analyses. To help prevent 
artefacts the brains were not dissected and divided among the different analysis teclmiques, 
instead a whole brain was used for each of the subsequent examinations.
2.2.3.1. Sample preparation for histological assessment
The tissue required to determine the severity of the inflammatory reaction induced by each 
treatment regimen was fixed in 4% neutral buffered formalin before processing to paraffin 
blocks. From these blocks, brain sections each of 3 pm thickness, were prepared. One 
section from each block was stained with haematoxylin and eosin (H&E) to assess the 
severity of the inflammatory reaction. Additional sections were stained using 
immunocytochemistry techniques to determine the degree of astrocytosis. The processing 
procedure required for the preparation of paraffin embedded tissue damages certain cell 
surface markers therefore samples were also taken for the preparation of frozen sections. 
To prevent the tissue from developing ice crystal artefact during the freezing procedure the 
brains were placed into PBS containing 30% sucrose and stored overnight at 4^C. 
Following cryoprotection, the blocks were embedded in OCT, snap frozen in liquid 
nitrogen and stored at -70^C until required. A cryostat as used to prepare 10pm thick 
sections from these frozen blocks. The sections were air dried, fixed in cold acetone for 10 
minutes and stored at -20^0 until required for staining.
2.2.3 2. Sample preparation for RT-PCR analyses
Following dissection the brain samples required for RT-PCR analyses were homogenised 
in 5ml of denaturing solution^' by gentle trituration through a 20 gauge hypodermic needle. 
Once homogenised the samples were aliquoted into diethyl pyrocrbonate (DEPC) treated 
1.5ml eppendorf tubes and stored at -2QpC until required. The precautions necessary for 
handling tissues for subsequent RNA extraction, including the significance of DEPC 
treatment, are discussed in more detail in Chapter 2, section 2.5 ‘Ribonucleic acid 
purification and quantification’.
Al The formulation for this solution is described in Appendix 1
34
2.3. Neuropathological assessment
Formalin fixed paraffin sections were stained with the standai'd histological H&E staining 
method. This is a popular staining method due to its simplicity and its ability to clearly 
demonstrate a wide variety of different tissue structiues in an array of tissue types. 
Essentially the haematoxylin component stains the cell nuclei blue, with good intra-nucleai’ 
detail. The eosin constituent of the teclmique stains the cell cytoplasm and most of the 
coimective tissue in varying shades and intensities of pink, orange and red. Brain sections 
stained in this maimer were used to assess the degree of severity of the CNS inflammatory 
reaction following trypanosome infection and induction of the PTRE.
The sections were examined under light microscopy using a magnification of 200 fold. 
The severity of the meningitis, the occurrence and extent of perivascular cuffing and the 
degree of inflammatory cell infiltration of the brain paienchyma were utilised to compile a 
standardised grading scale to define the severity of the CNS inflammatory reaction. The 
criteria defining each neuropathological grade are described in Table 2.1. In this scale a 
score of 0 was assigned to sections showing a normal histopathology with no infiltration of 
inflammatory cells. Mice displaying signs of a mild meningitis with a few inflammatory 
cells present in the meninges but no perivascular cuffing were graded as 1, while animals 
with a moderate meningitis and cuffing of some of the vessels were assigned grade 2. As 
the response worsened the severity of the meningitis increased further and perivascular 
cuffs became prominent, there was also mild infiltration of the neuropil by some 
inflammatory cells. Animals displaying this level of inflammation were assigned a 
neuropathological score of 3. A grading score of 4 was reserved for animals displaying 
severe meningitis, prominent perivascular cuffs and a severe encephalitis with the presence 
of many inflammatory cells in the neuropil. Each section was graded indeiDendently by 
two assessors in a blinded fashion.
2.4. Immunocytochemistry
Immunocytochemistry (ICC) is an established staining teclmique employed in routine 
diagnostic histopathology to demonstrate specific cellular or tissue components in tissue 
sections through the use of antigen-antibody interactions. The method relies on the 
availability of antibodies that will specifically bind with a particular tissue antigen of 
interest and their subsequent visualisation. The method can be used in a number of 
different formats and can be adapted for light microscopy, fluorescent microscopy and
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electron microscopy (Polak and Van Noorden, 1986). This study will employ ICC to stain 
specific cellular markers in both pai'affin and frozen sections.
2.4.1. Immunocytochemistry staining procedure
A  similar fundamental protocol was employed in ICC tlrroughout this study a schematic 
representation of the complete protocol is shown in Figure 2.2. Details of the antibodies 
used together with their optimal concentrations and their suitability for use on paraffin or 
frozen sections are given in Table 2.2.
In cases where paraffin embedded material was used the tissue sections were dewaxed and 
rehydrated before the staining procedure was performed. The wax was removed from the 
sections by placing the slides into 3 changes of xylene, each lasting for 5 minutes. Since 
xylene is not miscible with water the slides were then rehydrated by cycling them tlnough 
graded alcohols at concentrations of 100%, 90% and 70% ethanol. Again, the slides were 
allowed to remain in each concentration of ethanol for a 5 minute period. From here the 
slides were placed into rumring tap water for 5 minutes to complete the rehydration 
process.
Both frozen and paraffin embedded tissue sections contain endogenous peroxidase 
enzymes that can produce false positive results at the end of the staining procedure. To 
quench this activity the sections were placed into 0.5% hydrogen peroxide (H2 O2) in 
phosphate buffered saline (PBS) for 30 minutes and then rinsed in running tap water 
(Van Noorden, 1986). This step is only required if peroxidase is to be employed as the 
enzyme label at the end of the procedure and can be omitted if alkaline phosphatase is to 
be used. The slides were then wiped carefully with paper towel allowing a 3mm gap 
around the sections and placed into the humidity chamber. Certain tissues including 
collagen and reticulin, or areas of high inflammation or necrosis, show an apparent affinity 
for the immunoglobins used in the ICC staining sequence. To overcome this non-specific 
reaction approximately 300p,l of 5% bovine serum albumen (BSA) in PBS was placed over 
the section and allowed to react for 30 minutes at room temperature. The antibodies 
present in the BSA ‘block’ sites on the tissue section that could interect non-speciflcally 
with immunoglobins, perhaps thi'ough the Fc portion of the molecule. This step in the 
process substantially reduces background staining resulting from non-specific binding.
The formulation for this solution is detailed in appendix I
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A Primary antibody Biotin labelled secondary ^ antibody
^  Biotin
Avidin
Enzyme label; usually ^  Target antigen
#  peroxidase or alkaline 
phosphatase
  Cell membrane
*
Figure 2.2. Schematic representation of the immunohistochemistry 
technique.
The primary antibody binds with the antigen target in the tissue section. A 
secondary, biotinylated antibody, that binds to the primary immunoglobin 
molecule, is then added. Finally, the ABC -enzyme complex binds to the biotin 
label on the secondary antibody. The enzyme label subsequently determines the 
areas o f  antibody binding to the section through the use o f  a substrate solution 
that produces a coloured reaction product.
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During this blocking period the primary antibody was prepared by making the appropriate 
dilution in 2% BSA in PBS. Depending on the surface area to be covered, 100-200pl of 
diluted antibody solution was allowed for each section. After 30 minutes the blocker was 
drained from the section and the excess fluid wiped from the slides as before. The primary 
antibody was then applied to the sections using a glass pipette. To allow an even spread of 
the solution across the section the tip of the pipette was held roughly 5cm above the section 
and the antibody applied in a drop-wise mamrer. The sections were then transferred to 4®C 
overnight or incubated for 60-90 minutes at room temperature.
Following this incubation the sections were washed for 10 minutes in PBS to remove the 
primary antibody. This washing procedure was then repeated twice more using fresh PBS. 
During the washing steps the biotinylated secondary antibody was diluted to the 
appropriate concentration in 2% BSA in PBS and applied as previously described after the 
final wash. The secondary antibody was allowed to react with the section for 60-90 
minutes at room temperature. While the sections were incubating the ABC (Avidin Biotin 
Complex) reagent was prepared by making a 1:50 dilution of reagents A and B in PBS {i.e. 
Ipl A + IjLil B + 48pl PBS). Either an ABC-peroxidase kit or an ABC-alkaline 
phosphatase kit (Vecastain® Elite® ABC kit, Vecatastain® ABC-AP kit, Vector 
Laboratories Inc., Peterborough, UK.) was employed at this step in the procedure. To form 
the mature ABC reagent, the mixture was allowed to complex for 45 minutes at room 
temperature. Again 100-200pl of reagent were allowed for each section.
After incubation with the secondary antibody the sections were washed in 3 changes of 
PBS, each wash lasting for 10 minutes as before. The ABC reagent was applied to the 
sections following the wash procedure and incubated at room temperature for 60 minutes. 
The sections were then washed in 3 changes PBS before carrying out the visualisation 
procedure.
2.4.1.1. Detection of horseradish peroxidase labels
Diaminobenzidene tetrahydrochloride (Sigma-Aldrich) is employed to visualise the 
location of peroxidase enzyme labels in tissue sections (Van Noorden, 1986). DAB is a 
suspected carcinogen, therefore precautions must be taken to prevent contamination of the 
laboratory and persomiel. Double gloves should be worn at all times during procedures 
involving the use of DAB and the chemical should only be handled in a fume cupboard. 
The DAB was purchased in powder form as a 5g vial. A stock solution of DAB was
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prepared from this vial to avoid the inhalation risks associated with repeated weighing of 
the powder form of the chemical. To aid dissolution of the powder, 5ml of dimethyl 
formamide were initially added to the contents of the vial. Following this, 0.05M tris- 
buffered saline (TBS) pH7.4^’ was gradually added to the mixture to a total volume of 
50ml. The original container does not hold a 50ml volume, therefore, when approximately 
30ml of TBS had been added the solution was decanted carefully into a 50ml measuring 
cylinder and the remaining buffer added. To allow the powder to dissolve completely the 
mixture was left overnight on a magnetic stirrer in the firme cupboard. The stock solution 
was divided into 1ml aliquots and stored at -20^C until required.
The final substrate solution was prepared by placing 225ml 0.05M TBS and 25ml O.IM 
imidazole in 0.05M TBS into a 300ml staining dish. The presence of the imidazole helps 
to intensify the colour of the DAB reaction (Van Noorden, 1986). The 1ml aliquot of DAB 
and 125 pi of 30% H2 O2 were added to the solution immediately before use giving final 
concentration of 0.4mg/ml and 0.015% respectively. Following the final washes the 
sections were placed into this substrate solution for 5 minutes and allowed to react. In this 
procedure it is the H2O2 that is the substrate for the peroxidase enzyme rather that the DAB 
itself. In the presence of an electron donor such as DAB, the peroxidase enzyme will 
reduce the H2 O2 to water and atomic oxygen and oxidise the DAB producing an insoluble 
brown end product that can be detected on the section when examined under the 
microscope. After 5 minutes in this solution the sections were carefully removed and 
allowed to rinse in running tap water for 5 minutes. The sections were then counter- 
stained with haematoxylin, dehydrated tlirough graded alcohols and cleared through 3 
changes of xylene. Finally, glass coverslips were mounted onto the sections using 
Histomount mounting media.
It is necessary to decontaminate the fume cupboard and inactivate the remaining DAB 
solution before discarding it to the drain. This was cairied out by swabbing the work area 
with a weak solution of sodium hypochlorite solution. As the hypochlorite solution is 
corrosive and will corrode the metal casing of the fume cupboard it was necessary to repeat 
this swabbing procedure using tap water. Approximately 20ml of sodium hypochlorite 
was then added to the DAB solution and the solution left to stand for around 60 minutes to 
allow complete decativation of the DAB. After this time the inactivated DAB disposed of 
to the fume cupboard drain followed by 20ml of diluted hypochlorite solution and copious 
amounts of water. The staining dish used to hold the DAB solution was left to steep in
Al The formulation o f  this solution is detailed in appendix 1
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detergent overnight and thoroughly rinsed before being placed into the general glass 
washing facilities.
2.4.1.2. Detection of alkaline phosphatase labels
A commercially produced Vector® Red substrate kit (Vector® Red Alkaline Phosphatase 
Substrate Kit I, Vector Laboratories Inc. Peterborough, UK) was used to detected alkaline 
phospahtase labelled ABC reagents. This substrate kit produces an intense red reaction 
product in the presence of alkaline phosphatase. The product is insoluble in alcohol and 
xylene and can therefore be permanently mounted in histomount. The substrate solution 
was prepared according to the manufacturer’s instructions. Two drops of reagent 1 were 
added to 5ml of lOOmM Tris-HCl, pH8.2-8.5^' and mixed thoroughly. This was followed 
by 2 drops of reagent 2 and then 2 drops of reagent 3. The solution was mixed thoroughly 
following each addition of reagent. In addition, 5pl of IM levamisole was added to the 
substrate solution giving final concentration of lOmM. This inliibits any endogenous 
alkaline phosphatase activity but does not affect the calf intestine alkaline phosphatase 
used as the reporter on the ABC reagent (Van Noorden, 1986).
Following the final washing steps the substrate solution was applied to the sections and 
allowed to react for 20-30 minutes. Since the solution shows some light sensitivity the 
incubation was carried out in the dark. The slides were washed in PBS, counter-stained 
with haematoxylin, dehydrated thi’ough graded alcohols, cleared in xylene and permanently 
mounted using histomount.
2.5. Ribonucleic acid purification and 
quantification
2.5.1. Sample handling strategy
Ribonucleic acid (RNA) is an extremely labile molecule that can be easily degraded during 
experimental manipulations. Therefore, several precautions were taken when handling 
samples for subsequent RNA extraction. Ribonuclease (RNase), an enzyme that is present 
on the surface of the skin, is the major factor contributing to this unwanted breakdown of
A l The formulation o f  this solution is detailed in appendix 1
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RNA. To prevent contamination of equipment or samples with RNase, the following 
procedures were observed;
• disposable gloves were worn at all times throughout procedures involving 
RNA manipulation.
• all micro-centrifuge tubes were submerged in a 0.1% di-ethyl-pyro-carbonate 
(DEPC) solution, to denature any RNase that may be present, for at least two 
hours at room temperature followed by autoclaving
• commercially available RNase free disposable filter tips were used during 
pipetting stages
• samples were immediately placed into denaturing solution^*, this contains 
guanidium thiocyanate which lyses the cells and denatures any RNase
• samples and solutions were kept at 4^C prior to long-term storage of the 
samples at -20®C.
2.5.2. Sample preparation
The messenger RNA (mRNA) profiles of various cytokines, chemokines and adhesion 
molecules, within the murine CNS following various treatment regimens, were 
investigated. At sacrifice the animals were perfused with approximately 150ml of sterile 
0.9% saline by cardiac perfusion via the left ventricle, to remove any peripheral blood from 
the brain tissue. Each brain was carefully dissected from the skull and homogenised in 5ml 
of denaturing solution by several triturations thi'ough a sterile 20-gauge needle. The 
resulting homogenate was aliquoted into DEPC-treated 1.5ml micro-centrifuge tubes and 
stored at -20^C until required.
2.5.3. RNA extraction
Total RNA was extracted from brain tissue using a modified acid guanidium-thiocyanate 
phenol chloroform (AGPC) method (Chomczynski and Sacchi, 1987). The RNA was 
extracted from a total of 1ml of whole brain tissue / denaturing solution homogenate. Two
Al The formulation for this solution is describe in Appendix 1
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500pl aliquots of the homogenate were placed into 1.5ml micro-centrifuge tubes. 50pl of 
2M sodium acetate, pH 4.0^', 500pl of O.IM citrate buffer saturated phenol (pH 4.3) 
(Sigma) and 100pi of chloroform : isoamyl-alcohol (49:1) were added sequentially to each 
tube. Chloroform used in conjunction with phenol improves the efficiency of the nucleic 
acid extraction. Chloroform helps both to denature the protein and to remove lipid. Also, 
because of its high density, chloroform assists in the separation of the organic and aqueous 
portions of the mixture. Isoamyl-alcohol is added to the solution to help to prevent 
foaming of the mixture. The acid pH is an important factor in the success of this method 
as RNA remains water soluble in a solution containing 4M guanidium-thiocyanate at pH 4. 
Under these acid conditions most proteins and fragments of DNA separate into the organic 
phase of the mixture. This acidic environment is maintained by the presence of the sodium 
acetate pH 4 and the citrate buffer pH 4.3 used to saturate the phenol (Ausubel, Brent, 
Kingston, Moore, Seidman, and Smith, 1987)
After vortexing thoroughly the samples were incubated on ice for 15 minutes. Following 
this incubation the tubes were centrifuged at 12,000g for 20 minutes at 4^C to separate the 
aqueous and organic phases. The aqueous upper phase, containing the RNA, was then 
transferred to fresh 1.5ml micro-centrifuge tubes. The flocculent interphase and lower 
organic phase containing the proteinaceous material was discarded. The RNA was initially 
precipitated from the solution by the addition of 1ml of cold isopropanol and subsequent 
incubation at -70°C for 1 hour. The samples were then centrifuged as before, the 
supernatant was discarded and the resulting pellet resuspended in 15 Dpi of denaturing 
solution. At this point the RNA-denaturing solution mixture resulting from the two 
original 500pl aliquots were amalgamated into a single tube and precipitated with 2 
volumes of cold ethanol. Following another incubation at -70°C for 1 hour the samples 
were centrifuged at 12,000g for 20 minutes at 4^C as previously described. After 
centrifugation the pellet was resuspended in 1ml of 70% ethanol. The sample was then 
centriftiged as before and the 70% ethanol wash procedure repeated. Following this final 
wash step the ethanol was carefully discarded and the tube covered with perforated 
pai'afilm. The sample was allowed to stand at room temperature for approximately 1 hour 
to permit the evaporation of any residual ethanol. However, the newly extracted RNA was 
not allowed to dry out completely as this greatly decreases its solubility. When the pellet 
appeared ‘dry’ the RNA was dissolved in 60pl of DEPC-treated sterile water. If necessary 
the sample was incubated at 55^C for 20-30 minutes to aid dissolution of the RNA. The 
sample was then stored at -20^C until required.
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2.5.4. RNA quantification
The concentration of the extracted RNA was calculated by measuring the optical density of 
a 1 in 100 dilution of the original sample. This was prepared by the addition of Ipl of the 
sample to 9 9 pi of sterile water. The sample was placed in a quartz micro cuvette and the 
optical density assessed. The spectrophotometer was zeroed using water as a blank. The 
optical density of the sample was then measured at both 260nm (OD260) and 280nm 
(OD28 0) wavelengths. The puiity of the RNA sample was evaluated by calculating the 
OD2 60/OD280 ratio. Pure RNA yields a ratio of 2.0 therefore a ratio of 1.7 or higher was 
considered to be of an acceptable purity to allow further analyses. The concentration of the 
RNA, expressed in pg/ml, was calculated by multiplying the OD260 by 40 and correcting 
for the dilution factor. This information was used to prépaie a Ipg/pl RNA solution by 
dilution of the original sample with DEPC water as appropriate.
2.6. Reverse-Transcriptase Polymerase-Chain 
Reaction
The reverse-transcriptase polymerase-chain reaction (RT-PCR) procedure combines the 
technique of ‘reverse-transcription’ with the amplification of specific DNA sequences via 
the ‘polymerase-chain reaction’ (PCR). The expression of genes within tissues can be 
followed using this procedure since it allows the production of individual mRNAs to be 
detected in a sensitive and specific mamier under virtually all conditions.
2.6.1. Reverse-transcription
Under normal circumstances in the cell when a gene is expressed, DNA is transcribed into 
RNA and the RNA is translated into protein. Reverse transcriptase, an enzyme that is 
present in retroviruses, facilitates the synthesis of a complementary DNA (cDNA) 
molecule from an RNA template, the ‘reverse’ of the process found in the normal cell 
cycle.
Before an extracted RNA sample can be amplified by PCR it has to be tianscribed into a 
cDNA molecule. This step is carried out by the reverse-transcriptase enzyme described 
above and requires the presence of the RNA sample, dNTPs, and primers. Reverse- 
transcriptase is a RNA-dependent DNA polymerase that recognises single stranded RNA
4 5
as a template. The enzyme elongates primers bound to the template by incorporation of 
dNTPs to synthesise the new cDNA strand. The primers can be of a specific sequence that 
will anneal to a particular* region of the RNA molecule, oligo(dT) that will anneal to the 3’- 
poly-adenylated tail of mRNA or random primers. Random primers are short 
oligonucleotides, typical hexamers, which anneal randomly to the RNA molecule 
providing multiple sites to ‘prime’ the start of the reverse transcription process. This non­
specific priming reaction results in the conversion of the entire population of RNA into 
cDNA. The resulting cDNA can then be amplified with any specific PCR primers of 
interest allowing numerous different assays to be performed from only one reverse 
transcriptase reaction. If a specific primer is used the cDNA generated will only be of use 
in one particular PCR analysis.
2.6.2. PCR background information
The PCR teclinique was invented by Mullis and colleagues at the Cetus Corporation 
(Mullis and Faloona, 1987) although the principles behind the procedure had been 
described over a decade earlier (Kleppe, Ohtsuka, Kleppe, Molineux et a l, 1971; Panet 
and Kliorana, 1974). PCR allows the rapid in vitro amplification of specific DNA 
sequences thi'ough the use of primers that bind specifically to individual sequences on a 
DNA molecule and the subsequent extension of those primers to form new molecules of 
DNA that are complementary to the original strand. Amplifying the number of copies of a 
specific DNA species of interest allows the molecule to be easily detected or purified for 
use in further studies.
The theoretical basis of PCR is represented schematically in Figure 2.3. The template or 
sample DNA must be free from chemicals that would inhibit the reaction such as detergent, 
EDTA or phenol and the integrity of the molecule must be intact over the length of the 
sequence to be amplified with no nicks or breaks in the sequence.
The main requirements for the PCR ai*e; dNTPs, the DNA polymerase enzyme, specific 
primers, a DNA template {le. the sample under test) and a reaction buffer containing 
magnesium ions. The dNTPs provide both the energy and the nucleosides for the 
production of the new DNA molecule and ai*e supplied in excess. This allows the synthesis 
step to be repeated as necessary without the exhaustion of the dNTPs limiting the 
amplification reaction. A DNA-dependent DNA polymerase enzyme carries out the 
synthesis of the new DNA molecule. In PCR the most commonly used DNA polymerase
is Taq polymerase, isolated from the bacteria Thermus aquaticus. These bacteria are 
extreme thermophiles and thrive in high temperature environments. The enzyme therefore 
has the advantage of being heat stable and its activity is not reduced by the temperature 
cycling procedures necessary during the PCR. The magnesium ion concentration in the 
reaction buffer affects the performance of the Taq polymerase. In the absence of free 
magnesium ions the enzyme is inactive and conversely excess magnesium reduces the 
fidelity of the Taq polymerase. The optimum magnesium concentration should therefore 
be determined for each PCR reaction. The primers are generally designed as 
oligonucleotides ranging from 18-30 bases in length. Two different primers are used in 
each individual PCR reaction and again these are provided in excess. The nucleotide 
sequences of the primers are complementary to specific regions on each strand of the DNA 
molecule, one primer per strand, lying at a known distance apart. Each primer directs the 
synthesis of the new cDNA molecule, in the 5’ to 3’ direction, by the DNA polymerase 
enzyme. The end result is the de novo synthesis of the DNA flanked by the two primers.
2.6.3. PCR cycling parameters
To perform the PCR reaction a master mix, containing the components described above, 
together with the DNA sample must be subjected to a number of optimised temperature 
cycles. Each step in the cycle requires a minimum amount of time to be effective, however 
too long a period at each stage is not only a waste of time but also can be deleterious to the 
overall PCR. These cycles comprise a dénaturation step, an amiealing stage and an 
extension stage. Each of the steps in the reaction is critical to the success of the technique. 
During the dénaturation period the sample is heated to 94^C, this results in the separation 
of the double stranded DNA in the sample into single stranded DNA (ssDNA) molecules. 
Following this dénaturation the primers can anneal to the ssDNA. The optimal 
temperature for this step varies with the G-C content of the primers used. Primers with a 
low G-C content (<50%) may require relatively low annealing temperatures of 55^C or 
below whereas primers with a high G-C content will require a higher annealing 
temperature. Once the primers have attached to the template the new strand of DNA can 
be synthesised. This is carried out during the extension segment of the cycle. The prime 
temperature for this step in the reaction, when employing Taq polymerase, is 72®C. This is 
close to the optimal temperature for the enzyme (75^C) but is not so hot that the primers 
become detached from the template DNA.
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Figure 2.3. The polymerase chain reaction.
A schematic representation of the amplification pattern that occurs during the 
polymerase chain reaction resulting in the accumulation of a double stranded DNA 
molecule of a discrete size.
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Many PCR protocols include lengthened initial denatuiation and final extension periods. 
The increased initial dénaturation stage ensures that there is no secondary structure in the 
DNA molecule and ensures the complete separation of the two strands. Whereas the 
lengthened extension step attempts to produce final PCR products that are as complete as 
possible, with no bases missing from the ends.
2.6.4. Amplification pattern
During the initial round of synthesis the new DNA molecules produced are of intermediate 
length and like the parental strands can hybridise to the primers (Figure 2.3). These 
intermediate length molecules accumulate at an arithmetic rate during the subsequent 
cycles of dénaturation, amiealing to the primers and synthesis of new DNA. However, 
when these new molecules of DNA are used as the templates in the subsequent rounds of 
the PCR the DNA produced is of a discrete size. The formation of this discrete product 
occurs because the starting point for the synthesis of each of the new DNA strands has 
been determined by position of the primer on the original DNA and therefore no template 
exists beyond the 5’ end of the primer. The amount of the discrete product synthesised 
doubles with each subsequent round of cycling and accumulates exponentially. A PCR 
comprising of 30 cycles should therefore result in a 270 million fold amplification of the 
target DNA (Ausubel et a l, 1987).
2.6.5. Performance of the RT-PCR
By using RT-PCR the expression of various cytokines, chemokines and receptor molecules 
including; TNF-a, IL-la, IL-6, M IP-la, MCP-1, and RANTES was investigated in the 
murine CNS following diverse treatment regimens.
The cDNA template to be used in the subsequent PCR was synthesised by reverse 
transcription of 5pg of total RNA prepared from each brain sample. The reaction was 
performed in a 50pi reaction total volume containing Ix strand buffer (50mM Tiis/HCl, 
pH 8.3; 75niM KCl; 3mM MgCb) (Gibco BRL), lOmM dithiothieitol (DTT), 1.25mM 
deoxynucleoside triphosphates (dNTPs) (Hybaid), 25U RNase inliibitor (Hybaid), lOOU 
Moloney-murine leulcemia virus reverse-transcriptase (M-MLV-RT) (Gibco BRL) and Ipg 
random primers (Gibco BRL).
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To carry out the reverse transcriptase reaction a 5pg aliquot (5 pi of a 5pg/pl stock 
solution) of total RNA was placed into a 200pi thin walled PCR tube and heated to 65®C 
for 5mins on the PCR thermo-cycler. This procedure helps to remove any secondary 
structure present in the RNA molecule and aids the subsequent reverse transcription 
reaction. To prevent the RNA from refolding the tube was immediately transferred to ice 
and 45pi of the reverse transcriptase master mix, as detailed above, was added to the 
sample. The tube was then retunied to the thermo-cycler and incubated for 30mins at 37^C 
followed by a 60 minute incubation at 42^C. After this the temperature was raised to 94^C 
for 5mins to denature the M-MLV enzyme and stop the reaction. The cDNA was then 
stored at -20^C until required for PCR analyses.
The PCR reaction was performed in a 50pl total reaction volume containing; Ix reaction 
buffer (20mM Tris/HCl, pH 8.55; 16mM (NH4)2 S0 4 ; 1.5mM MgCh) (Hybaid-AGS), 
0.5pg 3’primer, 0.5pg 5’primer , 2 units Taq polymerase and 2.5pi of cDNA sample from 
the reverse-transcriptase reaction. No additional dNTPs were required in the reaction mix 
as these were already present in the cDNA aliquot. All PCR primers were coimnercially 
synthesised by MWG-biotech Ltd. The sequences and expected product sizes are detailed 
in Table 2.3. Each primer pair was designed so that the 5’ and 3’ primers would anneal to 
different exons in the target mRNA. This type of primer design allows the amplification of 
mRNA to be easily distinguished from possible amplification of contaminating DNA. The 
PCR products from amplification of DNA would contain the sequence information 
corresponding to the intron segment of the gene. Since this information is omitted from 
the mRNA molecule any products resulting from DNA amplification would be 
significantly larger those resulting from mRNA amplification.
The samples were placed in a Perkin Elmer thermo-cycler and heated to 94^C for 5 mins as 
an initial dénaturation step. The PCR was performed by denaturing the samples for 15 
seconds at 94^C, allowing the primers to anneal for 30 seconds at 60^C and an extension 
step of 90 seconds at 72^C to synthesise the new DNA strand. The samples were subjected 
to 35 cycles* of this heating and cooling procedrne followed by a lengthened final 
extension step of 10 mins at 72^C to allow completion of the synthesis reaction. On 
culmination of the thermo-cycling procedure the samples were removed from the PCR 
block and maintained at 4^C until the products were analysed.
Actin PCR was repeated for 30 cycles only
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2.6.6. PCR controls
Before the RT-PCR teclinique can be used to investigate the expression of any genes the 
integrity of the cDNA produced must be checked. To do this each sample was analysed 
for the presence of the housekeeping gene, p-actin. Housekeeping genes are expressed by 
all tissues at all times at low levels and should yield positive PCR results in all samples. 
They can therefore be used to determine whether the sample is of sufficient quality to 
under go the PCR. A negative p-actin PCR would indicate that the initial RNA was not 
adequately extracted and should not be used in subsequent PCR analyses.
Due to the highly sensitive nature of the PCR the inclusion of negative and positive 
controls is essential to the teclinique. In each PCR experiment one known positive sample 
and one negative control, that contains all the components of the PCR reaction with the 
exception of the template DNA, were included with the test samples. These controls 
demonstrate respectively that the PCR is functioning satisfactorily and that no 
contamination of the samples by extraneous material has occurred.
2.6.7. Analysis of RT-PCR products
The RT-PCR products are double stranded DNA molecules of a discrete length defined by 
the position of the primers. These molecules can be separated according to their size by 
electrophoresis tluough a 2% agarose gel. As DNA molecules have a slight overall 
negative charge they migrate tlu'ough the agarose towards the positive electrode. The rate 
of passage tlii'ough the agarose is primarily determined by their molecular weight with the 
smaller molecules travelling more quickly through the gel than the larger heavier 
molecules. The products can be visualised in the gel by the addition of ethidium bromide, 
a dye that intercalates between the DNA strands and fluoresces under ultraviolet 
illumination. The ethidium bromide can be added to the molten gel at a final concentration 
of 1 pg/ml or the gel can be stained following the electrophoresis by the addition of the 
ethidium bromide to the buffer. Ethidium bromide is a known carcinogen therefore great 
care was taken when preparing the working solution. To avoid having to weigh the 
powder lOOmg vials of the dye were purchased and 10ml of distilled H2 O added to give a 
lOmg/ml working solution.
To allow the size of the PCR products to be calculated a lOObp DNA molecular weight 
ladder (Gibco BRL) was added to the first lane in each gel. This ladder comprises 15
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Primer target Nucleic acid sequence Band Size
y  P-actin* CTC TTT GAT GTC ACG CAC GAT TTC 540bp5’ p-actin* GTG GGC CGC TCT AGG CAC CAA
3’ IL-la* AGG TCG GTC TCA CTA CCT GTG ATG AGT TTT GG 491 bp5’ IL-la* AAG ATG TCC AAC TTC ACC TTC AAG GAG AGC CG
3’ IL-6* 
5’ IL-6*
CAC TAG GTT TGC CGA GTA GAT CTC 
ATG AAG TTC CTC TCT GCA AGA GAC 638bp
3’ TNF-a* GTA TGA GAT AGC AAA TCG GCT GAC GGT GTG GG 354bp5’ TNF-a* TTC TGT CTA CTG AAC TTC GGG GTG ATC GGT CC
3’ MIP-la* TCA GGC AAT CAG TTC CAG GTC AGT GAT GTA TTC 279bp5’ MIP-la* ATG AAG GTC TCC ACC ACT GCC
3’ RANTES* 
5’ RANTES*
ACT TCT TCT CTG GGT TGG CAC 
GCT GCC CTC ACC ATC ATC CTC 222bp
3’ MCP-1* 
5’ MCP-1*
GTC ACA CTG GTC ACT CCT AC 
AGA GAG CCA GAC GGA GGA AG 519bp
Table 2.3. Oligonucleotide primers sequences. The nucleotide sequence of the 
oligonucleotide primers used in the RT-PCR analyses performed in these investigations are 
detailed together with the expected product sizes. * Primers synthesised from commercially 
prepared Clonetech primer sequences. ^Primer sequence taken from Godiska, Chantry, 
Dietsch, and Gray, 1995.
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blunt-ended fragments of DNA ranging from lOObp to ISOObp in length, rising in 
increments of lOObp with an additional fragment at 2072bp. The 600bp band in this ladder 
appears more brightly stained than the other fragments and provides a source of internal 
orientation if incomplete separation of the larger bands or loss of the smaller markers 
occiu’s. The commercial ladder was diluted 1 in 10 with PCR loading buffer'^' and NaCl 
added to a final concentration of 20mM before use. The prepared ladder was aliquoted 
into 50pl volumes and stored at -20*^ C. A 5pl aliquot of this working solution was used on 
each gel.
The gels were prepared by melting the required amount of agarose (2g/100ml) in tris- 
borate-electophoresis buffer (TBE)" '^ in the microwave with constant supervision to 
prevent the solution from boiling over. The ethidium bromide was added to the gel and the 
molten agarose poui'ed into a horizontal gel bed fitted with a medium toothed comb to 
form the sample wells and allowed to cool. Once solidified the comb was removed from 
the gel and the electrophoresis tank filled with TBE until the gel was covered. The 
samples were added to the wells and electrophoresed through the gel at 70 volts with a 
constant current of 0.35 amps. The rate of diffusion through the gel was monitored by the 
inclusion of 5pi of PCR loading buffer with each 15 pi sample of PCR product before 
loading on to the gel. The electrophoresis was stopped once the dye front had travelled 
approximately 8cm tlirough the agarose and the gel examined using an ultraviolent 
transilluminator. The gel was photographed as a permanent record and the size and 
comparative brightness of the bands noted.
2.6.8. Relative quantification of results
Theoretically, due to the exponential nature of the PCR there is a linear relationship 
between the number of cycles performed and the logaritlun of the number of molecules 
produced. However in practice several factors including competitive reactions, substrate 
exhaustion and inactivation of the polymerase enzyme, result in a decrease in efficiency of 
the amplification. Therefore, as the number of cycles increases the efficiency of the 
reaction decreases eventually producing a plateau effect. If the PCR products are to be 
analysed in a semi-quantitative fashion the reaction must be terminated during the 
exponential phase of the amplification. To ensure that this was case, PCR was performed 
and terminated after 20, 25, 30, 35, 40 and 45 cycles for each of the primer sets with the 
exclusion of (3-actin. For this primer pair the niunber of cycles ranged between 15 and 40.
The formulation for this solution is describe in Appendix 1
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These preliminary reactions showed that the PCRs, with the exception of (3-actin, were still 
in the exponential phase of the amplification after 35 cycles and had not reached the 
plateau stage (Figures 2.4 to 2.9). Therefore these PCRs were terminated following 35 
rounds of amplification to permit the results to be assessed in a semi-quantitative mamier. 
P-actin, however, reached the plateau stage earlier than the other primer pairs and this PCR 
was therefore performed with only 30 reaction cycles (Figure 2.10).
As each PCR was terminated during the exponential phase of amplificaton and since all the 
RT-PCR analyses were performed on a standard amount of both RNA starting material and 
resultant cDNA the results can be interpreted in a semi-quantitative manner. This 
experimental design allows comparisons to be made between the relative amounts of a 
specific PCR product by grading the brightness of the resulting PCR band on the agarose 
gel. The scale used to grade the intensity of the PCR bands is shown in Figure 2.11. This 
can be equated to the relative amount of target present in the original sample. However, 
these comparisons only apply within primer sets and cannot be made between different 
primers.
2.7. Statistical analyses
The data generated during these investigations was analysed using proprietary statistical 
analysis software. A range of descriptive hypothesis testing and estimation methods was 
used. Both parametric and non-parametric tests were employed depending on whether the 
response variables were measured on an interval or ordinal scale respectively. The 
analyses required depended on the experimental design and nature of data set generated. 
Therefore, the statistical tests are described in detail in each chapter of this thesis as 
appropriate. All statistical analyses undertaken in this investigation were performed with 
advice from Prof. George Gettinby, Department of Statistics and Modelling Science, 
University of Strathclyde, Glasgow.
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Figure 2.4. TNF-a banding pattern resulting from increasing amplification 
cycles. Photograph o f an ethidium bromide stained, 2% agarose gel showing the TNF-a 
reaction products following increasing numbers o f PCR amplification cycles. A lOObp 
ladder has been included to assess the size o f the resultant PCR bands (lane 1). PCR 
amplification was performed for 20 (lane 2), 25 (lane 3), 30 (lane 4), 35 (lane 5), 40 
(lane 6) and 45 (lane 7) cycles. A negative control (-ve) (lane 8) comprising the PCR 
master mix and water in place o f the cDNA template is shown following 45 cycles o f the 
PCR reaction (lane 9). The increasing intensity o f  the resultant bands demonstrate that the 
PCR is in the exponential phase o f  o f the reaction following 35 cycles o f  amplification.
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Figure 2.5. IL-1a banding pattern resulting from increasing amplification 
cycles. Photograph of an ethidium bromide stained, 2% agarose gel showing the IL -la  
reaction products following increasing numbers of PCR amplification cycles. A lOObp 
ladder has been included to assess the size of the resultant PCR bands (lane 1). PCR 
amplification was performed for 20 (lane 2), 25 (lane 3), 30 (lane 4), 35 (lane 5), 40 
(lane 6) and 45 (lane 7) cycles. A negative control (-ve) (lane 8) comprising the PCR 
master mix and water inplace of the cDNA template is shown following 45 cycles of the 
PCR reaction (lane 9). The increasing intensity of the resultant bands demonstrate that 
the PCR is in the exponention phase of the reaction following 35 cycles of amplification.
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Figure 2.6. IL-6 banding pattern resulting from increasing amplification 
cycles . Photograph of an ethidium bromide stained, 2% agarose gel showing the IL-6 
reaction products following increasing numbers of PCR amplification cycles. A lOObp 
ladder has been included to assess the size of the resultant PCR bands (lane 1). PCR 
amplification was performed for 20 (lane 2), 25 (lane 3), 30 (lane 4), 35 (lane 5), 40 
(lane 6) and 45 (lane 7) cycles. A negative control (-ve) (lane 8) comprising the PCR 
master mix and water inplace of the cDNA template is shown following 45 cycles of the 
PCR reaction (lane 9). The increasing intensity of the resultant bands demonstrate that 
the PCR is in the exponention phase of the reaction following 35 cycles of amplification.
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Figure 2.7. MIP-1a banding pattern resuiting from increasing amplification 
cycles . Photograph of an ethidium bromide stained, 2% agarose gel showing the M IP-la 
reaction products following increasing numbers of PCR amplification cycles. A lOObp 
ladder has been included to assess the size of the resultant PCR bands (lane 1). PCR 
amplification was performed for 20 (lane 2), 25 (lane 3), 30 (lane 4), 35 (lane 5), 40 
(lane 6) and 45 (lane 7) cycles. A negative control (-ve) (lane 8) comprising the PCR 
master mix and water inplace of the cDNA template is shown following 45 cycles of the 
PCR reaction (lane 9). The increasing intensity of the resultant bands demonstrate that 
the PCR is in the exponention phase of the reaction following 35 cycles of amplification.
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Figure 2.8. MCP-1 banding pattern resuiting from increasing aniplification 
cycles. Photograph of an ethidium bromide stained, 2% agarose gel showing the MCP-1 
reaction products following increasing numbers of PCR amplification cycles. A lOObp 
ladder has been included to assess the size of the resultant PCR bands (lane 1). PCR 
amplification was performed for 20 (lane 2), 25 (lane 3), 30 (lane 4), 35 (lane 5), 40 
(lane 6) and 45 (lane 7) cycles. A negative control (-ve) (lane 8) comprising the PCR 
master mix and water inplace of the cDNA template is shown following 45 cycles of the 
PCR reaction (lane 9). The increasing intensity of the resultant bands demonstrate that 
the PCR is in the exponention phase of the reaction following 35 cycles of amplification.
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Figure 2.9. RANTES banding pattern resulting from increasing amplification 
cycles. Photograph of an ethidium bromide stained, 2% agarose gel showing the 
RANTES reaction products following increasing numbers of PCR amplification cycles. 
A lOObp ladder has been included to assess the size of the resultant PCR bands (lane 1). 
PCR amplification was performed for 20 (lane 2), 25 (lane 3), 30 (lane 4), 35 (lane 5),
40 (lane 6) and 45 (lane 7) cycles. A negative control (-ve) (lane 8) comprising the PCR 
master mix and water inplace of the cDNA template is shown following 45 cycles of the 
PCR reaction (lane 9). The increasing intensity of the resultant bands demonstrate that 
the PCR is in the exponention phase of the reaction following 35 cycles of amplification.
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Figure 2.10. g-actin banding pattern resulting from increasing amplification 
cycles. Photograph of an ethidium bromide stained, 2% agarose gel showing the P-actin 
reaction products following increasing numbers of PCR amplification cycles. A lOObp 
ladder has been included to assess the size of the resultant PCR bands (lane 1). PCR 
amplification was performed for 15 (lane 2), 20 (lane 3), 25 (lane 4), 30 (lane 5), 35 
(lane 6) and 40 (lane 7) cycles. A negative control (-ve) (lane 8) comprising the PCR 
master mix and water in place of the cDNA template is shown following 40 cycles of the 
PCR reaction. The increasing intensity of the resultant bands demonstrate that the PCR is 
in the exponential phase of of the reaction following 30 cycles of amplification.
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PCR value 0.5
PCR value 1.0
PCR value 1.5
PCR value 2.0
PCR value 2.5
PCR value 3.0
PCR value 3.5
PCR value 4.0
Figure 2.11. Grading scale used to score intensity of PCR amplicon.
The banding pattern illustrated above is a composite figure prepared from a variety o f PCR 
products, visualised on a 2% agarose gel stained with ethidium bromide. The figure 
illustrates the scoring system o f  0 to 4, employed in grading the intensity o f the amplicons 
resulting from the PCR analyses used in this investigation.
C h a p t e r  3 
T r y p a n o s o m e - in d u c e d  c e l l u l a r  im m u n e
REACTIVITY WITHIN THE CNS
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3.1. Introduction
During the late-stage of human African trypanosomiasis, the presence of the pai’asites in 
the brain induces an inflammatory reaction within the CNS. This inflammatory reaction 
can be exacerbated by subcui'ative chemotherapy resulting in an extremely severe 
meningoencephalitis, known as the post-treatment reactive encephalopathy (PTRE). This 
reaction is characterised by the presence of macrophages, T-cells, B-cells and plasma cells 
within the meninges, perivascular spaces and brain parenchyma. The pathogenesis of this 
response remains unknown. Before the mechanisms and kinetics resulting in this 
inflammatory cell infiltration of the CNS can be investigated an appreciation of the 
complexity of the immune response is vital. Therefore, the evolution of an inflammatory 
reaction within the brain and the infiltration of the CNS by inflammatory cells will be 
discussed. In addition, the information cuiTently available regarding the cellular 
components identified in the CNS following trypanosome infection and the development 
of the PTRE will be detailed.
3.1.1. The inflammatory response
Human beings and other complex organisms respond to tissue injmy, infection and 
neoplastic change tlirough the process of inflammation. The primary function of this 
reaction is to protect the integrity of the organism and maintain the complex internal 
balance on which life depends. The immune response has been well characterised in the 
peripheral tissues and relies heavily on the trafficking of leucocytes, the most common and 
widely recognised component of the immune system, into the affected tissues and the 
subsequent initiation of appropriate effector mechanisms.
There are various cell types which belong to the leucocyte category, including, phagocytic 
cells such as monocytes / macrophages and polymorphonuclear granulocytes. These cells 
generally use a non-specific recognition system that allows them to bind to a variety of 
microbial products before internalising and destroying them. Consequently, they constitute 
the basis of the innate immune system and hold infections in check until the body can 
mount a specific or acquired immmie response against the pathogen or foreign material. In 
addition, some of these cells can act as antigen-presenting cells (APC’s) and are 
responsible for presenting antigens to a second group of leucocytes, loiown as 
lymphocytes, which includes both T-cells and B-cells. This antigen presentation process 
initiates the specific immune reaction and primes the lymphocytes to recognise particular
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antigenic molecules in a highly specific manner. Although these separate groups of 
leucocytes have been identified, there is a constant interplay between the sets with each 
cell type interacting with and controlling the actions of the other cell types. This results in 
a complex milieu of responses all designed to protect the organism from harm.
3.1.1.1. Innate immunity
The innate or natural immune response is controlled by various factors that are present in 
an organism from birth. The response is relatively non-specific and operates against a 
wide range of substances. No prior exposure to a pathogen is necessary to stimulate the 
innate immune response and the cells are immediately available to combat the unfamiliar 
substance. Therefore, this type of immune reaction forms the basis of an organism’s first 
line of defence against disease and foreign particles. The key cell types involved in innate 
immunity are; the monocytes / macrophages, the polymorphonuclear granulocytes 
including, neutrophils, eosinophils, basophils and mast cells; and the natural killer cells. 
As polymorphonuclear granulocytes and natural killer do not play a major role in the CNS 
inflammatory response to trypanosome infection these will not be described further.
3.1.1.1.1. Monocytes /  macrophages
Blood monocytes are produced from myeloid progenitor cells in the bone marrow and 
constitute a circulating pool of cells within the blood stream. The blood monocytes 
migrate through the blood-vessel walls into various organs and tissues and there 
differentiate into macrophages. Since blood monocytes are more easily obtained than 
macrophages many studies have been earned out utilising this cell type and their responses 
extrapolated to macrophages. Human blood monocytes are approximately 10-18pm in 
diameter and contain a horseshoe shaped nucleus. In addition the cells often hold faint 
azurophilic granules and many intracytoplasmic lysosomes. These lysosomes contain 
various enzymes, including, peroxidase and acid hyaluronidases that are important in the 
killing of microorganisms following their phagocytosis (Roitt, Brostoff, and Male, 2001).
To help them recognise and adhere to invading microorganisms monocytes / macrophages 
have a variety of cell surface receptors. One of the principle stimulators of the imiate 
immune system is lipopolysaccharide (LPS). LPS forms a component of the cell wall of 
many bacteria and is therefore a good target for a non-specific defence mechanism. 
Monocytes / macrophages express CD 14 on their cell surface, this receptor binds LPS, in
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conjunction with the serum protein, lipopolysaccharide-binding-protein, triggering an 
inflammatory reaction. Mamiosyl-fucosyl receptors (MFR) are also present on monocytes 
/ macrophages. These recognise and bind to sugars that are commonly found on the 
surface of microorganisms. In the body, pathogens can become coated with specific 
antibody and complement components. This renders the pathogen more attractive to 
phagocytic cells and allows them to be killed more readily. The attacliment of the 
phagocytic cells to the coated pathogen is facilitated by the presence of three distinct 
receptors for the Fc portion of the IgG and a receptor for the C3b component of 
complement on the monocyte / macrophage cell suiface. The tlnee isoforms of the Fcy 
receptors in humans are FcyRI (CD64), FcyRII (CD32) and FcyRIIl (GDI6); they have 
high, medium and low affinities, respectively, for the Fc portion of IgG. The equivalent 
murine homologues to these Fcy receptors are FcyRIIa, FcyRIIb/1 and FcyRIIIlo. If any of 
these cell suiface receptors are activated the monocyte / macrophage extends its cell 
membrane into pseudopodia that surround the bound microorganism forming a 
phagosome. Lysosomes then fuse with the phagosome to form a phagolysosome, and the 
infectious agent is killed (Janeway and Travers, 1996; Roitt et a l, 2001).
Monocytes / macrophages also have specialised cell surface receptors that bind IgE, these 
are known as FceRl. However, the binding of IgE does not activate the cell and this 
process only occurs when the attached IgE is cross-linked by binding to a multivalent 
antigen. Stimulation of the receptors in this manner results in the externalisation of the 
cytoplasmic vesicles and the killing of the pathogen in the external matrix.
Adhesion molecules, including, leucocyte function antigen (LEA) can also be found on the 
surface of monocytes /macrophages. These are important in the transmigration of the cells 
from the vasculature into specific organs. In addition monocytes / macrophages express 
receptors for a variety of cytokines and can therefore be ‘activated’ by T-cell derived 
mediators leading to increased phagocytosis and microbicidal activity (Janeway and 
Travers, 1996; Roitt et a l, 2001).
A number of monocytes / macrophages express major histocompatability (MHC) antigens, 
these are necessary for the presentation of antigen to specific sets of lymphocytes. 
Professional APC’s form a varied population of leucocytes. These cells can process 
antigens and display peptide fragments on their cell surface in conjunction with surface 
molecules to initiate lymphocyte activation.
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3.1.1.2. Acquired immunity
Acquired immunity is a more specialised form of immune response than innate immunity 
and is only present in vertebrates. The main difference between innate and acquired 
immimity is the ability of lymphocytes to recognise particular antigens in a specific 
manner. This is made possible tlii'ough the presence of cell surface receptors on the 
lymphocytes that recognise discrete parts of an antigen. These parts are known as 
antigenic determinant groups or epitopes. An acquired immune response results as a 
consequence of an encounter with a foreign substance displaying these epitopes. This 
triggers a chain of events which lead to a specific reaction against that particular 
component. Therefore, as the name suggests, acquired immunity develops only after the 
organism has encountered a specific antigen and in some cases can confer a life-long 
protective immunity to re-infection with the same pathogen. Although the acquired 
immune response appears in many ways superior to innate immunity the reaction is in fact 
highly dependent on the cells of the innate immune system and could not operate if they 
were not present. The two main cell types associated with the acquired immune response 
are the T-lymphocytes or T-cells, including CD4^ and CD8  ^ cell subsets, and the B- 
lymphocytes or B-cells. Both cell types have cell surface receptors that allow them to 
recognise specific antigen. However, the functions of the T-cells and B-cells are 
dissimilar.
3.1.1.2.1. T-lymphocytes
T-cells are derived from bone marrow stem cells and their progenitors migrate to the 
thymus early in the development process. Here the immature T-cells or thymocytes 
proliferate intensely and differentiate into mature T-cells. In mice, only around 2% of the 
thymocytes generated reach maturity and the remainder die, mainly tlirough apoptosis, 
within the thymus. This massive cell death is a necessary step in the development of the 
mature T-cells as they undergo intense screening for MHC restriction and self-tolerance 
before they can be exported to the periphery. As the thymocytes mature they pass tlirough 
distinct phases. Each stage in this process is marked by the expression of distinctive cell 
sui’face molecules.
3.1.1.2.1.1. CD4^ T-cells
T-cells that carry the CD4 siuTace marker mainly perform functions that ‘help’ or ‘induce’ 
an immune reaction and are therefore known as T-helper (Th) cells. These Th-cells can be
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further divided into at least two additional subgroups, Thl and Th2. The subgroups can be 
distinguished by the array of cytokines that they produce, Thl cells are particularly 
important for the eradication of intracellular pathogens including bacteria, parasites, yeast 
and viruses and will react to antigen only if it is presented in conjimction with MHC class 
II molecules. They typically express the cytokines IL-2, IFN-y and lymphotoxin which can 
activate further cytokine production by macrophages and stimulate microbicidal activity as 
well as inducing opsinization and complement fixation. In addition a Thl response can 
result in the activation of NK-cells and CDS T-cells (Lee, Kum, Cockram, Teoh et a l, 
1989; Mosmann and Sad, 1996). Th2 cells produce cytokines that induce B-cell 
proliferation, antibody production and eosinophil and mast cell activation. The cytokines 
expressed by the Th2 cells including IL-4, IL-5, IL-6 and IL-10. Consequently, Th2 cells 
primarily mediate functions associated with protecting the organism from free-living 
pathogens. Hence Thl cells are predominantly associated with cell-mediated immunity 
while Th2 cells induce strong antibody and allergic responses. Not only do these Thl and 
Th2 cell subset induce different effector pathways they also tend to hamper the 
development of the opposite cell type. Therefore, Thl cells tend to inhibit the actions of 
Th2 cells and Th2 cells tend to inhibit the actions of Thl cells. For example IL-10 
production by Th2 cells inhibits IFNy production by Thl cells and prevents subsequent 
macrophage activation while IFNy production by Thl cells inhibits the proliferation of Th2 
cells (Janeway and Travers, 1996).
However, this demarcation of cytokine production is not comprehensive since some Th- 
cells express cytokine profiles that overlap both Thl and Th2 cell subsets. These cells are 
known as ThO cells and can produce both the Thl cytokine IFNy and the Th2 cytokine IL- 
4. ThO cells are thought to be in a less differentiated state that Thl or Th2 cells and appear 
to occur when certain polarising signals are not present following T-cell activation. ThO 
cells can potentially develop into either Thl or Tli2 cell phenotypes and are therefore 
considered to be an intermediate stage in T-cell maturation (Janeway and Travers, 1996). 
The factors that determine whether a proliferating T-cell will become a Thl or a Th2 cell 
are not fully understood. However, it appears many inter-locking factors including the 
type of co-stimulatory signal resulting in the initial proliferation, the nature of the 
MHCipeptide complex stimulating the response as well as the presence of various 
cytokines in the vicinity of the T-cell all have an effect in the final outcome of the 
differentiation (Janeway and Travers, 1996; Roitt et a l, 2001).
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3.I.I.2.I.2. CD8  ^T-cells
T-cells that express the CDS cell surface marker are predominantly cytotoxic in function 
and are therefore known as T-cytotoxic (Tc) cells. There are no sub-divisions in this class 
of T-cell and naïve CD8  ^ T-cells can differentiate only into cytotoxic cells. The CD8^ 
cells perform a crucial role in the elimination of intracellular pathogens such as viruses and 
certain bacteria. Once inside the cells these pathogens ai’e not accessible to antibodies and 
can therefore only be destroyed by killing the infected cell.
When activated Tc-cells recognise pathogen derived peptides, in conjunction with MHC 
class I molecules, they inducing the cell to enter apoptosis resulting in the death of the 
infected cell. Following induction of the apoptotic pathway the Tc-cell disengages from 
the target cell and can recycle to kill multiple infected cells. The principle method tlirough 
which Tc-cells function involves the release of perforin and enzymes that induce apoptosis 
in the target cell. Tc-cells do not require the target cell to be coated with immunoglobin 
and will only kill a target cell if it can recognise the antigen specified by its T-cell receptor 
(TCR), presented on MHC class I molecules. Once dead the cellular debris attracts 
mononuclear cells that rapidly clear the cell fragments by phagocytosis. Tc-cells and NK- 
cells act in a complementary fashion. NK-cells survey the body to ensure all cells display 
MHC class I molecules and Tc-cells check the antigen tag associated with the MHC 
molecule. This double-checking process is of great importance in the body’s defence 
against certain viruses that have evolved mechanisms of avoiding detection by Tc-cells. 
These viruses reduce the cellular expression of MHC class I molecules to try and prevent 
their antigens from being displayed to the immune cells. However, this lack of MHC class 
I expression leaves the infected cells open to attack by NK-cells (Roitt et a l, 2001).
Alternative mechanisms for inducing apoptosis in their target cells are also employed by 
Tc-cells. Tc-cells can signal to their target cells via membrane bound receptors belonging 
to the TNF group of molecules. These receptors include, Fas (CD95) and the TNF type 1 
receptor (TNFR-1) (CD 120a). Another member of this TNF receptor family is the CD40 
molecule necessary for induction of expression of the co-stimulatory molecules B7.1 and 
B7.2 on B-cells. Mature Tc-cells and some activated CD4’*’ cells express the ligand for Fas 
(FasL). Both Fas and TNFR-1 have ‘death’ domains attached to the cytoplasmic region of 
the molecule that are involved in the recruitment of caspases. Caspase enzymes have an 
extensive remit and are involved in intracellular signalling, cell cycle control, DNA 
integrity and repair and intracellular adhesion. If the Fas receptor is bound to the FasL this 
induces a conformational change in the Fas receptor that subsequently recruits and
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activates caspases 8 and 10. The actions of these enzymes then lead to apoptosis of the 
target cell (Roitt et a l, 2001).
3.1.1.2.2. B~lymphocytes
Many human diseases result from infection with pathogens that multiple either in the 
extracellular spaces of the body or survive as intracellular forms that spread by moving 
from cell to cell tlnough the extracellular fluids. One of the main mechanisms employed 
by the host immune system to prevent the proliferation of these pathogens is the production 
of specific antibodies that bind to the antigens displayed by the infective agent. Coating of 
the pathogens with antibody facilitates their destruction by phagocytes and NK-cells. 
Intracellular' pathogens can become covered in antibody while moving between cells. 
These bound antibodies can prevent the pathogen from entering the new host cell and are 
therefore said to ‘neutralise’ the pathogen. The antibodies responsible for protecting the 
host in this fashion are produced by the B-lymphocytes or B-cells (Janeway and Travers, 
1996; Roitt et a l, 2001).
Like T-ceils, B-cells develop in the bone marrow. However, in contrast to T-cells the B- 
cells also mature in the bone mai'row before entering the bloodstream and migrating to the 
peripheral lymphoid organs. The naïve mature B-cells can only smvive in the periphery 
for a few weeks before they are killed by entering apoptosis. However, if these B-cells 
encounter the antigen specified by their cell suiface immunoglobin they become activated, 
proliferate and differentiate into plasma cells or memory B-cells (Roitt et a l, 2001).
B-cells comprise approximately 5-15% of the circulating lymphocyte population and can 
be defined by the presence of cell surface IgM and IgD. The antigen binding sites of all 
the immunoglobin molecules expressed on the surface of individual B-cells are identical. 
Therefore, a particular B-cell will only react with one distinct antigen and will ultimately 
produce only that antibody. However, many forms of antibody are expressed within the B- 
cell population. The B-cell surface antibody is associated with additional molecules that 
consist of disulphide bonded heterodimers of Iga and Ig|3. This complex of the surface 
antibody with Iga (CD79a) and Igp (CD79b) molecules forms the B-cell antigen receptor 
complex (BCR). The Iga and IgP molecules are thought to couple the surface antibody 
with the intracellular signalling pathways and are involved in the activation of the B-cell. 
In addition, the surface antibody helps to deliver bound antigen to the interior of the B-cell 
where it is processed and retui'ned to the cell surface in conjunction with MHC class II 
molecules for presentation to either naïve or primed T-cells.
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In general, naïve B-cells do not become activated following an encounter with antigen 
alone and require accessory signals to complete the transition from naïve to activated, 
differentiated cells. These accessory signals can be generated by either armed CD4^ cells 
or directly by certain microbial constituents. Therefore, B-cells are said to be activated 
either by a T-cell dependent antigen or by a T-cell independent antigen.
3.1.2. The CNS and ‘immuno-privilege’
Initial microscopic investigations of brain tissue rarely showed the presence of any 
inflammatory cells even following grafting of allogenic tissue into the brain (Hickey, Hsu, 
and Kimura, 1991). This initiated the belief that the brain was devoid of immune 
protection and instigated the concept of ‘immune privilege’ (Slnikant and Benveniste, 
1996; Streit and Kincaid-Colton, 1995).
The principal role of leucocytes is to defend the organism against disease. However, the 
potent substances that they secrete during an inflammatory reaction are also capable of 
destroying or harming neighbouring host cells. If these ‘bystander effects’ were to occur 
within brain tissue the resulting tissue damage could be extremely injurious to the 
organism. The inflammatory response is therefore a double-edged sword; it is vital to the 
survival of the organism but its effects could also be devastating if umestrained. 
Consequently, the passage of leucocytes from the vasculature to the CNS must be 
rigorously controlled. Therefore, the CNS is separated from the rest of the body, including 
the immune system, by the blood-brain barrier (BBB). The concept of such a barrier was 
developed in the early 19^ ’’ century following observations by Edwin Goldmann that dye 
molecules, when injected into the cerebrospinal fluid (CSF) of small animals, readily 
stained the brain tissue but were unable to enter the blood stream to stain the peripheral 
organs (Goldstein and Betz, 1986). It is now known that this barrier controls the 
trafficking of most items, including, nutrients and leucocytes, as well as the exchange of 
inflammatory mediators and antibodies, between the circulation and the CNS (Lassmami, 
Zimprich, Bossier, and Vass, 1991).
3.1.2.1. The blood-brain barrier
Physically the BBB takes two different forms. The first occurs in the endothelium of the 
micro vessels supplying the brain while the second is located in the choroid plexus 
epithelium found within the brain ventricles (Tuomanen, 1996). In contrast to the
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permissive vessels of the peripheral system, which are fenestrated and show active trans­
membrane pinocytosis, the endothelial cells of the cerebral vessels and the epithelial cells 
of the choroid plexus aie ‘joined’ continuously by tight junctions that prevent the passage 
of even small molecules such as dyes and antibiotics into the brain tissue. The barrier 
arising form these modifications is so formidable that specialised transport systems have 
developed to provide the brain with essential nutrients such as glucose, iron and the amino 
acids required to support the tissue behind the barrier (Tuomanen, 1996). These transport 
systems are highly complex and allow the capillary to strictly control the entry and exit of 
substances to and from the CNS. Some of these transporters facilitate osmotic diffusion 
while others are active transport mechanisms that require an energy source to enable 
movement of the compound across the barrier (Goldstein and Betz, 1986).
3.1.2.1.1. The microvascular endothelia! cell barrier
The most extensive site of the BBB can be found in the brain microvessels. As previously 
stated the presence of extremely strong tight junctions between the endothelial cells of the 
vessels and the lack of continuous channels or gaps tlnough the endothelium distinguishes 
this membrane from that foimd in the peripheral micro vasculature. In addition the 
endothelium of CNS microvessels is almost completely simounded by astrocyte foot 
processes. These glial processes were originally thought to constitute the barrier since the 
astrocytes are intimately associated with the endothelial cells (Compston, 1993). However, 
it is now known that tight junctions are not present between the astrocytic cells 
(Tuomanen, 1996) and that the endothelial cells alone establish the barrier. In addition, the 
processes of microglia also contact the brain endothelial cells (Prat, Biernacki, Wosik, and 
Antel, 2001). The exact role of the astrocytes and microglia in relation to the brain 
microvascular endothelial cells remains incompletely understood (Goldstein and Betz, 
1986). However, the function of the tight junctions is known to be influenced by these 
neuroglial cells (Prat et al, 2001) and the permeability of the bairier is increased by up to 
15 fold if the endothelial cells become disengaged from the basement matrix (Tuomanen, 
1996).
3.1.2.1.2. The choroid plexus epithelial cell barrier
The choroid plexus is a highly localised structure found only within the ventricles of the 
brain. Under light microscopy it appeal's as a network of highly branched fronds 
consisting of capillaries and surrounded by a single layer of epithelial cells. These 
epithelial cells form a polarised epithelium similar to that found in the kidney. The choroid
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plexus is responsible for the production of CSF that performs a number of essential 
functions such as supplying the specialised chemical micro-environment of nutrients 
required by the brain tissue. In addition, the CSF provides a certain degree of buoyancy to 
the brain that effectively reduces the true weight of the tissue by up to 30 fold (Spector and 
Johanson, 1989). Although tight junctions join the cells of the choroid plexus epithelium, 
the barrier exhibits a lower electrical resistance than that formed by the endothelial cells of 
the brain microvessels. This allows the passage of some blood components across the 
BBB that are required to form the CSF but this permissiveness also leaves the area more 
exposed to breach by invading organisms (Zhang and Tuomanen, 1999).
3.1.2.1.3. ^Gaps ’ in the barrier
The endothelial cells in the CNS form a continuous barrier throughout the majority of the 
brain microvessels. However, in several small regions of the brain the barrier is 
incomplete and gaps or chamiels traverse the endothelium enabling substances in the blood 
to enter the CNS. Most of these areas are situated close to the ventricle and are therefore 
known collectively as the circumventricular organs (Risau, 1994). Areas that show the 
presence of this Teaky’ barrier include the pituitary gland, the pineal gland and the median 
eminence of the hypothalamus. It is thought that the pathways thiough the endothelium 
are necessary in these ar eas to allow the passage of circulating hormones that must reach 
the neurons in the brain and complete the feedback loop that controls the regulation of their 
secretion (Goldstein and Betz, 1986). In addition, the subfornical organ, the organum 
vasculosum lamina terminalis and the area prostrema show the presence of endothelial 
cells that are fenestrated and do not form tight junctions (Risau, 1994).
3.1.2.2. Immune surveillance within the CNS
As previously stated the CNS has long been considered as an immuno-privileged organ 
due to its innate lack of cells belonging to the peripheral immune system. The BBB not 
only interferes with the passage of these cells into the CNS tissue but also controls the 
exchange of immunological mediators such as cytokines and antibodies between the 
circulation and the CNS. However, under defined circumstances the CNS can mount a 
highly effective immune reaction against invading pathogens or foreign material. 
Therefore intensive research has been carried out in order to characterise the events that 
allow the passage of immune cells into the CNS for purposes of immune surveillance and 
immunological defence (Lassmann et al, 1991).
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3.1.2.2.1. Macrophages in the CNS
The BBB is not impermeable to all cells. In fact it has been shown that there is a constant, 
slow, movement of monocytes into the brain parenchyma which differentiate into 
microglia, pericytes or macrophages within the brain (Flugel and Bradl, 2001; Matyszak, 
1998). In the case of microglia, it seems that most of these cells arrive before birth with 
only a very slow repopulation occurring. However, the resident perivascular cells and 
macrophages are continuously replenished from peripheral sourees (Hickey, 2001). The 
ultimate fate of these cells is still a subject of some debate. It remains unclear whether 
perivascular cells and macrophages can leave the CNS, carrying antigens for presentation 
to peripheral immune cells in the spleen and lymph nodes, and thereby prime the cells to 
antigens sequestered behind the BBB (Hickey, 2001). This would provide a method to 
continuously and effectively monitor the CNS for foreign material. However, experiments 
that directly introduced particulate antigen, which would be taken up by these 
macrophages, into the CNS have failed to induce an immune response to these antigens 
(Hickey, 2001).
3.1.2.2.2. T-ceiis in the CNS
It is also apparent that although resting T-eells are excluded from the CNS, activated cells 
can cross the BBB irrespective of their antigen specificity. The ability of activated T-cells 
to enter the CNS was demonstrated in animals given intravenous injections of activated T- 
cells that were later detected within the brain tissue. This phenomenon explains the 
development of experimental allergic encephalomyelitis (EAE) following intravenous 
injection of activated myelin basic protein (MBP) specific T-cells into healthy recipient 
animals but not following the injection of resting T-cells (Wekerle, Linington, Lassmann, 
and Meyermami, 1986). The results also suggest that under normal circumstances, in the 
healthy brain, the endothelial cells must express the prerequisite moleeules to allow this 
passage to take place.
The exact mechanisms that permit cell traffic tlnough the BBB have yet to be elucidated. 
However, it is thought that the expression of cellular adhesion molecules plays an 
important role in the process. It is known that in the normal brain the endothelial cells of 
the BBB express only low levels of these cellular adhesion molecules. This paucity of 
adhesion molecules may reflect the relatively low numbers of T-cells present in the healthy 
brain when compaied with other body organs (Hickey, 2001). A role for these circulating 
T-cells in the maintenance of the healthy CNS has also been suggested since, when
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activated, these cells can produce a variety of neurotrophic substances that could enhance 
the repair of CNS tissue (Hickey, 2001). As yet, the fate of T-cells entering the CNS, 
which do not encounter their specified antigen, remains unclear. Whether these cells 
recirculate to the periphery or are killed by the induction of apoptosis or by some other 
mechanism inherent to the CNS is unknown at present (Hickey, 2001).
3.1.2.2.3. B~cells in the CNS
The ability of B-cells to enter the CNS appears to follow similar criteria to the influx of T- 
cells since B-cells are known to be present in many pathological processes. It has also 
been shown that if antigen, to which an animal has previously been sensitised, is deposited 
behind the intact BBB, B-cells and plasma cells accumulate at the site of antigen 
introduction. This suggests that B-memory cells in the peripheral lymph nodes are 
activated by restimulation with the antigen and migrate through the tissues in search of 
further antigen. When they encounter the antigen in the brain the B-cells remain at that 
site, proliferate and develop into antibody secreting-plasma cells (Hickey, 2001).
3.1.2.2.4. Lymphatic drainage in the CNS
The ability of certain antigens to stimulate peripheral immune cells even though they are 
introduced behind the BBB raises questions with regard to lymphatic drainage in the CNS. 
Although there are no anatomically defined lymphatics in the CNS it would appear that the 
CSF partially accomplishes the role of the lymph within the brain. As the CSF travels 
through the brain tissue and Virchow-Robins spaces it penetrates areas beneath the 
cribiform plate and along the cranial and spinal nerve roots where anatomically 
recognisable lymphatics ai*e present. It is therefore feasible that the CSF can carry 
potential antigenic substances form the brain tissue to the lymphatic system and thereby 
facilitate in the immune surveillance of the CNS (Hickey, 2001).
3.1.2.3. CNS cells with immune roles
To compensate for the relative lack of immune system cells within the CNS, several 
endogenous types of cell have the potential to perform immune functions. Amongst these 
the cerebral endothelial cells of the BBB are capable of performing immune roles. In 
addition, the glial cells of the brain also possess immune capabilities. When the glial cells 
were first discovered during the 1800’s they were thought to belong to a single category of 
cell and to serve only as the ‘glue’ between the neurons and the spinal cord. However, by
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the eai’ly century tliree individual types of glial cell had been identified, the astrocyte, 
the oligodendrocyte and the microglia. By the 1970’s it had become apparent that the 
astrocytes played a major role in the immune response within the CNS. However, it was a 
further ten years before the immune functions of the microglial cells were demonstrated 
definitively (Streit and Kincaid-Colton, 1995).
3.1.2.3.1. BBB endothelial ceils
The endothelial cell constituents of the BBB may contribute to the instigation and control 
of inflammatory reactions in the brain. Cerebral endothelia cells can be induced to express 
the adhesion molecules and co-stimulatory molecules, MHC class II and B7.1 or B7.2, 
respectively, required to initiate a T-cell response. However their exact function in this 
scenario remains unclear since, in tissue culture, the endothelial cells fail to promote T-cell 
proliferation and the T-cells enter a state of anergy. This non-responsive condition can be 
overcome by supplementing the cultures with IL-2 which subsequently restores the 
proliferative response in the T-cells (Antel and Prat, 2000).
3.1.2.3.2. Microglia
In a similar mamier to peripheral tissues the CNS has a resident population of specialised 
macrophage cells that appear to phagocytose pathogens and present antigen in a similar 
fashion to their systemic counterparts. These specialised macrophages are the microglial 
cells and they comprise between 5-20% of the glia within the CNS and are more numerous 
in the grey rather than the white matter (Nakajima and Kohsaka, 2001). The cells were 
first identified in the late 19^ '^  century by Nissl who named them ‘rod cells’ and proposed 
that they had a eapacity for migration and phagocytosis. The idea of these cells being 
residents within the CNS was proposed by Rio-Hortega in the early 1900’s who 
differentiated the microglia from other glial cell types and suggested that the cells were 
derived from the mononuclear-phagocyte lineage (Barron, 1995; Male and Rezaie, 2001). 
However, it was not until 1985, with the discovery of monoclonal antibodies which 
distinguished reliably between microglia and astrocytes in tissue sections, and the 
development of pure microglial cell cultures that the attributes of this cell type were 
demonstrated definitively (Streit and Kincaid-Colton, 1995). In a similar- fashion, the 
derivation of the microglial cells also remained controversial for the majority of the 20^ '* 
century. However, as more specific antibodies became available it was shown that 
microglia react with those that recognise patterns exclusively found on cells of the immune
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system. In addition, certain antibodies demonstrated that the microglia were related to the 
macrophage cell type.
3.1.2.3.2.1. Microglial morphology
Microglia are the smallest of the tlnee glia cell types. When examined under light 
microscopy they have an oval or elliptical nucleus with little or no visible cytoplasm. In 
their resting state, the cells are highly ramified with many short spiny projections (Barron, 
1995). However, when the brain is injm-ed or affected by disease these ramified microglia 
retract their cellular processes and migrate to the site of injury or infection. Their cell 
bodies also enlarge and the cells become proliferative. The specific conformation of the 
newly activated microglial cell is usually dependent on the structure or the brain region in 
which the response is taking place. If space is available the cells may assume a bushy 
conformation. In contrast, if the microglia are required along thin neuronal projections 
they may adopt a more rod-like appearance. When the injury or infection in the CNS is 
resolved the microglia can revert to their original ramified resting state. However, a 
further change in the cellular morphology of the activated microglia can occur. In 
response to cell death within the bram, activated microglia can adopt a phagocytic 
conformation to facilitate the removal of the resulting eell debris. The ultimate fate of 
these phagocytic microglia remains unclear (Streit and Kincaid-Colton, 1995).
3.1.2.3.2.2. Microglia in the normal CNS
Microglia develop from bone maiTow derived-macrophage precursor cells that invade the 
brain during embryonic development and early post-natal life. The presence of microglia 
within the CNS is critical for the normal growth of the embryo. During this early stage of 
development the microglial cells phagocytose the cell debris that appears naturally tlirough 
apoptosis, resorption and remodelling of the developing brain (Nakajima and Kohsaka, 
2001). When this developmental process is complete the requirement to degrade large 
quantities of surplus cellular material decreases and the microglia cells transform into the 
ramified or resting forms commonly found in the mature CNS (Barron, 1995).
Although little is know about the functions of microglia in the normal mature CNS their 
branched structure is thought to allow the microglial cells to monitor the health status of 
surrounding cells. Interestingly microglial processes abut both astrocytes and neurons but 
do not comrect with other microglial cells (Streit and Kincaid-Colton, 1995). It has also 
been suggested, from evidence derived from microglial cell cultures, that these cells
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produce low levels of growth factors such as fibroblast and nerve growth factor that may 
facilitate the survival of mature glia and neurons (Streit and Kincaid-Colton, 1995).
3.1.2.3.2.3. Microglial response to injury or infection
Resting or ramified microglia show a down regulated phenotype with minimal expression 
of the cell surface antigens commonly found on macrophage type cells. However, as stated 
above, these cells undergo a dramatic conformational change following CNS injury or 
infection. This response occurs almost immediately, within minutes of the microglia 
detecting disruptive changes in the CNS microenvironment (Streit and Kincaid-Colton, 
1995). In addition to the structural alterations, the cells show enhanced or novel 
expression of a variety of macrophage differentiation mai’kers and effector properties 
(Aloisi, 2001). These include expression of complement receptor 3 and MHC class I and 
MHC class II molecules (Nakajima and Kohsaka, 2001). The co-stimulatory molecule 
B7.2 is expressed constitutively by microglial cells and B7.1 expression can be induced 
under inflammatory conditions (Antel and Prat, 2000). In addition, microglia have been 
shown to express a further co-stimulatory molecule, CD40, in multiple sclerosis (MS) and 
experimental allergic encephalomyelitis (EAE) brain lesions and the expression of this 
molecule can be induced by stimulation of microglia in culture by EPS or IFN-y (Aloisi, 
2001). Fuithermore, activated microglia in MS lesions have also been shown to express 
the adhesion molecule ICAM-1 (Aloisi, Ria, Penna, and Adorini, 1998). The presence of 
these adhesion and co-stimulatory molecules indicates that microglial cells are equipped to 
play a major role in antigen presentation and T-cell activation within the CNS in addition 
to their phagocytic functions.
3.1.2.3.3. Astrocytes
Astrocytes are the most abundant glial cell type within the brain comprising between 20- 
25% of its total volume and in some areas they constitute up to 50% of the brain tissue. 
Furthermore, astrocytes are ten fold more numerous that neurons in the mammalian CNS 
(Montgomery, 1994). Once thought to play a purely structural role within the CNS, 
astrocytes have now been shown to fulfil numerous and diverse functions. As well as 
providing support for neurons during development, astrocytes help to maintain the CNS 
micro environment. In addition, astrocyte can release a range of neuronal growth factors 
and have been shown to stimulate unspecialised cells to differentiate into neurons 
(Svendsen, 2002). Astrocytes, as previously mentioned, also help to preserve the integrity
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of the BBB. Furthermore, these cells can modulate immune reactions within the CNS 
(Eng, Yu, and Lee, 1992; Montgomery, 1994; Svendsen, 2002).
3.1.2.3.3.1, Astrocyte morphology
As the name suggests, astrocytes are stellate shaped cells that are found distributed 
throughout the brain and spinal cord. The major identifying ultrastructural feature of 
astrocytes is the presence of intermediate filaments composed mainly of glial fibrillary 
acidic protein (GFAP). GFAP is by and large specific for astrocytic cells and has therefore 
proved invaluable as a cellulai' marker in the study of this cell type both in vivo and in 
vitro. GFAP plays a structural role within the cell and is thought to be important in the 
formation of the cellular processes since astrocytes prevented from manufacturing this 
protein could no longer produce the cellular branches in response to neurons in cell culture 
(Engetal, 1992)
There appears to be two sub-populations of astrocyte although the classification for these 
cells remains equivocal. One system defines the two groups as protoplasmic and fibrous, 
while the second uses the terms type 1 and type 2 astrocytes. In general type 1 cells are 
proposed to be analogous with protoplasmic astrocytes and type 2 cells are thought to be 
comparable with fibrous astrocytes. The two sub-populations of astrocyte are believed to 
develop from specific progenitor cells. While the progenitor cells for type 1 astrocytes are 
thought to be committed to the astrocyte lineage, type 2 cells are believed to develop from 
bipotential 0-2A progenitor cells that can generate either oligodendrocytes or astrocytes 
(Montgomery, 1994).
Although astrocytes are distributed tlnoughout the CNS, type 1 cells are most commonly 
found in the white matter while type 2 cells predominate in the grey matter. When the 
cells are stained with haematoxylin and eosin for examination under light microscopy, type 
I astrocytes appear as pale staining cells with oval to round nuclei and little discernable 
cytoplasm. In comparison, type 2 astrocytes typically display more lob ate nuclei. It can be 
difficult to distinguish astrocytes from small neurons in tissue sections. However, neurons 
have distinct nucleoli, whereas, the nucleoli of astrocytes are frequently unapparent.
Astrocytes have intimate associations with other constituents of the CNS. Astrocyte 
processes surround neuronal cell bodies as well as the nodes of Ranvier of myelinated 
axons. These astrocytic processes also form the dense network of fibres known as the glial 
limitans and completely encircle blood vessels within the CNS. The relevance of these
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intimate connections may lie in the presence of gap junctions in the astrocyte cell 
membrane. Gap junctions are constructed of hollow transmembrane proteins, termed 
connexons, which join with similar proteins on an adjacent cell and allow the exchange of 
small molecules such as ions, oligosaccharides, amino acids, nucleotides and certain 
trophic factors, between the cells. These comiections can be made from astrocyte to 
astrocyte, astrocyte to ependymal cell or astrocyte to oligodendrocyte. However, the 
formation of gap junctions in the CNS is not restricted to the astrocyte population as they 
also exist between oligodendrocytes and between ependymal cells (Montgomery, 1994).
The astrocyte processes, pailiculai'ly those surrounding blood vessels, also show the 
presence of numerous orthogonal assemblies. These structures can only be viewed in 
freeze-fracture preparations and again may play a role in the transport of molecules 
between the astrocyte and the blood or CSF. In addition, these structures could be 
important in cellular adhesion processes. It appears that the interaction between astrocytes 
and cerebral endothelial cells is significant in the formation of the orthogonal arrays since 
fibroblasts, smooth muscle cells and non-cerebral endothelial cells fail to induce the 
formation of the orthogonal arrays in astrocytes in vitro (Montgomery, 1994).
3.I.2.3.3.2. Astrocytic responses to injury
Astrocytes respond vigorously to tramna or infection in a reaction commonly referred to as 
astrocyte activation, astrocytosis or astrogliosis. This is characterised by an increase in 
detectable astrocyte cell number at the site of insult. The augmentation of the 
demonstrable astrocyte population is thought to arise by migration of astrocytes from areas 
distal to the site of injury, proliferation of the neighbouring cells and phenotypic changes 
in the local astrocyte population. The phenotypic changes are complex and involve the de 
novo expression and upregulation of a variety of molecules including the production of 
GFAP. In addition to the increase in cell number, activated astrocytes also appear to be 
larger and have numerous, intricate cytoplasmic processes compared with quiescent or 
resting cells. Astrocytosis can occur extremely rapidly following insult and has been 
detected within 24 hours of infection with neurotropic viruses (Mucke and Eddleston, 
1993).
The dramatic response of astrocytes to injury can be either beneficial or detrimental 
depending on the circumstances. Astrocytosis can result in the production of growth 
factors and neurotrophins that promote neuronal survival and ablation of the astrocyte 
population has been shown to result in substantial neurodegeneration in the injured brain.
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However, astocytosis can also lead to the formation of dense gliotic scars that are thought 
to have disadvantageous characteristics since they can prevent the extension of axons 
tlirough the resulting astrocytic mass (Dong and Benveniste, 2001).
3.I.2.3.3.3. Astrocytes as immunocompetent cells
As stated earlier, astrocytes are found dispersed tlrroughout the CNS and their foot 
processes are in close apposition with the endothelial cells of the BBB. They are therefore 
ideally situated to influence the entry of inflammatory cells into the CNS and subsequently 
manipulate their activity in the brain. However, to control this process astrocytes would be 
required to express the prerequisite battery of adhesion and co-stimulatory molecules.
Astrocytes were the first CNS cell type shown to be capable of expressing the MHC class 
II molecules required for antigen presentation to T-helper cells (Wong, Bartlett, Clark- 
Lewis, Battye et a l, 1984). In these in vitro experiments, Wong and colleagues 
demonstrated that supplementing astrocyte cultures with the cytokine IFN-y induced the 
expression of MHC class II molecules by the cells. In contrast, TNF-a did not induce 
MHC class II expression when added to the astrocytes. When TNF-a was administered in 
conjunction with IFN-y the expression of MHC class II molecules by the astrocytes was 
enlianced. These cytokines are commonly found in CNS inflammatory conditions, 
including, MS, HIV-associated dementia and in the brains of animals with EAE (Dong and 
Benveniste, 2001). Nevertheless, the expression of MHC class II molecules by astrocytes 
in vivo remains a controversial topic. Although intrathecal injection of IFN-y does result in 
MHC class II expression by astrocytes, the presence of the molecules in disease states is 
equivocal with some researchers detecting their expression while others were unable to 
demonstrate MHC class II positive astrocytes (Slnikant and Benveniste, 1996).
Astrocytes have been shown to express adhesion molecules such as ICAM-1 and VCAM-1 
when stimulated with a variety of cytokines, including TNF-a, IL-lp and IFN-y, as well as 
EPS and viral proteins (Shiikant and Benveniste, 1996). It appears, however, that human 
astrocytes do not express the costimulatory molecules B7.1 or B7.2 either constitutively or 
following stimulation with IFN-y. Contradictory findings have been generated with regard 
to the expression of these molecules by murine astrocytes in both in vivo and in vitro 
models. Some investigators report the constitutive expression of one or other of the 
molecules with up regulation or de novo expression following stimulation with IFN-y or 
under disease conditions, while others could not detect the molecules either following ÏFN-
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Y stimulation or in CNS inflammatory states (Dong and Benveniste, 2001). The expression 
of another costimulatory molecule, CD40, by astrocytes also remains controversial. Again 
some authors fail to detect CD40 expression in astrocyte cultures following IFN-y 
stimulation, while others did observe the presence of the molecule (Aloisi et al, 1998; 
Dong and Benveniste, 2001). In contrast to B7.1 and B7.2 it appears that human foetal 
astrocytes constitutively express CD40 which is upregulated following stimulation with 
TNF-a, IL-p, IFN-y or LPS. However, the data taken from in vivo studies suggest that 
CD40 expression is confined to the microglial / macrophage population and does not occur 
on astrocytes (Dong and Benveniste, 2001).
At the present time, no definitive conclusions regarding the ability of astrocytes to present 
antigen to either activated or naïve T-cells can be drawn from the data available. If 
astrocytes cannot express the costimulatory molecules required to induce T-cells to 
proliferate and develop effector functions then, due to their ability to express MHC class II 
molecules it is possible that these cells induce a state of anergy in the T-cell population and 
effectively dampen immune reactions within the inflamed CNS.
3.1.3. CNS inflammation in disease states
Despite the ‘immuno-priveledged’ status of the brain many immune-mediated diseases of 
the CNS are now recognised that encompass a wide range of disease aetiologies. These 
conditions include those of a viral nature such as herpes simplex virus, polio, varicella 
zoster virus and HIV; many and varied bacterial agents; transmissible spongiform 
encephalopathies (TSE’s); and fungal infections (Adams and Graliam, 1998). In addition 
to the plethora of pathological agents that can cause CNS inflammatory reactions there are 
diseases associated with ageing such as Alzheimer’s disease. Pick’s disease and vascular 
dementia. There is also a diverse group of conditions known as the inflammatory 
demyelinating diseases of the CNS and perhaps the most well-known and commonly 
occurring inflammatory condition affecting the brain, multiple sclerosis (MS), belongs to 
this family of diseases (Bright and Sriram, 2001; Keegan and Noseworthy, 2002).
Over and above this array of CNS inflammatory conditions there are a wide range of 
parasitic infections that can produce severe immune responses within the CNS. These 
parasitic infections include Plasmodium spp., Toxoplasma gondii, as well as Trypanosoma 
spp. infections.
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3.1.3.1. Trypanosome-induced CNS inflammation
It has been Imown for many years that chronic trypanosome infection leads to CNS 
invasion by the parasite and results in an inflammatory reaction within the brain. At 
present the mechanisms and pathways used by the trypanosomes to gain entry and become 
established within the CNS remain unclear. In animal models, parasites have been 
localised in the choroid plexus, circumventricular organs and peripheral ganglia, areas, as 
previously mentioned, where the BBB is weak (Schultzberg, Ambatsis, Samuelsson, 
Ki’istensson et a l, 1988). However, this has yet to be definitively established as the route 
of parasite invasion into the CNS since investigations employing rodent models suggest 
that the BBB becomes progressively damaged as the disease advances (Pentreath et al, 
1994; Philip et al, 1994). In a rat model of trypanosome infection, fluorescent dye 
injected into the carotid artery could be detected in several brain areas, including, the 
thalamus and hypothalamus, by day 35 post-infection with T.b.brucei, indicating 
impairment of the BBB. By 40 days post-infection, this BBB damage had become 
extensive and the dye could be found tlrroughout both the grey and the white matter of the 
cortex (Philip et al, 1994). These studies suggest strongly that infection with trypanosome 
parasites has a direct effect on the function of the BBB that could ultimately leave the CNS 
vulnerable to insult and injury. In contrast to these findings it has been shown that the 
invasion of the CNS by trypanosome parasites does not necessarily result in an 
indiscriminate loss of tight junctions in the BBB (Mulenga, Mhlanga, Ki’istensson, and 
Robertson, 2001). The integrity of the tight junctions following trypanosome infeetion in 
rats was determined by demonstration of two tight junction proteins; occludin and zonula 
occludens 1, in brain sections using immunofluorescent histochemistry.
In humans, the CNS inflammatory reaction resulting from trypanosome infection develops 
as the disease progresses. Unfortunately, this reaction can be exacerbated by 
chemotherapy, and in 5-10% of treated patients leads to the generation of the post­
treatment reactive encephalopathy (PTRE). The CNS inflammatory cell infiltrate is 
comprised of macrophages, T and B-lymphocytes and plasma cells. The inflammatory 
reaction is also associated with a widespread astrocytosis and diffuse microglial 
hyperplasia (Adams and Graham, 1998; Adams et al, 1986; Molyneux et al, 1996). The 
PTRE is characterised by an increase in the severity of this CNS inflammatory reaction and 
in some instances can take the form of an acute haemorrhagic leucoencephalopathy 
(Adams eï a/., 1986).
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Comparable CNS inflammatory reactions have been reported in primate models of the 
disease (Sclimidt, 1983). Infiltration of the brain cerebral vessels by lymphocytes, plasma 
cells and macrophages has been described following T.b.rhodesiense-ixiÎQQtions in vervet 
monkeys. Proliferation of the microglial cells in immediate proximity to the inflammatory 
infiltrates was also detected. However, a fully developed meningoencephalitis, with the 
presence of inflammatory cells in the neuropil was only identified in one out of 20 
experimental animals. This author also foimd an equivalent degree of inflammation, in 
two additional monkeys during a separate series of experiments, following unsuccessful 
drug treatment of the trypanosome infection (Sclimidt, 1983). The development of this 
meningoencephalitic reaction, resulting from ineffectual trypanocidal therapy has been 
noted in additional investigations (Poltera, Sayer, Brighouse, Bovell et a l, 1985). In this 
study moderate to severe perivascular cuffing, microglial activation and the presence of 
plasma cells in the neuropil were demonstrated following subcurative diminazene aceturate 
treatment of T.b.rhodesiense-inÎQcXiom in vervet monkeys.
A CNS inflammatory reaction has been reported in experimental infections of goats 
(Whitelaw, Moulton, Morrison, and Murray, 1985), cattle and dogs (Morrison et al, 1983) 
following trypanosome infection. Again the main cell types constituting the inflammatory 
infiltrate were found to be lymphocytes, plasma cells and macrophages although 
differences in the distribution of the resulting lesions were present. The CNS 
inflammatory reaction observed in dogs was mainly confined to the choroid plexus and 
meninges, whereas, cattle and goats exhibited infiltration of the brain parenchyma by the 
inflammatory cells. However, since these dogs had received no trypanocidal therapy it is 
possible that a similar inflammatory pattern to that seen in the vervet monkey was present 
and subcui-ative treatment may have exacerbated the response producing a 
meningoencephalitis.
A similar pattern of cellular infiltration has also been described in rodent models of 
trypanosomiasis. T.b.rhodesiense-mÎQcXïon of NMRI-outbred mice has been shown to 
produce a clironic infection with the animals surviving for up to 9 weeks. A mild 
inflammatory infiltrate was detected in the brain connective tissue in animals killed 7 days 
after infection and the severity of the reaction increased as the disease progressed with a 
meningoencephalitis present in animals killed 4 weeks after infection (Fink and Sclimidt, 
1979). The inflammatory cells consisted of lymphocytes, plasma cells and macrophages. 
The study also found that the pattern of inflammatory cell infiltration in the CNS closely 
mirrored the invasion of the brain tissues by the parasites. In T. 6. hrace/-infections of OFl- 
outbred mice inflammatory changes were detected in the choroid plexus and meninges
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from approximately 4 weeks after infection and in advanced cases perivascular cuffing was 
observed in meningeal and cerebral vessels. Again the cells comprising this infiltrate were 
lymphocytes, plasma cells and macrophages (Poltera, 1980). An analogous pattern of 
inflammatory changes was also present when this strain of mouse was infected with 
T.b.gambiense although this produced a more clnonic infection, in some cases lasting for a 
22 month period (Poltera, Hoclimami, and Lambert, 1982).
It appear s that the severity of the inflaiumatory response can be exacerbated in the murine 
CNS by subcurative drug treatment of the infection in the same manner as previously 
described in the vervet monlcey and goat (Hunter and Kennedy, 1992; Jennings et al, 
1989). When NIH-inbred mice were infected with T.b.brucei a few inflammatory cells 
were found in the choroids plexus by 29 days post-infection. No significant perivascular 
cuffing was detected at this stage. However, if these mice were treated with a subcurative 
dose of diminazene aceturate on day 21 post-infection and then sacrificed at day 29 post­
infection, encephalitic lesions and large perivascular cuffs consisting mainly of 
lymphocytes and macrophages were observed. The severity of this reaction was further 
increased by a second subcurative drug treatment following relapse of the mice to 
parasitaemia (Hunter, Jennings, Adams, Murray et a l, 1992). Despite the severity of the 
inflammatory response induced in the CNS, several of the studies described above make 
note of the relative lack of neuronal damage that results from the inflamiuatory cell 
infiltration of the brain parenchyma (Fink and Schmidt, 1979; Morrison et al, 1983).
Although the basic cellular components of the reaction are known, the kinetics of the 
inflammatory cell invasion and an assessment of the specific cell types involved have yet 
to be performed. Another common feature described in these animal models is the 
increased severity of the CNS inflammation observed following subcurative drug 
treatment. This is analogous to the situation found in human patients who develop the 
PTRE. Therefore, this study aims to map the course of events that result in the generation 
of the inflammatory reaction and to evaluate the level of CNS infiltration by CD4^ and 
CD8"^  T-cell sub-sets, macrophages and B-lymphocytes. A time-course of the appearance 
of the inflammatory cells in the CNS together with the areas of the brain infiltrated by the 
cells will be determined following infection and induction of the PTRE.
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3.2. Materials and methods
The main aim of the following investigation was to determine the kinetics of the 
infiltration, and subsequent distribution, of immune system cells within the CNS following 
trypanosome infection. Each stage of the CNS inflammatory response, from the initial 
mild inflammation tlirough to the severe meningoencephalitis characteristic of the post­
treatment reactive encephalopathy, was examined using the mouse model of human 
African trypanosomiasis previously described in Chapter 2.
3.2.1. Animals, infections and treatments
Female CD-I mice (Charles River Breeding Laboratories) weighing 28-35g were infected 
with 2x10"^  T.b.brucei parasites of cloned stabilate GVR/C1.6 as previously described. The 
complete mouse model is explained in detail in Chapter 2 of this thesis and mice were 
induced to simulate each stage of the response. To mirror acute stage infections the mice 
were killed at 7 and 14 days after infection, while animals killed on days 21 and 28 post­
infection imitated the early CNS-stage of the disease. Further mice were treated on day 21 
after infection with a subcurative dose of diminazene aceturate (40mg/kg i.p.) to induce a 
more severe CNS response. Groups of these drug treated animals were killed at 7 and 14 
days following the diminazene aceturate treatment. The CNS reaction induced in these 
mice simulates the neuroinflammatory response found in patients with late-CNS stage 
infections. Additional mice were suhcuratively drug treated and then allowed to relapse to 
parasitaemia before receiving a second diminazene aceturate treatment. These mice were 
killed at 7 and 14 days following the second sub curative trypanocidal drug treatment and 
mirror the pathological reaction found in human patients who have died fi-om the PTRE.
The complete experiment was performed in duplicate. On both occasions, each of the 
levels of inflammation was induced in a separate group of mice. Each of the individual 
experimental groups was comprised of six animals in total.
3.2.2. Sample preparation and staining
At scheduled points during the experimental procedures mice were killed by cardiac 
perfusion with sterile saline while under terminal anaesthesia. The brains were then 
dissected and either placed into 5% neutral buffered formalin for processing to paraffin or
86
30% sucrose in PBS for cryoprotection before snap freezing for cryostat sectioning (See 
Chapter 2),
3.2.2.1. Paraffin sections
To allow the severity of the immune reaction within the CNS to be assessed, paraffin 
sections of 3 pm thickness were stained using the standard histological haematoxylin and 
eosin (H&E) staining method. The severity of the neuropathological response was graded, 
as described in Chapter 2, in sections prepared from each animal. To investigate the 
degree of astrocyte activation and lymphocyte infiltration additional sections were 
prepai'ed from a representative portion of the blocks and stained using the 
immunocytochemistry (ICC) proceduie again described in Chapter 2. The reagents utilised 
on these paraffin sections were anti-glial fibrillaiy acidic protein (GFAP) (DAKO), anti- 
B220 (Serotec) and anti-CD3 (DAKO) (Table 2.2). These antibodies will specifically react 
with GFAP, the intermediate filament protein of astrocytes; the high molecular weight, 
220kD fragment, of the CD45 antigen expressed by B-cells; and the CD3 cell surface 
marker commonly found on all T-cells respectively. The timing of the appearance of these 
cells and their distribution tlnoughout the brain was investigated.
3 .2 .2 .1.1. Neuropathology grading scale
Haematoxylin and eosin stained paraffin embedded sections were used to assess the 
severity of the inflammatory reaction induced in the CNS at each of the different stages of 
the animal model. The severity of the response was graded on a scale of 0-4 where 0 
indicates a normal pathology with no signs of inflammatory changes and 4 signifies a 
severe meningoencephalitic response with the presence of inflammatory cells in the 
neuropil. This scale is described in detail in Chapter 2 and the inflammatory criteria are 
listed in Table 2.1 of this thesis. The severity of the reaction in each section was graded 
independently by two assessors in a blinded fashion. The sections were examined at a 
magnification of 200 fold and the criteria described in the grading scale (Table 2.1) 
considered before a neuropathology score was assigned.
3.2.2 2. Frozen sections
Sections were prepared at a thickness of 10pm from cryoprotected snap frozen mouse 
brains. The sections were air dried and fixed for 10 minutes in cold acetone before storage
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at -20°C until required for ICC staining. Using frozen sections it was possible to quantify 
the levels of T-helper and T-cytotoxic cells infiltrating the CNS as the reaction developed. 
The reagents used to determine the degree of infiltration of the brain by the T-cell sub-sets 
were anti-CD4'*' and anti-CD8^ monoclonal antibodies (Pharmingen). The anti“CD4‘*‘ 
antibody binds specifically to the CD4^ cell surface marker found on T-helper cells while 
the anti-CD8  ^antibody specifically reacts with the CD8  ^cell surface marker found on T- 
cytotoxic cells. The progress of macrophage infiltration into the CNS was also examined 
using ICC of frozen sections. In this instance the antibody employed was F4/80 (Serotec). 
This recognises a 160kD plasma membrane component found on mature macrophages. 
The timing of the infiltration and the areas of the brain invaded by the inflammatory cells 
were monitored at each stage throughout the development of the neuroinflammatory 
response. Further details on this technique and the antibodies employed are described in 
Chapter 2 and Table 2.2.
3.2.2.2.1. Quantification of CD4* and CDS* ceil infiltration
The number of positively stained CD4'  ^ and CD8^ cells was counted at a 200-fold 
magnification under light microscopy. To standardise the area of the brain assessed a 100 
square grid, fitted into the eyepiece of the microscope, was used. Cell numbers were 
determined by counting the total number of stained cells in 5 sepai'ate areas of the 
meninges, one ai'ea of the corpus callosum, and two areas of the external capsule, caudate 
putamen and cerebral cortex. The average of the cell counts for each area was then 
calculated and the cell counts were converted and expressed as the number of cells per 
mm^ of tissue. The cellular infiltration of these particular brain areas was assessed as they 
form representative, idenitifiable, regions within the area of the CNS investigated. In 
addition, inflammatory changes are known to occur in these discrete regions, and, although 
not assessed individually, these regions form the basic composition of the sections used for 
grading the severity of the neuroinflammation as described in Chapter 2, Table 2.1.
3.2.3. Statistical analyses
All statistical tests were undertaken using the proprietary statistical software package, 
Minitab version 13, and P-values of less than 0.05 were considered significant. Means and 
standard errors (S.E.) aie shown as summary statistics.
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3.2.3.1. Grading of neuropathological response
Comparisons were made between groups of animals to assess the differences in the level of 
CNS inflammation following induction of a CNS inflammatory response by trypanosome 
infection and sub-cui'ative diminazene aceturate treatment. The severity of the reaction 
was analysed in mice killed at 7-day intervals after infection until day 28 post-infection. In 
addition the neuropathological reaction was measured in mice killed at 7 and 14 days 
following a single subcurative diminazene aceturate treatment and 7 and 14 days following 
a second diminazene aceturate treatment. The neuropathological scores for the individual 
mice were based on the average of two independent assessor scores. A Wilcoxon signed 
rank test was employed to ensure that the independent gradings were assigned in a uniform 
manner and were not biased by the individual assessor. Analyses were possible using 
parametric statistical tests. Comparisons across experiments were performed using general 
linear model procedures and the randomised block analyses of variance.
3.2.3 2. Assessing T-cell infiltration
The pattern of CD4^ and CD8^ cell infiltration into five separate brain areas was assessed 
in the groups of mice outlined above. To permit parametric tests to be employed in the 
analyses, the resulting data were transformed and the natural logarithm of the data set, as 
suggested by the Box-Cox test, was used in subsequent analyses. Differences between the 
treatment groups for each of the brain areas studied were identified using a one-factor 
analysis of variance technique followed by Tukey’s procedure to obtain individual p- 
values for each of the pairwise comparisons and their associated 95% confidence intervals. 
Differences between the brain areas for each of the treatment groups were similarly 
identified, however, in this case two-faetor analysis of variances were used to take account 
of measurements from the same mice for each area assessed. All analyses were carried out 
using general linear model procedures.
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3.3. Results
3.3.1. Assessment of the severity of the 
neuropathological response
Histopathological examination of brain sections prepared from animals killed at various 
points during the mouse model of human African trypanosomiasis showed inflammatory 
cell infiltration beginning in the meninges and ventricles. The severity of this 
inflammation worsened as the disease progressed. Perivascular cuffing of the cerebral 
vessels was commonly found and the infection culminated with the development of a 
severe meningoencephalitis. The inflammatory cells present throughout were mainly 
composed of lymphocytes and macrophages. Plasma cells became common as the 
inflammation developed, however neutrophils were rarely present in the infiltrate (Fig. 
3.1).
Two individual assessors independently graded the severity of the neuropathological 
response of mice to the trypanosome infection using the grading scale described in Table
2.1. The results of a Wilcoxon signed rank test demonstrated that there was no evidence of 
a difference between the neuropathology grades measured by the individual assessors and 
that the grading scale had been applied uniformly. Therefore it was possible to use an 
average of the two grades in all subsequent analyses. A summary of these results can be 
found in Table 3.1.
Analyses of the neuropathological response data using general linear model procedures 
showed that there was no significant difference (p=0.235) between the results gained from 
each individual experiment. The analyses also determined that there was a significant 
difference (p<0.001) in the severity of the inflammatory reactions induced by the 
individual treatment regimens. To determine where the individual difference lay, one way 
analysis of variance procedures were performed and individual p-values and confidence 
intervals determined using Tukey’s pair wise comparisons multiple range test. A summary 
of the results of the statistical analysis is detailed in Table 3.1.
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3.3.1.1. Acute and early-stage CNS infections
Brain sections, prepared from T. 6 . wee/-infected mice, killed at 7 and 14 days post­
infection, to mimic the acute stages of trypanosome infection, and 21 and 28 days post­
infection to imitate the early-stage CNS infection, were examined under light microscopy. 
No gross inflammatory changes were seen in animals at 7 days post-infection and these 
mice showed a neuropathology grade of 0.375 ± 0.072 (mean + S.E.). By 14 days after 
infection a few animals displayed a slight increase in the cellularity in the meninges and 
ventricles and this returned only a very minor increase in the pathology score (0.417 ±  
0.077). This increase was not statistically significant (p=1.000). The degree of 
neuroinflammation found in animals killed at 7 and 14 days post-infection was not 
significantly increased (p=0.3411, p=0.201 respectively) from neuropathological grading 
scores of the uninfected control animals (0.033 ± 0.023).
The severity of the neuroinflammation seen in animals killed at 21 days post-infection 
(1.021 ± 0.129) was significantly higher than the response found in mice killed at the 
earlier, 7 and 14-day time points (p=0.003, p=0.006 respectively). By 28 days post­
infection the severity of the inflammatory response (1.477 ± 0.186) was again significantly 
more severe that that seen in animals killed at 7 and 14 days after infection (p<0.0001). 
The severity of the response in these animals was also increased compared to that found in 
mice 21 days following infection. However, this increase was not significant (p=0.122). 
The neiu'opathological grading score attributed to animals killed at both 21 and 28-days 
post-infection was significantly (p<0.0001) higher than that assigned to the uninfected 
control mice.
The neuroinflammatory response occurring during the acute and early-CNS stages of the 
infection were significantly (p<0.0001) less severe than the reaction seen following the 
induction of the late-CNS stage of the disease and the PTRE.
3.3.1.2. Late-stage CNS infections and the PTRE
Sections were appraised from animals killed at 7 and 14 days following a single 
subcurative diminazene aceturate treatment to simulate the situation found in late-stage 
CNS infections and 7 and 14 days after a second diminazene aceturate treatment to mirror 
the reaction found in the PTRE.
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Mice killed at 7 days following a single diminazene aceturate treatment showed a 
neuropathology score of 2.833 + 0.117 while the response in those animals killed after 14 
days was 2.886 ± 0.123. The severity of the reaction foimd in animals killed at 7 and 14 
days following a second diminazene aceturate treatment was 3.281 + 0.010 and 3.375 + 
0.189 respectively. Although higher than those found in mice receiving only one 
trypanocidal drug treatment this increase was not considered significant. However, the 
severity of the neuropathological response in all groups of animals mirroring either the 
late-CNS stage of infection or the PTRE were significantly (p<0.0001) higher than those 
measured in the acute and early-CNS stage infections or uninfected mice.
3.3.2. Inflammatory cell infiltration and astrocyte 
activation
3.3.2.1. T-lymphocyte infiltration
The presence of helper (CD4’^ ) and cytotoxic (CD8 )^ T-lymphocytes within the brain of 
trypanosome-infected and subcuratively treated mice was investigated in a quantitative 
manner. The cellular infiltration pattern in the meninges, corpus callosum, external 
capsule, caudate putamen and cerebral cortex was assessed and analysed using the 
statistical methods outlined previously (Chapter 3, materials and methods). All cell counts 
are expressed as the number of cells per mm^ of tissue. Summary data comparing CD4^ 
and CD8^ cell infiltration is detailed in Tables 3.2-3.7 while summary data outlining the 
temporal and spatial pattern of either CD4"^  or CD8^ cell infiltration is given in Tables 3.8- 
3.31.
3.3.2.1.1. Comparison of CD4* and CD8* ceil infiltration
When the cell counts assessed in five brain ai'eas; meninges, corpus callosum, external 
capsule, caudate putamen and cerebral cortex, were combined (Table 3.2), no T-cells were 
detected in uninfected mice (data not shown) or in animals killed at 7 days post-infection. 
Small numbers of both CD4^ [0.1.420 ±1.170 (mean ± S.E.)] and CD8^ (0.700 ± 0.490) T- 
cells were found infiltrating the CNS by 14 days post-infection. Although the number of 
CD8  ^ cells was lower than CD4^ cells the difference between the cell counts was not 
significant at this point in the infection (p=0.685). By day 21 post-infection the numbers 
of both CD4^ (8.790 ± 1.950) and CD8  ^(0.938 ± 0.938) cells had increased with the CD4^ 
cell count remaining higher than that of the CD 8  ^ cell count, the difference between the
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two cell counts at this stage in the infection was significant (p=0.040). On day 28 
following infection a mean of 25.540 ± 5.660 CD4^ cells were detected while a 
significantly (p=0.031) lower nmnber of CD8"^  cells was found (6.110 ± 2.080). Following 
exacerbation of the CNS reaction by administration of a single diminazene aceturate 
treatment the population of both T-cell subsets increased. In animals killed 7 days 
following the diminazene aceturate treatment 255.800 + 76.900 CD4^ cells were detected 
in the brain areas studied and 31.100 CD8^ cells were found. No standard eiTor was 
calculated for this group of mice as only one animal provided a CD 8  ^cell count for all the 
brain areas investigated at this time-point in the infection and subsequently no significant 
difference was detected (p=0.164). By 14 days after the administration of the drug 
335.700 + 48.500 CD4^ cells and 91.400 + 2.950 CD8^ cells were detected. The number 
of CD4^ cells found in animals killed following this treatment regimen was significantly 
higher than the number of CD8  ^ cells detected (p<0.0001). To mirror the 
neuropathological reaction found in the PTRE, the severity of the CNS response was 
further inereased by the administration of a second diminazene aceturate treatment. The 
numbers of CD4^ (293.600 ± 14.800) and CD8^ (60.240 ± 5.400) cells detected in mice 
killed 7 days after the drug treatment remained similar to those found in animals at 14 days 
following a single diminazene aceturate treatment. By 14 days after administration of the 
second dose of diminazene aceturate the cell numbers had increased with 457.400 + 74.100 
CD4^ cells found and 105.300 ± 27.800 CD8"^  cells detected. The infiltration of CD4^ 
cells at both 7 and 14 days following the induction of the PTRE was significantly higher 
than the level of CD8^ cell infiltration (p=0.0001, p=0.042 respectively).
When the infiltration pattern of CD4"^  and CD 8  ^ cells into the meninges was examined a 
similar situation to that seen in the whole brain was found (Table 3.3). No T-cells were 
detected before day 14 post-infection at which point 1.370 + 1.210 CD4^ cells and 0.700 + 
0.490 CD8  ^cells were found. Although the number of CD8  ^cells was smaller than CD4^ 
cells this was not significantly lower at this time-point in the infection (p=0.693). By day 
21 post-infection an increased presence of both cell types was detected and the difference 
between the numbers of CD4^ (7.330 + 1.970) and CD8^ cells (0.938 + 0.938) showed 
borderline significance (p=0.051). On day 28 post-infection a significant (p=0.045) 
difference between the number of infiltrating CD4^ cells (18.330 + 6.140) and CD8  ^cells 
(4.440 + 1.290) was detected. Animals killed 7 days after exacerbation of the reaction 
showed a mean CD4‘^ cell infiltration of 110.300 + 58.200 while a lower, but not 
significantly reduced (p=0.085), number CD8^ cells were detected (17.080 + 7.720). By 
14 days after the drug treatment a highly significant difference (p<0.0001) was found 
between the numbers of cells present from the CD4^ (193.300 + 27.500) cell and CDS’*"
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(39.950 + 2.870) cell subsets. This highly significant difference (p<0.0001) in infiltration 
pattern was also found in mice killed 7 days following the induction of the PTRE when 
180.380 + 6.780 CD4^ cells and 32.690 + 4.790 CD8^ cells were detected. A further 
increase in the level of CD4^ (238.400 ± 52.800) and CD8"^  (36.400 ± 10.100) cell 
infiltration was by 14 days after the second diminazene aceturate treatment with the 
number of CD4^ cells remaining significantly (p=0.026) higher than the number of CD8^ 
cells.
No T-cell infiltration of the corpus callosum was detected until day 14 post-infection. At 
this time only a very small population of CD4^ cells were found (0.050 ±  0.050) and no 
CD8"^  cells were present (Table 3.4). By day 21 post-infection a slight increase in CD4^ 
cell (0.333 + 0.220) infiltration was seen and CD8^ cells (0.167 + 0.167) were detected. 
The difference in cell numbers between these two T-cell subsets was not significant on 
either day 14 or day 21 post-infection (p=0.347, p=0.5484 respectively). On day 28 post­
infection the number of CD4^ cells (1.875 ± 0.402) found was significantly (p=0.041) 
higher than that of CD8^ cells (0.417 + 0.300). When the animals were treated with a 
single diminazene aceturate an increase in the infiltration of the corpus callosum by both 
T-cell subsets was detected. By 7 days following the drug treatment the number of CD4^ 
cells had risen to 28.250 + 4.250 and the number of CD8^ cells had increased to 7.630 + 
2.620. The difference in T-cell subset population was not significant (p=0.068) at this 
time. However by 14 days after the administration of the drug the number of CD4'  ^ cells 
(48.410 + 7.800) was significantly (p=0.008) higher than the number of CD8^ cells (22.020 
± 3.790) detected. Mice killed 7 days after the induction of the PTRE showed a further 
increase in CD4^ cell (54.300 + 11.700) and CD8^ cell (11.740 + 1.690) infiltration with 
CD4^ cell numbers remaining significantly (p=0.002) higher than CD8^ cell numbers. By 
14 days after the administration of the second diminazene aceturate treatment the number 
of CD4^ cells had risen to 63.900 + 12.300. The CD8^ cell count at this point was 27.540 
± 7.110 and was not considered to be significantly (p=0.120) lower than that of the CD4^ 
cells.
When the T-cell infiltration of the external capsule was examined no cellular infiltration 
was detected until 21 days post-infection (Table 3.5). At this time the cell count for both 
CD4^ and CD8^ cells was 0.833 + 0.833. By 28 days post-infection both the CD4^ (4.583 
± 0.417) and the CD8  ^ (1.250 ± 0.722) cell count had increased. The difference in 
infiltration levels between these T-cell subsets showed a borderline level of significance 
(p=0.052) at this time. On exacerbation of the CNS response a further increase in CD4"^  
(48.520 + 3.120) and CD8^ (12.287 + 0.000) cell numbers was detected and the difference
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in these two populations was again of marginal significance (p=0.053). By 14 days after 
receiving a single diminazene aceturate treatment the level of CD4^ (61.880 + 8.520) cell 
infiltration was significantly (p=0.002) higher than that of the CD8^ (23.630 ± 3.210) T~ 
cell subset. Wlien the animals were treated with a second dose of diminazene aceturate, to 
induce an extremely severe meningoencephalitis, the infiltration pattern similar to that 
found 7 days following a single diminazene aceturate treatment was seen with 40.160 ± 
5.460 CD4^ cells and 12.030 + 1.180 CD8^ cells detected. By 14 days after induction of 
the PTRE the CD4^ cell population had raised to 69.380 + 1.250 while the CD8  ^ cell 
number was 25.00 ± 5.00. The CD4^ cell count, remained significantly higher than the 
CD8  ^cell count, at both time-points following the administration of the second diminazene 
aceturate dose (p=0.0004, p=0.035 respectively).
Only very few T-cells were found to in the caudate putameii during the acute and early 
CNS stage of trypanosome infection (Table 3.6). No T-cells were detected until day 21 
post-infection when 0.250 + 0.250 cells of each cell subset, CD4’’ and CD8 ,^ were found. 
On day 28 post-infection a slight increase in the number of CD4^ (0,750 + 0.520) cells was 
seen but no CD8^ cells were detected at this time. The difference between CD4^ and CD8^  
cell infiltration was not significant at either 21 or 28 days post-infection (p=1.000, p=0.830 
respectively). Following a single diminazene aceturate treatment the number of CD4^ cells 
found in the caudate putamen inereased to 19.780 + 6.340 and 3.094 + 0.281 CD8^ cells 
were detected. The levels of CD4^ (19.130 + 9.340) and CD8^ (3.710 + 1.440) cell 
numbers remained similar- in mice killed at 14 days after administration of the drug. At 
both time-points after exacerbation of the CNS response the CD4^ cell count was 
significantly higher than the CD8^ cell count (p=0.039, p=0.033 respectively). Seven days 
following the induction of the PTRE by administration of a second diminazene aceturate 
treatment 13.310+ 1.130 CD4^ cells and 2.453 + 0.736 CD8  ^cells were detected. Again 
the CD4^ population was significantly (p=0.003) greater in number than that of the CD8^ 
cells. By 14 days after the drug treatment CD4^ (24.310 + 9.060) cell numbers were no 
longer significantly (p=0.331) higher than CD8  ^(10.440 + 6.060) cell counts.
The infiltration of the cerebral cortex by CD4"^  and CD8^ cells was also assessed (Table 
3.7). A very occasional CD4^ cell (0.042 + 0.042) was detected in the cortex on day 21 
post-infection. No CD8  ^cells were found at this time. The difference between these two 
populations was not significant (0.374) on day 21 post-infection. Neither CD4^ nor CD8^  
cells were detected on day 28 post-infection. On exacerbation of the CNS response an 
increase in the detection of both CD4^ (6.750 + 0.000) and CD8  ^ (2.250 + 0.000) was 
found and this rise continued on day 14 after the administration of the drug with 12.790 +
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3.950 CD4^ cells and 3.100 + 0.816 CD8^ cells found at this time. The number of CD4^ 
cells counted in the cortex of these mice was significantly (p=0.013) higher than the 
number of CD8’*' cells present. When a severe meningoencephalitis was induced in the 
mice the number of CD4'*' (4.430 + 1.600) was not significantly (p=0.098) higher than the 
number of CD8^ (1.328 + 0.465) cells by 7 days after administration of the second dose of 
diminazene aceturate. However, if the mice were killed at 14 days after receiving the drug 
a significantly (p= 0.011) higher level of CD4’*’ (16.340 + 1.220) cell infiltration compared 
with CD8^ (5.969 + 0.469) cell infiltration was detected in the cortex of the animals.
3.3.2.1.2. Pattern of CD4* cell infiltration
Following trypanosome infection a few CD4"^  cells (1.370 + 1.120) were detected in the 
meninges 14 days after infection (Table 3.8). The number of CD4^ cells increased as the 
infection progressed thi'ough days 21 and 28 post-infection (7.330 ±  1.970, 18.330 + 6.140 
respectively). This increased number of cells was not considered significantly higher than 
found at early time-points in the infection. Seven days following the exacerbation of CNS 
reaction the CD4^ cell (110.300 + 58.200) number showed a further increase. The 
infiltration of the meninges by CD4^ cells at this time was significantly more substantial 
than that found during the acute and early-CNS stages of the reaction (p<0.0001, 
p<0.0001, p=0.0001 and p=0.0003 respectively). The CD4^ cell (193.300 + 27.500) count 
increased further in mice killed 14 days following the administration of a single 
diminazene acetuiate treatment. This was again significantly higher than the infiltration 
levels encountered in the animals killed before diminazene aceturate administration 
(p<0.0001, p<0.0001, p<0.0001, p=0.0001) but was not considered significantly different 
to the cell count assessed in mice killed 7 days after the drug treatment (p-0.990). In 
animals killed 7 days after the induction of the PTRE, 180.380 ± 6.780 CD4^ cells were 
detected in the meninges. This was significantly higher than the cell count detected in the 
acute and early CNS-stages of the infection (p<0.0001, p<0.0001, p=0.0001 and p=0.0004) 
but was not changed significantly from animals in which the late-CNS stage of the disease 
had been induced (p=0.993, p=1.000). By 14 days after the administration of the second 
diminazene aceturate treatment the CD4^ cell count had increased to 283.400 + 25.800. 
Although this was considered significantly higher than the infiltration seen in animals at 7, 
14, 21 and 28 days post-infection (p<0.0001, p<0.0001, p< 0.0001, and p=0.0001) the 
increase cell count was not significantly higher than that resulting from the induction of the 
late-stage CNS reaction or that found 7 days following the induction of the PTRE 
(p=0.999, p=0.901,p=0.929).
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A similar overall pattern of CD4^cell infiltration was found in the corpus callosum (Table 
3.9). However in this area of the brain, CD4^ cell counts (1.875 ± 0.402) from animals 
killed at 28 days post-infection were significantly higher than those found in mice at earlier 
time-points in the infection (p=0.0002, p=0.0004, p=0.016). This difference was not 
apparent in the meninges. Following the induction of the late-CNS stage of the infection 
and the PTRE an increased CD4^ cell count was found. The infiltration level of the corpus 
callosum by CD4'*' cells at each of these times was significantly higher than that 
encountered in the acute and early-CNS stages of the disease (p<0.0001 in each case). 
Although an increase in CD4^ cell infiltration was found in animals with the PTRE 
compared to those with late-CNS stage infections, this rise in cell number was not 
considered significant.
When CD4^ cell infiltration of the external capsule was investigated an analogous pattern 
to that found in the corpus callosum was seen (Table 3.10). Again animals killed on day 
28 post-infection showed a significantly higher CD4^ cell (4.583 ± 0.417) infiltration than 
that seen in the mice killed at the earlier time-points (0.0001, p<0.0001, p=0.0005). 
Following induction of the late-stage CNS response and the PTRE the number of CD4^ 
cells infiltrationg the corpus callosum increased significantly compared with all animals 
killed during the acute and early-stage CNS infections (p<0.0001 in each case). No 
significant changes were apparent between any of the groups of mice killed during the late- 
CNS stage of the infection or the PTRE.
An investigation of the CD4^ cell infiltration of the caudate putamen (Table 3.11) showed 
a pattern similar to that found in the meninges where no significant changes were detected 
between groups of animals killed during the acute and early-CNS stage of the disease. 
Mice killed 7 days after administration of a single diminazene aceturate treatment 
displayed increased levels of CD4^ cells in the caudate putamen which were significantly 
higher than the cell count found during the acute and early-CNS stage of the infection 
(p<0.0001, p<0.0001, p==0.0001, p=0.0003). The cell count found at 14 days after the drug 
treatment remained significantly higher than that measured in the earlier groups (p<0.0001, 
p<0.0001, p<0.0001, p=0.0001). When the PTRE was induced, by treating relapsed mice 
with a second dose of diminazene aceturate, CD4^ cell counts in animals killed at 7 
(p<0.0001, p<0.0001, p=0.0001, p=0.0004) and 14 (p<0.0001, p<0.0001, p<0.0001, 
p=0.0001) days after the drug treatment remained significantly higher than that seen during 
the acute and early-CNS stages of the disease. Again no significant differences were 
detected between the CD4^ cell counts in the caudate putamen from any group of animals 
following the induction of the late-CNS stage of the infection or the PTRE.
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This pattern was again followed in the CD4^ cell infiltration of the cerebral cortex (Table 
3.12). Only a very occasional CD4^ cell was detected during the acute and early-CNS 
infections and no significant differences were found between these groups. Seven days 
after exacerbation of the CNS reaction, by administration of a subcurative diminazene 
aceturate dose, the CD4^ cell (6.750 + 0.000) number was significantly higher than that 
seen in all groups of animals killed previously (p<0.0001, p<0.0001, p=0.0002, p=0.0001). 
The CD4^ cell (12.790 + 3.950) count increased in animals killed at 14 days after 
administration of the drug and remained significantly higher than that found during the 
acute and early-CNS stages of the infection (p<0.0001 in all cases). In mice killed 7 days 
following the induction of the PTRE the CD4^ cell (4.430 + 1.600) remained significantly 
higher than that seen in the acute and early-CNS stage mice (p=0.0002, p=0.0002, 
p=0.001, p=0.0007) but was reduced compared to that found in animals at 14 days after 
induction of the late-CNS stage reaction. The reduction in CD4^ cell infiltration showed a 
borderline significance level (p=0.052) when compared to this group of late-CNS stage 
animals. By 14 days after the induction of the PTRE the CD4^ (16.340 + 1.220) cell 
infiltration had again increased and was significantly higher than that seen in groups of 
mice killed during the acute and early CNS-stage of the infection (p<0.0001 in each case). 
In addition, the CD4^ cell count seen in the cerebral cortex at this time was shown to be 
significantly higher than that found in animals killed at 7 days following the induction of 
the PTRE (p=0.017).
Differences in the infiltration pattern of CD4^ cells between each brain area, following the 
various treatment regimens, were also examined. No CD4^ cells were detected in any of 
the areas at 7 days post-infection. At 14 days post infection (Table 3.13) a few cells were 
apparent in the meninges and corpus callosum but no significant differences between the 
CD4^ cell population infiltrating each area were found at this time. In animals killed on 
day 21 post-infection (Table 3.14) the CD4^ cell (7.330 + 1.970) count in the meninges 
was significantly higher than that found in the corpus callosum (0.333 ± 0.220), external 
capsule (0.833 ± 0.833), caudate putamen (0.250 + 0.250) and cerebral cortex (0.042 + 
0.042) with p-values of 0.002, 0.003, 0.001, 0.001 respectively. At day 28 post-infection 
(Table 3.15) this significant increase in CD4^ population in the meninges (18.330 ± 6.140) 
compared with the remaining brain areas was still apparent (p=0.002, p=0.028, p=0.0003, 
p=0.0001). The level of CD4’^ cells in the cerebral cortex (0.000 ± 0.000) at this time was 
significantly lower that seen in the corpus callosum (1.875 + 0.402) and the external 
capsule (4.583 + 0.417) (p=0.046, p=0.003 respectively). In addition, the external capsule 
showed a significantly (p=0.018) higher CD4^ count than that found in the caudate 
putamen (0.750 + 0.520).
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Following the exacerbation of the CNS response, to mirror the late-stage CNS disease, 
CD4^ cells were detected in all brain areas. The number of CD4^ cell found in the 
meninges (110.300 + 58.200) 7 days after the induction of the reaction (Table 3.16) was 
significantly higher than that seen in the corpus callosum (28.250 + 4.250), caudate 
putamen (19.780 ± 6.340) and cerebral cortex (6.750 + 0.000) (p=0.037, p=0.018, p=0.004 
respectively). No significant difference (p=0.138) was detected between the CD4^ count in 
the meninges and the external capsule (48.520 ± 3.120) at this time. By 14 days after the 
administration of a single diminazene aceturate treatment (Table 3.17) the meninges 
(193.3000 + 27.500) showed a significantly higher CD4^ cell level than the corpus 
callosum (48.410 ± 7.800), external capsule (61.880 + 8.520), caudate putamen (19.310 + 
9.340) and cerebral cortex (12.790 + 3.950) with p-values of 0.0005, 0.003, <0.0001 and 
<0.0001 respectively. The number of CD4^ cells found in the corpus callosum and 
external capsule was significantly higher than that found in the caudate putamen (p=0.002, 
p-0.0003 respectively) and cerebral cortex (p=0.004, p=0.0001 respectively).
Seven days following the induction of the PTRE (Table 3.18), the CD4^ population in the 
meninges (180.380 ± 6.780) was significantly higher than the number of CD4^ cells found 
in the corpus callosum (54.300 ± 11.700), external capsule (40.160 ± 5.460), caudate 
putamen (13.310 + 1.130) or cerebral cortex (4.430 + 1.600) (p=0.022, p=0.003, p=0.0001, 
p<0.0001 respectively). The CD4^ population in the corpus callosum was not significantly 
different to that seen in the external capsule (p=0.842), but was significantly higher than 
that found in the caudate putamen (p=0.016) and the cerebral cortex (p=0.0002). This 
situation was also apparent in the external capsule, which showed a higher CD4^ cell 
infiltration of borderline significance than the caudate putamen (p=0.056) and a 
significantly higher CD4^ count than that seen in the cerebral cortex (p=0.0005). The 
presence of CD4^ cells in the caudate putamen was found to be significantly greater than 
the CD4^ infiltration seen in the cerebral cortex (p=0.044) at this time. By 14 days after 
the induction of the severe meningoencephalitis (Table 3.19) the CD4^ population in the 
meninges (138.400 + 52.800) remained significantly higher than in the corpus callosum 
(63.900 + 12.300), external capsule (69.380 ± 1.250), caudate putamen (24.310 ± 9.060) 
and cerebral cortex (16.340 ± 1.220) (p=0.009, p=0.013, p=0.001, p=0.0009 respectively). 
In addition, the infiltration level foimd in the corpus callosum and the external capsule was 
higher than that seen in the caudate putamen (p=0.040, p=0.029 respectively and the 
cerebral cortex (p=0.016, p=0.012 respectively).
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3.3.2.1.3. Pattern of CDS* cell infiltration
Following trypanosome infection a few CD8^ cells (0.700 + 0.490) were detected in the 
meninges at 14 days after the infection (Table 3.20). The number of CD8^ cells in the 
meninges increased on days 21 (0.938 + 0.938) and 28 (4.440 ± 1.290) post-infection as 
the infection progressed. On day 28 post-infection the level of CD8  ^ infiltration was 
significantly higher than that seen at either 7 days post-infection (p=0.0008) or 14 days 
post-infection (p=0.013) but was not increased significantly compared with animals killed 
at day 21 post-infection (p=0.142). When the late-CNS stage of the infection was induced 
by a subcurative diminazene aceturate treatment a further increase in CD8  ^cell (17.080 ± 
7.720) infiltration was found. This was significantly higher than the level seen in animals 
at 7 (p<0.0001), 14 (p<0.0001) or 21 (p=0.0003) days post-infection, not significantly 
altered compared with animals killed on day 28 post-infection (p=0.070). By 14 days after 
the drug treatment the CD8^ cell (38.950 + 2.870) number was significantly higher than 
that found in all groups of mice killed during the acute and early-CNS stage of the disease 
(pO.OOOl, p<0.0001, p<0.0001, p=0.0001) but was not altered compared to mice killed 7 
days after exacerbation of the CNS reaction (p=0.090). Following the induction of the 
PTRE by administration of a second dose of diminazene aceturate, animals killed 7 days 
following the drug treatment showed a CD8  ^cell count of 32.690 + 4.790. This count was 
again significantly higher than that witnessed in the acute and early-CNS stage infections 
(p<0.0001, p<0.0001, p<0.0001, p=0.0003). By 14 days after the induction of the PTRE 
the CD8  ^ level (36.400 ± 10.100) remained significantly elevated compared with animals 
killed on days 7, 14, 21 and 28 post-infection (p<0.0001, p<0.0001, p<0.0001, p=0.0001). 
No significant changes in the CD 8  ^cell infiltration in the meninges were detected between 
groups of animals killed following the induction of the late-stage CNS response or the 
PTRE.
Infiltration of the corpus callosum by CD8^ cells was not detected until day 21 post­
infection when a small number of cells was counted (0.167 ± 0.167) (Table 3.21). This 
increased slightly on day 28 post-infection (0.417 ± 0.300). No significant alterations in 
the CD8^ cell population were detected in any of the groups of mice killed during the acute 
or early-CNS stage of the infections. A rise in the level of CD8^ cell (7.630 ± 2.620) 
infiltration was found in animals killed 7 days after exacerbation of the CNS response. 
The CD8  ^cell count measured in these mice was significantly higher than that seen in any 
of the groups killed during the acute or early-CNS stage of the infection (p<0.0001 in all 
cases). A fiirther increase in CD8  ^cell (22.020 ± 3.790) count was found in animals killed
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14 days after the administration of a single diminazene aceturate treatment. The CDS’*” 
population in the corpus callosum of these mice was significantly higher than in animals 
killed at 7, 14, 21, and 28 days post-infection (p<0.0001 in all cases) and that found in 
mice killed at 7 days after the induction of the late-CNS stage response (p=0.005). The 
CDS’*" cell (11.740 + 1.690) count in animals killed 7 days following the induction of the 
PTRE was not significantly different to that found in either group of mice exhibiting the 
late-CNS stage of the infection (p=0.636, p=0.072 respectively) but was significantly 
higher than the acute and early-CNS stage groups (p<0.0001 in all cases). By 14 days after 
the induction of the PTRE the CD8  ^ cell (27.540 + 7.11) count was significantly raised 
compared with mice killed at 7, 14, 21, and 28 days post-infection (p<0.0001 in all cases) 
as well as mice killed at 7 days after administration of a single diminazene aceturate 
treatment (p=0.003) and mice killed 7 days after the induction of the PTRE (p=0.037).
When the CD 8  ^cell infiltration pattern of the external capsule was examined no cells were 
detected until day 21 post-infeetion when a few CD8  ^cells (0.833 + 0.833) were counted 
(Table 3.22). The number of CD8^ cells (1.250 + 0.722) detected increased slightly by day 
28 post-infection. No statistically significant changes were found in the CD8^ cell 
numbers between groups of mice killed during the acute of early-CNS stage of the 
infection. A further rise in the CD8^ cell (12.287 + 0.000) population was seen in mice 
killed 7 days following the exacerbation of the CNS reaction. The cell count seen in these 
animals was significantly higher that that found in mice killed during the acute and early- 
CNS stage of the disease (p<0.0001, p<0.0001, p=0.0006, p=0.002). The CD8  ^ cell 
(23.630 + 3.210) count in animals killed 14 days after administration of the diminazene 
aceturate dose was also significantly higher than that seen in non-diminazene aceturate 
treated animals (p<0.0001 in all cases). In addition, the CD8^ cell counts in mice killed at 
7 (12.030 ± 1.180) and 14 (25.000 + 5.000) days following the induction of the PTRE were 
significantly higher than those found in mice during the acute and early-CNS stage of the 
infection (p<0.0001 in all cases). No significant changes were detected in the level of 
CD8  ^cell infiltration between any of the groups of animals exhibiting the late-CNS stage 
of the disease and the PTRE.
Only the very occasional CD8^ cell (0.250 ± 0.250; day 21 post-infection) was detected in 
the caudate putamen during the acute and early-CNS stage of trypanosome infection (Table 
3.23). A slight increase in the number of CD8^ cells (3.094 + 0.281) was seen 7 days after 
the administration of a single diminazene aceturate dose. The CD8^population in these 
animals was significantly higher than that found in mice killed at 7 (p=0.008), 14 
(p=0.008) and 28 (p=0.017) days post-infection. The increase was of borderline
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significance (p=0.052) when compared to mice killed at day 21 post-infection. By 14 days 
after the exacerbation of the CNS response the CDS’*" cell (3.170 + 1.440) count was 
significantly higher than that seen in any of the non-diminazene aceturate treated mice 
(p=0.0005, p=0.0005, p=0.012, p=0.003). The level of CDS'" cell (2.453 ± 0.736) 
infiltration found in mice killed 7 days following the induction of the PTRE remained 
significantly higher than that seen in animals killed at 7 (p=0.0006), 14 (p=0.0006), and 28 
(p=0.019) days post-infection but was not significantly altered from the population found 
at 21 (p=0.069) days post-infection. By 14 days after the administration of a second 
diminazene aceturate treatment the CD8^ cell (10.440 + 6.060) count was again 
significantly greater than that found in all groups of animals killed during the acute or earl- 
CNS stage of the infection (p<0.0001, p<0.0001, p=0.0003, p=0.0001). The CD8^ cell 
populations found in all the groups of mice killed following either a single or double dose 
of diminazene aceturate were not significantly different to each other.
No CD8^ cells were detected in the cerebral cortex of mice killed during the acute or early- 
CNS stage of trypanosome infection (Table 3.24). By 7 days after the induction of the 
late-CNS stage of the disease a few CD8^ cells (2.250 + 0.000) were fomid. This cell 
population was significantly higher than in any of the earlier groups of mice (p=0.006, 
p=0.006, p=0.009, p=0.009). In animals killed at 14 days after the administration of a 
single diminazene aceturate treatment the CD 8  ^cell (3.100 + 0.816) remained significantly 
greater than that found during the acute or early-CNS stage of the disease (p<0.0001 in all 
cases). Seven days following the induction of the PTRE the CD8  ^ cell (1.328 + 0.465) 
remained significantly higher than that found in mice killed at 7, 14, 21 or 28 days post­
infection (p=0.002, p=0.002, p=0.008, p=0.008). This increased presence of CD8^ cells 
(5.969 + 0.469) was also seen in mice killed at 14 days after treatment with a second dose 
of diminazene aceturate and the infiltration level of the cerebral cortex was significantly 
higher than that seen in mice during the acute or early-CNS stage of the infection 
(p<0.0001 in all cases). Furthermore, the CD8^ population found in mice 14 days after the 
induction of the PTRE was significantly greater than that seen in mice killed at 7 days 
following the second diminazene aceturate treatment (p=0.0006). No additional 
differences were detected in CD8^ cell infiltration between any other groups of mice killed 
following the induetion of the late-CNS stage of the infection or the PTRE.
In addition to examining the CD 8  ^cell infiltration in individual brain areas following each 
treatment regimen, differences in the CD8  ^ population between each brain area studied 
were investigated. No CD8^ cells were found in any of the brain areas monitored at 7 days 
post-infection. By 14 days after the infection a few CD8^ cells were detected in the
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meninges (0.700 + 0.490) (Table, 3.25). However, the presence of these cells was not 
considered to be a significant increase in population compared with the remaining brain 
areas. On day 21 post-infection CD8  ^ cells were found in the meninges (0.938 + 0.938), 
the coipus callosum (0.167 + 0.167) and the external capsule (0,833 ± 0.833) (Table 3.26). 
CD8^ cells were not seen in the cerebral cortex in this group of mice. No significant 
alterations to the CD8^ cell population were detected between the various areas of the brain 
studied at this time. On day 28 post-infection 4.440 ± 1.260 CD8  ^cells were found in the 
meninges (Table 3.27). This was significantly higher than that seen in the corpus callosum 
(0.417 + 0.300), caudate putamen (0.000 + 0.000) or cerebral cortex (0.000 + 0.000) with 
p-values of 0.008, 0.002 and 0.002 respectively. The raised level of CD8  ^cell infiltration 
seenin external capsule (1.250 + 0.722) was of borderline significance (p=0.050) to that 
found in the meninges.
Following exacerbation of the CNS reaction by administration of a single diminazene 
aceturate treatment, CD8^ cells were found in the meninges (17.080 ± 7.720), corpus 
callosum (7.630 + 2.620), external capsule (12.287 ± 0.000), caudate putamen (3.094 + 
0.281) and cerebral cortex (2.250 + 0.000) 7 days after administration of the drug (Table 
3.28). No significant differences were detected in the CD8^ cell infiltration between the 
various brain areas following this regimen. In mice killed 14 days after the induction of 
the late-CNS stage response the number of CD8  ^ cells in the meninges (38.950 ± 2.870) 
was significantly higher than the number of CD8’*' cells in the caudate putamen (3.710 + 
1.440) and cerebral cortex (3.100 ± 0.816) (p<0.0001 in both cases) (Table 3.29). 
differences were apparent between the CD 8  ^ cell population found in the meninges and 
that found in either the corpus callosum (22.020 + 3.790) or external capsule (23.630 + 
3.210) (p=0.203, p=0.334 respectively). The number of CD8^ cells seen in the corpus 
callosum and external capsule was significantly higher than the CD8^ cell infiltration of 
either the caudate putamen (p=0.0001, p<0.0001 respectively and cerebral cortex 
(p=0.0001, p<0.0001 respectively). No difference in CD8  ^ cell infiltration was apparent 
between the population found in the caudate putamen and the cerebral cortex (P=0.999).
In animals killed 7 days following the induction of the PTRE the number of CD 8  ^ cells 
infiltrating the meninges (32.690 ± 4.790) was significantly higher that that seen in the 
corpus callosum (11.740 + 1.690), external capsule (12.030 + 1.180), caudate putamen 
(2.453 + 0.736) and cerebral cortex (1.328 + 0.456) (p=0.007, p=0.009, p<0.0001, 
p<0.0001 respectively) (Table 3.30). The CDS’*" population in the corpus callosum and 
external capsule was also significantly higher than seen in the caudate putamen (p=0.0005, 
p=0.0004 respectively) and the cerebral cortex (p=0.0001, p<0.0001 respectively). No
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significant difference in the infiltration of CD8^ cells was found between the caudate 
putamen and the cerebral cortex (p=0.493). When mice were killed 14 days after 
administration of a second diminazene aceturate treatment the number of CD8  ^cells found 
in the meninges (36.400 + 10.100) remained significantly (p=0.035) higher than that found 
in the cerebral cortex (5.969 + 0.469), No further significant differences were found 
between the CD8^ cell infiltration in the corpus callosum (27.540 ± 7.110), external 
capsule (25.000 ± 5.000), and caudate putamen (10.440 + 6.060) at this stage in the disease 
(Table 3.31).
3.3.2.2. Macrophage infiltration
A small number of macrophages were detected within in the meninges and blood vessels of 
uninfected animals and those killed at 7 days post-infection. As the neuroinflammatory 
response progressed, the number of macrophages infiltrating the brain increased. By day 
28 post-infection these cells were found in the corpus callosum and an occassional 
macrophage was seen in the caudate putamen. No macrophages were detected in the 
cerebral cortex during the acute or early-CNS stages of the infection. If the CNS reaction 
was exacerbated by the administration of a single diminazene aceturate treatment 
numerous macrophages could be seen in the meninges, perivascular cuffs, corpus callosum 
and external capsule. Positively stained cells were also detected in the caudate putamen 
and cerebral cortex at this stage. If a second dose of diminazene aceturate was given to the 
infected animals to induce a severe meningoencephalitis no fuither increase in macrophage 
infiltration was found and the numbers of these cells remained largely stable despite the 
increase in the severity of the CNS reaction induced by this treatment regimen. The 
absolute number of macrophages within the inflammatory infiltrate was not assessed.
3.3.2 3. B-lymphocyte infiltration
The presence of B-lymphocytes within the CNS was examined in a qualitative manner and 
was not quantified. No B-lymphocytes were detected in the brains of uninfected or 
T. 6 . infected mice during the acute or early CNS-stage of the infection. Following 
induction of the late-CNS stage of the disease by diminazene aceturate treatment, a few B- 
cells could be found infiltrating the meninges and in the perivascular cuffs. The presence 
of the B-cells increased with the severity of the CNS reaction and larger numbers of these 
cells were found following the administration of a second diminazene aceturate treatment 
to further augment the nemoinflammatory response. Furthermore, as the CNS
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inflammatory response developed, increasing numbers of plasma cells were found in the 
inflammatory cell infiltrate. The majority of the B-cells and plasma cells remained 
confined to the meninges, perivascular cuffs and the ventricles. Only a small proportion of 
the B-cell population was detected infiltrating the brain parenchyma.
3.3.2.4. Astrocyte activation
Astrocyte activation, as characterised by an increase in; the production of glial fibrillary 
acidic protein (GFAP), the degree and complexity of cellular stellation, and in the numbers 
of GFAP positive eells was detected in the brains of mice rapidly following trypanosome 
infection (Figure 3.1, GFAP positive cells show brown staining pattern). Initial signs of 
astrocyte activation were seen in animals by 14 days after infection. At this point 
astrocytes in the hippoeampus and surrounding the ventricles displayed an increased level 
of GFAP compared to uninfected mice. As the severity of the neuroinflammation 
increased the degree of astrocyte activation was also found to increase. The astrocytes 
stained more intensely for GFAP, increased in size and number and developed longer and 
more complex cellular processes. Following sub-curative drug treatment activated 
astrocytes were seen in the hippocampus and diffusing tlnoughout the brain. Intense 
GFAP staining was detected around blood vessels and delimiting the ventricles and 
meninges. A further increase in the astrogliosis was foimd following the induction of the 
PTRE and reactive cells were widespread throughout the brain tissue. At this point the 
cells were large, displayed numerous highly complex cellular processes and stained 
intensely for GFAP. Although the astrocyte activation was diffuse, the population within 
the hippocampus appeared greater in number and stained more intensely for GFAP that the 
reactive cells found in the cerebral cortex and caudate putamen (Figui'e 3.1).
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3.4. Discussion
Histopathological assessment of brain sections, prepared from trypanosome-infected mice 
killed at various stages thi'oughout the course of the disease process, showed a developing 
meningoencephalitis with activation of astrocytes and infiltration of a range of 
inflammatory cells. The inflammatory cell infiltration seemed to proceed in an ordered 
sequential pattern throughout the meninges, corpus callosum, external capsule, caudate 
putamen and cerebral cortex. The inflammatory cells initially appeared to infiltrate the 
meninges closely followed by the corpus callosum and the external capsule. As the 
severity of the reaction increased the cells moved deeper into the brain parenchyma and 
could be detected in the caudate putamen. The cerebral cortex appeared to be the final area 
of the brain to be infiltrated by the inflammatory cells. CD4^ cells were detected in larger 
numbers than CDS^cells and, in general, preceded the appearance of the CDS'*’ cells. 
Macrophages were found in mounting numbers and diffused throughout the brain tissue as 
the severity of the inflammatory reaction increase. This augmentation of the macrophage 
population was fomid until the late-CNS stage of the infection was reached, at which point 
their numbers appeared to plateaux. B-cells and plasma cells were only detected during 
the late-CNS stage of the disease and in the post-treatment reactive encephalopathy 
(PTRE) and were not seen during the acute or early-CNS stage of the infection.
Following infection no pathological changes were observed in the CNS of the mice until 
14 days after the animals had been infected with the parasites. At this stage only very mild 
inflammatory changes were apparent with the initiation of astrocyte activation and the 
appearance of a few CD4'*’ and CDS'*' cells in the meninges. The occasional CD4'*' cell was 
also found in the corpus callosum at this point. As the disease progressed into the early- 
CNS stage, the CD4^ and CD8  ^ cells became more numerous and the severity of the 
overall inflammatory reaction was significantly greater than that found during the acute 
stage of the disease. By day 28 post-infection, CD4'*' cells could be detected in the caudate 
putamen together with the occasional macrophage. No CD8'*’ cells were present in this 
brain region at this time in the infection. Apart from the detection of an infi-equent CD4'*’ 
cell in the cerebral cortex at day 21 post-infection this area appeared to remain generally 
free from inflammatory changes throughout the acute and early-CNS stage of the disease. 
Astrocyte activation, characterised by an increase in cell number and intensity of GFAP 
staining, became more widespread as the infection progressed.
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When the severity of the CNS reaction was exacerbated, by treating the mice with a 
snbcnrative diminazene aceturate treatment to mirror the late-CNS stage of the infection, a 
substantial increase in the number of inflammatory cells was found. Fui'thermore, CD4'*' 
cells, CD8  ^cells and macrophages were all detected in the cerebral cortex at this time. B- 
cells were also appar ent following exacerbation of the reaction; however, they were largely 
confined to the meninges, ventricles and perivascular cuffs. On induction of the PTRE a 
moderate increase in the severity of the inflammatory reaction was found. Although this 
was accompanied by an overall rise in the numbers of CD4^ and CDS’*" cells present, this 
was not a significant increase compared with the cell numbers found during the late-CNS 
stage of the disease. In fact, a slight decrease in the T-cell populations, compared with 
those seen 14 days after induction of the late-CNS stage, was detected 7 days following the 
onset of the PTRE. This is also true of the macrophage population since this appeared to 
stabilise following the induction of the late-CNS stage of the disease and did not continue 
to increase on further exacerbation of the CNS reaction. This suggests that the increased 
level of B-cell infiltration and the appearance of numerous plasma cells seen during the 
PTRE may help to account for the increase in the severity of the neuroinflammatory 
response found at this stage of the disease.
In the mouse model of human African trypanosomiasis used in this investigation the 
parasites have been shown to become established within the CNS between 14 and 21 days 
after the mice have become infected (Jennings, Whitelaw, Holmes, Chizyuka et a i, 1979). 
T-cells were not detected in uninfected animals or mice killed on day 7 post-infection. The 
first signs of CNS inflammation, including astrocyte activation and T-cell infiltration, were 
detected in mice killed on day 14 post-infection. Therefore, the initiation of the 
inflammatory reaction occurs before the parasites have invaded the brain tissue. The 
primary signal for induction of this reaction remains unclear. Since astrocytic foot- 
processes are in close proximity with the endothelial cells forming the blood-brain barrier 
(BBB) it is possible that these cells detect the presence of soluble factors, produced either 
directly by the trypanosomes or by the developing inflammatory response in the peripheral 
system, that induce the astrocytes to adopt an activated conformation. Following 
activation astrocytes have been shown to be capable of expressing cellular adhesion 
molecules and a range of inflammatory mediators (Slirikant and Benveniste, 1996) that 
could help facilitate the subsequent infiltration of inflammatory cells into the CNS. If the 
initiation of the reaction takes place in this manner, it is possible that the activated 
astrocytes control the initial development of the early CNS inflammatory reaction seen 
following trypanosome infection.
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The activation of the astrocytic population is not the only possible scenario that would 
result in the development of the neuroinflammatory reaction. It is known that naïve T-cells 
do not cross the BBB and are excluded from the brain tissue. This has been demonstrated 
by the lack of a T-cell response to allogenic tissue or pathogens when the material is 
delivered directly into the brain parenchyma (Aloisi, Ria, and Adorini, 2000). However, 
once T-cells have become primed by the presence of specific antigens in the peripheral 
system they can cross the BBB and enter the CNS for the purpose of immune surveillance. 
This phenomenon has been shown in the development of experimental allergic 
encephalomyelitis (EAE), the animal model of multiple sclerosis (MS), seen following the 
transfer of T-cells activated against myelin basic protein into the bloodstream of normal 
healthy animals. In contrast, transfer of naïve T-cells does not result in the generation of 
EAE in the healthy recipients (Wekerle et al, 1986). Although this infiltration of the CNS 
by activated T-cells does occur, the numbers of T-cells entering the brain is vastly reduced 
compared with that found in non-CNS tissue (Hickey, 2001). Following trypanosome 
infection, T-cells in the periphery will become activated thi'ough the presence of the 
parasite antigens, allowing their subsequent entry into the CNS and this may explain the 
presence of the occasional CD4'*' cell in the corpus callosum detected during the acute stage 
of the reaction.
The regulation of T-cell recruitment is not strictly controlled in all brain areas as a 
substantial T-cell and monocytic response is found in the meninges, cerebral ventricles and 
choroid plexus when allogenic tissue or pathogens are placed within the cerebral ventricles 
(Aloisi et al, 2000). This may be a result of the presence of a weaker BBB in these areas, 
in which the tight junctions between the endothelial cells exhibit a lower electrical 
resistance compared to that created by the endothelial cells forming the BBB siuTOunding 
the brain micro vessels (Zhang and Tuomanen, 1999). The cellular infiltration pattern 
associated with trypanosome infection seems to follow this precedent since the appearance 
of inflammatory cells was first detected in the meninges and ventricles. It is unclear 
whether the appearance of activated astrocytes or the infiltration of inflammatory cells 
occurs first in the brain following trypanosome infection. Therefore, it is feasible that the 
presence of the activated inflammatory cells, rather than the induction of astrocyte 
activation, controls the development of the CNS inflammation seen during the acute and 
early-CNS stage of the reaction and may be responsible for the initial activation of the 
astrocytic population.
Following parasite invasion of the CNS the severity of the response increased significantly 
and a corresponding rise in the number of inflammatory cells was seen. The introduction
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of pai'asite antigen within the brain tissue could augment this inflammatory response and 
stimulate the clonal expansion of the individual T-cells already patrolling the CNS 
compartment. This could result in a further exacerbation of the inflammation since the 
primed T-cells would become fully activated and secrete additional inflammatory 
mediators including cytokines and chemokines. On induction of the late-CNS stage of the 
disease a more severe neuroinflammatory response was seen with increased numbers of T- 
cells and macrophages. B-cells were detected for the first time in brain sections prepared 
from animals exhibiting this stage of the infection. The ability of B-cells to enter the 
normal CNS for the purposes of immune surveillance has not been demonstrated 
unequivocally. However, following the initiation of an immune response within the CNS 
the presence of B-cells in the brain is not uncommon and oligoclonal bands can be found in 
the cerebrospinal fluid (CSF). This indicates that under inflammatory conditions B-cells 
can enter the CNS, clonally expand and differentiate into antibody secreting plasma cells 
(Hickey, 2001). Human African trypanosomiasis is characterised by a non-specific 
polyclonal B-cell expansion and elevated levels of IgM in the serum that are most 
pronounced in the early-stages of the disease. During the CNS-stage of the infection, 
increased IgM levels are found in the CSF. The detection of elevated IgM levels in the 
CSF is used as a valuable indicator that the disease has progressed beyond the peripheral 
compartments and is manifest in the CNS (Greenwood and Whittle, 1980). The presence 
of IgM in the CSF could reflect the infiltration of the CNS by B-cells and their subsequent 
differentiation into antibody secreting plasma cells. The discovery of B-cells in the CNS 
in the mouse model of HAT used in this study substantiates this hypothesis. Following the 
induction of the PTRE numerous B-cells and plasma cells were seen in the CNS. The 
presence of B-cells, CD4’’" cells and specific parasite antigen within the brain at this time 
could permit the proliferation and differentiation of the B-cells into antibody producing 
plasma cells, in a CD4’’' cell-dependent manner. Whether the increased number of B-cells 
is the result of this type of clonal expansion or due to the influx of additional B-cells from 
the periphery remains to be elucidated and are not mutually exclusive.
Probably the most methodically investigated inflammatory disease affecting the brain is 
MS. MS is an inflammatory condition of the CNS white matter and the disease patterns 
found in MS brain are simulated in EAE. This model has indicated a significant role for 
autoreactive CD4^ T-cells in the generation of the CNS inflammatory reaction. In EAE 
these CD4'*’ cells are directed against CNS antigens such as myelin basic protein (MBP) or 
proteolipid protein (PLP) and are consequently involved in the demyelination associated 
with the disease pathogenesis. Moreover, the condition can be induced in normal animals 
following passive transfer of autoreactive T-cells taken from an affected animal, further
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demonstrating the importance of this cell type in the development of the disease state 
(Bright and Sriram, 2001), Such autoreactive T-cells have also been demonstrated in 
patients with MS. It appears that these cells become activated in the periphery, by an 
unknown mechanism, allowing their entry to the CNS. Once in the brain, the cells 
recognise specific antigen presented by local APC’s or glial cells leading to cellular 
proliferation and disease progression. However, there are some anomalies between the 
inflammatory reaction seen in the animal model and that of MS patients. The lesions 
found in EAE are composed largely of CD4^ cells whereas CD8  ^ cells generally 
predominate in MS lesions (Bauer, Rauschlca, and Lassmann, 2001; Gay, Drye, Dick, and 
Esiri, 1997). This may explain why the disease can be ameliorated in EAE by 
administration of anti-CD4^ antibody, but the treatment does not result in the resolution of 
the condition in patients suffering from MS despite an overall reduction in the total number 
of CD4'*' cells in the peripheral blood (Bright and Sriram, 2001). It is possible that such 
anomalies also exist between the murine model of human African trypanosomiasis and the 
disease pathogenesis seen in patients. This seems unlikely, however, as the CNS 
inflammation induced in the model results from the initial infection with trypanosomes, as 
is the case in the hiunan disease. The causes and precipitating factors in the development 
of MS remain unknown. Although there is strong evidence indicating that the CNS 
inflammation is the consequence of an autoimmune disease directed against CNS myelin 
or oligodendrocytes, the possibility of the existence of a causative agent for the disease has 
yet to be discounted unequivocally (Bright and Sriram, 2001; Keegan and Noseworthy, 
2002). Therefore, in the animal model of MS the disease is initiated by an artificial means 
that may be distinct from the instigating factors of the CNS inflammatory reaction seen in 
human cases of MS and could alter the course of the disease.
In contrast to trypanosome induced CNS inflammation where CD4^ cells predominate in 
all of the brain areas studied, CD8  ^ cells are more numerous in the brain parenchyma in 
MS (Gay et al, 1997; Woodroofe, Bellamy, Feldmami, Davison et a l, 1986). In MS the 
CD8  ^cells infiltrate the brain parenchyma while the CD4^ cells remain largely confined to 
the meninges and perivascular cuffs (Gay et al, 1997). In trypanosome-induced 
neuroinflammation both T-cell subsets diffuse throughout the brain tissue, the appearance 
of the CDd"*" cells in the parenchyma precedes the infiltration of the CD 8  ^ cells and the 
number of CD4^ cells in each region outweighs the CD 8  ^ cell population. Multiple 
sclerosis is characterised by the presence of focal demyelination in association with T-cell 
and macrophage infiltration. The presence of inflammatory cells leads to axonal damage 
and deteriorated neuronal function (Bar-Or, Oliveira, Anderson, and Hafler, 1999). As the 
reaction progresses, the inflammatory lesions develop into a plaque or scar associated with
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activated astrocytes and microglial cells (Meinl, Aloisi, Ertl, Weber et a l, 1994). In 
trypanosome-induced CNS inflammation little neui'onal damage (Fink and Sclimidt, 1979; 
Morrison et al, 1983) has been detected despite the severity of the meningoencephalitic 
reaction. Some occurrence of demyelination, with no concomitant neuronal damage, has 
been reported in cases of human trypanosome infections (Cegielski and Durack, 1997), 
although this demyelination was not apparent in the mouse model used in tins investigation 
(personal communication. Prof. I. Griffiths, University of Glasgow Veterinary School)
The contrasting T-cell infiltration patterns seen between these conditions may help to 
account for the extensive differences in the neuropathological outcomes resulting from the 
two disease states. CD8  ^ cells are responsible for the elimination of intracellular 
pathogens such as viruses and certain bacteria and parasites. When activated the CD8  ^
cells recognise specific pathogen derived peptides, displayed on the surface of the infected 
cell, in conjunction with MHC class I molecules. Since virtually all cells in the body are 
capable of expressing MHC class I molecules, in conditions where an autoimmune 
mechanism is suspected, any cell expressing the autoantigen could become the target for 
CD8  ^ cell mediated cytotoxicity. This could result in major tissue damage through the 
induction of apoptotic pathways by the CD8  ^ cells, either via receptor mediated 
cytotoxicity involving the interaction of Fas-ligand and Fas-receptor or through the release 
of cytotoxic granules, containing perforin and granzymes, by the CDS’*' cell. Once 
apoptosis has been induced in the tar get cell, the CD8  ^cell disengages from the target and 
can recycle to kill numerous cells displaying the specific antigen in conjunction with MHC 
class I molecules. The cellular debris resulting from the destruction of the target cell then 
attracts macrophages to the site, which rapidly clear the cell fragments by phagocytosis. 
This pattern of tissue damage and inflammatory cell infiltration appears to outline the 
disease process found in MS (Bar-Or et al, 1999). Further evidence to support a role for 
CD8'*’ cells in the development of the neurological symptoms associated with MS comes 
from studies using a MS model, based of infection with Theiler's murine 
encephalomyelitis virus (Mui'ray, McGavern, Lin, Njenga et a l, 1998). In these 
investigations, CD8  ^and MHC class I molecule deficient mice developed the characteristic 
demyelination seen in MS but did not display the neurological impairment associated with 
the disease. When perforin and MHC class II molecule knockout mice were employed the 
neurological effects were restored in the animals thereby implicating perforin release by 
CDS'*" cells as the most likely cause of the neurological symptoms.
In trypanosome infections tissue damage within the CNS is not commonly found despite 
the development of a severe meningoencephalitic reaction. This may reflect the reversal of
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the CD4VCD8^ cell populations seen in the trypanosome-infected mice in this study since 
fewer cytotoxic CD8  ^ cells ai'e found and CD4^ cells predominate in the inflammatory 
reaction both in the meninges and the parenchyma. In contrast to CDS’*’ cells, CD4'*' cells 
are not generally responsible for the induction of cellular cytotoxicity. The main function 
of CD4^ cells is to help or induce an inflammatory response through the production of 
inflammatory mediators such as cytokines and chemokines. Furthermore, in order to 
trigger an immune response, primed CD4’*' cells must encounter their specific antigen 
presented in conjunction with MHC class II molecules. These MHC class II molecules, 
unlike the MHC class I molecules, cannot be expressed by all cell types and are generally 
only exhibited by professional antigen presenting cells such as macrophages, dendritic 
cells and B-cells. Other cell types, including astrocytes and microglia, can be induced to 
express these molecules following stimulation with certain molecules such as interferon-y 
(IFN-y) (Keegan and Noseworthy, 2002). Once activated the CD4^ cells proliferate and 
secrete cytokines that influence the course of the inflammatory response. The range of 
cytokines produced by the CD4^ cell is dependent on many overlapping factors that remain 
to be fully elucidated. In some circumstances the CD4^ cells will express cytokines such 
as IL-2 IFN-y, TNF-a and lymphotoxin that can entrance macrophage functions and induce 
opsinization and complement fixation as well as stimulate CD8  ^ cell activation. CD4'*' 
cells producing this range of cytokines are known as Thl cells and are important in the 
removal of intracellular pathogens due to their augmentation of the cell mediated immune 
response. On the other hand, CD4’*’ cells can express cytokines including IL-4, IL-5, IL- 6  
and IL-10, and are known as Th2 cells. This range of cytokines stimulates B-cell 
proliferation and antibody production and therefore favours a humoral rather than a cell 
mediated immune response (Mosmaim and Sad, 1996). The CD4^ cells present in MS and 
EAE seem to follow the Thl paradigm (Karpus and Ransohoff, 1998), and may therefore 
enhance the activation of the predominant CD 8  ^ cells and macrophages inadvertently 
leading to additional tissue damage. The situation in the murine model of trypanosome 
infection differs fiom that seen in MS since the most abundant T-cells belong to the CD4^ 
T-cell subset. In addition, the cytokine profile expressed in the brain during the CNS-stage 
of trypanosomiasis does not easily conform to a Thl or Tli2 type response since niRNA 
transcripts for IL-la, IL-6 , TNF-a, IL-4, and IFN-y have all been detected (Hunter, Gow, 
Kemiedy, Jemiings et a l, 1991; Hunter, Jemiings, Kemiedy, and Murray, 1992a). 
However, the cellular source of these inflammatory mediators has yet to be identified.
Plasma cells have been reported to be present in MS lesions, however it is thought that the 
B-cells in this condition do not cross the intact BBB and only enter the CNS following
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disruption of the barrier by the disease process (Keegan and Noseworthy, 2002; 
Woodroofe et al, 1986). This is perhaps also the case in the development of the CNS 
reaction associated with trypanosome infection. In this study no B-cells were detected in 
the brains of infected animals mitil the late-CNS stage of the disease when the CNS 
inflammatory response was significantly more severe than that seen during the acute and 
early-CNS stage of the reaction. The ability of B-cells to enter the CNS only at this point 
in the development of the CNS response could reflect some impairment of the BBB due to 
the on-going inflammatory reaction. Although damage to the BBB is a widely accepted 
consequence of the development of the CNS reaction, conflicting evidence exists regarding 
the breakdown of the BBB in this condition. In a study using fluorescent dye penetration 
of the CNS as an indication of BBB damage, severe impairment of the barrier was detected 
in rats at 40 days post-infection with T.b.brucei GVR35/C1.3 (Philip el al, 1994). 
However, the results of experiments investigating the effects of trypanosome infection on 
the BBB tight junction proteins occludin and zonula occludens 1, showed that T.b.brucei 
eould penetrate the rat CNS while causing no loss of the tight junction proteins (Mulenga 
et al, 2001). Therefore, the degree of impairment to the BBB resulting from trypanosome 
infection remains controversial.
The importance of T-cells in the development of a number of additional CNS 
inflammatory conditions has also been highlighted. Perhaps the most severe complication 
of infection with Plasmodium falciparum is the development of cerebral malaria. The 
neuropathology found in post-mortem examinations of brain tissue prepared from patients 
who have died from cerebral malaria is characterised by the congestion of the cerebral 
microvessels with parasitised red blood cells. Haemorrhages, the deposition of malarial 
pigment and oedema are also commonly found. In addition, damage to the BBB can occur 
and a reduction in the expression of the tight junction proteins zonula occludens 1 , 
oceludin and vinculin has been found. The invasion of the CNS by inflammatory cells is 
an inconsistent finding (Medana, Chaudlu'i, Chaii-Ling, and Hunt, 2001). However, T- 
cells have been shown to play a key role in the generation of cerebral malaria in animal 
models of the disease (Medana et al, 2001; Yanex, Manning, Cooley, Weidanz et a l,
1996). The contribution of T-cells to this reaction was demonstrated in studies that 
showed that athymic mice do not succumb to disease. Further work demonstrated that the 
action of the CD4^cells was important in the induction of the neuropathology since 
depletion of this T-cell subset protected the mice from the disease (Grau and Lou, 1995). 
A Thl mediated response has been implicated as the pathway used by the CD4^ cells in the 
development of cerebral malaria since knockout mice that could not synthesis IL-2 or IFN-
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y failed to acquire the condition whereas IL-4 and IL-10 knockout mice succumbed to 
cerebral malaiia (Yanex et al, 1996). In addition a requirement for fimctional CD8  ^cells 
in the development of the condition has also been shown using p2 -microglobulin knockout 
mice that do not express functional CD8  ^ receptors and in mice where the CD8  ^ cell 
population has been depleted using monoclonal antibodies to specifically remove the CD8  ^
cells. In these experiments no cerebral malaria developed in the mice following 
elimination of the CD8  ^cells (Yanex et al, 1996). The presence of B-cells does not seem 
to be a prerequisite for the development of cerebral malaria and the condition was found in 
B-cell deficient mice (Yanex et al, 1996).
Toxoplasma gondii is a protozoan parasite that can cause toxoplasmic encephalitis. 
Normally the development of the encephalitic response is inhihited by the host’s immune 
system and the infection is generally asymptomatic and the parasites lie dormant in the 
form of cysts within the brain. These cysts cause little or no inflammatory reaction in the 
CNS. In immunocompromised patients a reactivation of the parasites occurs resulting in 
the development of encephalitis (Gazzinelli, Xu, Hieny, Cheever et a l, 1992). 
Investigations, using a mouse model of toxoplasmosis, to discover the components of the 
immune response responsible for controlling the disease have shown that both CD4  ^ cells 
and CD8  ^ cells act in a synergistic mamier to maintain the quiescent nature of the 
infection. Removal of either CD4"^or CD8  ^ cells did not result in the reactivation of the 
response. However, when both cell types were depleted simultaneously necrotic lesions 
were found in the brain tissue following rupture of the parasitic cysts. A similar result was 
found when the mice were treated with anti-IFN-y monoclonal antibody or a combination 
of anti-IFN-y and anti-CD4^ antibodies. These findings suggest that the presence of IFN-y 
is crucial in the control of the parasitic infection and that the presence of CD4  ^cells is not 
necessary for the development of neuropathological response seen following reactivation 
of the infection (Gazzinelli et al, 1992). Both CD4^ cells and CD8  ^ cells can produce 
IFN-y and this may explain why it is necessary to remove the T-cell subsets simultaneously 
to reactivate the infection. The finding that the pathological reaction develops following 
removal of the CD4^ cells, in conjunetion with the IFN-y, suggests that the development of 
the necrosis and neuroinflammation may be the result of activation of the CD8  ^ cell 
population.
The development of the meningoencephalitis associated with trypanosome-infection and 
suhcui'ative drug treatment involves the infiltration of the meninges, ventricles, 
perivascular cuffs and brain parenchyma by inflammatory cells and a widespread
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astrogliosis. The first sign of the initiation of the CNS inflammatory response was the 
identification of activated astrocytes in the hippocampus and the presence of a few 
infiltrating T-cells. The appearance of these inflammatory changes could not be 
temporally distinguished and therefore the initiating or controlling elements for the 
generation of the reaction remain unclear. An interesting point to note is the abundance of 
CD4^ cells found in the brains of the mice following trypanosome infection and suh- 
curative drug treatment. In previous investigations of trypanosome infection using a rat 
model of the disease, a key role for CD8  ^ cell was postulated in the provision of an 
enviromnent favourable for trypanosome proliferation (Balcheit, Olsson, Van Der Meide, 
and Ki'istensson, 1990; Olsson, Bakhiet, Edlund, Hojeberg et a l, 1991). These 
experiments demonstrated that the parasites produced a factor, subsequently termed 
trypanosome-derived T-lymphocyte triggering factor (TLTF), which could stimulate the 
production of IFN-y by the CD8  ^cells. The IFN-y was taken up by the parasites and acted 
as a growth factor. The CNS is considered a hostile location for parasite growth due to the 
relatively nutrient depleted environment (Enanga, Burclimore, Stewart, and Barrett, 2002). 
As the parasite has a means to alter the surrounding milieu to provide a more favourable 
atmosphere it seems odd that CD4^ cells, rather than CD8  ^cells were the most abundant T- 
cell subset detected. The TLTF phenomenon may however prove to be species specific as 
no effect on parasite growth was noted when the trypanosomes were treated with human 
IFN-y and no IFN-y production was induced when human CD8  ^cells were stimulated with 
TLTF (Olsson er a/., 1991).
The pattern of inflammatory cell infiltration found in this model follows a pattern that 
would be expected in the immune response to extracellular parasites. In this scenario, the 
predominance of CD4^ cells would control the reaction, enhance macrophage activity and 
stimulate B-cell differentiation and antibody production leading to the removal of the 
parasites. In addition, several of the inflammatory mediators produced by these cells, 
including, IL -la  and IL- 6  have been shown to have neuroprotective capabilities (Hirano, 
1994; Lenzlinger, Morganti-Kossmami, Laurer, and McIntosh, 2001; Stoll, Jander, and 
Schroeter, 2000). The reduced number of CD8 '*' cells present together with the general 
absence of polymorphonuclear granulocytes may help to prevent the occurrence of any 
bystander damage caused to the brain tissue as a result of cell mediated cytotoxicity or the 
release of toxic enzymes by these groups of inflammatory cells.
Now that the inflammatory cell infiltration pattern occurring as a result of trypanosome 
infection and subcurative drug treatment has been elueidated it would be of great interest to
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further dissect this response, in order to outline the roles of the vaiious cell types in more 
detail. Future studies employing mice deficient in specific lymphocyte subsets or the use 
antibody depletion techniques to inliibit individual inflammatory cell types would highlight 
whether these cells play a predominantly damaging or protective role in the 
meningoencephalitic response. This knowledge would highlight the most suitable target 
cells types for novel drug intervention strategies to prevent or ameliorate the devastating 
adverse CNS reaction that at the present time results from chemotherapy of the disease.
C h a p t e r  4  
C y t o k in e  a n d  c h e m o k in e  r e s p o n s e s  in  a
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4.1. Introduction
Trypanosome infection is associated with the development of a severe inflammatory 
reaction within the CNS. The generation of such an inflammatory response is often 
governed by the presence of cytokines and chemokines. The participation of cytokines and 
chemokines in the pathogenesis of human African trypanosomiasis and the development of 
the CNS inflammatory reaction is unequivocal. However, the exact role played by these 
inflammatory mediators remains to be fully elucidated. In this Chapter the expression 
patterns of the cytokines IL-la, IL- 6  and TNF-a, together with the ehemokines RANTES, 
M IP-la and MCP-1 within the CNS, will be investigated following trypanosome infection 
and sub curative trypanocidal drug treatment. These mediators have been chosen for study 
as they are known to be induced following trypanosome infection and they can be 
expressed in brain tissue. Moreover, these eytokines and chemokines would be likely to 
generate an inflammatory reaction comparable to the response found in the CNS following 
trypanosome infeetion. This introduction will familiarise the reader with cytokines and 
chemokines as well as describe the roles of the particular inflammatory molecules, chosen 
for further study, within the CNS and the peripheral system. A review of the knowledge 
already available with regard to the cytokines and chemokines associated with 
trypanosome infection is also included.
4.1.1. What are cytokines and chemokines?
4.1.1.1. Cytokines
Cytokines are peptide or glycoprotein molecules, ranging in size from approximately 6  to 
60 kilodaltons (kD) although more typically 15 to 30kD. They are produced by many 
different cell types in response to a multitude of diverse stimuli and over 1 0 0  cytokines 
have now been identified (Rothwell and Luheshi, 2000). These stimuli include infectious 
agents such as bacteria, viruses, fungi and parasites; mechanical injury; and toxic stimuli as 
well as the cytokines themselves (Fitzgerald, O'Neill, Gearing, and Callard, 2001). While 
cytokines and polypeptide hormones share many common features, the existence of 
multiple cell types, each capable of synthesising a variety of cytokines, rather than the 
presence of an endocrine gland responsible for the production of specific hormones, is one 
of the main differences between these mediators (Clemens, 1991).
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Cytokine molecules are excreted by cells or expressed on the cell suiface. They can 
influence the behaviour of eells in both an autocrine and a paracrine fashion by binding to 
specific receptors and initiating a variety of intracellular signal transduction pathways that 
eventually result in gene activation. Their effects are generally local, however, they can 
act systemically in an endocrine like manner. Cytokines ai’e an extremely diverse group of 
molecules that elicit a wide range of effects. Most share some structmal and functional 
features (Oppenheim and Saklatvala, 1993). Cytokines are all typically small protein 
molecules, although some are modified by the addition of carbohydrate side-chains before 
secretion and are therefore glycoproteins.
4 .1.1.1.1, Control of cytokine production and action
Under normal circumstances cytokine production is tightly controlled, heing induced or 
suppressed by the presence of external specific stimuli. Their half-life in the bloodstream 
or other extracellular fluids is generally short and they are potent at concentrations as low 
as 10'^ ® to 10'^  ^ M (Clemens, 1991). Some cytokines are synthesized before they are 
required and sequestered in various forms within the body to provide a rapidly available 
source on stimulation. Cytokines such as TGF-p and GM-CSF can be stored in 
cytoplasmic granules, TNF-a and IL-ip may be integrated into the cell membrane and 
TGF-p and MIP-ip can be complexed with cell surface binding proteins or the 
extracellular matrix. The majority of cytokines however are rapidly produced tlnough 
gene expression in response to the appropriate stimulation of the cell and are not pre­
manufactured.
Many cytokines require further processing following production to create the free or active 
moiety. Some can be synthesised as the biologically active molecule, produeed in the form 
of an integral membrane protein that has to he cleaved from the membrane to release the 
active cytokine molecule. Alternatively, cytokines can be synthesised in a larger, 
biologically inactive, precursor form that is later enzymatically processed to give the active 
molecule. The production and activity of the cytokines IL -la  and TNF-a can be 
controlled using both of these mechanisms.
Soluble binding proteins that complex with cytokines in the blood and tissue fluids have 
been described. Some of these binding molecules are highly specific, including, those 
present for IL -la, TNF-a and IL-6 , and are similar to cytokine cell surface membrane 
receptors. Other cytokine binding proteins, such as a 2 -macroglobulin, have more general
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binding properties, and will bind with several cytokine molecules. The soluble binding 
proteins may act in a variety of ways. Once bound to their target they can extend the half- 
life or, by effectively removing the molecule from the circulation, promote fuiiher 
production of the specific cytokine. It is also possible that this complex of binding protein 
and cytokine may form a biologically active molecule that can further stimulate specific 
receptors. This scenario is known to occur in IL- 6  pathways. Conversely the binding 
proteins may control the effects of the cytokine by preventing the cytokine fi:om binding 
with and thereby further stimulating the cell surface receptors (Fitzgerald et a l, 2001).
4,1.1.1.2. Cytokine function
It is impossible to assign a single or clearly defined role to individual cytokines as most 
have multiple, overlapping biological activities with many cellular targets. This provides a 
system where there is significant redundancy in the actions of these mediators, which can 
allow alternative pathways to supersede in instances where the optimal route of action may 
have become damaged or inhibited. Furthermore cytokines can effectively stimulate the 
production of other cytokines, and cytokine receptors, as well as regulate their own 
secretion. Complex cascades of cytokines that can interact with each other in both a 
synergistic and antagonist fashion therefore control many essential processes in the body. 
Cellular renewal and wound healing as well as both cellular and humoral immune 
responses against invading pathogens are mediated by the interaction of a range of these 
molecules.
4.1.1.1.2.1. Thl and Th2 cytokines
One useful basis that assists in unravelling the highly complex interactions of the various 
cytokine functions in the immune response is the existence of what has been termed Thl 
and Th2 cytokines. These cytokines are in general produced by different subgroups of the 
T-helper cell population and support either cell mediated immunity or antibody-mediated, 
humoral, immune reactions. The antibody-mediated type of response is favoured by Th2 
cytokines such as IL-4, IL-5, IL-6 , IL-10 and IL-13. These cytokines promote B-cell 
functions and induce the preferential production of IgE and IgA by the antibody-producing 
cells as well as enliance eosinophil and mast cell functions.
The Thl and Tli2 groups of cytokines not only promote different immune pathways but 
also hinder the development of the opposite response. The presence of the Thl cytokine 
IFN-y inhibits the production of Tli2 cytokines, while the Th-2 cytokines IL-10, IL-4 and
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IL-13 inliibit the production of Th-1 cytokines. The factors determining whether an 
immune reaction will be biased towards a Thl or Th2 response are as yet unclear. It 
appears that many intercomiecting determinants such as the nature of the antigen inducing 
the response, the co-stimulatory signal received by the T-cell, the nature of the cytokine 
milieu present at the induction of the reaction, as well as genetic make up of the 
responding animal all influence the final outcome of the response. The polarization of the 
cytokine response to either Thl or Tli2 can contribute to the pathogenesis of immune- 
mediated diseases. Thl cytokines have been shown to contribute to the development of 
organ specific autoimmune diseases while Th2 cytokines ai'e concerned with the 
generation of allergic disorders (Fitzgerald et a l, 2001).
4.1.1.2. Chemokines
Chemokines, although members of the cytokine superfamily, have a distinct identity with 
their own discrete actions. The majority of chemokines have been discovered using 
molecular cloning teclmiques and based on these findings it has been estimated that there 
could be 40-50 human chemokines. As the name suggests, chemokines have a chemotactic 
effect on cells and their migratory influence over cells of the immune system is perhaps 
their best-characterised function. Unlike other chemotactic mediators such as formyl 
peptides and complement factors, chemokines deliver migratory signals to highly specific 
cellular targets (Vaddi, Keller, and Newton, 1997). This is not the only function of 
chemokines sinee certain members of the group play an important role in angiogenesis and 
neovascularisation while others influence haematopoiesis (Rollins, 1997).
4,1.1.2.1. Chemokine families
Chemokines are generally small peptide molecules that range from 8  to 12kD in size and 
are, in the main, defined by the presence of four cysteine molecules that are expressed in 
highly conserved locations in the structure of the molecule. The chemokines can be 
divided into four families depending on the positioning of the conserved cysteine 
molecules. The CC (or P) chemokines express two adjacent cysteine residues towards the 
N-terminal of the molecule. In CXC (or a) chemokines, the two N-terminal cysteines are 
separated by a single amino acid, while the cysteines in CX3 C (or 6 ) chemokines are 
separated by tluee amino acid molecules. Fractalkine is the only known member of the 
CX3 C group of chemokines. The two remaining cysteines in each of these three 
chemokine families are located at conserved sites further downstream in the structure of
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the molecule. The fourth chemokine family has, at present, only two known members, 
lymphotactin and single cysteine motif-1 (SCM-1). These molecules are of the eorrect size 
for chemokines and have a powerful chemotactic action on T-cells but they are structurally 
different from the other members since they expresses only two cysteine molecules. The 
positioning of these amino acids matches the location of the second and the fourth cysteine 
molecule in the conventional chemokine structure. Lymphotactin and SCM-1, have been 
classified as belonging to a separate group known as the C (or y) chemokine family 
(Rollins, 1997; Vaddi et a l, 1997). A schematic representation of these structural 
similarities is detailed in Figure 4.1.
In general CXC chemokines induce migration of neutrophils, eosinophils and basophils 
while CC chemokines target monocytes and lymphocytes. There are exceptions to this 
broad rule since the CXC chemokines IL-8 , IP-10 (y-interferon inducible protein-10) and 
MGS A (melanoma growth stimulatory activity) are attractive to T-cells while the CC 
chemokines MCP (monocyte chemoattractant protein)-1, MCP-3, RANTES (regulated on 
activation, normal T-cell expressed and secreted) and MIP (macrophage inflammatory 
protein)-la are chemotactic to basophils (Vaddi et a l, 1997).
4.1.1.2.2. How are chemokines chemotactic?
The transmigration of immune cells from the bloodstream into the tissue is a complex 
process requiring a number of coordinated steps that must be performed in sequential 
order. One theory suggests that the leucocytes roll along the vascular endothelium forming 
loose interactions with the cellular adhesion molecules until they reach an area with high 
concentrations of chemokines bound to the membrane or presented on cell surface 
molecules. In this immobilised state the chemokines are thought to interact with the 
leucocytes to increase their integrin affinities and strengthen their adhesiveness with the 
membrane. In addition, the chemokine leucocyte interactions induce changes in the 
cytoskeleton of the inflammatory cells that facilitate their subsequent diapedesis tlirough 
the membrane. However, to permit chemokines to exert an attractive effect, the target cells 
of the chemokines must express cell sui face receptors that ai e not only capable of deteeting 
the presence of the chemokine but also are able to perceive changes in the concentration of 
particular chemokines in the microenvironment. This allows the chemokines to direct the 
movement of specific immune cell types by forming a concentration gradient with the cells 
migrating towards increasing intensities of the chemokine. Extravasated leucocytes are
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thought to follow such concentration gradients and establish in areas of high chemokine 
density elaborated by cells at inflammatory foci (Rollins, 1997; Vaddi et al, 1997).
4.1.1,2.3. Chemokine receptors
Chemokine receptors are integral membrane glycoproteins that are on average 350 amino 
acids long with a calculated molecular weigh of approximately 40kD. Structurally the 
molecules consist of seven a-helices that traverse the cell membrane. The N-terminal of 
the glycoprotein molecule lies on the external surface of the membrane while the C- 
terminal occupies the cytoplasmic side of the membrane. The receptors are coupled with 
GTP-binding proteins on the cytoplasmic side of the membrane and therefore belong to the 
G-protein coupled receptor superfamily of proteins. Triggering of these receptors leads to 
signal transduction with subsequent influx of calcium ions and phosphatidyl inositol 
turnover.
There is an apparent promiscuity in the use of chemokine receptors since chemokines can 
signal via multiple receptor types and each receptor type is capable of binding several 
different chemokines. However, it appears that in general these receptors will bind either 
CC or CXC group chemokines but not both types. There are eleven known CC chemokine 
receptors (CCRl-11) and five described CXC chemokine receptors (CXCRl-5) as well as 
one CX]C receptor (CX3 CRI) and one receptor for C family chemokines (XCRl). In 
addition the Duffy blood group antigen has been shown to bind chemokines belonging to 
both CC and CXC families and has been termed the Duffy antigen receptor for chemokines 
(DARC) (Bajetto, Bonavia, Barbero, Florio et a l, 2001; Rollins, 1997).
4.1.2. Cytokines and chemokines in the CNS
A wide variety of both cytokines and chemokines have been recognized in the CNS where 
they have been shown to act as crucial mediators in the host immune response and in 
neuronal and glial functions. Some of these mediators are not only produced following 
induction of an inflammatory reaction but are manufactured within the normal CNS in 
response to neuotransmitters and neuropeptides. These constitutively expressed cytokines 
and chemokines play key roles in regulating glial functions and affect neuronal survival 
(Hesselgesser and Horuk, 1999; Szelenyi, 2001).
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Since an immense number of cytokines and chemokines have been demonstrated to 
influence normal brain functions, as well as the immune response within the CNS, this 
study will concentrate on the actions of thi-ee cytokines, IL-1, IL- 6  and TNF-a and tlnee 
chemokines M IP-la, MCP-1 a  and RANTES which have been shown previously to be 
induced following trypanosome infection. Their general functions together with their roles 
in normal and pathophysiological CNS as well as their functions in the immune response 
are discussed below.
4.1.2.1. Interleukin-1
Interleukin 1 (IL-1) was originally described as a monocyte-derived compound and was 
given varions names including lymphocyte-activating factor (LAF), endogenous pyrogen 
(EP), leucocyte endogenous mediator (LEM), monocyte cell factor (MCF) and catabolin 
(Fitzgerald et al., 2001; Oppenlieim and Saklatvala, 1993). There are two forms of IL-1 , 
IL -la  and IL-1 [5, these show only approximately 20% homology and are derived from two 
distinct genes. Although these molecules appear to be dissimilar, they bind to the same 
receptors and have largely analogous if not identical biological properties.
IL-1 binds to two different forms of IL-1 receptor, the 80 kDa type I receptor (CDwl21a) 
and the 6 8  kDa type II receptor (CDwl21b) both of which can bind either IL -la  or IL-1|3, 
The type I receptor requires the binding of IL-1 and an accessory protein before signal 
transduction is initiated while the smaller type II receptor lacks an intracellular domain and 
therefore binding of the ligand to this receptor does not initiate the intracellular signalling 
pathways (Rothwell and Luheshi, 2000). The IL-1 type I and type II receptors are both 
transmembrane glycoprotein molecules found widely distributed on many cell types, 
including, T-cells, B-cells, monocytes, NK-cells, neutrophils, eosinophils, basophils, 
dendritic cells, endothelial cells, and neural cells. As well as IL -la  and IL-ip, a third 
member of the IL-1 type family, IL-1 receptor antagonist (IL-lra), exists. IL-lra is a 
highly selective receptor antagonist that competes mainly with IL-ip in binding with the 
IL-1 type I receptor. If IL-lra binds with this receptor it does not induce subsequent signal 
transduction as it fails to accommodate the accessory protein. IL-lra binding with the IL-1 
type I receptor therefore blocks all actions of IL -la  and IL-lp and as such acts as an 
endogenous inhibitor of the cytokines (Fitzgerald et a l, 2001; Rothwell and Luheshi,
2000).
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IL-la, IL-lp and IL-Ira are produced as precursor molecules. IL -la  and IL-lra are 
biologically active in this pro-form however IL-ip requires enzymatic cleaving to release 
the active moiety. The enzyme responsible for this reaction, and therefore indirectly the 
production of functional IL-p, is caspase 1 or IL-lp converting enzyme (ICE) and was the 
first member of the caspase family of cysteine proteases to be identified (Rothwell and 
Luheshi, 2000). This enzyme appears to be cell surface associated and is under the control 
of cell membrane inliibitors. Cleavage of the IL-lp precursor by ICE releases the 17 kDa 
mature cytokine together with 14 kDa and 17.5 kDa fragments from the cell. In contrast 
IL -la  shows biological activity in both its pro- and mature forms (Dinarello, 1998). 
However, the actions of IL -la  are for the most part produced by the membrane bound 
form of the molecule. This fixed positioning of the matuie IL -la  may allow direct 
signalling of the target cell to occur in a highly precise maimer as well as result in an 
extremely high concentration of the cytokine in exactly focussed areas (Dinarello, 1998).
A wide variety of different cell types have been shown to secrete IL-1. These cell types 
include monocytes, macrophages, T-cells, B-cells, NK-cells, smooth muscle fibres, as well 
as vascular endothelial cells, astrocytes and microglia. To match this extensive list of IL-1 
sources, IL-1 can also act on a broad spectrum of target cells such as B-cells, T-cells and 
monocytes/macrophages among others. In vivo IL-1 can induce several responses 
including hypotension, fever, appetite suppression, neutrophilia, the development of 
systemic shock and the acute phase response as well as inducing local inflammatory 
reactions (Fitzgerald et a l, 2001; Martiney, Cuff, Litwak, and Berman, 1998).
Low levels of IL-la, IL-ip, IL-lra as well as the accessory protein necessary for effective 
signal transduction can be synthesised by resident brain cells and can be found at low 
levels in the normal healthy CNS. IL-1 has been shown to be biological activity at 
concentrations as low as in the femto-molar range. The exact source of these molecules in 
the brain and the pathways involved in the control of their production remain uncertain. 
Microglia, astrocytes, oligodendrocytes, neurones and vascular endothelial cells have all 
been shown to express IL-1 (Rothwell and Luheshi, 2000). In addition, IL-la, IL-ip and 
IL-lra can enter the brain from the periphery by crossing the BBB using a saturable 
transport system (Kastin, Pan, Maness, and Banks, 1999). In the normal CNS 
endogenously produced IL-1 has been demonstrated to play a role in the regulation of sleep 
patterns since IL-lra decreases the slow wave sleep irrespective of the presence of 
infection (Opp and Krueger, 1991) and IL-1 type I receptor knockout mice show a reduced 
sleep period compared with wild-type mice (Krueger, Fang, Taishi, Chen et a l, 1998).
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In inflammatory reactions IL-1 is first and foremost a pro-inflammatory cytokine that is 
produced in response to injury, immunological challenge or infection. Local production of 
IL-1 can lead to the migration of infiannnatory cells to this site, possibly through the 
induction of chemokine synthesis by monocytes, fibroblasts and endothelial cells amongst 
others. Under many circumstances the production of the cytokine IL- 6  is under direct 
control of IL-1, since mice given an intramuscular injection of turpentine fail to express 
IL- 6  when the actions of IL-1 are blocked by concurrent administration of anti-IL-1 
antibodies (Dinarello, 1998). Following infection or injury either within or outside the 
CNS, IL-1 production is induced in the brain tissue resulting in several reactions associated 
with the host defence response including fever, hypophagia, somnolence, neuroendocrine 
alterations and ‘sickness behaviour’ (Kennedy and Karpus, 1999; Konsman, Parnet, and 
Dantzer, 2002). The signals that induce this IL-1 production remain equivocal although 
several mediators have been implicated, including, circulating IL- 6  and direct neuronal 
stimulation. In addition to these neuroimniune responses evidence suggests that IL-1, in 
particular IL-lp, plays a key role in conditions where acute neuronal degeneration is 
found. In mice, conditions that result in severe neuronal loss such as, ischaemia, hypoxia 
and excitotoxic and traumatic insult, induce the rapid production of ÏL-L Furthermore, IL- 
lra, when administered to rodents after induction of this type of injury, attenuates oedema 
and glial activation as well as improves subsequent neurological function. This raises 
speculation regarding the benefits of administration of this antagonist to alleviate 
neurodegenerative responses following injury in the human CNS (Rothwell and Luheshi,
2000). The neurotoxic effect of IL-1 may be dependent on the presence of other mediators 
since, in the absence of inducible nitric oxide sythetase (iNOS), IL-P exerts a protective 
effect on neurons following hypoxia and excitotoxic injury (Stoll et al, 2000).
The pyrogenic effect of IL-1 results from the action of the cytokine, in conjunction with 
additional mediators such as IL-6 , on particular areas within the hypothalamus. More 
specifically, IL-1 acts by decreasing the firing rate of the warm-sensitive cells and 
increasing that of the cold sensitive neurones in the preoptic anterior hypothalamus. This 
effectively produces a rise in the body temperature. Injection of IL-lra into various areas 
of the rat brain leads to a reduction in the fever induced by peripheral injection of LPS 
further indicating a key role for IL-1 in the generation of the pyi’ogenic response. In 
addition to the induction of fever, IL-1 stimulation of the ventromedial hypothalamas 
appears to control appetite suppression whereas IL-1 actions in the paraventricular nuclei 
seem to mediate the activation of the hypothalamic-pituitary-adrenal (HPA) axis and
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subsequent release of corticosteriods (Rothwell and Luheshi, 2000; Tilders, DeRijk, Van 
Dam, Vincent et a l, 1994).
4.1.2.2. Interleukin-6
Interleukin- 6  (IL-6 ) is a 21-28 kDa glycoprotein molecule comprised of four anti-parallel 
a-helices with two long and two short loop coimections. Both the C-terminus and the N- 
termiiius appear to play a critical role in the function of the IL- 6  molecule (Hirano, 1998). 
This cytokine was first reported in 1985 and was originally described as a substance with 
anti-viral properties and named IFN-p2 - The anti-viral function of IL- 6  was later attributed 
to the ability of the cytokine to induce the secretion of IFN-a/p. IL- 6  was also known by a 
variety of other names including IL-1-inducible 26 IcDA protein, hepatocyte stimulating 
factor, cytotoxic T-cell differentiation factor, B-cell differentiation factor (BCDF) and B- 
cell stimulatory factor 2 (BSF-2). This reflected the wide variety of functions originally 
attributed to IL- 6  (Fitzgerald et a l, 2001; Oppenheim and Saklatvala, 1993).
Functional IL- 6  receptors are a complex of two transmembrane glycoproteins; gpl30, a 
130 kDa molecule (CD 130), and a smaller 80 kDa IL- 6  binding protein, IL-6 R, (CD 126). 
The larger gpl30 molecule forms the signal transduction unit of the receptor and at least 
three different pathways including JAK/STAT, Ras/Raf and the Src-family of kinases can 
be activated on receptor binding. Soluble, blood borne forms of both of these subunits 
exist. The soluble form of the 80 kDa molecule, sIL-6 R, is thought to arise via both 
proteolytic processing and alternative splicing. The pathways leading to the production of 
soluble gpl30 remain unclear, however, two alternative splice variants lacking the 
transmembrane portion of the molecule have been reported (Diamant, Rieneck, Mechti, 
Zhang et a l, 1997). The soluble gpl30 molecules appear to function as down-regulators 
of IL- 6  activity and do not elicit signal transduction within cells. On the other hand sIL-6 R 
binds with circulating IL- 6  and extends the half-life of the cytokine and forms a signal 
transducing complex by binding with cell surface gpl30.
Like IL-1, IL- 6  is a highly multi-functional cytokine that is produced by a wide range of 
cells, including, T-cells, B-cells, macrophages, fibroblasts, kératinocytes, endothelial cells, 
cerebral cortex nemons, astrocytes and microglia (Mai'z, Cheng, Gadient, Patterson et a l , 
1998; Oppenlieim and Saklatvala, 1993). Many stimuli have been shown to induce 
production of IL-6 . Following stimulation by mitogens or specific antigens, T-cells can be 
induced to secrete IL- 6  and LPS eiiliances IL- 6  production in macrophages and fibroblasts.
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This eiilianced IL- 6  production can be abrogated by glucocorticoids. Other cytokines 
including IL-1 and TNF have also been shown to induce the expression of IL-6 , whereas, 
IL-4 and IL-13 appear to inhibit IL- 6  production by monocytes (Hirano, 1998). IL- 6  has 
been described as a cytokine with both pro- and anti-inflammatory properties and, as 
suggested by the plethora of previous names, IL- 6  exerts a bewildering range of effects on 
a wide variety of target cells. Following stimulation with appropriate antigen, B-cells 
differentiate into antibody-secreting plasma cells. This cellular transformation occurs 
under the influence of various mediators and IL- 6  has been found to a play key role in the 
induction of the synthesis of secretory immunoglobin (Hirano, 1998). IL- 6  is also an 
integral mediator in the activation, growth and differentiation of T-cells. Another central 
role of IL- 6  is the induction of the acute phase reaction in the liver in response to injury 
and infection (Clemens, 1991).
In addition to these classical immunological roles, IL- 6  has been shown to induce the 
development of PCI2 cells into neural cells and can support the survival of neurons in 
tissue culture (Hirano, 1998). However, transgenic mice over-expressing IL- 6  exhibit an 
acute neui'odegenerative pathology (Campbell, Abraliam, Masliah, Kemper et a l, 1993). 
Like IL-1, IL- 6  has been implicated in mediating the HP A axis and can stimulate the 
discharge of ACTH. IL- 6  can also induce the release of anterior pituitary hormones such 
as prolactin releasing hormone (PRL), leutenising hormone (LH) and growth hoimone 
(GH) and cells in the anterior pituitary can spontaneously produce IL- 6  itself. IL- 6  can act 
as a growth factor for a variety of cell types, including, plasmacytoma, myeloma, 
hybridoma, renal cell carcinoma and Kaposi’s sarcoma. In contrast, breast carcinoma, 
ovarian carcinoma and myeloleukaemic cell lines show growth retardation in the presence 
of IL- 6  (Hirano, 1998).
4.1.2.3. Tumour necrosis factor-a
Tumour necrosis factor-a (TNF-a) was discovered in 1975 as a factor, induced by 
bacterial endotoxin, that exhibited potent anti-tumour activity (Beutler and Cerami, 1989; 
Carswell, Old, Kassel, Green et a l, 1975). Subsequently the integral role of TNF-a in 
immune regulation and inflammatory reactions was uncovered. TNF-a has also been 
known as cachectin, macrophage cytotoxin, necrosin, cytotoxin, haemorrhagic factor, 
macrophage cytotoxic factor and differentiation-inducing factor (Fitzgerald et a l, 2001). 
Human TNF-a is a non-glycosylated polypeptide whereas murine TNF-a is N- 
glycosylated. The cytokine can exist as either a 26 kDa membrane bound protein or a 17
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kDa soluble molecule produced by proteolytic cleavage of a precursor molecule by the 
metalloprotease enzyme TNF-a converting enzyme (TACE or ADAM 17) (McDermott,
2001). Both of these forms of the cytokine are biologically active although the soluble 
molecule is reputedly more potent than its membrane bound counterpart (Decoster, 
Vanliaesebroeck, Vandenabeele, Grooten et a l, 1995). Again the name of this cytokine 
can be misleading as it reflects the history of the molecule’s discovery and although TNF- 
a  can cause the regression of some types of tumour it also has a wide variety of other 
functions.
There are two different reeeptors for TNF-a; the TNF type I receptor (TNFRI) (CD 120a) 
and the TNF type II reeeptor (TNFRII) (CD 120b). TNFRI is a 55 kDa transmembrane 
glycoprotein expressed by a wide range of mammalian cells where as TNFRII is a 75 kDa 
transmembrane glycoprotein predominately expressed by leucocytes and endothelial cells. 
Stimulation of the TNFRI can lead to cellular apoptosis via a cascade of signalling events 
culminating in the induction of caspase 2 or 8  enzyme activation within the cell. Apoptosis 
is not the only outcome associated with TNFRI binding since NF-kB can also be activated 
following TNFRI stimulation. This diverts the apoptotic pathways and leads to the 
induction of pro-inflammatory cytokine expression (Fitzgerald et a l, 2001). The function 
of TNFRII remains equivocal with the main physiological effects of TNF-a apparently 
being mediated though TNFRI. Since this receptor lacks a death domain its signalling 
pathways will differ from TNFRI. TNFRII appears to be involved in binding with 
membrane bound TNF-a rather than the free form of the cytokine. A role for TNFRII in 
the transfer of soluble TNF-a to the TNFRI has also been suggested (Fitzgerald et a l, 
2001; McDermott, 2001). Soluble forms of both TNFRI and TNFRII exist and are though 
to result by enzymatic cleavage of the membrane bound receptor. These soluble receptors 
are known to block the activity of TNF-a, however, the pathways that result in the 
shedding of these receptors remain unclear (McDermott, 2001).
TNF-a, like IL -la  and IL-6 , can be secreted by a vast array of cell types such as 
macrophages, monocytes, T-cells, B-cells, astrocytes, microglia and neurons among others 
(Allan and Rothwell, 2001; Fitzgerald et a l, 2001; Lieberman, Pitha, Shin, and Shin, 
1989). TNF-a production by these cells can be induced by many different stimuli, 
including, LPS as well as the presence of other cytokines such as TNF-a itself, IL-1, IL-6 , 
interferons and colony stimulating factors. Additional molecules including immune 
complexes and Substance P can also induce expression of this cytokine (Nair and 
Schwartz, 1995). TNF-a shows a wide spectrum of biological activities and together with
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IL -la  and IL-6 , plays an integral role in both the innate and adaptive immune response. 
This cytokine can increase the phagocytic properties of cells such as macrophages and 
neutrophils, thereby improving iimate immunity. In addition TNF-a can augment the 
adaptive immune response to particular pathogens by enliancing the proliferation of T-cells 
induced by specific stimuli.
TNF-a was named due to its cytotoxic effects on specific tumours. Regression of the 
tumoui's can be initiated either by a direct cytotoxic action of the cytokine on the cancer 
cells or by TNF-a’s ability to increase the capacity of NK-cells and macrophages to kill 
these abnormal cells. TNF-a production can also lead to the destruction of the vascular 
tissue supplying the tumour resulting in tissue necrosis of the isolated growth. Another 
striking effect of this cytokine is the induction of a debilitating combination of responses, 
including, weight loss, malnutrition and anaemia collectively termed cachexia. This is 
thought to result, in part, through the ability of TNF-a to inhibit lipoprotein lipase and 
other enzymes required for the storage of fat in adipose tissue (Beutler, Greenwald, 
Hulmes, Chang et a l, 1985). Also fundamental to the development of cachexia is the 
onset of anorexia or a reduced appetite induced by TNF-a in experimental animals 
(Clemens, 1991).
As well as these actions, TNF-a has been implicated in the pathogenesis of a variety of 
autoimmune conditions including rheumatoid artlnitis, Crolm’s disease, systemic lupus 
erythematosus, and multiple sclerosis. Furthermore, a role for TNF-a has been suggested 
in the development of infectious diseases such as cerebral malaria, septic shock, and 
chi'onic hepatitis (McDermott, 2001).
Within the normal brain TNF-a has recently been demonstrated to enhance synaptic 
activity by increasing the surface expression of a-amino-3-hydroxyl-5-methyl-4- 
isoxazolepropionic acid (AMPA) receptors and is therefore continually required to 
maintain the synaptic strength at excitatory synapses (Beattie, Stellwagen, Morishita, 
Bresnahan et a l , 2002). TNF-a can be expressed by many resident CNS cells, including, 
microglia, astrocytes and neui'ons (Pan, Zadina, Harlan, Weber et a l, 1997). Many of the 
actions of TNF-a in the CNS mirror those previously described for IL-1, such as, the 
induction of fever and sickness behaviour (Beattie et al, 2002; Konsman et al, 2002). In 
addition to TNF-a created locally within the CNS, a transport system to carry the cytokine 
across the BBB also exists allowing systemically produced TNF-a to enter the brain 
(Gutierrez, Banks, and Kastin, 1993). This transport system has been shown to be
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upregulated following compressive injury to the spinal cord (Pan, Kastin, Bell, and Olson,
1999).
TNF-a appears to have a dual role within the inflamed or injured CNS. This cytokine can 
affect the BBB resulting in leucocyte infiltration and cerebral oedema and as previously 
stated can induce cellular apoptosis. It is therefore not surprising to find that inliibition of 
TNF-a activity results in enhanced motor function recovery following traumatic brain 
injury indicating a detrimental role for the cytokine. In contrast, transgenic mice lacking 
TNF-a receptors have been shown to be more vulnerable to traumatic brain injury 
suggesting a beneficial function for TNF-a. Furthermore, transgenic mice unable to 
express TNF-a protein show a better neurological motor score than their wild-type 
counterparts. This beneficial effect of the removal of TNF-a is short-lived since wild-type 
animals recover fi’om the initial injury more quickly than the TNF-a knockout animals. 
This indicated a bimodal effect of TNF-a in the injured brain where its initial effects may 
be detrimental but the presence of the cytokine at later time points following injury is 
beneficial to the recovery of the animal (Lenzlinger et al., 2001).
4.1.2.4. RANTES
Regulated on activation, normal T-cell expressed and secreted (RANTES), a CC 
chemokine, also known as TY-5 or SIS-Ô, is an 8  kDa protein molecule. Under the new 
classification nomenclature RANTES is known as CCL5 (Zlotnik and Yoshie, 2000). The 
chemokine was identified originally in 1988 as a transcript that was expressed in T-cells 
but not B-cells following stimulation with mitogens or antigens (Schall, 1994). 
Chemokines bind to multiple receptors and RANTES mediates its action by binding to 
CCRl, CCR3, CCR4, CCR5 or DARC (Appay and Rowland-Jones, 2001; Schall, 1994). 
The chemokine has numerous target cells and can recruit T-cells, monocytes, basophils, 
eosinophils, NK-cells, dendritic cells and mast cells to sites of inflammation. Recently, 
interest has focused on RANTES due to its ability, in conceit with two additional 
chemokine molecules, M IP-la and MIP-1(3, to inhibit the replication of HIV (Appay and 
Rowland-Jones, 2001). Aggregates of RANTES that form on the cell surface in vitro have 
been shown to be potent leucocyte activators and show similar effects to those seen 
following mitogen stimulation. It therefore appears that the effects of RANTES are 
dichotymous. At low concentrations RANTES acts in a monomeric or dimeric form and 
directly stimulates specific chemokine receptors. At high concentrations RANTES 
molecules can form aggregates that can interact with cell-surface glycosaminoglycans
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(GAGs) resulting in mitogen like activation of the cell. The suppressive effects of 
RANTES on HIV infection, although not fully characterised, appear to be dependent on 
the presence of the GAG molecules on the target cell surface (Appay and Rowland-Jones,
2001).
RANTES can be secreted by many cell types, including, T-cells, monocytes, mesangial 
cells, eosinophils, microglia and astrocytes but is predominantly produced by CD8  ^ T- 
cells, epithelial cells, fibroblasts, and platelets. The upregulation of RANTES production 
has been found in a wide variety of inflammatory conditions such as transplant rejection, 
atherosclerosis, artliritis, asthma, delayed type hypersensitivity reactions and 
glomerulonephritis. RANTES has also been implicated in the pathogenesis of several 
inflammatory CNS disorders such as multiple sclerosis, Alzheimer’s disease, stroke and 
cerebral lupus. In addition, a role for RANTES in the development of non-inflammatory 
CNS diseases, including, motor neuron disease and axonal neuropathies has been 
suggested (Appay and Rowland-Jones, 2001; De Groot and Woodroofe, 2001). RANTES 
has also been shown to induce the migration of dorsal root ganglia in vitro and to 
encourage the differentiation of these cells into the nonciceptive phenotype subset. This 
indicates that RANTES may have an important function in the development and 
maintenance of the normal brain (Bajetto et al, 2001)
4.1.2.5. Monocyte chemoattractant protein-1
Monocyte chemoattractant protein-1 (MCP-1) belongs to the CC family of chemokines and 
is a small protein molecule of approximately 8-12 kDa (Vaddi et a l, 1997). The molecule 
was first isolated from conditioned tissue culture fluid taken from baboon aortic smooth 
muscle cells as a factor that could attract monocytes but not neutrophils (Rollins, 1997). 
MCP-1 has various alternative names including monocyte chemotactic and activating 
factor (MCAF), lymphocyte-derived chemotactic factor (LDCF), glioma derived 
chemotactic factor (GDCF), tumour derived chemotactic factor (TDCF), smooth muscle 
cell derived chemotactic factor (SMC-CF) and JE gene product (Vaddi et a l, 1997). 
Under the new nomenclature system MCP-1 is called CCL2 (Zlotnik and Yoshie, 2000). 
This chemokine will bind with a vaiiety of chemokine receptors such as CCR2, CCR9 and 
CCRll (Bajetto et al, 2001) and has numerous target cells, including, monocytes, 
haematopoietic precursors, T-cells, basophils, eosinophils, mast cells, NK-cells, cardiac 
myocytes and microglia (Vaddi et a l, 1997).
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MCP-1 is a powerful monocyte chemoattractant and induces the expression of the 
prerequisite integrin molecules necessary for cellular chemotaxis. In in vitro 
transendothelial migration assays MCP-1 has been shown to attract activated CD4^ and 
CD8  ^memory cells but not B-cells or NK-cells. In contrast, in assay systems that do not 
incorporate endothelial cells MCP-1 does show some attraction for NK-cells and T-cells 
(Rollins, 1997). MCP-1 has been shown to provoke the migration of astrocytes in vitro 
(Bajetto et al, 2001). In addition to these migratory inducing effects MCP-1 can stimulate 
NK-cells and CDS’*" cytotoxic cells to degranulate and induces the release of histamine by 
basophils (Schall, 1994). A possible role for MCP-1 in the prevention of tumour growth 
has been suggested by findings that implantation of tumourigenic cells, engineered to 
express MCP-1, fail to induce tumours in recipient mice. The mechanisms involved in this 
anti-tumour effect are unknown although an increased number of monocytes and 
macrophages were detected at the site of implantation. Sarcoma clones expressing MCP-1 
also showed a reduction in growth that was proportional to the levels of MCP-1 produced 
by the cells (Schall, 1994). In a variety of inflammatory models, transgenic mice in which 
the MCP-1 gene has been specifically disrupted show defects in the recruitment of 
monocytes and macrophages to the sites of inflammation. An accumulation of monocytes 
has been described in the pancreas and brain following genetic manipulation of pancreatic 
islet cells and oligodendrocytes, respectively, to over express MCP-1. These monocyte 
infiltrates show few signs of activation suggesting that although MCP-1 is a powerfiil 
monocyte chemoattractant it has little ability to induce further activation of these cells 
(Asensio and Campbell, 2001).
A wide variety of cell types can produce MCP-1. These inelude monocytes and 
macrophages, endothelial cells, smooth muscle cells, cardiac myocytes and epithelial cells 
(Vaddi et a l, 1997). Both astrocytes and microglia can be induced to produce MCP-1 and 
this chemokine is known to be expressed constitutively within the CNS (Asensio and 
Campbell, 2001). The function of MCP-1 in the normal physiology of the CNS remains 
unclear. Transgenic mice over-expressing MCP-1 under the control of the myelin basic 
protein promoter show a mai'ked monocytic infiltrate in the CNS. Furthermore, the 
expression of a variety of chemokines including MCP-1 has been associated with the 
progression of EAE and administration of MCP-1 neutralising antibodies to EAE animals 
prevents relapse of the disease. In MS and EAE, the astrocytes have been the most 
commonly reported cell type expressing MCP-1 (De Groot and Woodroofe, 2001). An 
increase in the expression of MCP-1 has also been reported following experimental 
ischaemia and sterile traumatic brain injury. In Alzheimer’s disease, MCP-1 has been
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demonstrated in matine senile plaques and reactive microglia suggesting a possible role for 
this chemokine in the pathogenesis of this disease (Bajetto et al, 2001).
4.1.2.6. Macrophage Inflammatory Protein-1 a
Macrophage inflammatory protein-1 a  (MIP-la) is an 8-12 kDa protein molecule 
belonging to the CC-family of chemokines. This molecule has also been called GOS19, 
LD78, pAT464, TY5 and SISa (Vaddi et a l, 1997). Following the new guidelines for 
chemokine nomenclature M IP-la should now be termed CCL3 (Zlotnik and Yoshie,
2000). This chemokine was originally purified from a LPS-stimulated murine macrophage 
cell line in tissue culture and was termed ‘macrophage inflammatory protein’. M IP-la 
mediates its action by binding to CCRl, CCR4 and CCR5, and has a range of target cells 
including T-cells, B-cells, monocytes, neutrophils, eosinophils, basophils, mast cells, NK- 
cells and astrocytes (Rollins, 1997; Schall, 1994; Vaddi et a l, 1997). In addition to the 
wide range of possible target cells M IP-la can be produced an aiTay of tissue sources 
including fibroblasts, monocytes, lymphocytes, neutrophils, eosinophils, smooth muscle 
cells, mast cells, platelets, bone marrow stromal cells, micoglial cells, astrocytes and 
epithelial cells (Vaddi et a l, 1997).
M IP-la has been shown to be a powerful monocyte chemoattractant and activating factor, 
although it is less effective than MCP-1 in this task. In in vitro studies that do not involve 
endothelial cells M IP-la attracts principally CD8  ^ T-cells, whereas, in transendothelial 
assays both CD4^ and CD8  ^T-cells are attracted by this chemokine (Rollins, 1997). MIP- 
l a  has been shown to be chemotactic for B-cells. Eosinophils are not only attracted by 
M IP-la but also show a modest level of activation following stimulation with this 
chemokine (Schall, 1994). Further to these chemoattractant effects, M IP-la appears to 
enliance the adhesive properties of T-cells for endothelial cells.
Within the CNS, M IP-la production appears to be associated with several disease states. 
Expression of nominal levels of M IP-la has been demonstrated in unstimulated cultured 
microglia suggesting that this chemokine may be present in the normal physiological brain 
(Bajetto et al., 2001). In studies examining the pathogenesis of MS, using the animal 
model of EAE, treatment with anti-MIP-la antibodies inliibited the development of acute 
disease (Glabinski and Ransohoff, 1999b) while, as stated above, treatment with anti- 
MCP-1 antibodies prevented relapse of the condition. It has therefore been hypothesised 
that M IP-la controls the recruitment of mononuclear cells during acute EAE whereas
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MCP-1 directs the mononuclear cell infiltration during relapsing disease (Bajetto et al,
2001). In samples prepared from human cases of MS, M IP-la was found in inflammatory 
cells associated with active MS plaques (Glabinski and Ransohoff, 1999b). Increased 
levels of M IP-la, correlating with leucocyte and protein concentrations, have been 
reported in the CSF of patients exhibiting several inflammatory conditions, including, MS 
following relapse, Behcet’s disease and HTLV-1 associated myelopathy (Glabinski and 
Ransohoff, 1999a), Unlike RANTES and MCP-1, M IP-la fails to induce the migration of 
dorsal root ganglia in tissue culture systems, although, astrocyte recruitment was observed 
in in vitro scenarios following M IP-la treatment (Bajetto et al, 2001). A role for this 
chemokine in the development of Alzheimer’s disease has been suggested by findings that 
amyloid |3 peptide stimulates M IP-la production by human monocytes. If this mechanism 
occurs in vivo the presence of the chemokine could account for the recruitment of 
macrophages and astrocytes resulting in the accumulation of these cells within the senile 
plaques (Bajetto et al, 2001). M IP-la may also mediate pyrogenic responses in the host 
since injection of the chemokine directly into the anterior hypothalamic pre-optic area 
results in the induction of a slow onset monophasic fever that persists for a considerable 
period of time (Bajetto et al., 2001). In addition, injection of M IP-la into this area of the 
brain can result in appetite suppression and a reduced food intake in rats (Vaddi et a l, 
1997).
4.1.3. CNS cytokines and chemokines; helpfui or 
harmful?
As can be seen from the above data, cytokines and chemokines play pivotal roles in both 
the autocrine and paracrine regulatory processes that arise in response to injury or infection 
and in some instances mediate aspects of normal physiological reactions. Whether the 
actions of these molecules within the CNS result in beneficial or detrimental changes 
appears to be largely dependent on the individual circumstances surrounding each incident. 
As previously stated both IL -la  and TNF-a play key roles in the regulation of the sleep- 
wake cycle and the levels of these cytokines within brain seem to follow diurnal patterns 
(Krueger, Obal, Fang, Kubota et a l, 2001). A rise in the levels of IL -la  mRNA 
transcripts have been detected in the hypothalamus following restraint and nociceptive 
stimulation, suggesting a role for the molecule in the development of the phsyco-emotional 
stress reaction under non-inflammatory conditions (Tringali, Dello, Preziosi, and Navarra,
2000). If these mediators were absent from the CNS several normal physiological
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processes could be severely impaired. The presence of these molecules in the intact CNS 
is therefore, not only beneficial to the organism but required for facilitating normal brain 
functions.
The non-specific indications of infection, including, fever, malaise, lassitude, appetite 
suppression and depression are collectively termed ‘sickness behaviour’. The data 
presented above clearly indicate that this phenomenon is largely mediated by the effect of 
cytokines such as IL-la, TNF-a and IL- 6  within the CNS. These symptoms are often 
considered to be of little importance and are generally regarded by doctors as an 
uncomfortable but unavoidable result of infection. However, if these criteria are 
considered in the context of the organism’s reaction to the infection it becomes apparent 
that each component plays an important role in a highly organised scheme to 
systematically fight the infection. The induction of fever benefits the infected organism as 
it encourages the proliferation of inumme cells while providing an environment that is 
unfavourable for bacterial or viral growth. This rise in body temperature is accompanied 
by a decrease in the plasma levels of minerals such as zinc and iron that are required by 
dividing micro-organisms. The general malaise and lassitude associated with sickness 
behaviour encourages the infected individual to rest thereby reducing the energy 
expenditure associated with everyday tasks. This is advantageous since the metabolic cost 
of fever increases proportionally with the rise in body temperature and there is little 
provision for unnecessary activities. Finally the changes in food intake resulting form 
infections alter the food preferences of the sick individual in favour of high carbohydrate 
and low fat food items. Although initially this may seem strange, as fatty foods possess a 
higher calorific value that cai'bohydrates, increased cytokine levels result in lipolysis and 
hypertriglyceridaemia in the organism and consequently, under these circumstances, 
increased lipid intake would prove detrimental to the recovery of the host (Kennedy and 
Kai'pus, 1999). Therefore, the unpleasant symptoms, initiated by cytokine effects within 
the CNS and collectively termed ‘sickness behaviour,’ produce a motivational behaviour 
pattern with an overall beneficial effect on the organism’s ability to successfully fight 
infection and recovery to health.
In many cases animal models have been used to study the cytokine profiles produced in the 
CNS under various disease conditions. In the EAE animal model of MS, the CNS lesions 
are chai-acterised by the presence of T-cells, B-cells, plasma cells and macrophages which 
leave the blood and infiltrate the brain tissue in response to the presence of chemokine 
molecules, including, MCP-1, M IP-la and RANTES, expressed within the CNS (Godiska, 
Chantry, Dietsch, and Gray, 1995). The expression of pro-inflammatory cytokines,
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including, IL-la, TNF-a and IL- 6  induce the upregulation of adhesion molecules such as 
ICAM-1 and VCAM-1 thereby facilitating the extravasion of the inflammatory cells into 
the brain (Merrill and Benveniste, 1996). In numerous instances a positive correlation 
exists between the degree of cellular infiltration and the loss of oligodendrocytes and 
axonal demyelination found in the CNS lesions seen in MS patients suggesting that the 
inflammatory process forms a key step in the pathogenesis of the disease (Kivisakk, 
Trebst, Eckstein, Kerza-Kwiatecki et a l, 2001). The effect of cytokine and chemokine 
production in MS would appeal' to be detrimental to the well being of the affected animal, 
however, the presence of IL-6 , in combination with additional growth factors, has been 
shown to induce the differentiation of oligodendrocyte precursors into mature fimctional 
myelinating cells and stimulate oligodendrocyte migration and survival (Merrill and 
Benveniste, 1996). Consequently, in this scenario, the production of IL- 6  would result in 
changes within the CNS that would prove largely beneficial to the amelioration of the 
disease. Nevertheless, the production of cytokine and chemokine inflammatory mediators 
in MS and EAE appears, overall, to precipitate the development of the disease and as such 
can be considered as harmflil to the organism.
The picture found following focal brain ischaemia and traumatic brain injury, cannot be so 
clearly defined and there is conflicting data regarding the effects of cytokines in these 
conditions. For instance, one study found that intracerebroventricular administration of 
TNF-a prior to middle cerebral artery occlussion resulted in an increase in the size of the 
ensuing infarct. Whereas a second study showed that TNF-a administration prior to focal 
cerebral ischaemia had protective effects against subsequent damage. These findings were 
corroborated in transgenic animals lacking TNF-a receptors, where an increase in infarct 
size was detected following ischaemic brain injury, again indicating a neuroprotective 
action for TNF-a (Stoll et al, 2000). More conflicting data have been generated from the 
use of TNF-a deficient mice. Following traumatic brain injury, the lack of TNF-a initially 
appears to be advantageous to the animals since they show less severe neurological 
damage but, since these animals do not recover from the injury as efficiently as wild-type 
mice, this beneficial effect of the removal of TNF-a is short lived (Lenzlinger et al, 2001).
Transgenic animals over-expressing specific cytokines within the brain have also been 
developed. These models highlight how the effects of cytokine production within the CNS 
can contrast maikedly depending on the site of the expression, and the particular cells 
targeted. In animals producing excess IL- 6  in astrocytes, under the control of the GFAP 
promoter, the presence of sui'plus cytokine has been linked with cognitive impairment,
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astrocytosis, BBB deficiencies, vascular abnormalities, neurodegeneration and subsequent 
neurological disease. However, when IL- 6  production is limited to the neuronal population 
by utilising the neuron-specific endolase promoter, no overt neuronal, vasculai* or 
behavioural changes aie seen although the animals still exhibit a strong astrocytic reaction. 
In IL- 6  knockout mice a reduction in the astrocytic reaction is seen leading to an increase 
in neuronal cell loss following injury. Therefore, in the case of IL- 6  at least, the 
production of the cytokine seem to result in both beneficial and damaging outcomes since 
the cytokine promotes an inflammatory reaction but simultaneously enliances neuronal 
sui'vival (Lenzlinger et al, 2001).
It would appear that the exact nature and severity of the CNS damage, as well as the 
precise location and timing of cytokine expression, may prove decisive in determining 
whether the overall outcome of cytokine production within the brain will be detrimental or 
beneficial to the organism. Moreover, it is clearly imperative that these divergent findings 
are carefully considered when novel chemotherapeutic regimens involving either the 
depletion or addition of cytokines are devised.
4.1.4. Cytokines and chemokines in 
trypanosomiasis
Although a role for cytokines and chemokines in the pathogenesis of human African 
trypanosomiasis is beyond question there is a paucity of information with regard to the 
profiles of these important inflammatory agents during the course of the disease. The first 
experimental indication, that factors mediating the development of the disease were 
produced following trypanosome infection, was discovered just after the turn of the 
century in 1912. In these experiments, Laveran showed that blood taken from 
trypanosome-infected rabbits and injected into mice, following destruction of the parasites, 
induced hypothermia, convulsive movements, fatigue and death. From these findings 
Laveran concluded that the destruction of the parasites had released a ‘trypanotoxin’ into 
the rabbit blood that was responsible for the pathological effects seen in the mice. Almost 
70 years later, the mediator induced by the ‘trypanotoxin’ was shown to be cachectin or 
TNF (Lucas, Magez, Songa, Daiji e ta l,  1993).
TNF-a production has also been suggested to lead to the immunosuppression associated 
with trypanosome-infection, either by a direct mechanism or an indirect pathway involving 
IFN-y production. Evidence for this comes from animal experiments using neutralising
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antibodies against the two cytokines. When IFN-y was removed, the reactivity of the T- 
cells in the lymph nodes and macrophages was restored. Similaiiy, treatment of 
trypanosome-infected animals with anti-TNF-a monoclonal antibodies re-established the 
proliferative T-cell response in the lymph nodes. It therefore appears that these two 
cytokines are integrally involved in the development of trypanosome-elicited 
immunosuppression (Lucas et al, 1993). In addition to an immunosuppressive role, TNF- 
a  has also been shown to have a direct action on trypanosomes with the cytokine exerting 
a trypanolytic effect in vitro and reducing the parasite load in vivo (Lucas et al, 1993; 
Magez, Lucas, Daiji, Songa et a l, 1993). This effect of TNF-a on the development of the 
parasitaemia is reflected in late-stage human infections where the number of blood borne 
trypanosomes is extremely low while the levels of TNF-a in the serum are high (Okomo- 
Assoumou, Daulouede, Lemesre, N'Zila-Mouanda et a l, 1995).
A role for TNF-a in the development of the neuropathological response associated with 
trypanosome infection and chemotherapy has also been suggested (Hunter et al, 1991). In 
this study mRNA transcripts for TNF-a could be consistently detected in the nucleic acid 
extracted from the brains of 716.6rwcci-infected mice following induction of a 
meningoencephalitic response by subcurative trypanocidal drug treatment. More recent 
investigations examining T.b.brucei-mÎQCûom in TNF-a knockout mice confirmed the 
involvement of TNF-a in both the development of the parasitaemia and the control of the 
pathological response to trypanosome infection (Magez, Radwanska, Beschin, Sekikawa et 
a l, 1999). This work demonstrated that pathological features of the disease, including, 
immunosuppression and sensitivity to LPS, were greatly reduced in TNF-a knockout mice 
compared to wildtype animals. This decrease in immunopathological response was not the 
result of a reduction in parasite load since the peak levels of parasitaemia were found to be 
strongly increased in the knockout mice. This finding concurs with those deseribed above 
indicating a reduction in parasite load due to the presence of TNF-a. In TNF-a knockout 
mice TNF-a is not present; therefore, one factor that plays a role in controlling the growth 
of the parasite population has been removed leading to an increase in the levels of 
parasitaemia.
An upregulation in the production of TNF-a and IL- 6  transcripts was also demonstrated 
(Eckersall, Gow, McComb, Bradley et a l, 2001), in the liver and brain of T.b.brucei- 
infected mice both during the early stages of the disease, from 7 days post-infection, and 
following the induction of the PTRE by subcurative trypanocidal drug treatment. Using 
the same model system, expression of IL-la, IL-4, TNF-a, MIP-1, IL- 6  and IFN-y was
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detected in nucleic acid extracted fiom the brains of T.b.brucei-mfQcXQà mice following 
induction of the meningoencephalitis. IL-2 transcripts were not detected in these animals 
(Hunter et al, 1991). The early induction of MIP-2, MIP-1 a, RANTES, and MCP-1 
within the CNS was also investigated in a Tb.brucei rat model of trypanosomiasis 
(Sharafeldin, Eltayeb, Pashenkov, and Balchiet, 2000). These studies showed an 
upregulation in the number of cells in the rat brain expressing MIP-2, MIP-1 a  and 
RANTES only 6 hours following infection of the animal. By 12 hours post-infection an 
increase in MCP-1 positive cells was also found. Immunocytochemistry double staining 
procedures demonstrated that the resident brain astrocytes and microglia as well as 
infiltrating inflammatory cells were the cellular source of these chemokines. This increase 
in the expression of chemokines within the rat brain occurred very quickly following 
infection, at a time well before the trypanosomes are thought to have entered the CNS 
compartment, indicating that their expression may be induced by an indirect stimulus 
rather that the direct effect of the parasite within the CNS. The ability of human astrocytes 
and neurons to express the chemokines IL-8, MIP-1 a, MIP-1 p, MCP-1 and RANTES has 
been demonstrated in dissociated cell cultures prepared from first trimester forebrain 
(Bakliiet, Mousa, Seiger, and Andersson, 2002). Following stimulation of these cultures 
with either trypanosome-derived lymphocyte triggering factor, a novel compound 
produced by trypanosomes (described more fully below) or with LPS, an upregulation in 
the expression of each of IL-8, MIP-1 a, MIP-1 p, MCP-1 and RANTES was detected using 
immunocytochemistry and in situ hybridsation. In contrast, when the cultures were 
stimulated with trypanosome VSG, no increase in chemokine expression was found.
4.1.4.1. Trypanosome-derived lymphocyte triggering 
factor
Ful'ther evidence linking cytokines to the pathogenesis and disease development of African 
trypanosomiasis was indicated by experiments carried out in the early 1990’s (Bakheit et 
al, 1990). In these experiments T.b.brucei-infection in rats was shown to induce a rapid 
and marked increase in splenic IFN-y. The removal of CD8^ cells prevented this induction 
of IFN-y production, checked parasite growth and increased the survival rates in the 
experimental animals. The presence of a trypanosome-derived mediator with a specific 
action on a subset of lymphocytes was elucidated using a two-chambered tissue culture 
system that allows diffusion of soluble factors between the compartments. These 
experiments suggested that lymphocytes, specifically CD8^ T-cells, were induced to 
express IFN-y by a soluble factor produced by the trypanosomes that could diffuse tlirough
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the membrane sepai’ating the two compartments. This IFN-y also moved tlii'ough the 
barrier and was subsequently taken up by the parasites increasing their growth rate. This 
growth modulating effect of IFN-y on the pai'asite was found to be species dependent since 
no increase in parasite growth rate was noted following treatment with human IFN-y or 
stimulation of human CD8^ cells by T.b.brucei (Olsson et al, 1991). The parasite-derived 
signalling molecule was termed trypanosome-derived lymphocyte triggering factor (TLTF) 
and has subsequently been cloned and sequenced (Vaidya, Bakliiet, Hill, Olsson et a l,
1997). More recently this factor has been further eharacterised and TLTF has now been 
shown to be derived from trypanosome cytoskeletal proteins that play a key role in cellular 
motility, cell trafficking of proteins and cell division (Hill, Hutchings, Grandgenett, and 
Donelson, 2000).
4.1.4.2. Cytokines and differential susceptibility to 
trypanosomiasis
Within several species of animal, individual strains have been shown to display an innate 
resistance to trypanosomiasis and are more capable of controlling the development of 
parasitaemia, survive longer following infection and show a reduction in the 
immunosuppression associated with the disease. Cattle breeds indigenous to West Africa 
such as the N ’dama and the West African Shorthorn show a degree of tolerance to 
trypanosome infections while other breeds including European cattle and Bos indicus 
(Boran) cattle are more susceptible to the disease (Murray et al, 1984). This differential 
susceptibility to infection is found between strains of mice, e.g., C57BL/6 mice show a 
degree of resistance to infection while BALB/c mice are highly susceptible (Kaushik, 
Uzonna, Zhang, Gordon et a l , 2000). The genetic basis for these differences has yet to be 
defined definitively and is thought to involve a variety of genes. The differential ability of 
each strain to produce cytokines has been implicated as one possible factor influencing 
resistance to trypanosome infection. Bone marrow-derived macrophages prepared from 
resistant C57BL/6 mice and stimulated with whole cell extracts of T.b.brucei or 
T.congolense have been shown to produce significantly higher levels of TNF-a and IL-12 
than those from susceptible BALB/c animals implicating these cytokines in the ability of 
C57BL/6 mice to resist trypanosome infection. Furthermore bone marrow derived 
macrophages prepared from BALB/c mice expressed significantly higher concentrations of 
IL-6 and IL-10 suggesting that production of these cytokines enhances susceptibility of the 
mice to the disease (Kaushik, Uzomia, Radzioch, Gordon et a l, 1999; Kaushik et al, 
2000).
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The cytokine IFN-y has also been suggested to play a role in determining the tolerance of 
specific breeds or strains of animal to trypanosome infection. C57BL/6 mice are normally 
more resistant to trypanosome infection and produce a strong Thl profile of cytokines in 
response. IFN-y knockout C57BL/6 mice infected with T.b.rhodesiense were found to 
have lost their innate resistance to the parasite. This finding suggests that the presence of 
the IFN-y within the Thl response is critical in establishing the resistance of the animal to 
trypanosomes (Hertz, Filutowicz, and Mansfield, 1998). In contrast to these results higher 
plasma levels of IFN-y have been found in susceptible BALB/c mice compared with 
C57BL/6 mice following infection with T.congolense (Uzonna, Kaushik, Gordon, and 
Tabel, 1998). When anti-IFN-y antibodies were given to these Tcongolense-miQCiQÔ. 
BALB/c animals the mice displayed a more resistant phenotype with lowered parasitaemia 
and increase survival periods suggesting that IFN-y results in the animal being more 
susceptible to trypanosome infection. Suppression of parasite growth and an increase in 
survival times has also been demonstrated following the depletion of IFN-y in T.b.brucei- 
infected mice (Bakliiet, Olsson, Ljungdahl, Hojeberg et a l, 1996). This increased 
resistance to trypanosome infections was found irrespective of the normal level of 
susceptibility of the mouse to infection. Therefore, the role of IFN-y in the ability of 
animals to resists trypanosome infection remains controversial.
The cytokine profiles produced as a result of T.congolense infection in trypanotolerant 
N ’dama cattle and susceptible Boran cattle have also been studied in cultures of peripheral 
blood mononuclear cells prepared from groups of each breed of infected animal. In these 
experiments, differences in the expression pattern of IL-4 and IL-6 were found tlnoughout 
the coui'se of infection. Trypanosome-resistant N ’dama cattle expressed a higher level of 
IL-4 than Boran cattle, while Boran cattle appear to produce more IL-6 than their 
trypanotolerant counterpails. These profiles suggest a protective role for IL-4 and a 
disease-enhancing function for IL-6 (Mertens, Taylor, Muriuki, and Rocchi, 1999). 
Further evidence to indicate that IL-4 may play a role in controlling the development of 
trypanosomiasis can be seen in the results of studies investigating the expression of IL-4 in 
wildtype BALB/c, BALB/c nude and SCID mice. These experiments demonstrated that 
BALB/c and BALB/c nude mice could control the development of parasitaemia following 
T.b.gambiense infection to varying degrees, with BALB/c nude animals showing a liigher 
parasitaemia than BALB/c mice. In contrast, SCID mice that do not have functional T- or 
B-cells were highly susceptible to the disease. When the CD4^ T-cell population in 
BALB/c animals was depleted by anti-CD4^ antibody administration, levels of 
parasitaemia were similar to those seen in the nude mice indicating a role for CD4"^  T-cells
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in the reaction. Administration of anti-IL-4 antibodies to T.b.gambiense-inÎQoXQd BALB/c 
mice increased the periods of par asitaemia suggesting a role for this cytokine in the control 
of the trypanosome infection (Inoue, Inoue, Kuriki, Yamaguchi et a l, 1999). A 
significantly higher expression of IL-4 was also shown in spleen mononuclear cells 
prepared from trypanotolerant C57BL/6 mice when stimulated with TLTF, compared with 
those prepared from susceptible C3H/He mice, again suggesting a protective role for IL-4 
(Bakhiet e/fl/., 1996).
It is apparent from the evidence presented above that cytokines and chemokines play a 
complex and significant role in the development and control of trypanosome infections not 
only in humans but also in their other animal hosts. A clearer understanding of the 
expression pattern of these mediators following infection may denote the beneficial and 
detrimental effects associated with their production and facilitate improved drug targeting 
for treatment of the disease. In this chapter the expression of the cytokines IL-la, IL-6 
and TNF-a as well as the chemokines RANTES, MIP-1 a  and MCP-I will be investigated 
within the CNS during each phase of the disease from the early-stage, through the CNS- 
stage, to the development of the PTRE. These cytokines have been chosen since they have 
previously been shown to be induced during trypanosome infections and their expression 
has also been reported in brain tissue. Furthermore, the different functions of the selected 
mediators indicate that they would be highly likely to induce and control a CNS 
inflammatory reaction of a similar nature to that associated with trypanosome infection and 
subcurative chemotherapy. The induction and expression of these molecules will be 
investigated at various time points tlii'oughout the course of the disease using both 
molecular and histological teclmiques. The results of these experiments will provide a 
profile of the expression of these mediators as the infection progresses and may indicate 
possible chemotherapeutic targets and feasible intervention time points.
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4.2. Materials and methods
The main aim of the following section of this thesis was to determine the expression 
patterns of specific cytokines and chemokines, induced within the CNS by trypanosome 
infection and subsequent subcuiative drug treatment. The mouse model of human African 
trypanosomiasis, previously described in Chapter 2, was used to investigate the expression 
profiles of the cytokines IL-la, TNF-a and IL-6 and the chemokines MIP-1 a, MCP-1 and 
RANTES at each stage of the infection and following the induction of the PTRE. The 
expression of these inflammatory mediators was examined using a variety of techniques 
including; the reverse-transcriptase polymerase chain reaction (RT-PCR) to determine the 
time course and expression levels of specific mRNA species, immunocytochemistry, to 
identify the presence of the protein within tissue sections and in-situ techniques to 
demonstrate the cellular source of the molecules.
4.2.1. Animals, infections and treatments
Female CD-I mice (Charles River Breeding Laboratories) weighing 28-35g were infected 
with 2x10"^  T.b.brucei parasites of cloned stabilate GVR35/C1.6 as previously described. 
Each stage in the development of the disease from the eaiiy acute infection to the post­
treatment reactive encephalopathy was induced in the animals. To emulate the 
development of CNS reaction during the early stage of the disease animals were killed at 7 
and 14 days following the infection, while those killed at days 21 and 28 post-infection 
were used to mirror the situation found during the early CNS stage of the disease when, the 
parasites are known to have invaded the CNS compartment. Additional infected mice were 
treated on day 21 post-infection with a subcurative dose (40mg/kg i.p.) of the trypanocidal 
drug diminazene aceturate. This drug treatment clears the parasites from the peripheral 
compartments but cannot cross the blood-brain barrier to kill the trypanosomes present in 
the CNS. This induces a more severe inflammatory reaction within the brain of the 
infected mice. Groups of these treated mice were killed at 7 and 14 days following the 
drug treatment. The pathology exhibited in the brains of these mice mimics that of patients 
with late-stage sleeping sickness. Further subcuratively treated mice were allowed to 
progress until they relapsed to parasitaemia, at which time they were given a second 
subcurative dose of diminazene aceturate and killed 7 and 14 days following the treatment. 
This regimen induces an extremely severe CNS inflammatory reaction in the infected 
animals, similar to that found in patients who have died of the PTRE. The complete mouse 
model is described in detail in Chapter 2 of this thesis.
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The experimental model was performed in duplicate. On each occasion the various 
severities of CNS-reaction were induced in separate groups of mice. Each of these 
individual treatment groups comprised six animals and each group was included in 
triplicate in the experimental design. This allowed samples to be taken for section 
preparation from both frozen and paraffin blocks, permitting histological and 
immunocytochemical assessment, while the remaining sample was used for extraction of 
RNA allowing subsequent RT-PCR analyses. The various samples were prepared as 
previously described in Chapter 2.
4.2.2. RT-PCR analyses
The temporal expression patterns of the cytokines IL-la, IL-6 and TNF-a together with 
the chemokines MIP-1 a, MCP-1 and RANTES were investigated using the RT-PCR 
procedure described in Chapter 2. These studies were performed prior to 
immunocytochemistry or in-situ techniques to determine the treatment regimens that 
induce the expression of the inflammatory mediators and thereby indicate which CNS 
tissue sections to examine in order to ascertain the cellular source of the material.
4.2.3. Immunocytochemistiy
The teclmique of immunocytochemistry (ICC) is described in detail in Chapter 2 of this 
thesis. A list of antibodies employed in the cytokine staining procedures is detailed in 
Table 4.1. In an effort to stain the cytokine proteins successfully, a variety of alterations to 
the standard approach were employed. These modifications are described in below.
4.2.3.1. Fixation of cryostat sections
The cryostat sections produced from frozen brain blocks were prepared from unfixed 
material. Therefore, in an attempt to achieve successfril staining of cytokines within the 
tissue, as well as imfixed sections, a range of different fixative protocols were used prior to 
ICC staining. The various fixation methods included treatment of the tissue sections with 
one of the following procedures;
• cold acetone for 20 minutes
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• cold 4% paraformaldehyde^* for 5 minutes
• B ouin’s fixative *
• Lana’s Fix for 30 seconds at -20^C followed by acetone for 30 seconds at -20^C
Acetone treatment, paraformaldehyde and Bouin’s fixative are well recognised, established 
methods for the fixation of frozen seetions (Polalc and Van Noorden, 1986). Lana’s fix, 
followed by acetone treatment, was personally recommended by Prof. Krister Kristensson, 
Karolinska Institute, Stockholm, Sweden.
4.2.3.2. Antigen retrievai techniques
Formalin fixation followed by paraffin embedding is the most commonly used technique 
for histological examination of tissues. Tissue treated in this manner yields sections with 
superior preservation and morphology than that of frozen blocks or alternatively fixed 
material and it is therefore the preferred method of producing sections for all forms of 
subsequent histological analyses. Unfoifunately, formalin treatment, and the process of 
paraffin wax embedding, commonly result in alterations to, or masking of, the antigens 
present within the tissue thereby preventing the use of such material for many ICC 
applications. The mechanisms that lead to these chemical changes in the tissues remain 
lai'gely unknown. However, the development of ‘antigen retrieval’ techniques has 
overcome some of the difficulties associated with the use of these sections in ICC.
The initial attempts to improve the immunoreactivity of formalin fixed tissue antigens 
involved digestion of the tissue sections with proteolytic enzymes prior to staining. These 
enzymes help to expose antigens that have become hidden within the tissue due to the 
protein cross-linking caused by the formalin fixation. In essence the proteolytic enzymes 
digest some of bonds revealing the concealed antibodies. Enzymes used in these antigen 
retrieval teclmiques include trypsin, pepsin and pronase. Although enzyme digestion 
proved successful in the unmasking of many antigens it failed to yield acceptable immuno- 
staining of numerous additional important antigens (Van Noorden, 1986). Therefore, the 
search continued for a simple technique that could be used effectively to retrieve these 
targets.
A t The formulation for this solution is described in Appendix 1.
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An entirely new approach to this problem was adopted that relied on a wet heat pre­
treatment system to restore the antigen within the section (Shi, Cote, and Taylor, 2001). 
This restoration of the target molecule resulted in these methods being termed ‘antigen 
retrieval’ techniques. Initially this heating procedure was performed in water but as the 
technique developed it became apparent that the pH of the solution as well as the 
temperature had a major influence on the effectiveness of the technique. Consequently 
buffers and commercially prepared retrieval solutions replaced the water in this system. 
Although this heat-induced antigen retrieval technique is now widely used in pathology the 
mechanisms resulting in the restoration of the antigenic site remain unknown and the 
technique is still not applicable to every antigen.
Due to the superior morphology found in paraffin sections both proteolytic enzyme 
digestion and wet heat antigen retrieval teclmiques were used in this study. These 
techniques were applied to help demonstrate cytokine staining in formalin fixed paraffin 
embedded tissue sections of trypanosome infected mouse brain.
4.2.3.2.1. Proteolytic enzyme digestion
Proteolytic enzyme treatment was carried out on formalin fixed paraffin embedded 
sections using either a 0.1% trypsin or a 0.4% pepsin solution. Trypsin digestion was 
performed in a solution of 0.1% calcium chloride adjusted to pH 7.8 with O.IM sodium 
hydroxide while pepsin digestion was used in a solution of 0.1% hydrochloric acid. In 
both cases the sections for digestion were deparaffinised in tlnee changes of xylene and 
rehydrated tlii'ough graded alcohols. The endogenous peroxidase activity was then 
quenched by a 20 minute incubation in 0.5% hydrogen peroxide in phosphate buffered 
saline'^* (PBS) followed by a 5 minute rinse in rumiing tap water as previously describe. 
The slides were then placed in proteolytic enzyme buffer pre-warmed to 37^C and allowed 
to equilibrate for 5 minutes before being transferred to the complete enzyme solution. The 
sections were allowed to digest at 37^C for various time periods ranging from 5 to 15 
minutes. Rinsing the slides in cold miming tap water for 5 minutes then stopped the 
reaction (Van Noorden, 1986). The remainder of the ICC staining procedure was then 
performed as described in Chapter 2.
A1 The formulation for this solution is described in Appendix I .
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4.2.3.2 2. Wet-heat antigen retrieval
Antigen retrieval by incubation of formalin fixed paraffin embedded sections in hot buffer 
solutions was also performed to achieve successful ICC staining of cytokines. Two 
approaches to this technique were followed. The first strategy utilised 0.0 IM citrate buffer 
pH 6.0 while the second used a commercially prepared retrieval solution, Serotec tissue 
umnasking fluid (STUF) (Serotec Ltd, Oxford, UK).
4.2.3.2.2.I. Citrate buffer antigen retrieval protocol
Two different approaches were followed in the use of this antigen retrieval technique. 
These procedures are detailed below.
• 600ml of 0.0 IM citrate buffer pH 6.0 were placed into a large heat-proof 
staining dish. Deparaffinsed, rehydrated sections were then placed into the 
buffer and the fluid level was marked on the outside of the container. The 
slides were then microwaved at full power (700W) for a total of 20 minutes.
The fluid level was checked at 5 minute intervals and restored to the marked 
volume with fresh buffer. Following the heating period the slides were 
allowed to cool in the buffer for a further 20 minutes. The sections were then 
rinsed in three changes of cold distilled water, each wash lasting for a 5 minute 
period. This was followed by a 5 minute wash in PBS The endogenous 
peroxidase activity was then quenched and the standard ICC protocol followed 
as previously described.
• 250ml of 0.01 M citrate buffer pH 6.0 were added to a heat-proof staining dish 
containing deparaffinised, rehydrated slides. This was then microwaved at full 
power (700W) for 5 minutes. The slides were then transferred to fresh buffer 
and microwaved for a further 5 minute period at medium power. Again the 
slides were transferred to fresh buffer and microwaved for a final 5 minutes at 
low power. On completion the slides were removed from the microwave and 
placed into PBS at room temperature and allowed to equilibrate for 5 minutes.
The endogenous peroxidase activity was then quenched and the standard ICC 
procedure followed as previously described.
The formulation for this solution is described in Appendix 1.
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4.2.3.2.2.2. Sertoc tissue unmasking fluid (STUF)
STUF is a commercially prepared antigen retrieval solution supplied as a x3 concentrate. 
The solution can be used to reactivate hidden epitopes in formalin fixed paraffin embedded 
sections or to enliance the performance of ICC staining in paraffin or cryostat sections. 
Before use the STUF concentrate was diluted 1:3 with distilled water and placed in a 
waterbath at 90^C to pre-warm in a suitable staining dish. Depai'affinised, rehydrated 
sections or cryostat sections were then incubated in the hot STUF for 10 minutes in the 
90^C waterbath. The staining dish was then removed from the waterbath and allowed to 
cool for 15 minutes. Following the eooling period the slides were rinsed in two changes of 
distilled water followed by two changes of PBS. All washes were performed at room 
temperature and lasted for 5 minutes each. The endogenous peroxidase activity was then 
quenched and the standard ICC procedure followed as previously described.
4.2.3.S. Tissue permeablisation
In some cases, permeablisation of tissue sections is recommended prior to immunostaining. 
This allows entry of the antibodies into the cell thi'ough the cell surface membrane, thereby 
permitting staining of intracellular components. This permeablisation procedure was 
performed on both cryostat and formalin fixed, pai’affm embedded sections to facilitate the 
staining of intracellular cytokines. Two permeabilisation teclmiques were employed and 
are described below
• Saponin introduces pores in the cell membrane without appearing to damage 
the morphology. It accomplishes this by penetrating the plasma membrane at 
cholesterol groups, resulting in a reversible permeabilisation of the membrane.
To achieve this permeabilisation and allow the antibodies to penetrate the cell,
0.1% saponin was included in the buffer at each of the wash stages and in the 
antibody diluent in the standard ICC protocol. It is important that saponin is 
included at each stage of this procedure as it could be washed out of the section 
leading to the loss of the cellular permeability. Saponin was not included in 
the final washes, prior to the visualisation step.
The non-ionic detergent Triton X~100 is often used in biochemical applications 
to solubilize proteins. In ICC procedures 0.01% Triton X-100 can be 
incorporated into the wash buffers used during the staining protocol. This 
permeabilises the cell membrane and allows the antibodies to bind with
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intracellular targets. Triton X-100 was included in each wash stage during the 
antibody phase of the staining technique but was omitted from the final washes 
prior the visualisation of the bound antibody.
4.2.4. In situ techniques
In-situ procedures have developed from nucleic acid hybridisation techniques and ean be 
used to detect and localise mRNA transcripts within tissue sections. This ability, to 
identify particular mRNA species within tissue sections, allows the cellular source of the 
individual proteins to be determined. In-situ procedures were performed to identify the 
cell types responsible for cytokine production within the CNS following trypanosome 
infection and subcurative drug treatment in our mouse model. There are a variety of 
different in-situ approaches that can be followed; these are described in more detail below.
4.2.4.1. /n-s/Tu hybridisation
In-situ hybridisation (ISH) can be used to visualise specific genes and mRNA sequences 
within intact cells. The procedure was developed in 1969 by two groups of researchers 
working independently (Jolm, Birnstiel, and Jones, 1969; Pardue and Gall, 1969). The 
teclmique involves the use of probes designed specifically to bind with particular nucleic 
acid sequences in the tissue section. These probes can be labelled with various reporter 
molecules e.g. radioisotopes, fluorescence, digoxigenin or biotin. At the end of the 
procedure the reporter molecules allow the presence of the bound probe to be visualised 
and the location of the target sequences to be determined within the tissue section or cell 
preparation (Leitch, Schwarzaclier, Jackson, and Leitch, 1994; Polak and McGee, 1991).
In this study, ISH was adopted to identify the cell types expressing mRNA transcripts for 
the cytokines IL-la, IL-6 and TNF-a. The ISH procedure was performed using a 
commercially prepared ''in-situ workstation” (British Bio-teclmology Products Ltd., Oxon. 
UK). The protocol supplied with this kit was employed. Both cryostat and formalin fixed 
paraffin wax embedded sections were used. Since the target sequence to be detected was 
composed of mRNA, the precautions detailed in Chapter 2, with regard to the handling of 
the sample to prevent the degradation of the nucleic acid were strictly followed. These 
precautions included, wearing disposable gloves throughout the procedure, where possible, 
all glassware, equipment and solutions were di-ethyl-pyrocarbonate (DEPC) treated and
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autoclaved to denature any contaminating RNase, and disposable RNase free filter tips 
were used during all the pipetting stages of the techinique.
4.2.4.1.1 ISH of murine CNS sections
Formalin fixed, paraffin wax embedded sections were dewaxed, rehydrated tlirough graded 
alcohols and rinsed for 5 minutes in DEPC water. The sections were then washed in 2 x 
salt sodium citrate buffer'^* (SSC) followed by a 5-minute rinse in DEPC water^*. To allow 
the probe to gain access to the mRNA target within the cells, the sections were 
permeablised by protease digestion, for 60 minutes at 37°C, with proteinase K. The 
enzyme was used at various concentrations ranging from 5pg/ml to 60pg/ml and was 
diluted in proteinase K diluent, containing, 50mM EDTA and lOOmM TRIS, pH8.0. 
Following proteinase K digestion the sections were rinsed in PBS for 1 minute and then 
post-fixed in 4% paraformaldehyde for 20 minutes at 4^C. This post-fixing step terminates 
any residual proteinase K activity and prevents the subsequent diffusion or loss of mRNA 
target from the permeabilised section. Before the hybridisation step, any non-specific 
binding sites within the tissue section were blocked to prevent background staining. This 
was acheived by incubating the section in prehybridisation solution. This solution is 
identical to the buffer used dui'ing the hybridisation stage without the addition of the 
specific probe. While the slides were post-fixing in the paraformaldehyde the 
prehybridisation solution was placed in a waterbath at 37^C with periodic agitation to pre­
warm. This process dissolves any residual salt precipitates that may have formed in the 
buffer during storage and the mixing ensures that the reagents are distributed 
homogenously tlnoughout the viscous solution.
The prehybridisation / hybridisation solution provided in the kit contained 0.6M salt, 30% 
formamide, and 150pg/ml sonicated salmon sperm DNA. The specificity of the 
hybidisation is controlled by the stringency of the conditions used. The stringeney of the 
conditions is dictated by two main factors, the salt concentration in the buffer and the 
temperature at which the hybridisation is performed. Low salt concentrations and high 
temperatures constitute highly stringent conditions and will only permit the formation of 
nucleic acid duplexes with extremely high homology. High salt concentrations and low 
temperatures provide low stringency conditions. Under these circumstances non-specific 
interactions between non-homologous strands can occur. Unfortunately, high temperature 
are detrimental to the morphology of the tissue, therefore formamide is added to the
A1 The formulation for this solution is described in Appendix 1.
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prehydridisation / hybridisation solution. Formamide disrupts the hydrogen bonds between 
the nucleic acid strands and destabilises non-homologous duplex formations thereby 
reducing non-specific binding of the probe. Consequently, the inclusion of the formamide 
allows the use of lower temperatures which, in turn, help to preserve the tissue sections 
during the procedure.
Following the post-fixation stage, the sections were drained and rinsed in DEPC water to 
eliminate the residual paraformaldehyde. The excess fluid was then removed by wiping 
carefully around the tissue section with a clean paper tissue. Each section was placed on a 
staining rack and 3 00pi of pre-warmed hybridisation buffer applied over the section. The 
slides were then transferred to a humidity chamber and incubated at 37^C for 60 minutes.
During the prehybridisation step the hybridisation solution was prepaied by the addition of 
the specific probes. The probes used were commercially prepared by R&D systems 
Europe Ltd. (R&D systems Europe Ltd., Oxon., UK). They consisted of eocktails of 
oligonucleotides complementary to specific regions of the target mRNA sequences. All 
the oligonucleotides were single stranded, ranged from 28 to 30 bases in length and were 
modified at both the 5’ and 3’ ends by the addition of a digoxigenin reporter molecule. 
The probe cocktails consisted of an equimolar mixture, of the exon specific probes, and 
were supplied as 50ng/pl solutions. The probe cocktail used to detect IL -la  mRNA 
contained oligonucleotides specifically designed to bind with regions in exons 5, 6 and 7 of 
the murine mRNA sequence. The IL-6 cocktail consisted of four oligonucleotides that 
bind with regions in exons 2, 3, 4 and 5 of the murine IL-6 mRNA sequence while the 
probe used for the detection of TNFa expression was designed to bind specifically with 
four regions, one from exon 3 and three individual areas from exon 4, of the murine TNFa 
mRNA molecule. The recommended working concentration for oligonucleotide probes of 
approximately 30 bases is 200ng/ml, although a wide range of concentrations has been 
employed. To achieve successfril ISH staining in this study the probe cocktails were added 
to the hybridisation buffer to give final concentrations between 200ng/ml and 5,000ng/ml. 
The complete hybridisation buffer was mixed gently but thoroughly to ensure an even 
distribution of the probe mix. The solution was then placed at 37^C until required.
On completion of the prehybridisation stage, the sections were removed from the humidity 
chamber, the solution was drained from the slide and the excess liquid wiped carefully 
from around the section using a clean paper tissue. 20pl of the complete hydridisation 
buffer was then applied to each section and covered with a clean glass coverslip. Any air
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bubbles present in the hybridisation solution were removed by gentle tapping of the 
coverslip. The section were then returned to the humidity chamber and incubated at 37^C 
overnight.
Following hybridisation, it is necessary to remove all the non-specifically bound 
oliginucleotides while retaining those that have bound with their specific target sequence. 
To achieve this, the sections were removed from the humidity chamber and washed in a 
series of post-hybridisation washes of increasing stringency. The first wash in this 
procedure was comprised of a solution containing 4 x SSC pre-heated to 37^C. This 
provides an environment with similar stringency conditions to those used during the 
hybridisation stage and will therefore remove only excess and extremely loosely bound 
probe. On removal from the humidity chamber, the slides were immediately placed into 
this wash solution. The coverslips were not removed from the slides before being placed 
in the solution as they float off of the section during the wash procedure. Manual removal 
of the coverslips can result in unnecessary damage to the delicate tissue section. The 
sections were allowed to rinse in this solution for 5 minutes before transfer to the second 
wash solution. This buffer was slightly more stringent than the first and contained 2 x 
SSC, however, the procedure was performed at room temperature. The sections were 
incubated in this solution for 20 minutes, transferred to fresh 2 x SCC and the incubation 
repeated. Following the second wash in 2 x SSC at room temperature, the slides were 
transferred to fresh 2 x SSC. This wash was performed at 37®C for 20 minutes to increase 
the stringency slightly. As before, this wash stage was performed in duplicate. The wash 
conditions followed in this procedure were designed to be of low stringency. This was to 
ensure that specifically bound probe was not removed together with non-specifically bound 
oligonucleotides. Once a signal has been detected using the technique the stringency of the 
post-hybridisation washes can be increased as appropriate. This increase in stringency can 
be achieved by, reducing the salt concentration of the washes, increasing the wash 
temperatures and the inclusion of formamide in the solutions. Following completion of the 
post-hybridisation washes any probe remaining bound to the section can be detected using 
an immunocytochemical detection procedure, similar to that described for ICC. The 
procedure for visualising the digoxigenin reporter molecule is described below.
A similar protocol was employed using cryostat sections as an alternative to formalin fixed 
paraffin embedded samples. In this scenario the sections were fixed in 4% 
paraformaldehyde at 4^C for 20 minutes and then rinsed in DEPC water. The procedure 
detailed above was then followed, beginning with the proteinase K digestion step.
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4.2.4.1.1.1 ISH control sections
The inclusion of control sections in any histochemical techniques, particularly those 
designed to detect nucleic acid sequences, is essential to exclude the possibility of 
misleading or false positive results. Control slides for ISH consist of both positive and 
negative control sections. In this case the positive control slides were prepared from the 
brain of a trypanosome-infected mouse following a double diminazene aceturate treatment. 
This treatment regimen has been shown, by RT-PCR analyses, to induce the expression of 
the cytokines of interest and therefore should provide a good source of the target mRNA 
within the tissue sections.
It is possible that the reagents used in the tissue pre-treatment stages, or in the 
hybridisation solution itself, may react non-specifically with elements in the tissue section 
resulting in background staining that could be interpreted as a positive reaction. 
Consequently, it is essential to include a negative control section in each ISH run. This 
negative control is treated in an identical manner to the test section but has no probe added 
to the hybridisation solution. If positive staining is detected in this slide then it must be 
due to background noise. A second variety of negative control is also recommended. This 
involves treatment of the tissue section with RNase prior to the hybridisation step. This 
will degrade the mRNA in the section and eliminate the nucleic acid target sequence. This 
form of negative control was not included in this study due to the possible risk of 
contamination of the test sections, or samples destined for RT-PCR analyses, by the RNase 
enzyme.
4.2.4.1.2. Visualising the digoxigenin reporter molecule
The location of the digoxigenin reporter molecule in the tissue sections was demonstrated 
using an anti-digoxigenin antibody labelled with alkaline phosphatase. This anti- 
digoxigenin antibody was pui'chased from Boelninger Mannheim (Boerhinger Mannheim 
UK, East Sussex, UK) and comprised the Fab fragments of anti-digoxigenin sheep IgG. 
During the detection procedure various Tris buffer solutions were used. These are detailed 
below.
Buffer 1 ; lOOmM Tris, 150mM sodium chloride, pH7.5.
Buffer 2; lOOmM Tris, lOOmM sodium chloride, 50mM magnesium chloride, pH9.5
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Buffer 3; lOmM Tris, ImM EDTA, pH8.0
Before the antibody was applied to the sections the slides were washed for 1 minute in 
buffer 1. Non-specific binding of the antibody was then prevented by incubating the 
sections, for 30 minutes at room temperature, in a blocking solution containing 2% normal 
sheep serum and 0.3% triton X-100 diluted in buffer 1. Following the blocking stage, the 
solution was drained from the slides and the excess wiped carefully from around the 
section using a clean paper tissue. The anti-digoxigenin antibody, diluted at 1:500 in the 
blocking solution, was then applied to the sections and allowed to incubate for 2 hours at 
room temperature. After 2 hours the slides were washed in two, 10 minute, changes of 
buffer 1. After the second wash, buffer 1 was replaced with buffer 2 and the slides were 
washed for a further 2 minutes.
A stock substrate solution containing 18.75mg/ml of nitro blue tétrazolium chloride (NBT) 
and 9.4mg/ml of 5-bromo-4chloro-3indolyl phosphate (BCIP) was purchased from 
Boehiinger Mannheim (Boerhinger Mannlieim UK, East Sussex, UK). This was used to 
prepare the substrate solution required for the detection of the alkaline phosphatase label 
conjugated to the anti-digoxigenin antibody. The working substrate solution was prepared 
by the addition of 200pl of NBT/BCIP stock to 10ml of buffer 2. To quench any 
endogenous alkaline phosphatase activity, 100pi of IM levamisole was added to the 
substrate solution.
After 2 minutes, buffer 2 was drained from the slides and the excess removed by wiping 
around the section with a clean paper tissue. The slides were placed in a humidity chamber 
and the working substrate solution was applied to the sections. The slides were placed in a 
dark enviromnent and reaction allowed to proceed at room temperature. After an initial 
30-minute incubation time, the colour development was monitored by periodic 
microscopic examination of the sections. A positive reaction can be seen by the presence 
of a dark blue/black reaction product in the section. If no satisfactory staining became 
apparent the colour development was allowed to continue overnight. On completion, the 
reaction was stopped by washing the slides in buffer 3 for 5 minutes. The sections were 
then counterstained with neutral red to emphasize any blue/black staining and to ease 
subsequent histological examination. Since the end product of the alkaline phosphatase 
NBT/BCIP reaction is alcohol soluble, the slides were mounted in Aquamount®, an 
aqueous mounting medium that does not require dehydration and clearing of the sections 
before its use.
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4.2.4 2. In-situ reverse-transcriptase polymerase chain 
reaction
In-situ reverse-transcriptase polymerase chain reaction (IS-RT-PCR) is a teclmique that 
can be used to amplify specific mRNA sequences within tissue sections to allow their 
subsequent detection . This amplification of specific nucleic acid target sequences helps to 
circumvent the problems associated with the detection of low copy number mRNA species 
using conventional ISH. The proceduie utilises the RT-PCR reaction as described in 
Chapter 2. However, in IS-RT-PCR the nucleic acid tai'get sequences are not extracted 
from the sample but are amplified in-situ within the tissue section thus allowing the cells 
responsible for the production of the nucleic acid to be identified.
IS-RT-PCR can take two forms, direct and indirect IS-RT-PCR. In this study both forms 
of this procedure were utilised to ascertain the som'ce of the cytokines IL-la, IL-6 and 
TNFa, within the murine CNS following trypanosome infection and subcurative drug 
treatment.
4.2A.2.1. Direct IS-RT-PCR
Direct IS-RT-PCR uses the teclmique of RT-PCR to amplify specific mRNA sequences in 
tissue sections without the need for prior extraction of the nucleic acid. During the PCR 
procedure a nucleotide, labelled with a reporter molecule, such as, digoxigenin, biotin or 
fluorescein, is incorporated directly into the resulting amplicon. This reporter molecule 
can then be detected in the section and the location of the mRNA target determined 
(Embelton, 1998).
To perform IS-RT-PCR the following protocol was followed. Formalin fixed paraffin 
embedded sections were cut and mounted three per slide. This allows the inclusion of 
control sections on each individual slide as shown in Figure 4.2. Two sets of slides from 
each tissue block were included in each IS-RT-PCR run. The sections were dewaxed, 
rehydrated through graded alcohols and then rinsed in PBS. To obtain the optimal 
permeablisation of the tissue, one set of slides was incubated overnight with 20pg/ml 
proteinase K at room temperature. The second set of slides was treated for 90 minutes 
with 40pg/ml proteinase K at 37^C. Following the enzyme treatment the sections were 
rinsed in PBS, supplemented with O.IM glycine, to stop the digestion process. The slides
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were then dehydrated tlii'ough graded alcohols and stored until ready to continue the 
protocol.
When performing IS-RT-PCR there is a danger that genomic DNA within the section will 
be amplified dining the PCR stage of the procedure. Since the amplification procedure is 
performed in the tissue section, the PCR products of mRNA and genomic DNA cannot be 
differentiated by assessing the size of the amplicon. Therefore, to eliminate the risk of 
generating false positive results, it is necessary to treat the test seetions with DNase to 
degrade the genomic DNA. This DNase treatment also helps to prevent the generation of 
false positive results due to incorporation of the labelled nucleotide into genomic DNA 
sequences by the cellular DNA repair mechanisms. The test section and the negative 
control section on each slide (Fig.4.2) were therefore treated with lOU of DNase, diluted in 
a buffer containing lOOmM sodium acetate and 5mM magnesium sulphate. The enzyme 
was applied to the sections and allowed to digest overnight at room temperature. The third 
section on the slide was not treated with DNase and served as a positive control. The 
sections were dehydrated following DNase digestion.
As with tissue sections it is necessary to convert the mRNA in the tissue sections to cDNA, 
using reverse transcriptase, before the PCR stage can be performed. The reverse 
transcriptase reaction was performed on only the test section on each slide (Fig. 4.2). The 
cDNA was generated in a 50pi reaction volume. The solution comprised IX strand 
buffer (5mM Tris pH8.3, 75mM potassium chloride and 3niM magnesium chloride), 600U 
M-MLV reverse transcriptase, lOmM dithiothreitol (GIBCO BRL®), 1.25mM dNTP’s, 
3OU RNase inhibitor and 2ug random hexamers (Hybaid, UK). The reverse transcriptase 
mix was applied to the sections and the slides were incubated for 30 minutes at 42^C. The 
sections were then rinsed for 5 minutes in 50mM Tris pH8.0 and dehydrated through 
graded alcohols prior to the PCR.
To perform the PCR a master mix containing IX PCR buffer (20mM Tris pH8.55, 16mM 
ammonium sulphate and 1.5mM magnesium chloride), 6U Taq DNA polymerase (Hybaid, 
UK) Ing 3’primer, Ing 5’primer, lOmM digoxigenin-11-dUTP (Boehiinger Mamiheim 
UK, East Sussex, UK), 50mM dNTP’s and 2% BSA (Sigma). The reaction volume 
allocated for each section was 50pl. The primers used in this study were designed to 
amplify IL-la, IL-6 and TNF-a. These primers were identical to those used in the 
procedure described in Chapter 2 for tube PCR and their nucleotide sequence is detailed in 
Table 2.3. The concentration of each reagent used in IS-RT-PCR is much higher than that 
used for tube PCR. This is due to the presence of inliibitors within the tissue section that
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Figure 4.2
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are absent in extracted nucleic acid samples. Thermo-cycling blocks designed by both 
Perkin-Elmer and Hybaid were used in the IS-RT-PCR proeedure. Each block has specific 
requirements to seal the PCR mix with the tissue section. Therefore, the master mix was 
applied to the sections and the slides were assembled according to the manufactures 
recommendations before being plaeed onto the thermo-cycling block. To help achieve 
successfril IS-RT-PCR staining a range of cycling parameters were used in this procedure. 
During the initial dénaturation step the slides were heated to 94°C for 5 minutes. This was 
followed by a short denaturing step of 94^C for 15 seconds to 3 minutes, an amiealing step 
of 60^C for 30 seconds to 4 minutes and an extension step of 72®C for 1 minute 30 seconds 
to 5 minutes. This profile was repeated for between 10 and 35 cycles. A final extension 
step of 72°C for 10 minutes was performed at the end of the cycling procedure. Following 
the PCR procedure the slides were removed from the cycling block and washed for 10 
minutes at room temperature in PBS to remove the excess PCR mix. The digoxigenin-11- 
dUTP labelled PCR product was then detected using the visualisation procedure described 
above.
4.2.4.2.Z  Indirect IS-RT-PCR
Indirect IS-RT-PCR, utilises a combination of RT-PCR and ISH techniques. The target 
mRNA is first converted to cDNA and then amplified within the tissue section. No 
labelled nucleotides are employed in indirect IS-RT-PCR, therefore, the product of this 
RT-PCR reaction is detected with the use of specific probes tlirough the ISFI procedure 
(O'Leary, 1998).
The protocol used for indirect IS-RT-PCR largely followed that described for direct IS-RT- 
PCR. Flowever, after the reverse transcriptase reaction the sections were post-fixed in 
0.4% paraformaldehyde for 20 minutes at 4®C before dehydration. The PCR master mix 
also differed from that used in the direct method as no digoxigenin-11-dUTP was added to 
the mix. On completion of the PCR cycling the section were post fixed in 0.4% 
paraformaldehyde for 20 minutes at 4^C to prevent loss of the amplicons, then rinsed in 
PBS and dehydrated.
A hybridisation buffer comprising 2 x SSC, 5% dextran sulphate and 0.2% dried milk 
powder was prepared. To this, a specific oligonucleotide probe, labelled with either biotin 
or digoxigenin, was added to a final concentration of lOpmol/lOOpl. In this study 
oligonucleotide probes, labelled with either biotin or digoxigenin, designed specifically to
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bind with the PCR product of IL -la amplification were employed. The nucleotide 
sequence of this IL -la  specific probe was as follows:
5’-CTC TTC TTC AGA ATC TTC CCG TTG CTT GAC-3’
The complete hybridisation buffer was applied and the slides heated to 95*^ C for 5 minutes 
to denature the double stranded PCR amplicons in the tissue sections. The slides were then 
incubated overnight at 42^C to allow the probe to hybridise with the target sequence. 
Following the hybridisation the sections were rinsed in 4 x SSC for 10 minutes, followed 
by two 20 minute washes in 2 x SCC. All post-hybridisation washes were performed at 
room temperature.
The visualisation procedures employed following the hybridisation depended on the 
reporter molecule used to label the probe. A biotin label was detected using the standard 
ABC protocol detailed in the ICC procedure described in Chapter 2 while a digoxigenin 
label was detected using the visualisation procedure described above.
4.2,5. Statistical analyses
Statistical analyses were performed on the data generated from the assessment of the level 
of cytokine and chemokine transcription in the muiine CNS following trypanosome 
infection and subcurative drug treatment. Differences in the expression levels of these 
inflammatory mediators were investigated using a visual assessment scale to grade the 
intensity of the resulting PCR band following amplification (Figure 2.11). The data 
produced using this scoring system were analysed using non-parametric statistical tests. 
Significant differences in the expression levels of these mediators across the groups of 
mice were detected using the Kruskal-Wallis test. This was then followed by Dunn’s test, 
a pairwise comparison proceduie for non-parametric data, to highlight differences between 
the median values from individual groups. All statistical tests were performed using the 
proprietary statistical software packages, Minitab version 13 and Sigmastat 2.03.
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4.3. Results
4.3.1. Kinetics of cytokine and chemokine 
expression
The RT-PCR analyses of nucleic acid extracted from murine CNS tissue following 
trypanosome infection and subcurative drug treatment was employed to detect any 
variations in the levels of cytokine niRNA expression that occur during the course of the 
disease. Significant changes in the levels of the transcripts for these inflammatory agents 
were detected through formal statistical analyses of the data generated from assessing the 
intensity of the resultant PCR bands when examined on a 2% agarose gel stained with 
ethidium bromide. Such alterations in cytokine and chemokine expression may indicate 
that these important mediators play a central role in the disease pathogenesis. This 
information could help to establish novel drug targets to help prevent the development of 
the CNS-inflammatory response associated with trypanosome infection.
4.3.1.1. Observational differences and trends in cytokine 
expression
Pictures of the PCR products obtained on amplification of pooled mRNA from animals in 
each treatment regimen are shown in Figures 4.3-4.9. Although six mice were included in 
each group at the outset of the experiment, due to death or euthanasia of the mice prior to 
the endpoint of the experiment, or unsatisfactory RNA extraction the number of animals 
comprising each analysis group are listed in Figures 4.10-4.15. Before any comparisons 
were made regarding the levels of cytokine expression in the mice the quality of the 
mRNA was checked by amplification of the mRNA of the housekeeping gene p-actin. 
This resulted in bands of a similar intensity (Fig. 4.3) indicating that differences in the 
banding pattern for subsequent analyses would be the result of variations in the amount of 
target transcript present in the initial sample and would therefore provide an indication of 
the transcription levels of the cytokine or chemokine being examined.
The broad interpretation of the RT-PCR results indicated that cytokines such as IL-a and 
TNF-a were expressed in the brains of normal uninfected mice and continued to be present 
following infection. IL-6 mRNA transcripts were never detected in uninfected animals but
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were always present by 7 days post-infection. The chemokines M IP-la, MCP-1 and 
RANTES were also expressed in uninfected animals and thi'oughout the course of the 
infection.
The gel staining pattern found on examination of IL -la expression (Fig. 4.4) shows that 
the expression of this cytokine appears to rise from 14 days post-infection tlirough to 28 
days post-infection. Following the administration of a subcurative diminazene aceturate 
dose, to exacerbate the CNS inflammatory response, the levels of transcript dropped 
slightly compared with mice killed at 28 days post-infection. This level was also observed 
in mice 7 days following the induction of a severe meningoencephalitis by treatment with a 
second dose of diminazene aceturate. However, by 14 days after the second diminazene 
aceturate the levels of IL -la  mRNA found were similar to those seen in animals killed at 
28 days post-infection. Moderate levels of IL -la transcription were found to be 
constitutiveiy expressed in uninfected animals.
In contrast to IL-la, no IL-6 expression was seen in uninfected mice (Fig. 4.5). 
Transcripts for this cytokine were found in mice by 7 days post-infection and this remained 
relatively constant through to day 21 post-infection. A slight increase in the intensity of 
the PCR band was seen in animals at day 28 post-infection compared to those killed during 
the earlier stages of disease. Seven days after the exacerbation of the CNS inflammation, 
by administration of a single dose of diminazene aceturate, the level of IL-6 found was 
similar to that seen in the early infection and this dropped slightly more by 14 days after 
the drug treatment. This pattern was not echoed in mice in which the severe 
meningoencephalitic reaction had been induced and more intense PCR bands were 
detected in these mice.
Transcripts for TNF-a were detected in animals at similar levels on days 7 and 14 post­
infection (Fig. 4.6). The intensity of the resultant PCR bands was higher when the RT- 
PCR was performed on mice killed at the later time points of days 21 and 28 post­
infection. A similar level of expression was found in animals killed 7 days after receiving 
a single dose of diminazene aceturate. However, this level had dropped by day 14 post- 
diniinazene aceturate and only very weak PCR bands were found. Low levels of TNF-a 
transcription were also seen in uninfected animals.
When the expression of MCP-1 was investigated weakly staining bands were found in 
uninfected mice (Fig. 4.7). By 7-days post-infection the intensity of this band had
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increased a little and appealed to strengthen slightly further as the degree of the 
neui-oinflammation became more severe. This was not true for mice killed 14 days after 
the administration of a second diminazene aceturate dose. Although this treatment 
regimen induces a severe meningoencephalitis the intensity of the band seen following the 
amplification MCP-1 transcripts, was lower than in other groups in which the CNS 
reaction had been induced and was similar- to that found 7 days after the mice had been 
infected.
Transcripts for M IP-la were found in uninfected mice and the intensity of PCR bands 
increased only slightly following infection (Fig. 4.8). In animals killed at 21 and 28 days 
post-infection, a further moderate rise in the expression levels was seen. Following 
exacerbation of the CNS response no gross changes in the intensity of the staining pattern 
were found. Animals killed 7 days following the administration of a second dose of 
diminazene aceturate once more showed higher levels of M IP-la expression. However, 
by 14 days after this drug treatment the intensity of the resulting band had dropped to 
levels comparable with those seen in iminfected mice.
RANTES transcription was detected in uninfected animals (Fig. 4.9). The intensity of the 
PCR band was increased following infection and this remained at largely similar levels 
through to day 28 post-infection. When the animals were given a single dose of 
diminazene aceturate the level of RANTES transcription appeared to rise at 7 days after the 
drug treatment and fall again by 14 days following the diminazene aceturate. A similar 
pattern of expression was found when the extremely severe meningoencephalitic reaction 
was induced by treating the infected mice with a second dose of diminazene aceturate. 
This regimen again initially resulted in an increase in the transcription of RANTES that 
appeared to reduce by 14 days after the diminazene aceturate treatment.
4.3.1.2. Statistical analyses of RT-PCR results
Significant alterations in the expression levels on IL-la, IL-6, TNF-a, MCP-1, M IP-la 
and RANTES were detected on statistical analyses of the results of the interpretation of the 
banding patterns as seen on a 2% agarose gel stained with ethidium bromide after RT-PCR 
analysis. The data were generated by assigning a numerical grading score describing the 
intensity of staining of the PCR reaction product from each individual mouse. In all cases 
p-values of less than 0.05 were considered to indicate a significant change in the level of 
specific cytokine or chemokine transcription. Treatment groups where significant
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differences in these expression levels were detected are listed in Table 4.2. Summary data 
for each cytokine or chemokine in the individual and combined experiments, together with 
graphs depicting trends in the expression patterns are described in Figures 4.10-4.15.
No significant differences were found in the expression levels of IL -la  within the CNS 
thi'oughout the progression of the neuroinflammatory reaction. Uninfected animals 
showed a median PCR value on 2.75. These levels were slightly reduced (median 2.00) in 
mice killed at 7 and 14 days after infection with T.b.brucei GVR35/C1.6. By 21 days post­
infection this had increased to a median value 2.5 and a further rise was seen on day 28 
post-infection (median 3.00). Following treatment with a single diminazene aceturate dose 
the level of IL -la  expression retuined to that seen at 7 and 14 days post-infection (median
2.00). This increased slightly when the mice were killed 7 days after a second diminazene 
aceturate treatment (median 2.25) and increased further by 14 days after administration this 
drug treatment (median 3.00) (Fig. 4.10).
When the expression of IL-6 was examined significant differences in the levels of 
transcription were detected between the various treatment groups. Transcripts were never 
detected in any of the uninfected animals and returned a median PCR value of 0.00. By 7 
days post-infection expression of IL-6 was foimd (median 1.00). This expression level 
remained relatively stable in animals killed on day 14 post-infection (median 0.75) and 21 
days post-infection (median 1.00) and a slight increase in the PCR banding intensity was 
detected in animals killed on day 28 post-infection (median 1.50). Significant differences 
were found in the expression of IL-6 between animals killed on days 21 and 28 post­
infection and the uninfected control mice. Mice treated with a single diminazene aceturate 
dose also returned a median PCR value (median 1.00) that was significantly different to the 
uninfected animals. However, by 14 days after the drug treatment this expression level had 
dropped to a median value of 0.05 and this was no-longer different to that seen in the 
uninfected mice. An increase in the transcription of IL-6 was found in animals killed 7 
days following treatment with a second dose of diminazene acetiuate. These animals 
returned a median PCR value of 1.75 and this had increased further by 14 days after the 
drug treatment (median 2.00). Both groups of mice treated with two doses of diminazene 
aceturate showed significantly increased levels of IL-6 transcription compared to 
uninfected control animals (Fig. 4.11).
TNF-a expression was detected in uninfected mice and a median PCR value of 0.75 was 
found. By 7 and 14 days post-infection this expression had increased (median 1.25) but 
this could not be considered significant. A further rise in the expression of this cytokine
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was seen in animals killed at 21 days post-infection (median 2,50) and 28 days post­
infection (median 3.00). The increased level of transcription found in mice killed on day 
28 post-infection was significantly different to the levels seen in control animals. Animals 
killed 7 days following the administration of a single diminazene aceturate treatment 
returned a median PCR value of 2.5 this dropped dramatically in animals killed at day 14 
after drug treatment (median 0.00). The level of TNF-a transcription found in this group 
of mice was significantly lower than that seen in mice killed at 28 days post-infection and 
7 days after a single diminazene aceturate treatment. Animals treated with a second 
diminazene aceturate treatment and killed 7 days later returned a median PCR value of 
2.75. This was considered significantly higher than that found 14 days after a single 
diminazene aceturate dose. When the period between diminazene acetuiate administration 
and termination of the mice was extended to 14 days a slight drop in the transcription level 
for TNF-a was found (median 1.00) (Fig. 4.12).
Low levels of MCP-1 expression were seen in uninfected mice and these animals returned 
a median PCR value of 0.50. By 7 and 14 days after infection this median had increase to 
2.00. A further increase was noted on day 21 post-infection (median 2.50) but this had 
dropped back down slightly by day 28 post-infection (median 2.25). The levels of MCP-1 
transcription seen in these groups of infected animals was not considered significantly 
different to that found in the uninfected mice. The median PCR value found in mice 7 
days after a single diminazene aceturate dose was 2.5. This figure was significantly higher 
than that found in the uninfected mice. By 14 days post-diminazene aceturate the 
expression level was again slightly higher than that seen after 7 days post drug treatment. 
A rise in the transcription level of MCP-1 was seen in mice killed 7 days after receiving a 
second diminazene aceturate treatment. These animals returned a median PCR value of 
3.00; this was significantly higher than the expression level seen in uninfected mice. A 
reduction in the level of MCP-1 transcription was found in mice killed 14 days after 
treatment with a second dose of diminazene aceturate (median 1.75) (Fig.4.13).
The expression of M IP-la in the uninfected mouse brain returned a median PCR value of 
1.50. In animals killed at 7 days post-infection this had increased to 2.5 and remained at 
this grade tlirough to day 14 post-infection. On days 21 and 28 post-infection the levels of 
M IP-la expression continued to rise and gave median PCR values of 3.00 and 3.50 
respectively. The transcription level, seen animals killed at 28 days post-infection, was 
significantly higher than that found in uninfected animals. Treatment of the infected mice 
with a single diminazene aceturate dose resulted in a reduction in the transcription of this
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chemokine. Mice killed 7 days after receiving the drug showed a median level of 3.00, 
which dropped still further in mice killed 14 days after diminazene aceturate treatment 
(median 2.00). When the infected animals were treated with a second dose of diminazene 
aceturate, the expression levels returned to those seen in mice killed on day 28 post­
infection (median 3.50). This was again significantly higher than the levels seen in 
uninfected mice. On day 14 after the second diminazene aceturate treatment the 
expression of M IP-la was reduced to levels compaiahle with those seen in uninfected 
animals (median 1.50) (Fig.4.14).
The chemokine RANTES was found to be expressed in uninfected mice. These animals 
returned a median PCR value of 1.50. This level increased following infection and a 
median of 3.00 was found in groups of mice killed at 7, 14, 21 and 28 days post-infection. 
Groups of animals killed at 14 and 28 days after infection were considered to express 
higher levels of RANTES than uninfected mice. When animals were treated with a single 
dose of diminazene aceturate the transcription of RANTES was further increased (median
4.00), however this was reduced by 14 days after drug treatment (median 2.50). Seven 
days following administration of a second dose of diminazene aceturate the median 
expression levels return to 4.00. This was significantly higher than the median PCR value 
found in uninfected animals. A reduction in this median PCR value was found in mice 
killed on day 14 after receiving the second diminazene aceturate treatment (median 2.75) 
(Fig.4.15).
4.3.2. Immunocytochemistry
Immunocytochemistry (ICC) was performed to determine the location of cytokine proteins 
within the CNS of trypanosome-infected mice following various drug regimens. Before 
this technique was performed, the presence of the mRNA transcripts for these 
inflammatory mediators had been shown in nucleic acid extracted from the CNS of 
trypanosome-infected animals killed on day 7 post-infection and in all subsequent samples. 
This strongly suggests that the protein product of this mRNA should also be found in the 
CNS of these mice.
A wide range of ICC protocols were used to try and achieve staining of the cytokine 
proteins. However, none of these techniques proved successful in this study. Despite the 
use of antibodies from multiple different clones no cytokine protein could be detected 
using the standard ICC teclmique with either cryostat or paraffin embedded tissue sections.
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Therefore, a variety of tissue permeablisation and antibody retrieval techniques were 
attempted. Unfortunately none of these methods produced successful staining results.
4.3.3. In-situ techniques
4.3.3.1. /n-s/fu hybridisation
This investigation attempted to use ISH to localise mRNA transcripts from IL-la, IL-6 and 
TNF-a. Sections stained using this procedure, including the negative control slide, either 
showed high levels of background staining that was indistinguishable from true staining or 
no staining at all. A range of alterations to the technique described in the Materials and 
Methods section were instigated in an effort to achieve successful staining using ISH. 
These modifications included, vai'ying the concentration of proteinase K and the duration 
of the digestion used to permeablise the tissue, altering the concentration of the probe, 
raising the hybridisation temperature to 42^C and changing the stringency of the post­
hybridisation washes. The teclmique was also tried using cryostat sections however, the 
fl'ozen material was extremely fragile and often floated off of the slide during the lengthy 
procedure and no improvements in the staining patterns were found. None of these 
modifications were successful and the use of ISH to localise the mRNA sequences failed. 
Since this failure could have been the result of low copy numbers of the mRNA transcripts 
the IS-RT-PCR procedure was performed.
4.3.3.2. IS-RT-PCR
Both direct and indirect IS-RT-PCR teclmiques were employed in this study. Initial 
investigations using this technique were performed by means of the Perkin Elmer 
GeneAmp in-situ PCR System 1000 thermocycler while later trials used the Hybaid 
OmniSlide System.
The production of the misleading staining patterns and floating sections was common to 
both IS-RT-PCR machines. However, each platform had its own additional drawbacks. 
The Perkin Elmer machine is of a similar basic format to a regular Perkin Elmer PCR 
thermocyler in design, however the heating block is designed as a series of vertical plates 
that the slides are placed between, on their edge, before being tightly clamped into place. 
The block will only hold a total of 10 slides. Many slides did not survive the 
thermocycling stage when using this system and broke during the procedure. The
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assemblage of the slides for use in this machine is also cumbersome. The PCR mix was 
sealed onto the surface of the slide by applying a specially designed gasket, held in place 
by a metal clip. Due to the size of the resulting assemblage some doubt existed as to the 
accuracy of the temperatures reached in the section during the temperature cycling 
procedure.
Similar problems with regard to the generation of false positive staining patterns were 
found when IS-RT-PCR was transferred to the OmniSlide System. This system is a flat 
bed thermocycler with a novel racking system that allows up to 20 slides to be processed in 
one run. No clamping mechanisms ar e required and therefore no breakage of slides was 
encountered when using this machine. Using this system the slides are placed, section 
uppermost, onto a flat thermocycling block. The PCR mix is sealed onto the sections by 
the use of specially designed self-adhesive foam frames and plastic coverslips. This 
system is simple to assemble and is available in a range of sizes to suit every section. 
However, problems with regard to maintaining the integrity of the seal during the 
temperature cycling procedure were evident as the PCR mixture was found to have 
evaporated from many of the slides following the amplification stage.
The first IS-RT-PCR technique attempted was a direct labelling procedure where 
digoxigenin labelled dUTP was incorporated directly into the PCR product during the 
amplification reaction. The main problems with this technique were the production of 
strongly positive areas within the negative control section, no staining at all and the section 
floating from the slide during the procedure. No sections stained using this teclmique 
yielded interpretable results.
As the generation of false positive staining is a recognised difficulty in direct IS-RT-PCR 
an indirect approach was attempted. Again severe problems with the section floating from 
the slide during the procédure were encountered. In sections that managed to survive the 
lengthy procedme positive staining was once more detected on the negative control slides. 
Despite discussions regarding the teclmique with an expert in the commercial sector, who 
provides an IS-RT-PCR staining service, these difficulties could not be resolved and no 
meaningful results were gained through the use of this technique.
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Figure 4.3. p-actin check gel for groups of animals used to investigate the 
time-course of cytokine and chemokine expression in trypanosome 
infection.
To ensure the mRNA extracted from each group o f mice was o f  similar quality, 
amplification o f the mRNA for the housekeeping gene p-actin was carried out. RT-PCR 
was performed on material extracted from the CNS o f mice infected with T.b.brucei 
GVR35/C1.6 and killed 7 (lane 1), 14 (lane 2), 21 (lane 3) and 28 (lane 4) days later. 
Groups o f  mice were treated on day 21 post-infection with diminazene aceturate (40mg/kg 
i.p.) to exacerbate the CNS inflammatory response. These animals were killed 7 (lane 5) 
and 14 (lane 6) days following the drug treatment. To induce a severe 
meningoencephalitis some mice were allowed to relapse to parasitaemia following the 
initial diminazene aceturate treatment. These mice were given a second dose o f 
diminazene aceturate and killed 7 (lane 7) and 14 days (lane 8) after the administration o f  
the drug. Amplification o f material from uninfected control mice (lane 9), a known 
positive (lane 10) and a negative control where water was substituted for template (lane 11 ) 
are also shown. The banding pattern seen is similar for each group o f  mice thereby 
permitting comparisons to be made, with regard to the levels o f  cytokine and chemokine 
expression, between the different groups o f  mice using the RT-PCR techique.
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Figure 4.4. IL-1a transcription pattern through the various stages of 
trypanosome-infection.
RT-PCR was performed, to detect IL -la  expression on the mRNA extracted from mice 
infected with T.b.brucei GVR35/CI.6 and killed 7 (lane 1), 14 (lane 2), 21 (lane 3) and 28 
(lane 4) days later. Groups o f  mice were treated on day 21 post-infection with diminazene 
aceturate (40mg/kg i.p.) to exacerbate the CNS inflammatory response. These animals 
were killed 7 (lane 5) and 14 (lane 6) days following the drug treatment. To induce a 
severe meningoencephalitis some mice were allowed to relapse to parasitaemia following 
the initial diminazene aceturate treatment. These mice were given a second dose o f  
diminazene aceturate and killed 7 (lane 7) and 14 days (lane 8) after the administration o f  
the drug. Amplification o f material fi*om uninfected control mice (lane 9), a known 
positive (lane 10) and a negative control where water was substituted for template (lane 11) 
are also shown. A slight increase in the intensity o f the staining can be seen in animals 
from 1 4 - 2 8  days post-infection (lanes 2-4) with the highest level o f expression found on 
day 28 post-infection (lane 4) and 14 days following a second diminazene aceturate 
treatment (lane 8). Bands o f moderate intensity are present in material from uninfected 
mice (lane 9).
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Figure 4.5. IL-6 transcription pattern through the various stages of 
trypanosome-infection.
RT-PCR was performed, to detect IL-6 expression on the mRNA extracted from mice 
infected with T.b.brucei GVR35/C1.6 and killed 7 (lane 1), 14 (lane 2), 21 (lane 3) and 28 
(lane 4) days later. Groups o f mice were treated on day 21 post-infection with diminazene 
aceturate (40mg/kg i.p.) to exacerbate the CNS inflammatory response. These animals 
were killed 7 (lane 5) and 14 (lane 6) days following the drug treatment. To induce a 
severe meningoencephalitis some mice were allowed to relapse to parasitaemia following 
the initial diminazene aceturate treatment. These mice were given a second dose o f 
diminazene aceturate and killed 7 (lane 7) and 14 days (lane 8) after the administration o f 
the drug. Amplification o f material from uninfected control mice (lane 9), a known 
positive (lane 10) and a negative control where water was substituted for template (lane 11) 
are also shown. No IL-6 expression was seen in uninfected mice (lane 9). By 7 days post­
infection (lane 1) IL-6 transcripts were detected and increased through day 28 post­
infection (lane 4). Following a single diminazene aceturate treatment the intensity o f the 
amplicon bands reduced (lanes 5 & 6). More intensely staining PCR products are seen in 
mice killed after the induction o f a severe meningoencephalitis (lanes 7 & 8).
GOÜb:
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Figure 4.6. TNF-a transcription pattern through the various stages of 
trypanosome-infection.
RT-PCR was performed, to detect TNF-a expression on the mRNA extracted from mice 
infected with T.b.brucei GVR35/C1.6 and killed 7 (lane 1), 14 (lane 2), 21 (lane 3) and 28 
(lane 4) days later. Groups o f mice were treated on day 21 post-infection with diminazene 
aceturate (40mg/kg i.p.) to exacerbate the CNS inflammatory response. These animals 
were killed 7 (lane 5) and 14 (lane 6) days following the drug treatment. To induce a 
severe meningoencephalitis some mice were allowed to relapse to parasitaemia following 
the initial diminazene aceturate treatment. These mice were given a second dose o f  
diminazene aceturate and killed 7 (lane 7) and 14 days (lane 8) after the administration o f  
the drug. Amplification o f  material from uninfected control mice (lane 9), a known 
positive (lane 10) and a negative control where water was substituted for template (lane 11) 
are also shown. An increased intensity o f staining can be seen in animals killed on day 21 
(lane 3) and 28 (lane 4) post-infection. Raised TNF-a expression levels were also found in 
mice killed 7 days after a single diminazene aceturate treatment (laneS) and 7 days 
following the second diminazene aceturate treatment (lane 7). This increase was not 
sustained in mice killed at 14 days after administration o f either drug dose (lanes 6 & 8). 
Transcripts for TNF-a were detected in uninfected mice (lane 9).
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Figure 4.7. MCP-1 transcription pattern through the various stages of 
trypanosome-infection.
RT-PCR was performed, to detect MCP-1 expression on the mRNA extracted from mice 
infected with T.b.brucei GVR35/C1.6 and killed 7 (lane 1), 14 (lane 2), 21 (lane 3) and 28 
(lane 4) days later. Groups o f  mice were treated on day 21 post-infection with diminazene 
aceturate (40mg/kg i.p.) to exacerbate the CNS inflammatory response. These animals 
were killed 7 (lane 5) and 14 (lane 6) days following the drug treatment. To induce a 
severe meningoencephalitis some mice were allowed to relapse to parasitaemia following 
the initial diminazene aceturate treatment. These mice were given a second dose o f  
diminazene aceturate and killed 7 (lane 7) and 14 days (lane 8) after the administration o f  
the drug. Amplification o f material from uninfected control mice (lane 9), a known 
positive (lane 10) and a negative control where water was substituted for template (lane 11) 
are also shown. Uninfected animals showed an extremely low expression level o f MCP-1, 
which was difficult to capture on film (lane 9). Expression increased following 
trypanosome infection (lanes 1 -4) and after a single diminazene aceturate treatment (lanes 
5 & 6). Moderate band intensities were found in animals killed following a second 
diminazene aceturate treatment (lanes 7 & 8).
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Figure 4.8. MIP-1a transcription pattern through the various stages of 
trypanosome-infection.
RT-PCR was performed, to detect M IP-la expression on the mRNA extracted from mice 
infected with T.b.brucei GVR35/C1.6 and killed 7 (lane 1), 14 (lane 2), 21 (lane 3) and 28 
(lane 4) days later. Groups o f mice were treated on day 21 post-infection with diminazene 
aceturate (40mg/kg i.p.) to exacerbate the CNS inflammatory response. These animals 
were killed 7 (lane 5) and 14 (lane 6) days following the drug treatment. To induce a 
severe meningoencephalitis some mice were allowed to relapse to parasitaemia following 
the initial diminazene aceturate treatment. These mice were given a second dose o f  
diminazene aceturate and killed 7 (lane 7) and 14 days (lane 8) after the administration o f  
the drug. Amplification o f material from uninfected control mice (lane 9), a known 
positive (lane 10) and a negative control where water was substituted for template (lane 11) 
are also shown. Transcripts for M IP-la were detected in uninfected mice (lane 9). An 
increase in the intensity o f  the resulting bands was found at 7 and 14 days post-infection 
(lanes 1 & 2 respectively) and again on days 21 and 28 post-infection (lane 3 & 4). This 
level o f transcription remained relatively stable following a single diminazene aceturate 
treatment (lanes 5 and 6). A more intense band was found 7 days following a second 
diminazene aceturate treatment (lane 7). This was reduced by 14 days ater the drug 
treatment (lane 8).
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Figure 4.9. RANTES transcription pattern through the various stages of 
trypanosome-infection.
RT-PCR was performed, to detect RANTES expression on the mRNA extracted from mice 
infected with T.b.brucei GVR35/C1.6 and killed 7 (lane 1), 14 (lane 2), 21 (lane 3) and 28 
(lane 4) days later. Groups o f mice were treated on day 21 post-infection with diminazene 
aceturate (40mg/kg i.p.) to exacerbate the CNS inflammatory response. These animals 
were killed 7 (lane 5) and 14 (lane 6) days following the drug treatment. To induce a 
severe meningoencephalitis some mice were allowed to relapse to parasitaemia following 
the initial diminazene aceturate treatment. These mice were given a second dose o f  
diminazene aceturate and killed 7 (lane 7) and 14 days (lane 8) after the administration o f  
the drug. Amplification o f material from uninfected control mice (lane 9), a known 
positive (lane 10) and a negative control where water was substituted for template (lane 11 ) 
are also shown. Transcripts o f RANTES were detected in uninfected animals (lane 9) and 
increased in intensity following infection (lanes 1-4). Treatment with diminazene aceturate 
appeared to increase the expression levels further in animals killed 7 days after 
administration o f  either one or two doses o f the drug (lanes 5 & 7). This level had reduced 
slightly when the interval between drug treatment and termination was extended to 14 days 
(lanes 6 & 8).
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UIC 7DPI 14DPI
Treatment Groups 
21 DPI 28DPI 7DPD 14DPD 7DPDD 14DPDD
Experiment 1
Median 2.00 1.00 1.50 3.00 3.00 2.00 2.00 2.50 3.00
Upper quartile 2.25 1.00 2.00 3.00 3.00 2.00 2.25 3.00 3.00
Lower quartile 2.00 0.75 1.00 1.75 1.75 1.75 1.00 2.00 3.00
Maximum 3.00 1.00 2.00 3.00 3.00 2.00 3.00 3.00 3.00
M inimum 2.00 0.00 1.00 1.00 1.00 1.00 1.00 2.00 3.00
Number 6 6 6 6 6 6 6 4 3
Experiment 2
M edian 3.25 3.00 2.25 3.25 3.25 3.25 NA 2.00 NA
Upper quartile 3.50 3.00 3.125 3.50 3.50 3.5 NA 2.875 NA
Lower quartile 2.875 3.00 1.00 2.75 2.75 2.375 NA 1.50 NA
M aximum 3.50 3.00 3.500 3.5 3.5 3.5 NA 3.00 NA
M inimum 2.50 3.00 1.00 2.00 2.0 2.0 NA 1.50 NA
N umber 6 6 6 6 6 6 NA 4 NA
Experiments 1 & 2
M edian 2.75 2.00 2.00 2.5 3.00 2.00 2.00 2.25 3.00
U pper quartile 3.375 3.00 2.375 3.375 3.375 3.375 2.25 3.00 3.00
Lower quartile 2.00 1.00 1.00 2.00 2.25 2.00 1.00 1.625 3.00
M aximum 3.50 3.00 3.50 4.00 3.50 3.50 3.00 3.00 3.00
M inimum 2.00 0.00 1.00 2.00 1.00 1.00 1.00 1.50 3.00
N umber 12 12 12 12 12 12 6 8 3
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Figure 4.10. Summary statistics for IL-la
The expression level o f IL -la  in mouse brain was assessed at various time points following 
trypanosome infection (7DPI, 7 days post-infection; 14DPI, 14 days post-infection; 21 DPI, 
21 days post-infection, 28DPI, 28 days post-infection) and subcurative drug treatments 
(7DPD, 7days post-diminazene aceturate; 14DPD, 14 days post-diminazene aceturate; 
7DPDD, 7 days post-second diminazene aceturate; 14 DPDD, 14 days post-second 
diminazene aceturate). Samples from uninfected control (UIC) mice were also assessed. 
Following RT-PCR analyses the intensity o f the resulting PCR band, as seen on a 2% agarose 
gel stained with ethidium bromide, was taken as an indication o f  the quantity o f IL -la  mRNA 
present in the initial sample. The intensity o f  staining was graded on a scale o f 0 to 4, where 
0 indicated no band and 4 indicated an extremely intense PCR band. Summary statistics are 
given for each group o f animals and the medians o f the combined results from experiments 1 
and 2 are plotted to indicate any expression trends. NA, not assessed.
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UIC 7DPI 14DP1
Treatment Groups 
21 DPI 28DP1 7DPD 14DPD 7DPDD 14DPDD
Experiment 1
M edian 0.00 1.00 1.25 1.00 1.25 1.00 0.50 2.00 2.00
U pper quartile 0.00 1.00 1.625 1.50 3.00 1.00 1.00 2.00 2.00
Lower quartile 0.00 0.50 0.50 0.41 0.375 0.50 0.00 1.625 2.00
M aximum 0.00 1.00 2.00 1.50 3.00 1.00 1.00 2.00 2.00
M inimum 0.00 0.50 0.50 0.125 0.00 0.50 0.00 1.50 2.00
Number 6 6 6 6 6 6 6 4 3
Experiment 2
M edian 0.00 0.75 0.50 1.25 1.25 2.25 NA 1.00 NA
U pper quartile 0.00 1.00 1.125 1.625 1.50 2.50 NA 1.75 NA
Lower quartile 0.00 0.188 0.00 0.875 1.00 1.75 NA 1.00 NA
M aximum 0.00 1.00 1.50 2.00 1.50 2.50 NA 2.00 NA
M inimum 0.00 0.00 0.00 0.50 1.00 1.00 NA 1.00 NA
Num ber 6 6 6 6 6 6 NA 4 NA
Experiments 1&2
M edian 0.00 1.00 0.75 1.00 1.50 1.00 0.50 1.75 2.00
U pper quartile 0.00 1.00 1.50 1.5 2.75 2.375 1.00 2.00 2.00
Lower quartile 0.00 0.50 0.125 0.625 1.00 1.00 0.00 1.00 2.00
M aximum 0.00 1.00 2.00 2.00 3.00 2.50 1.00 2.00 2.00
M inimum 0.00 0.00 0.00 0.125 0.00 0.50 0.00 1.00 2.00
Num ber 12 12 12 12 12 12 6 8 3
IL-6 EX PRESSIO N  PATTERN
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Figure 4.11. Summary statistics for IL-6
The expression level o f  IL-6 in mouse brain was assessed at various time points following 
trypanosome infection (7DPI, 7 days post-infection; 14DPI, 14 days post-infection; 21 DPI, 
21 days post-infection, 28DPI, 28 days post-infection) and subcurative drug treatments 
(7DPD, 7days post-diminazene aceturate; 14DPD, 14 days post-diminazene aceturate; 
7DPDD, 7 days post-second diminazene aceturate; 14 DPDD, 14 days post-second 
diminazene aceturate). Samples from uninfected control (UIC) mice were also assessed. 
Following RT-PCR analyses the intensity o f the resulting PCR band, as seen on a 2% 
agarose gel stained with ethidium bromide, was taken as an indication o f the quantity o f IL- 
6 mRNA present in the initial sample. The intensity o f staining was graded on a scale o f 0 
to 4, where 0 indicated no band and 4 indicated an extremely intense PCR band. Summary 
statistics are given for each group o f  animals and the medians o f the combined results from 
experiments 1 and 2 are plotted to indicate any expression trends. NA, not assessed.
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UIC 7DPI 14DPI 21 DPI
Treatment Groups 
28DPI 7DPD 14DPD 7DPDD 14DPDD
Experiment 1
M edian 0.50 0.00 1.00 0.75 2.50 1.00 0.00 1.25 1.00
Upper quartile 0.50 0.50 2.00 1.25 3.00 2.00 0.625 1.875 1.00
Lower quartile 0.375 0.00 0.00 0.00 0.875 0.875 0.00 1.00 1.00
M aximum 0.50 0.50 3.00 2.00 3.00 2.00 1.00 2.00 1.00
Minimum 0.00 0.00 0.00 0.00 0.50 0.50 0.00 1.00 1.00
Number 6 6 6 6 6 6 6 4 3
Experiment 2
M edian 1.00 2.25 1.75 3.5 3.25 3.5 NA 3.75 NA
U pper quartile 1.50 3.125 2.625 4.00 3.50 3.50 NA 4.00 NA
Lower quartile 1.00 2.00 1.25 3.375 2.50 3.375 NA 3.50 NA
M aximum 1.50 3.50 3.00 4.00 3.50 3.50 NA 4.00 NA
M inimum 1.00 2.00 0.50 3.00 2.50 3.00 NA 3.50 NA
Number 6 6 6 6 6 6 NA 4 NA
Experiments 1&2
Median 0.75 1.25 1.25 2.50 3.00 2.50 0.00 2.75 1.00
Upper quartile 1.00 2.375 2.00 3.50 3.375 3.50 0.625 3.875 1.00
Lower quartile 0.50 0.00 0.50 0.625 2.125 1.00 0.00 1.125 1.00
M aximum 1.50 3.50 3.00 4.00 3.50 3.50 1.00 4.00 1.00
M inimum 0.00 0.00 0.00 0.00 0.50 0.50 0.00 1.00 1.00
Number 12 12 12 12 12 12 6 8 3
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Figure 4.12. Summary statistics for TNF-a
The expression level o f TNF-a in mouse brain was assessed at various time points following 
trypanosome infection (7DPI, 7 days post-infection; 14DPI, 14 days post-infection; 21 DPI, 
21 days post-infection, 28DPI, 28 days post-infection) and subcurative drug treatments 
(7DPD, 7days post-diminazene aceturate; 14DPD, 14 days post-diminazene aceturate; 
7DPDD, 7 days post-second diminazene aceturate; 14 DPDD, 14 days post-second 
diminazene aceturate). Samples from uninfected control (UIC) mice were also assessed. 
Following RT-PCR analyses the intensity o f the resulting PCR band, as seen on a 2% agarose 
gel stained with ethidium bromide, was taken as an indication o f the quantity o f TNF-a 
mRNA present in the initial sample. The intensity o f staining was graded on a scale o f  0 to 4, 
where 0 indicated no band and 4 indicated an extremely intense PCR band. Summary 
statistics are given for each group o f  animals and the medians o f  the combined results from 
experiments 1 and 2 are plotted to indicate any expression trends. NA, not assessed.
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UIC 7DPI
Treatment Groups 
14DPI 21 DPI 28DPI 7DPD 14DPD 7DPDD 14DPDD
Experiment 1
M edian 0.50 1.50 2.00 2.50 2.25 2.50 2.75 2.75 1.75
U pper quartile 1.00 2.00 2.00 3.00 * 3.00 * * *
Lower quartile 0.00 1.00 2.00 2.50 * 2.00 * * *
Maximum 1.00 2.00 2.00 3.00 3.00 3.00 3.00 3.00 2.00
Minimum 0.00 1.00 2.00 2.50 1.50 2.00 2.50 2.50 1.50
Number 5 3 3 3 2 3 2 2 2
Experiment 2
M edian 0.75 2.50 1.25 2.00 2.25 2.75 NA 3.00 NA
Upper quartile 1.00 3.00 2.625 3.50 3.50 3.00 NA 3.00 NA
Lower quartile 0.438 1.875 1.00 0.75 1.50 2.25 NA 3.00 NA
Maximum 1.00 3.00 3.00 3.50 3.50 3.00 NA 3.00 NA
Minimum 0.25 1.50 1.00 0.00 1.50 1.50 NA 3.00 NA
Number 6 6 6 6 6 6 NA 4 NA
Experiments 1&2
Median 0.50 2.00 2.00 2.50 2.25 2.50 2.75 3.00 1.75
Upper quartile 1.00 2.75 2.25 3.25 3.375 3.00 * 3.00 *
Lower quartile 0.25 1.50 1.00 1.25 1.50 2.25 * 2.872 *
Maximum 1.00 3.00 3.00 3.50 3.50 3.00 3.00 3.00 2.00
Minimum 0.00 1.00 1.00 0.00 1.50 1.50 2.50 2.50 1.50
Number 11 9 9 9 8 9 2 6 2
MCP-1 EXPRESSION PATTERN
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Figure 4.13. Summary statistics for MCP-1
The expression level of MCP-1 in mouse brain was assessed at various time points following 
trypanosome infection (7DPI, 7 days post-infection; 14DPI, 14 days post-infection; 21 DPI, 
21 days post-infection, 28DPI, 28 days post-infection) and subcurative drug treatments 
(7DPD, 7days post-diminazene aceturate; 14DPD, 14 days post-diminazene aceturate; 
7DPDD, 7 days post-second diminazene aceturate; 14 DPDD, 14 days post-second 
diminazene aceturate). Samples from uninfected control (UIC) mice were also assessed. 
Following RT-PCR analyses the intensity of the resulting PCR band, as seen on a 2% agarose 
gel stained with ethidium bromide, was taken as an indication of the quantity of MCP-1 
mRNA present in the initial sample. The intensity of staining was graded on a scale of 0 to 4, 
where 0 indicated no band and 4 indicated an extremely intense PCR band. Summary 
statistics are given for each group of animals and the medians of the combined results from 
experiments 1 and 2 are plotted to indicate any expression trends. NA, not assessed; * too 
few data points.
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UIC 7DP1 14DP1 21 DPI
Treatment Groups 
28DP1 7DPD 14DPD 7DPDD 14DPDD
Experiment 1
M edian 1.00 2.00 1.50 1.50 2.00 1.50 2.00 2.25 1.50
U pper quartile 1.50 2.00 2.00 2.00 * 1.50 3.00 * *
Lower quartile 0.00 2.00 1.50 1.50 * 1.00 1.50 * *
Maximum 1.50 2.00 2.00 2.00 2.00 1.50 3.00 3.00 2.00
Minimum 0.00 2.00 1.50 1.50 2.00 1.00 1.50 1.50 1.00
Number 5 3 3 3 2 3 3 2 2
Experiment 2
M edian 1.50 3.00 3.00 3.00 3.50 3.250 NA 3.50 NA
Upper quartile 2.00 3.125 3.00 3.00 3.50 3.50 NA 3.50 NA
Lower quartile 1.375 2.375 2.50 2.875 3.375 3.00 NA 3.50 NA
Maximum 2.00 3.50 3.00 3.00 3.50 3.50 NA 3.50 NA
M inimum 3.50 1.00 2.00 2.50 2.50 3.00 NA 3.00 NA
Number 6 6 6 6 6 6 NA 4 NA
Experiments 1&2
M edian 1.50 2.50 2.50 3.00 3.50 3.00 2.00 3.50 1.50
Upper quartile 1.50 3.00 3.00 3.00 3.50 3.50 3.00 3.50 *
Lower quartile 1.00 2.00 1.75 1.75 2.25 1.50 1.50 2.625 *
Maximum 2.00 3.50 3.00 3.00 3.50 3.50 3.00 3.50 2.00
Minimum 0.00 2.00 1.50 1.50 2.00 1.00 1.50 1.50 1.00
Number 11 9 9 9 8 9 3 6 2
MIP-1 EXPRESSION PATTERN
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Figure 4.14. Summary statistics for MIP-la
The expression level o f M IP-la in mouse brain was assessed at various time points following 
trypanosome infection (7DPI, 7 days post-infection; 14DPI, 14 days post-infection; 21 DPI, 
21 days post-infection, 28DPI, 28 days post-infection) and subcurative drug treatments 
(7DPD, 7days post-diminazene aceturate; 14DPD, 14 days post-diminazene aceturate; 
7DPDD, 7 days post-second diminazene aceturate; 14 DPDD, 14 days post-second 
diminazene aceturate). Samples from uninfected control (UIC) mice were also assessed. 
Following RT-PCR analyses the intensity o f the resulting PCR band, as seen on a 2% agarose 
gel stained with ethidium bromide, was taken as an indication o f  the quantity o f M IP-la  
mRNA present in the initial sample. The intensity o f staining was graded on a scale o f 0 to 4, 
where 0 indicated no band and 4 indicated an extremely intense PCR band. Summary 
statistics are given for each group o f  animals and the medians o f the combined results from 
experiments 1 and 2 are plotted to indicate any expression trends. NA, not assessed; * too few 
data points.
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UIC 7DPI
Treatment Groups
14DPI 21DPI 28DPI 7DPD 14DPD 7DPDD 14DPDD
Experiment 1
M edian 1.00 1.50 2.50 3.00 2.75 2.00 2.50 2.50 2.75
Upper quartile 2.00 3.00 3.00 3.00 * 3.00 3.00 * *
Lower quartile 0.75 1.50 2.50 2.50 * 1.50 2.00 * *
M aximum 3.00 3.00 3.00 3.00 3.00 3.00 3.00 3.00 3.00
Minimum 0.50 1.50 2.50 2.50 2.50 1.50 2.00 2.00 2.50
Number 5 3 3 3 2 3 3 2 2
Experiment 2
M edian 1.50 3.00 3.50 3.00 3.25 4.00 NA 4.00 NA
Upper quartile 2.00 3.00 3.50 3.00 3.50 4.00 NA 4.00 NA
Lower quartile 1.50 3.00 3.00 3.00 3.00 4.00 NA 4.00 NA
M aximum 2.00 3.00 3.50 3.00 3.50 4.00 NA 4.00 NA
Minimum 1.50 3.00 3.00 3.00 3.00 4.00 NA 4.00 NA
Number 6 6 6 6 6 6 NA 4 NA
Experiments 1&2
M edian 1.50 3.00 3.00 3.00 3.00 4.00 2.50 4.00 2.75
Upper quartile 2.00 3.00 3.50 3.00 3.50 4.00 3.00 4.00 *
Lower quartile 1.00 2.25 2.75 3.00 3.00 2.50 2.00 2.75 *
M aximum 3.00 3.00 3.50 3.00 3.50 4.00 3.00 4.00 3.00
M inimum 0.50 1.50 2.50 2.50 2.50 1.50 2.00 2.00 2.50
Number 11 9 9 9 8 9 3 6 2
RANTES EXPRESSION PATTERN
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Figure 4.15. Summary statistics for RANTES
The expression level of RANTES in mouse brain was assessed at various time points 
following trypanosome infection (7DPI, 7 days post-infection; 14DPI, 14 days post-infection; 
21 DPI, 21 days post-infection, 28DPI, 28 days post-infection) and subcurative drug 
treatments (7DPD, 7days post-diminazene aceturate; 14DPD, 14 days post-diminazene 
aceturate; 7DPDD, 7 days post-second diminazene aceturate; 14 DPDD, 14 days post-second 
diminazene aceturate). Samples from uninfected control (UIC) mice were also assessed. 
Following RT-PCR analyses the intensity of the resulting PCR band, as seen on a 2% agarose 
gel stained with ethidium bromide, was taken as an indication of the quantity of RANTES 
mRNA present in the initial sample. The intensity of staining was graded on a scale of 0 to 4, 
where 0 indicated no band and 4 indicated an extremely intense PCR band. Summary 
statistics are given for each group of animals and the medians of the combined results from 
experiments 1 and 2 are plotted to indicate any expression trends. NA, not assessed; * too 
few data points.
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4.4. Discussion
The investigations performed in the present study clearly demonstrate variations in the 
expression levels of the inflammatory mediators IL-la, IL-6, TNF-a, MCP-1, M IP-la and 
RANTES within the CNS following trypanosome infection and during the development of 
the associated neuroinflammatory reaction. Initially following infection elevated levels of 
transcription of IL-6, TNF-a, MCP-1, M IP-la and RANTES were detected and the 
expression of these mediators, with the exception of RANTES, continued to rise as the 
infection progressed. IL -la  transcription was found at a reduced level compared to 
uninfected mice inunediately following infection although this did increase as the infection 
progressed. On exacerbation of the CNS inflammatory reaction by the administration of a 
single diminazene aceturate treatment, a more varied cytokine and chemokine response 
was found. Levels of IL-la, IL-6, TNF-a and M IP-la dropped following diminazene 
aceturate treatment while MCP-1 remained relatively stable. This trend was continued in 
animals killed 14 days following administration of the diminazene aceturate, RANTES 
expression increased following drug treatment and remained at this level in animals killed 
at the later time-point. Subsequent to the induction of a severe meningoencephalitis, by 
treatment of the relapsed mice with a second dose of diminazene aceturate, a mixed 
response in the transcription of the cytokines and chemokines was again seen. In this 
scenario IL-la, IL-6, TNF-a, MCP-1 and M IP-la all showed an increase in their 
transcription levels while RANTES expression was reduced. IL -la  and IL-6 transcription 
continued to increase in animals killed 14 days after being given the second diminazene 
aceturate treatment but levels of TNF-a, MCP-1 and M IP-la fell at this stage. In contrast, 
RANTES transcription was reduced immediately following the seeond diminazene 
aceturate treatment and was increased in animals killed at the 14-day post-treatment time- 
point.
In the mouse model of human African trypanosomiasis (HAT) used in this study, the 
parasites become established within the CNS between day 14 and day 21 post-infection 
(Jennings et al., 1979). Only the beginnings of an extremely mild CNS inflammatory 
response can be detected on histological examination of brain sections prepared from 
animals killed during the acute stage of the infection (Chapter 3). Despite the lack of overt 
neuropathological changes, an elevated level of transcription, compared to that found in 
uninfected animals, was detected for all of the cytokines and chemokines assessed with the 
exception of IL-la. The early induction of chemokine expression within the CNS has
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been described following trypanosome infection in rats (Sharafeldin et al, 2000). In this 
study increased expression of M IP-la and RANTES was detected 6 hours after infection 
and MCP-1 expression was upregulated by 12 hours after infection. Since parasites have 
not become established within the CNS at this point they cannot be directly responsible for 
the initiation of the inflammatory response. The presence of chemotactic molecules such 
as, MCP-1, M IP-la and RANTES, which attract lymphocytes and monocytes, could 
account for the early infiltration of the brain by inflammatory cells seen on day 14 post­
infection.
The peripheral levels of the cytokines and chemokines were not assessed in this 
investigation. However, raised levels of IL -la, IL-6 and TNF-a have been detected in the 
liver of mice 7 days after infection with T.b.brucei GVR35/ CL3 in a previous study 
utilising this model of HAT (Eckersall et al, 2001). A rapid increase in the serum TNF-a 
levels has also been described in mice following the injection of T.b.brucei soluble extracts 
(Magez et al, 1993). This elevation in serum TNF-a was detected within 72 hours of 
administering the injection. It is possible that in this investigation the initial induction of 
the expression of these pro-inflammatory molecules within the CNS, found at day 7 and 14 
post-infection, was indirectly triggered by increased levels of the cytokines and 
chemokines in the blood and peripheral tissues due to the presence of the parasites. This 
enhanced expression of cytokines within the CNS is loiown to occur dur ing infections that 
do not necessarily directly affect the brain tissue resulting in the initiation of sickness 
behaviour (Konsman et al, 2002). Resident brain cells including, astrocytes, microglia 
and neurons as well as the endothelial cells of the BBS can produce these cytokines 
(Fitzgerald et a l, 2001). However, the early signs of astrocyte activation found in sections 
prepared from mice 14 days after infection (Chapter 3) implicate these cells as the likely 
source of the cytokines. A correlation between astrocyte activation and the production of 
cytokines has been suggested previously (Hunter et al, 1992a), In this study the 
expression of IL-la, TNF-a, M IP-la, IL-6 and IFN-y was investigated in the brains of 
mice infected with T.b.brucei. IL -la was constitutiveiy expressed in the brains of all mice 
but in contrast to the findings of the present study, expression of the remaining cytokines 
was not detected until day 21 post-infection. The discrepancy between these results could 
be due to the differences in the methodology adopted to perform the RT-PCR. In Hunter’s 
paper new cDNA was synthesised for each cytokine investigated using the 3’-primer as the 
starting sequence for the reverse transcriptase enzyme. This may lead to variations in the 
quality of the cDNA generated for the individual molecules and alter the sensitivity of the 
subsequent PCR assay. In the current investigation random primers were employed to
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synthesise a complete pool of cDNA that could be used in each of the individual PCR 
assays. This would eliminate variation due to the presence of low levels of target mRNA 
in the original sample and those caused by differences in the quality of the resulting cDNA 
due to primer disparity.
The passage of IL-la, IL-6, TNF-a and MIP-1 (3 tlnough the BBB has been described (Pan 
and Kastin, 1999). Therefore, it is feasible that these inflammatory agents eould be 
transported into the brain tissue and directly stimulate local expression within the CNS. In 
addition, cytokine molecules are known to mediate their own production and that of MCP- 
1, M IP-la and RANTES. Consequently, their presence within the CNS could initiate the 
rise in chemokine synthesis detected during the acute stage of trypanosome infection. A 
rise in cytokine levels within the CNS, as a result of transport across the BBB, would not 
be detected using the methodology employed in this study as the levels of specific mRNA 
transcripts and not the protein end products were assessed.
The general levels of cytokine and chemokine expression within the CNS remained largely 
constant following trypanosome infection until day 21 post-infection when the expression 
of IL-la, IL-6, TNF-a, MCP-1, and M IP-la began to increase. This rise in cytokine and 
chemokine transcription coincides with the invasion of the CNS by the parasites and is 
associated with an increased neuroinflammatory reaction akin to the early CNS-stage seen 
in human infections. A fuilher rise in the expression levels of IL-la, IL-6, TNF-a and 
M IP-la was seen when the inflammatory reaction was allowed to progress until day 28 
post-infection while MCP-1 expression dropped slightly. RANTES transcription remained 
at a constant level, higher than that found in uninfected mice, following trypanosome 
infection and thi'oughout the development of the early CNS response. The elevated 
expression levels of the cytokines and chemokines were accompanied by a further 
augmentation of the CNS-inflammatory response (Chapter 3).
The administration of a single dose of diminazene aceturate, to exacerbate the 
neuroinflammatory reaction and mirror the pathology found during the late-CNS stage of 
HAT, resulted in a more varied cytokine and chemokine response. The levels of IL-la, 
IL-6, TNF-a and M IP-la were reduced compared to those seen at 28 days post-infection 
and continued to fall in mice killed at 14 days following the drug treatment. In contrast, 
transcription of MCP-1 remained similar to that found at 28 days post-infection and 
increased slightly in animals killed at 14 days post diminazene aceturate administration. 
RANTES expression increased in animals killed 7 days after diminazene aceturate
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treatment and remained at the same level in mice killed at 14 days following administration 
of the drug. The drop in the transcription of IL -la and IL-6 seen within the CNS 
following diminazene aceturate treatment of trypanosome-infected mice has been reported 
previously in a study investigating the expression of IL-6, IL -la  and TNF-a in the liver 
and CNS and comparing this expression pattern with the levels of the acute phase proteins 
haptoglobin and serum amyloid A in the serum (Eckersall et al, 2001).
The findings from both studies are enigmatic and do not immediately correlate with the 
increased CNS inflammation that is associated with this diminazene aceturate treatment 
regimen. If the levels of these inflammatory agents within the CNS are being controlled by 
the presence of factors in the periphery, it is possible that, due to the clearance of the 
trypanosomes following the diminazene aceturate treatment, the inflammatory reaction 
out-with the CNS could be down regulated resulting in a reduction in the production of a 
number of cytokines and chemokines within the CNS. However, the persistent presence of 
the trypanosomes within the brain may stimulate the increased expression of RANTES and 
MCP-l while maintaining the lowered degree of expression of the other mediators. The 
presence of these cytokines and chemokines could induce the continued migration of 
already activated inflammatory cells into the CNS from the periphery resulting in the 
augmentation of the neuroinfiammatory reaction seen at this stage of the infection.
The situation found in mice following the induction of the severe post-treatment reactive 
meningoencephalopathy (PTRE) was complex and did not mimic the pattern seen during 
the late-stage of the CNS infection. Treatment of trypanosome infected mice with a 
second dose of diminazene aceturate resulted in an up-regulation of the transcription of IL- 
la , IL-6, TNF-a, MCP-l and M IP-la, 7 days following administration of the drug. At 
this point the expression of RANTES was reduced compared to that found in mice killed 
after a single diminazene aceturate treatment. This pattern of cytokine and chemokine 
expression was not maintained in animals killed at 14 days after administration of the 
diminazene aceturate. In these animals IL -la  and IL-6 levels continued to rise while a 
reduction in the levels of TNF-a, MCP-l and M IP-la, and an increase in the expression of 
RANTES, was detected. The initial rise in chemokine expression detected following a 
second diminazene aceturate treatment may be responsible for the increase in the level of 
inflammatory cell infiltration associated with this treatment regimen. Numerous B-cells 
and plasma cells are found in the inflammatory infiltrate at this time. M IP-la has been 
shown to be a B-cell chemoattractant (Schall, Bacon, Camp, Kaspari et a l, 1993) and IL-6 
plays a key role in the differentiation of B-cells into antibody secreting plasma cells
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(Hirano, 1998). Although the PTRE is characterised by an extremely severe 
meningoencephalitis, it has been shown that very little neuronal damage occurs (Fink and 
Schmidt, 1979; Morrison et al, 1983). Since there is evidence that both IL-1 and IL-6 can 
fiilfil a neuro-protective role in CNS inflammatory reactions (Hirano, 1998; Lenzlinger et 
al, 2001; Stoll et al, 2000), this sparing of the neuronal elements could be the result the 
continued increase in expression of these cytokines seen in animals killed at the later time- 
point.
The presence of cytokines and chemokines within the CNS has been implicated in the 
pathogenesis of a range of CNS disorders with a variety of aetiologies. Early cytokine and 
chemokine expression has been detected in experimental autoimmune encephalomyelitis 
(EAE), the animal model of multiple sclerosis (MS), where distinct patterns of expression 
have been associated with each phase of the disease. The acute stage of EAE is associated 
with increased expression of niRNA for a number of pro-inflammatory cytokines, 
including IL -la  and IL-6. Levels of IL-6 mRNA were found to decrease when the clinical 
disease stabilised and the animals moved into the recovery or chronic stage of EAE but 
levels of IL -la  expression remained elevated (Eng, Ghirnikar, and Lee, 1996). In contrast 
to these findings, investigation of IL-6 expression using immunocytochemistry and in situ 
hybridisation demonstrated only low levels of IL-6 during the acute stage of the disease 
and foimd higher levels of the cytokine in the protracted relapsing phase of the condition 
(Diab, Zhu, Xiao, Mustafa et a l , 1997).
The temporal demarcation of specific roles for particular inflammatory mediators is 
perhaps most clearly demonstrated in the pattern of chemokine expression associated with 
the valions stages in EAE progression. The expression of MCP-l, M IP-la and RANTES 
mRNA has been detected in the spinal cord in muiine EAE before the onset of clinical 
symptoms and remains elevated thioughout the clinical course of the acute disease 
(Godiska et al, 1995; Martiney et al, 1998). Treatment of the animals with anti-MIP-la, 
but not anti-MCP-1 antibodies, prevented the onset of acute clinical EAE (Karpus and 
Ransohoff, 1998). The converse of this situation was seen in the treatment of relapsing 
EAE where administration of anti-MCP-1 antibodies, but not anti-MIP-la decreased the 
clinical severity of the response (Kennedy, Strieter, Kunkel, Lukacs et a l, 1998). These 
findings strongly suggest that M IP-la plays a key role in the initiation of the acute stage of 
EAE while MCP-l mediates the relapsing stage of the disease. Administration of anti- 
RANTES antibodies did not appear to effect the progression of the clinical disease 
irrespective of the timing of the treatment. The cytokine TNF-a appears to be involved in
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the pathogenesis of EAE during the cln'onic stage of the disease. Administration of TNF-a 
augments EAE in rats by prolonging the condition and inducing relapses. The detrimental 
effects of TNF-a in chronic EAE have been confirmed in studies that demonstrated a 
prevention or amelioration of the condition following blockade of the TNFRl receptor 
(Klinkert, Kojima, Lesslauer, Rinner et a l, 1997)
Another well recognised CNS disease of non-infectious origin is Alzheimer’s disease. The 
most commonly described features associated with the condition are the presence of 
reactive astrocytes and microglia, the extracellular deposition of (3-amyloid protein 
forming senile plaques, neinofilbrillary tangles and neuronal cell death (Hull, Lieb, and 
Fiebich, 2002). In a transgenic murine model of Alzheimer’s disease, in which the animals 
express human p-amyloid precursor protein, elevated levels of the pro-inflammatory 
molecules; IL-la, IL-6, TNF-a and MCP-l have been detected in astrocytes and microglia 
in close proximity to senile plaques. Sub-populations of reactive astrocytes have also been 
shown to express TGF-P and IL-10 indicating that both pro and anti-inflammatory 
pathways are activated in this disease (Apelt and Schliebs, 2001; Sly, Krzesicki, Brashler, 
Buhl et a l, 2001).
Cytokine and chemokine expression has also been demonstrated in CNS inflammatory 
diseases resulting from viral infections. Subacute sclerosing panencephalitis is a fatal form 
of encephalitis, caused by defective measles virus replication in the neurons and glial cells, 
which results in diffuse pathological changes within the CNS. Cytokines including TNF- 
a, IL-ip, IL-6, TNF-p and IFN-y have been found associated with the mononuclear cells 
infiltrating the brain in sections prepared from patients that have died from the condition 
(Nagano, Nakamura, Yoshioka, Onodera et a l, 1994). Lymphocytic choriomeningitis 
virus (LCMV)-infection is a fatal disease characterised by the infiltration of the meninges, 
choroid plexus and ependymal membranes by lymphocytes and macrophages. Increased 
levels of TNF-a, IL-la, IL-ip and IL-6 mRNA were detected in the brains of mice 
inoculated with this virus early after infection. Mice infected in this manner develop 
convulsive seizures 6-8 days after infection that culminate in death. The expression of 
these molecules increased as the disease progressed. High levels of INF-y expression were 
found late in the infection and correlated with the onset of clinical disease (Campbell, 
Hobbs, Kemper, and Oldstone, 1994). The expression of several chemokines has also been 
demonstrated in the CNS during the course of LCMV-infection. mRNA transcripts for IP- 
10, RANTES, MCP-l, MCP-3 and MIP-ip were detected 3 days after the infection, this 
was followed by late the appearance of M IP-la on day 6 post-infection (Asensio and
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Campbell, 1997). Perhaps the most topical of viral diseases that results in CNS 
involvement is HIV. The most severe manifestation of HIY-infection is the development 
of HIV-associated dementia (HAD) or AIDS dementia complex (ADC). This is 
characterised by the presence of microglial nodules, multinucleated giant cells and diffuse 
astrocytic and microglial activation (Zhao, Kim, Morgello, and Lee, 2001) Perivascular 
cuffing is present with macrophages and T-lymphocytes comprising the majority of the 
cells in the infiltrate. The occasional B-cell is also found among the inflammatory cells 
(Tyor, Glass, Griffin, Becker et a l, 1992). Increased IL-1, TNF-a, IL-6 expression (Tyor 
et al, 1992) and elevated levels of M IP-la, MIP-lp, MCP-l and RANTES (Rausch and 
Davis, 2001) have been detected in brain samples from autopsy tissue taken from the HIV 
patients.
Malaria results from infection with the protozoan parasites of Plasmodium spp. A  severe 
complication of Plasmodium falciparum infection is the development of cerebral malaria. 
The condition is characterised by congestion of the cerebral microvessels with parasitized 
red blood cells leading to haemorrhage and oedema. The degree of inflammatory cell 
infiltration of the brain in this condition is inconsistent although T-lymphocytes and 
macrophages have been identified. Several cytokines have been detected in brain tissue 
generated from the murine model of cerebral malaria including the expression of TNF-a 
and IL-1 p. It is interesting to note that IL-6 was not detected in the CNS of these infected 
mice (Medana et al, 2001). Toxoplasma gondii is another protozoan parasite that can 
infect humans. Under normal circumstances the infection is controlled by the host’s 
immune system and results in an asymptomatic infection. Once infected with T. gondii the 
parasite forms latent cysts within the CNS of the host that persist tlirough the life-time of 
the animal. These cysts provoke little or no inflammatory response within the CNS. 
However, in patients with a compromised immune system these cysts can reactivate 
resulting in a neuroinfiammatory reaction and the development of toxoplasmic 
encephalitis. Due to the increasing numbers of patients with immunodeficiency diseases 
such as AIDS, and those receiving immunosuppressive therapies, the incidence of 
toxoplasmic encephalitis is becoming more common. In a mouse model of toxoplasmic 
encephalits mRNA transcripts for IL-la, IL-ip, IL-6, TNF-a and M IP-la were detected 
within the CNS following infection with the parasite (Hunter, Roberts, Murray, and 
Alexander, 1992b). These cytokines have been implicated in the development of the 
neuropathological reaction seen in toxoplasmic encephalitis (Hunter and Remington, 1994; 
Hunter et al, 1992b).
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It is interesting to note, from the information detailed above, that the specific cytokines and 
chemokines investigated in the present study have been shown to play a role in the 
pathogenesis of many CNS conditions with varied aetiologies. It would appear' that the 
neuropathogenesis of the CNS inflammatory reaction found in the acute stage of 
trypanosome-infection is also mediated by the presence of pro-inflammatory cytokines and 
chemokines including, IL-la, IL-6, TNF-a, MCP-l, M IP-la and RANTES. During the 
acute stage of the infection the factor instigating the increase in expression of these 
inflammatory mediators remains unclear as this could be the end result of a range of 
initiating pathways that may act independently, or in a concerted manner, to stimulate the 
production of the cytokines and chemokines within the CNS. The patterns of expression 
found in the later stages of the CNS inflammation are more difficult to interpret. It is 
important to remember that cytokines and chemokines rarely act as individual entities and 
they often act in either a synergistic or an inliibitory manner. Within the CNS this situation 
becomes more complex as these mediators often have dual roles acting as both 
inflammatory mediators and regulators of normal physiological functions. In addition, as 
the neuroinfiammatory process develops it is possible that the integrity of the BBB 
becomes compromised allowing components normally confined to the peripheral system to 
enter the CNS and further exacerbate the inflammatory reaction (Philip et al, 1994). 
However, this breakdown of the BBB has not been unequivocally confirmed following 
trypanosome infection since no damage to the BBB was detected in a rat model of chionic 
T.è.ôr wee/-infection (Mulenga et al, 2001).
It is important to consider that the approach used in the present investigation detects the 
mRNA transcription products that will ultimately produce the final cytokine and 
chemokine molecules. The presence of these transcripts does not necessarily indicate that 
the proteins will be manufacture. This would also have been true of any information 
gained from in-situ RT-PCR (IS-RT-PCR) or in situ hybridisation staining of these murine 
brain sections although additional data indicating the cellular source of the mRNA 
molecules would have been available. Failure to detect the mRNA in the tissue sections 
was most likely due to the degradation or loss of the transcripts at some point during the 
either the processing of the tissue for section preparation or the performance of the lengthy 
staining procedures.
It is unfortunate that the immunocytochemistry (ICC) technique used in this investigation 
failed to provide positive staining profiles. Although a variety of different primary 
antibodies were employed, together with alterations in the ICC protocol, no staining of 
cytokines was achieved in the tissue sections. Many reasons exist for the inability to detect
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cytokines using this method. Alteration to the conformation of the cytokine by the fixation 
techniques employed leading to changes in the antigenic site recognised by the antibody 
would prevent the molecule from being detected by the antibody. If cytokines are rapidly 
excreted from the cell following synthesis then they could easily be lost from the tissue 
during the processing and staining procedures. Therefore, failure to detect these molecules 
is not uncommon and cytokine staining using ICC procedures has been described as 
“somewhat of an art” (Whiteside, 2002).
Changes in ICC staining patterns may have indicated whether the upregulation in cytokine 
and chemokine transcription conelated with an increase in the detection of the protein end 
products. This coupled with the cellular source of the transcripts would have provided a 
strong indication of the cell types involved in mediating the development of the CNS 
inflammatory response seen following trypanosome infection and subcurative drug 
treatment. Although we can deduce that cytokines and chemokines play a role in 
mediating the neuroinflammation the actual function of the individual molecules within the 
brain cannot be determined from the findings gained from the present study. This 
information could only be ascertained by neutralising the individual molecules either 
thi'ough the use of specific antibodies or gene knockout mice. This approach would 
present its own series of problems. The use of neutralising antibodies or knockout mice 
may result in the removal of the mediators from the peripheral system as well as the CNS. 
This would not help to elucidate the role of centrally synthesised cytokines and 
chemokines in the control of the reaction. Furthermore, in antibody neutralising 
experiments the efficacy of the teclmique in removing the inflammatory mediators from 
the CNS would be questionable since the ability of the antibody to penetrate the BBB 
would be difficult to establish. The pleiotropic nature of the cytokine and chemokine 
network allows many different pathways to reach the same end result and therefore a great 
deal of redundancy is built into the system. This type of structure would be difficult to 
study using traditional knockout mice as these animals could circumvent the lack of a 
single cytokine by upregulation or synthesis of an alternative mediator. We have 
previously encountered this phenomenon in the use of Imockout mice (Chapter 6) 
(Kennedy, Rodgers, Bradley, Hunt et a l, 2003).
Without information detailing the specific roles of the individual inflammatory mediators it 
would be difficult to determine the feasibility of cytokine or chemokine therapy as a novel 
treatment to reduce or prevent the onset of the CNS inflammation associated with 
trypanosome-infection and subcurative drug treatment. If cytokines such as IL-1 and IL-6 
are acting in a neuro-protective manner in the late-stage of this disease, then their removal
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may not only reduce the level of inflammatory cell infiltration, but also, ultimately, 
increase the amount of neuronal damage resulting from the inflammatory response. This 
paradoxical effect of lowered inflammation and increased neuronal damage has previously 
been encountered in the treatment of trypanosonie-induced neuroinflammation following 
the administration of aspirin in a rat model of the disease (Quan, Mhlanga, Whiteside, 
Kristensson et a l, 2000). Further research to dissect the functions of these mediators in 
this condition is therefore required before novel chemotherapeutic approaches involving 
the manipulation of cytokine levels can be perused.
C h a p t e r  5 
T he  a c t io n  o f  e f l o r n it h in e  in
TRYPANOSOME-INDUCED CNS INFLAMMATION
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5.1. Introduction
Eflornithine, otherwise known as DL-a-difluoromethylornithine or DFMO, was originally 
developed in the 1970’s, by Merrell Dow Pharmaceuticals, as a potential anti-cancer agent 
and is the most recently licensed drug in the battle against CNS-stage human African 
trypanosomiasis. The potential application of this drug in the treatment of trypanosome- 
infections was indicated by the dramatic results of efficacy studies using eflornithine 
treatment in a murine model of the disease (Bacchi, Nathan, Hutner, McCann et al., 1980) 
and clinical trials soon followed. In this introduction the existing knowledge with regard 
to the mechanism of action of eflornithine, its efficacy as an anti-cancer drug and its use in 
CNS inflammatory conditions will are considered. In addition, the story of the rise and fall 
of eflornithine in the chemotherapy of human African trypanosomiasis, since its initial 
application in the treatment of this disease, will be outlined.
5. f. f. Polyamines and eflornithine
Polyamines such as putrescine, spermidine and spermine are organic poly-cations that play 
important roles in many cellular functions, including, maintenance, proliferation, 
differentiation, neoplastic transformation, apoptosis and anti-angiogenesis (Zou, Vlastos, 
Yang, Wang et a l, 2002). The mechanisms used by the polyamines to fulfil these roles 
remain unclear. It is known that they associate with nucleic acids, cause conformational 
changes in DNA and interact with proteins and cellular organelles (Zou et al, 2002). 
Inhibition of ornithine decarboxylase (ODC), the enzyme that performs the rate-limiting 
step in the polyamine biosynthesis pathway, rapidly depletes cells of these compounds. 
Cells that have become depleted of polyamines proliferate extremely slowly. However, if 
an exogenous source of polyamine is provided this growth inhibition is quickly reversed 
and the cells return to their normal growth-rates. The requirement of dividing cells for 
polyamines has been exploited in the search for novel anti-cancer drugs and has led to the 
development of compounds that specifically inliibit ODC. One compound arising from 
this research was eflornithine.
5. f .2. Eflornithine as an anti-cancer agent
In many tumours and rapidly dividing cells, ODC expression is known to be upregulated. 
Eflornithine is a highly specific, irreversible inhibitor of ODC and as such prevents the de
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novo synthesis of polyamines thereby reducing or preventing cellular proliferation. 
Eflornithine has been shown to possess anti-tumour and anti-metastatic qualities in the 
treatment of several types of carcinoma development. Many cases of colonic neoplasms 
are associated with an increased polyamine content in the affected mucosa compared with 
normal mucosa. In patients with a history of colonic adenoma, treatment with low doses, 
0.20-0.40gm/m^, of orally administered eflornithine resulted in a decrease in the polyamine 
content in the mucosa (Gwyn and Sinicrope, 2002). Eflornithine has also been employed 
in a topical form in a randomised placebo-controlled study investigating the progression of 
actinic keratoses, the pre-malignant precursor cells, of squamous cell carcinoma in skin 
biopsy specimens (Einspahi', Nelson, Saboda, Warneke et a l, 2002). In this study 
application of eflornithine significantly reduced the numbers of these precursors and 
lowered the polyamine content. An increase in the expression of ODC has also been 
suggested as an independent adverse prognostic factor in the overall survival of human 
breast cancer (Manni, Washington, Griffith, Verderame et a l, 2002). In an in vivo murine 
study, administration of 2% eflornithine in the animals’ drinking water reduced the growth 
rate of highly aggressive implanted human breast cancer cell lines and resulted in a 
significant reduction in the oecurrence of lung metastasis in these mice (Mamii et al, 
2002).
Unfortunately early trials of eflornithine, using oral doses of lOg or more per day were 
often associated with a host of adverse side effects including, diarrhoea, nausea, emesis, 
abdominal pain and anorexia. Occasionally bilateral hearing impairment and 
tlii'ombocytopenia were encountered. These reactions were generally reversible on 
cessation of the drug treatment. In addition the eflornithine treatment commonly did not 
produce the anti-tumour response that was hoped for (Schechter, Barlow, and Sjoerdsma, 
1987), This led to use of the drug being largely abandoned. The discovery that lower 
doses of the drug can elicit favourable outcomes in the treatment of colonic neoplasms, 
without the onset of adverse clinical signs, and that combination chemotherapy regimens, 
utilising eflornithine and non-steroidal anti-inflammatory drugs (NSAID’s) increases the 
efficacy of the treatment has re-stimulated interest in eflornithine as an potential anti­
cancer agent. Many of these combination therapy approaches are currently under clinical 
trials for the treatment and prevention of various forms of intestinal neoplasm (Gwyn and 
Sinicrope, 2002)
229
5.1.3. Eflornithine in non-cancer related conditions
The spread of AIDS in the human population has led to an increase in the number of cases 
of opportunistic infections including Pneumocystis carinii pneumonia. This disease is 
characterised by fever, dry cough, weight loss, progressive dyspnoea and tachypnoea 
leading to respiratory failuie. This infection is now one of the most common causes of 
death in patients with AIDS. The currently recommended treatment protocols for 
Pneumocystis carinii pneumonia in AIDS patients are less than satisfactory and a high 
incidence of allergic or toxic reactions is seen. Eflornithine treatment has been given to 
these patients on a compassionate basis when the accepted regimens have failed to resolve 
the infection or become intolerable, with a success rate of approximately 74% (Schechter 
et al, 1987). Another opportunistic infection that commonly occurs in AIDS is 
Cryptosporidium resulting in severe intestinal symptoms. Initial trials of eflornithine in the 
treatment of this infection gave inconclusive results and further studies are necessary to 
determine the value of this treatment.
Eflornithine has shown potential in the treatment of malaria. In in vitro culture systems of 
Plasmodium falciparum, eflornithine at a concentration of 5mM or higher was shown to 
reduce the ability of the parasite to divide (Bacchi and McCann, 1987). The ability of 
eflornithine to induce protection against subsequent malarial infections has been 
demonstrated in a murine model of Plasmodium berghei-mÎQCtïon (Gillet, Bone, Lowa, 
Char lier et a l, 1986). When mice were inoculated with these parasites during a course 
eflornithine treatment, administered as a 1% solution in their drinking water, 55% of the 
animals developed a protective immunity against subsequent parasitic challenge that 
endured for a period of up to six months. This percentage was increased to 60% when the 
mice were given a concurrent course of chloroquine to help prevent the development of a 
lethal pai'asitaemia following the initial infection.
5.1.4. Eflornithine in brain injury
In the gerbil brain, transient ischaemic brain injury results in an increase in the expression 
of ODC and polyamines which are thought to play important roles in the resulting oedema 
and neuronal cell loss (Kindy, Hu, and Dempsey, 1994). Gerbils, pretreated with 
eflornithine 30 minutes prior to the induction of the ischaemia and reperfusion injury, 
showed a dose dependent reduction in the levels of ODC and putrescine in the damaged 
tissue. In addition, this treatment prevented the development of the neuronal cell loss that
2 3 0
is associated with brain injuries of this type. The attenuation of the damage was not found 
when concurrent treatment with putrescine was administered. The findings are in contrast 
to those seen in a rat model of transient cerebral ischaemia (Luklcarinen, Kauppinen, 
Grolm, Oja et a l, 1998). In this model of transient ischaemic brain injury was induced in 
transgenic rats over-expressing ODC. In animals treated with 2% eflornithine in their 
drinking water, from one week before the induction of the ischaemia, a significant increase 
in the number of stroke lesions was found compared with non-treated rats. An increase in 
the degree of oedema was also found in the eflornithine-treated rats. These results were 
confirmed in another rat model of forebrain ischaemia where the presence of ODC 
activation was shown to play a pivotal role in the survival of neurons following ischaemic 
damage (Zoli, Zini, Grimaldi, Biagini et a l, 1993). The value of eflornithine treatment 
following stroke in the human situation therefore remains equivocal.
Studies have also been performed to investigate the effect of polyamines on astrogliosis. 
In a rat model of mechanical brain injury a marked decrease in the resulting astrocyte 
activation was seen in animals treated with eflornithine (Zini, Zoli, Grimaldi, Merlo Pich et 
a l, 1990). This effect was prevented when an exogenous source of putrescine was 
provided in the eflornithine-treated animals. The suppression of astrocyte activation by 
eflornithine was also seen in another rat model of astrogliosis (Jeglinski, Skup, Zaremba, 
and Oderfeld-Nowak, 1996). In this model astrocyte activation was induced by transection 
of the lateral fimbria. Treatment of these rats with eflornithine treatment dramatically 
reduced the resulting astroglial reaction compared with non-operated control animals. In 
contrast, when astrocyte activation was induced by neurotoxic insult by l-methyl-4- 
phenyl-1,2,3,6-tetrahydropyridine treatment, eflornithine administration had no effect on 
the degi'ee of astrogliosis (O'Callaghan and Seidler, 1992). The effects of eflornithine on 
the development of astrocytic reactions therefore appear to vary dramatically with the 
injury type.
5.1.5. Cosmetic applications for eflornithine
Following the unfavourable outcomes seen during the initial trials of eflornithine as an 
anti-cancer agent, continued production of the drug became largely abandoned by the 
pharmaceutical companies despite its dramatic effects in the treatment of human African 
trypanosomiasis (discussed below). Recently a new interest in eflornithine has arisen due 
to the discovery of an alternative use for the drug as a depilatory (Wickware, 2002). This 
depilatory effect of eflornithine is thought to result from the inliibition of ODC in the hair
231
follicles leading to a reduction in hair growth. A decrease in facial hirsutism was reported 
in 58% of patients treated with a topically applied eflornithine cream (Balfour and 
McClellan, 2001). The cuirent course of topical treatment entails the application of a 
13.9% eflornithine cream twice daily for a period of 24 weeks. The depilatory effect may 
last for up to eight weeks following treatment before a repeat course of the eflornithine 
cream is necessary. This finding opened the market for eflornithine sales to the affluent 
nations of the world and the cost of a month’s course of treatment with eflornithine cream 
is estimated to be approximately $50 to the pharmacist (Shenenberger and Utecht, 2002),
5.1.5.1. Benefits of a commercially viable eflornithine 
application
The development of eflornithine as a depilatory instigated the continued manufacture of 
the drug by the pharmaceutical companies as a commercially viable product. The 
eflornithine cream is now produced by Bristol-Myers Squibb and Gillette, who advertise 
the product under the trade name Vaniqa®, and is available for use in the USA. Licensing 
applications have also been submitted to allow the international marketing of the product 
(Balfour and McClellan, 2001). The existence of these affluent consumers inadvertently 
led to development of a partnership between WHO in collaboration with Médecins Sans 
Frontières (MSF), and Aventis (formerly Hoechst Marion Roussell Inc.), who hold the 
patent rights for the manufacture of eflornithine, and Bristol-Myers Squibb together with 
Dow Chemicals Co, Akorn Manufacturing Inc. to produce and donate 60,000 doses of 
eflornithine for use in the treatment of human African trypanosomiasis. This supply 
should last until approximately June 2004. Currently, discussions between Bristol-Myers 
Squibb and WHO/MSF are in progress to try and secure the continued manufacture of 
eflornithine after 2004. The main stumbling block again appears to be related to the final 
charge for the drug since synthesis of this fluorinated compound is resource intensive and 
highly corrosive to the manufacturing plant. The final outcome of these talks is awaited 
although it is known that MSF would like to agree on a pre-arranged price of $10 per dose, 
this is half the cost of purchasing the drug in 1997 before the advent of the alternative 
market (WHO, 2001b).
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5.1.6. Eflornithine treatment of African 
trypanosomiasis
5.1.6.1. Polyamines and ODC in African trypanosomes
In the blood stream form of T.b.brucei putrescine and spermidine, constitute the main pool 
of polyamines produced by ODC. Spermine was not detected in these parasites (Bacchi, 
1981). The ability of eflornithine to inhibit trypanosome ODC over mammalian ODC does 
not arise from a unique sensitivity of the parasitic enzyme to the drug but is the result of 
two basic differences between the mammalian cells and the parasites. In both cell types all 
three polyamines are taken up if an exogenous source of the compounds is provided. 
However, uptake of the polyamines is 100 fold slower in the parasites compared with 
uptake by mammalian cells (Bacchi and McCann, 1987). In addition, the turnover of ODC 
within the trypanosome occurs more slowly than that seen in mammalian cells resulting in 
a prolonged period of ODC inactivity following eflornithine treatment (Ghoda, Phillips, 
Bass, Wang et a l, 1990).
During normal metabolic processes, and in the immune response to infection, cells produce 
reactive oxygen species. These molecules can result in oxidant damage to the cells; 
therefore, in order to avoid injury, both mammalian calls and trypanosomes must be able to 
remove these harmful molecules. In mammalian cells, this balance is maintained by the 
enzyme catalase, in conjunction with glutathione reductase and glutathione. In this system 
reduced glutathione (GSH), acts as a carrier for the free radicals resulting from the 
degradation of hydrogen peroxide or the superoxide anion, producing oxidised glutathione 
(GS-SG) (Bacchi and McCann, 1987; Van Bogaert and Haemers, 1989).
2GSH + R-O-OH — ► GS-SG + H2O + ROH
The regeneration of reduced glutathione is catalysed by the enzyme glutathione reductase 
using the reduced form of nicotimadine adenine dinucleotide phosphate (NADPH) as an 
electron donor. The electrons from the molecule are transferred by glutathione reductase 
to GS-SG thereby regenerating the two molecules of GSH.
GS-SG + NADPH+ H^ — ► 2GSH + NADP^
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However, in trypanosomes this pathway is not complete as glutathione reductase is not 
present. Therefore an alternative mechanism involving a two-step process is followed to 
recycle the GSH. In this pathway the GS-SG is reduced by the transfer of electrons from a 
molecule known as trypanothione. In the first step of the process trypanothione disulphide 
[T(S)2] is reduced to dihydrotrypanothione [T(SH)2] by the enzyme trypanothione 
reductase in a NADPH dependent manner. This enzyme is largely similar to glutathione 
reductase but is specific for trypanothione and will not react with glutathione.
T(S)2 +NADPH+ H’" — ► T(SH)2 + NADP+
In the second stage of the reaction, the T(SH) 2  donates the additional electron to the GS- 
SG molecule in a non-enzymatic exchange.
GS-SG + T(SH)2 — ► 2GSH + T(S)2
This reaction regenerates the reduced form of glutathione and allows the molecule to 
continue scavenging for reactive oxygen species thereby maintaining the redox balance 
within the parasite.
The trypanothione molecule is synthesised from the polyamine spermidine and is 
dependent on the presence of this compound for its production. Thus, drugs that inliibit the 
polyamine biosynthesis pathway, such as eflornithine, would have a profound effect on the 
ability of the trypanosome to maintain a steady redox state. The fundamental difference 
between these pathways in mammalian cells and trypanosomes, together with the slow 
ODC turnover and uptake of exogenous polyamine, makes the parasites more vulnerable to 
attack by eflornithine than the cells of their mammalian host thus, indicating ODC as a 
logical target for anti-trypanosomal drugs (Bacchi and McCann, 1987; Van Bogaert and 
Haemers, 1989).
5.1.6.2. Eflornithine studies in experimental infections
The use of eflornithine to treat in vivo trypanosome infections was first demonstrated using 
a mouse model of the disease (Bacchi et al, 1980). In this study mice were infected with 
T.b.brucei and treated with a range of doses of eflornithine, administered either in the 
animals drinking water or by intubation. In untreated mice, infected in this manner, the 
survival time is approximately 5 days. The treatment regimes were given during the early 
stage of the disease, beginning 24 houi s post-infection. The chemotherapy was considered
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to be curative if the mice survived for a period exceeding 35 days. To confirm the cured 
status and ensure that no parasites were sequestered within the CNS of these animals, their 
brain was homogenised and transferred to uninfected animals. These recipient mice were 
monitored for a further 30-day period for the development of the disease. Successful cures 
were found in animals treated with 1% eflornithine in their drinking water for tliree days 
with an estimated eflornithine intake of 150mg. The administration of the drug in the 
drinking water was a more effective method of eflornithine dosing than intubation. This is 
most likely the result of the short half-life of eflornithine in rodents. Therefore, more 
frequent intake of the drug results in more efficacious treatment schedules (Bacchi et al, 
1980).
In further experiments the effect of eflornithine treatment, supplied as a 4% solution in the 
drinking water, on the trypanosomes during the course of infection in T.b.brucei-mÎQCtQà 
rat was studied (Bacchi, Garofalo, Mockenhaupt, McCann et a l, 1983). Parasites isolated 
from infected rats, following 36 houi's of eflornithine treatment, displayed a short stumpy 
conformation and showed additional morphological changes. Many of these trypanosomes 
had several nuclei and kinetoplasts and the cytoplasm appeared granular. In contrast, 
parasites prepared flom non-drug treated animals had a long slender shape with the 
presence of only an occasional stumpy form. No morphological abnormalities were noted 
in these parasites. Treatment of infected rats with 4% eflornithine in their drinking water 
for periods longer than 36 hours resulted in a rapid clearance of the trypanosomes from the 
bloodstream and the effect of longer exposure times of the trypanosome to the drug could 
not be determined. These morphological changes, induced in the tiypanosomes by 
eflornithine, were confirmed in experiments investigating the effect of the drug on the 
parasite in both in vivo and in vitro scenarios (Giffm, McCann, Bitonti, and Bacchi, 1986). 
In these experiments T.b.brucei parasites were either maintained in tissue culture and 
exposed to 50pM or lOOpM eflornithine or used to infect rats that were subsequently 
treated with 4% eflornithine in their drinking water. Trypanosomes exposed to eflornithine 
in either situation displayed a short stumpy conformation and alterations to their nuclear 
morphology.
5.1,6.2.1. Innate resistance to eflornithine treatment
The differential susceptibility of various trypanosome strains to eflornithine treatment has 
also been investigated in experimental murine infections (Bacchi, Nathan, Livingston, 
Valladares et a l, 1990). These studies employed one strain of T.b.brucei as a reference 
strain, two strains of T.b.rhodesiense supplied from the American Type Culture Collection
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(ATCC) and 14 T.b.rhodesiense strains, originally isolated from human blood or 
cerebrospinal fluid, supplied from the Kenyan Trypanosomiasis Research Institute 
(KETRI) strain bank. In the T.b.brucei infections 2% eflornithine in drinking water for a 
period of 3 days resulted in a cure rate of higher than 80%. If the treatment period was 
extended to 6 or 9 days then a 100% cure rate was obtained. Five of the T.b.rhodesiense 
isolates from KETRI showed a response to eflornithine treatment similar to that seen in the 
T.b.brucei strain. Six other KETRI isolates and the two ATCC strains were more resistant 
to eflornithine and a dose regimen of 4% eflornithine for 9 days had to be employed to 
cure the infections. The remaining three KETRI isolates were refractory to eflornithine 
treatment. Even when the animals infected with these strains were treated with higher 
doses of the drug the infections could not be cured although longer survival times were 
achieved following eflornithine chemotherapy. It would therefore appear that certain 
T.b.rhodesiense infections show an innate resistance to eflornithine treatment since these 
isolates had not previously been exposed to the drug.
Combination therapy approaches to try and circumvent the innate resistance of specific 
T.b.rhodesiense strains to eflornithine treatment were employed (Bacchi, Nathan, Yariett, 
Goldberg et a l, 1994). In these studied eflornithine resistant strains of T.b.rhodesiense 
that were also refractory, or moderately resistant, to melarsan oxide, were used to infect 
mice. It was found that cures could be obtained by administering a regimen of eflornithine 
plus suramin or eflornithine plus melarsan oxide. These drugs when given as 
monotherapies were ineffectual in the treatment of the infection. The results from these 
experiments suggest that eflornithine treatment, in combination with other trypanocidal 
drugs, may be useful in the treatment of melarsoprol refractory disease even where the 
parasites have shown innate resistance to eflornithine therapy.
The potentiation of arsenical drugs such as melarsan oxide and melarsoprol had been 
demonstrated previously in a T.b.brucei murine model of CNS-stage disease (Jennings, 
1988a; Jennings, 1988b). Here it was shown that combining eflornithine and melarsoprol 
treatment protocols resulted in a five-fold increase in the efficacy of the treatment regimen 
compared with melarsoprol monotherapy. These studies also indicated that use of a 
combination therapy approach could allow reduced dosages of melarsoprol and shorter 
treatment periods to be employed while still successfully curing the infection.
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5.1.6.3. Eflornithine trials in human trypanosome 
infections
Shortly after the discovery that eflornithine could be used to cure experimental 
trypanosome infections (Bacchi et al, 1980) human trials using the drug were instigated. 
The first field trial of eflornithine was cairied out in the Sudan using an orally administered 
form of eflornithine (Van Nieuwenhove et al, 1985). Based on the geographical location 
and the clinical course of the disease, the patients in this study were considered to be 
infected with T.b.gambiense. Twenty patients were included in the trial, 18 of these 
patients were diagnosed with late-stage infections and two were treated duiing the early 
stage of the disease. Sixteen of the 18 late-stage patients presented with melarsoprol 
refractory infections while the remaining two late-stage patients had received no previous 
treatments for the infection.
The first patient was treated with eflornithine in 1981 and was given an oral dose of 
258mg/kg/day for a period of 44 days. This patient was diagnosed with late-stage disease 
and had received no previous trypanocidal therapy. Unfortunately this man showed 
evidence of a relapsed infection 10 weeks following cessation of the eflornithine treatment. 
The patient was placed on a course of intravenous melarsoprol that he did not complete. 
The occurrence of a relapsed infection in this patient prompted the investigators to increase 
the dosage of eflornithine to 400mg/kg/day administered as four separate doses at six-hour 
intervals for the treatment of the melarsoprol refractory infections. The second patient who 
had not been previously treated with any trypanocidal drugs was given 266mg/kg/day for a 
37-day period. Although the course was not complete at this time point the patient left the 
hospital due to the fear of his imminent lumbar puncture. On follow up at 23 months after 
cessation of the eflornithine treatment the patient appeared to be free from infection. Of 
the remaining 16 patients with late-stage melarsoprol refractory infections, 13 completed 
the eflornithine course of 400mg/kg/day. Only two of these patients developed a relapsed 
infection. The two patients treated with either 218mg/kg/day or 203mg/kg/day eflornithine 
during the early stage of the infection were also successfully cured of the disease. The 
follow up period on the patients involved in this trial ranged from 3-23 months. The drug 
was generally well tolerated and adverse reactions did not precipitate cessation of the 
chemotherapy. The adverse side effects of oral eflornithine were reported as
gastrointestinal complaints and occasional anaemia. These reactions dissipated on 
completion of the treatment coui'se. This initial trial indicated that eflornithine was a
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highly effective and relatively non-toxic drug useful for the treatment of all stages of HAT, 
including, melarsoprol refractory infection.
In another trial 14 patients with late-stage T.b.gambiense infection in the Cote D’Ivoire 
were studied (Doua, Boa, Schechter, Miezan et a l, 1987). Twelve of these cases were 
considered to be refractory to melarsoprol treatment and the remaining two patients had 
not received previous trypanocidal therapy. The patients were given a course of 
eflornithine consisting of 400mg/kg/day administered intravenously for 14 days followed 
by 300mg/kg/day given orally for 21-28 days. This regimen rapidly cleared the parasites 
from the body fluids and resulted in a rapid reversal of the clinical signs and symptoms of 
the diseases. Again, diarrhoea, abdominal pain and anaemia were the most common side 
effects of the drug although these adverse reactions quickly disappeared on withdrawal of 
the eflornithine. All of the treated patients appear ed to be cured of the infection and in four 
of the cases followed for 2 years no relapses were recorded. The high success of this 
regimen indicates that a combined intravenous and oral approach is more efficacious than 
eflornithine administered purely using the oral route. A synergism between eflornithine 
and melarsoprol has also been demonstrated in the treatment of T.b.gambiense infections 
(Simarro and Asumu, 1996). In this case conventional trypanocidal treatment regimens 
and eflornithine monotherapy failed to cure the disease. However, when the patient was 
treated with a combination of melarsoprol and eflornithine the infection was successfully 
resolved.
The initial success of eflornithine treatment for T.b.gambiense infections was unfortunately 
not mirrored in the treatment of T.b.rhodesiense infections. Initial studies on tlii’ee cases of 
melarsoprol refractory T.b.rhodesiense infection gave disappointing results and all thiee 
cases given eflornithine at 400mg/kg/day subsequently relapsed (Bales, Jr., Harrison, 
Mbwabi, and Schecter, 1989). More promising results have been reported when 
eflornithine has been used in combination with suiamin to treat T.b.rhodesiense infections 
(Clerinx, Taelman, Bogaeits, and Vervoort, 1998; Taelman et al, 1996). In these studies 
intravenous suramin was given together with either 400 or 800mg/kg/day of intravenous 
eflornithine for a 14-21 day period. This was followed by eflornithine administered orally 
at a dosage of 300mg/kg/day for 10-21 days. All patients responded well to the 
chemotherapy and all patients treated with these regimens appeared to be cured of the 
infection. Due to the equivocal results gained from eflornithine treatment of 
T.b.rhodesiense infection only scarce documentation is available regarding the use of the 
drug for this form of HAT. This is unfortunate as eflornithine remains the only available 
drug for the treatment of melarsoprol refractory late-stage infections and initial trials
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combining eflornithine with other conventional trypanocidal drugs have proved 
encouraging.
5.1.7. Additional pharmacological actions of 
eflornithine
A  study investigating the effect of eflornithine treatment on the CNS inflammation 
associated with subcurative drug treatment of late-stage trypanosome infections and the 
development of the post treatment reactive encephalopathy (PTRE) in experimental murine 
infections produced interesting results (Jennings et al, 1997). This study utilised a strain 
of T.b.brucei that was resistant to the effect of eflornithine and continued to divide 
normally even in the presence of curative levels of the drug. Various groups of mice were 
infected with these eflornithine resistant trypanosomes and the infection allowed to 
progress naturally. At 14 days post-infection one group of mice was given 2% eflornithine 
in their drinking water. This treatment was continued for a 14-day period. On day 21 
post-infection, halfway through the eflornithine course, the mice were treated with a 
subcurative dose of diminazene aceturate. This treatment induces a CNS inflammatory 
reaction in the infected animals that becomes apparent by 7 days after the diminazene 
aceturate treatment. Groups of mice were killed at 7 and 14 days after the subcurative dmg 
administration. Their brain tissue was examined histologically for neuropatholo gical 
changes and compared with non-eflornithine treated mice subjected to a similar regimen. 
Using this model, eflornithine treatment was shown to prevent the development of the 
neuroinfiammatory response associated with subcurative drug treatment of late-stage 
infections.
A second group of mice were infected and treated with diminazene aceturate on day 21 
post-infection. The CNS inflammation was allowed to develop for a 7-day period and then 
the mice were given the 14-day eflornithine regimen. On completion of the course of 
chemotherapy the animals were killed and the brains examined for inflammatory changes. 
The brains of these animals showed a dramatic reduction in the severity of the 
neuroinflammation compared with mice that had not received eflornithine. These findings 
indicated that eflornithine treatment could ameliorate an established CNS inflammatory 
reaction.
This murine model was also used to investigate the effects of eflornithine treatment on the 
extremely severe CNS inflammatory reaction that can occur in human cases of the disease
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following melarsoprol treatment. This PTRE was induced in infected mice by treating the 
animals on day 21 post-infection with diminazene aceturate to instigate the CNS 
inflammatory changes. When these animals relapsed to parasitaemia they were given a 
second diminazene aceturate treatment. This regimen ftirther exacerbates the CNS 
inflammation resulting in an extremely severe meningoencephalitis similar to that found in 
the PTRE. If animals treated in this mamrer were given a 14-day course of eflornithine as 
described above, begimiing 7 days after the second diminazene aceturate treatment, the 
severity of resulting CNS pathology was substantially reduced compared to animals not 
given eflornithine. This indicates that eflornithine treatment can ameliorate not only 
moderate CNS inflammatory reactions but also the extremely severe meningoencephalitis 
that is characteristic of the PTRE.
The ability of eflornithine to prevent the development of CNS inflammation and to 
ameliorate established neuroinfiammatory reactions appeal's to be independent of the drugs 
trypanostatic action since an eflornithine resistant trypanosome stabilate was used in these 
infections. Furthermore, the effect of eflornithine on ODC was shown to be only partially 
responsible for this anti-inflammatory action since concurrent administration of putrescine 
with the eflornithine course only partially restored the CNS inflammatory response.
From the data presented in the study detailed above there appears to be a pharmacological 
action of eflornithine in addition to its ability to inliibit ODC. This was also suggested by 
the dramatic clinical improvement seen in comatose sleeping sickness patients treated with 
eflornithine even when it failed to resolve the infection. This finding resulted in 
eflornithine being nicknamed “the resurrection” drug (WHO, 1990). In this chapter the 
effect of eflornithine on the development and amelioration of the CNS inflammatory 
reaction associated with trypanosome infection and treatment will be further investigated. 
It is possible that treatment with eflornithine inhibits the production of pro-inflammatory 
mediators thereby decreasing the severity of the resulting CNS reaction. Therefore, the 
expression of the cytokines, IL -la, IL-6 and TNF-a as well as the chemokines M IP-la, 
MCP-l and RANTES will be examined in the presence and absence of eflornithine 
chemotherapy. As previously stated, these mediators have been shown to be play a role in 
the pathogenesis of trypanosomiasis and are known to be present within the CNS. The 
effect of eflornithine treatment on the severity of the CNS inflammatory response will also 
be examined.
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5.2. Materials and methods
Eflornithine chemotherapy can both prevent and ameliorate the CNS inflammatory 
reaction associated with trypanosome infection and subcurative drug treatment. Studies 
previously performed in our laboratory have indicated that eflornithine may possess 
pharmacological actions in addition to the inhibition of ornithine decarboxylase (ODC) 
(Jennings et al, 1997). Since the mRNA transcripts for the inflammatory mediators IL-la, 
IL-6, TNF-a, M IP-la, MCP-l and RANTES are present in the brains of trypanosome- 
infected animals it is possible that eflornithine mediates its anti-inflammatory action by 
inliibiting the production of one or more of these inflammatory agents. Therefore, the 
effect of eflornithine treatment on the severity of the neuroinfiammatory reaction and the 
transcription of IL-la, IL-6, TNF-a, M IP-la, MCP-l and RANTES was studied using our 
murine model of trypanosomiasis.
5.2.1. Parasites
In order to differentiate between the anti-inflammatory effects arising directly as a result of 
the chemotherapy and those that would occur due to the elimination of the parasitaemia 
normally associated with eflornithine treatment, trypanosomes that were resistant to the 
effects of the drug were used in these experiments. These parasites were developed in 
Glasgow University Veterinary School, by Dr Frank W Jennings and continue to divide 
when exposed to normally curative levels of eflornithine. The procedure used to create the 
eflornithine resistant trypanosomes is outlined schematically in Figure 5.1.
To generate these drug resistant trypanosomes six mice were infected with the normal 
working stabilate of T.b.brucei GVR35/C1.3 and housed under a 2-hour light 4-hour dark 
regimen. The infection was allowed to progress until day 21 post-infection when the mice 
were given a 14-day course of 2% eflornithine administered in their drinking water. When 
one of the six mice relapsed to parasitaemia the animal was killed and exsanguinated by 
cardiac puncture. The parasitaemic blood was then used to infect a further group of six 
mice. In addition, an intermediate trypanosome stabilate was prepared by infecting two 
irradiated mice, allowing the parasitaemia to develop and then storing the parasitaemic 
blood in liquid nitrogen. The whole procedure of infection, eflornithine treatment, relapse 
and exsanguination was repeated for a further seven rounds. Intermediate stabilates were 
prepared thioughout the process in case the ‘resistant’ trypanosome was lost at any time. 
Following the final infection series the mice were treated on day 21 post-infection with 4%
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Infect 6 mice with T.b.brucei GVR35/C1.3
21 days post-infection 2% eflornithine X  Blood used to infect 6 more mice 
given for 14days in drinking water following relapse to parasitaem ia
2 irradiated mice infected 
for preparation of 
intermediate stabilate 
GVR35/C1.3 DFMO 1
2% eflornithine course
2% eflornithine course
^  2% eflornithine course
2% eflornithine course
GVR35/C1.3 DFMO 2
2% eflornithine course
I
GVR35/C1.3 DFMO 3
2% eflornithine course
I
GVR35/C1.3 DFMO 4f 2% eflornithine course
GVR35/C1.3 DFMO 5 
Reserve Stabilate 21 days post-infection treated with 4% eflornithine course. All animals remained parasitaem ic
Working Stabilate GVR35/C1.3 DFMO 5.1
Figure 5.1. Production of eflornithine resistant T.b.brucei GVR 35/Cl.3 DFMO 5.1
An initial group o f  mice were infected with T.b.brucei GVR35/C1.3. At 21 days post-infection the 
animals were given 2% eflornithine in their drinking water ad libitum for 14 days. W hen one o f  
these mice relapsed to parasitaemia (red oval) the blood was used to infect 6 more mice. The 
procedure was repeated a further seven times. Animals were maintained under a 2-hour light 4-hour 
dark regimen. Following the final round o f  infections the mice rem ained parasitaem ic through 
treatment with double the normal dose o f  eflornithine (red oval with blue chevrons). These parasites 
were considered to be eflornithine resistant and a working stabilate was prepared from  the reserve. 
Intermediate stabilates were prepared, by infecting irradiated mice (green oval), at intervals 
throughout the process in case the parasite was ‘lost’. W orking stabilates are prepared from the 
reserve stabilate as required. The current working stabilate is GVR35/C1.3 DFM O 5.2.
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eflornithine in their drinking water. This treatment had no effect on the trypanosomes and 
the animals remained parasitaemic. This parasite was considered to be resistant to 
eflornithine and was stored in liquid nitrogen as stabilate GVR35/DFM05. Working 
stabilates were prepared from this original reserve stabilate as required. The current 
working stabilate is GVR35/DFM05.2
5.2.2. Animals infection and treatments
The mouse model of human African trypanosomiasis, as detailed in Chapter 2, was used to 
mirror the CNS-stage of human African trypanosomiasis and the post-treatment reactive 
encephalopathy (PTRE). The animals were infected with 2x10"^  T.b.brucei parasites of 
cloned stabilate GVR35/DFM05.2 and the treatment regimens outlined in Figure 5.2 
followed. Six mice were included in each experimental group. Due to death or euthanasia 
of the mie before the endpoint of the experiment the number of animals comprising the 
analysis groups are detailed in Tables 5.2-5.3 (neuropathology) and Figures 5.12-5.17 and 
Figures 5.25-5.30 (cytokine and chemokine expression).
5.2.2.1. Prevention of the CNS inflammatory response
In this experimental regimen infected mice were given a course of eflornithine, 
administered as a 2% solution in their drinking water beginning on day 14 post-infection. 
The drug was available ad libitum and the mice were housed under a 2 hour light / 4 hour 
dark lighting regimen. This is known to encourage a more frequent drinking pattern in the 
mice and therefore regulates the intake of the eflornithine. The drug was administered in 
this fashion for a 14-day period. On day 21 post-infection the mice were treated with 
diminazene aceturate (40mg/kg i.p.) to induce a CNS inflammatory response. On day 28 
post-infection the eflornithine treatment was withdrawn and the mice were killed. At each 
termination point the animals were killed by cardiac perfusion with sterile saline while 
under terminal anaesthesia and their brains extracted and processed for histopathological 
examination or RNA extraction.
5.2.2 2. Amelioration of an established 
meningoencephalitis
In this experimental design infected animals were treated on day 21 post-infection with 
diminazene aceturate (40nig/kg i.p.). The parasitaemia in the animals was monitored on a
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Prevention of the CNS inflammatory response
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D
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Figure 5.2. Schematic representation of the treatment regimens utilised to 
determine the effects of eflornithine treatment. In this model experimental groups 
of mice were infected (I) with 2x10^ T.b.brucei parasites of cloned stabilate 
GVR35/C1.6/DFM05. Animals were administered diminazene aceturate (D) and 
eflornithine (E) as indicated. The regimens were terminated when the mice were killed 
(K). The number of days post-infection is shown below the treatment regimen. The 
interval between the initial diminazene aceturate treatment and the second injection of the 
drug is dependent on the length of time taken by the animals to relapse to parasitaemia. 
Therefore, the time points marked * are approximate dates and vary slightly with each 
experiment.
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weekly basis by examining wet blood films prepared from tail snips. When more than 
50% of the mice had relapsed to parasitaemia the animals were given a second diminazene 
aceturate treatment. This regimen induces an extremely severe meningoencephalitis in the
mice, similai* to than found in patients that have died of the PTRE, which is apparent by 7 
days following the diminazene aceturate treatment. The mice were given a course of 
eflornithine as described above beginning 7 days after the second diminazene aceturate 
injection. Groups of mice were sacrificed, after receiving 7 and 14 days of eflornithine 
chemotherapy.
5.2.2.3. Control animals
In parallel with the experimental regimens, groups of infected animals were treated in an 
identical mamier to the groups described above, barring the administration of eflornithine. 
In addition uninfected mice were treated with the drug regimens described to ensure that 
these protocols did not induce changes in the CNS in the absence of trypanosome 
infection.
5.2.3. Neuropathological assessment
Although it is known that eflornithine treatment can both prevent and ameliorate the CNS 
inflammatory reaction associated with trypanosome infection (Jennings et al, 1997), this 
anti-inflammatory effect has never been determined using a quantifiable system. 
Therefore, the severity of the neuroinflammatory reaction resulting from each treatment 
regimen was assessed using the neuropathological grading scale described in Chapter 2 and 
in Table 2.1. Again, haematoxylin and eosin stained brain sections were scored, by two 
individual assessors, in a blinded fashion.
5.2.3.1 .Astrocyte activation
The gross level of astrocyte activation found in each of these groups of mice was assessed 
using immunocytochemistry (ICC) as described in Chapter 2 to detect glial fibrillary acidic 
protein (GFAP). GFAP is a major intermediate filament protein peculiar to astrocytes and 
is therefore an ideal marker to identify this cell type. Formalin fixed paraffin sections were 
stained with a polyclonal anti-GFAP antibody (Table 2.2) raised in rabbits. This was 
subsequently detected by the addition of a biotinylated swine anti-rabbit antibody followed
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by the avidin-biotin peroxidase complex. Positively labelled eells were visualised using 
diaminobenzidine (DAB) as the chromogen. The sections were counterstained with 
haematoxylin to distinguish the nuclei and to facilitate spatial orientation within the section 
during subsequent histopathological examination.
5.2.4. RT-PCR analyses
To determine the effect of eflornithine treatment on the transcription pattern of the 
cytokines IL-la, IL-6 and TNF-a and the chemokines M IP-la, MCP-1 and RANTES the 
nucleic acid extraction procedure and the semi-quantitative RT-PCR technique described 
in Chapter 2 was followed.
5.2.5. Statistical analyses
Statistical analyses were performed on the data generated from the assessment of the 
severity of the neuropathological response and the levels of cytokine and chemokine 
transcription.
The severities of the neuropathological reactions were compared, between groups of mice 
given various treatment regimens, using the average of independent assessor scores. The 
severity of the reaction was measured in sections prepared from each individual animal. A 
Wilcoxon signed rank test was employed to show that each assessor had applied the 
neuropathological grading scale uniformly. Data generated from grading the CNS 
inflammatory response were analysed using parametric statistical tests. In particular, the 
general linear model procedure was used to implement a randomised block analysis of 
variance design. This procedure tested for differences in the mean neuropathological 
responses among groups of mice.
Differences in the expression levels of cytokine and chemokines were investigated using a 
visual assessment scale to grade the intensity of the bands resulting from amplification of 
the individual inflammatory agents in nucleic acid extracted from the CNS of each mouse. 
The data generated from this scoring system were analysed using non-parametric statistical 
tests. Significant differences across the groups of animals were detected using the Kuskal- 
Wallis test. This was followed by Dumi’s test, a pairwise comparisons procedure for non- 
parametric data, to highlight differences between the median values from individual 
groups.
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All tests were undertaken using the proprietary statistical software packages; Minitab 
version 13 and Sigmastat 2.03. Tests returning p-values of less 0.05 were considered 
significant.
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5.3. Results
5.3.1. Assessment of the severity of the 
meningoencephalitis
5.3.1.1. Prevention of the neuroinflammatory response
Histopathological examination of brain sections prepared from miee infected with 
eflornithine resistant T.b.brucei showed only a slight reduction in the severity of the 
meningoencephalitis when treated with a 14-day course of eflornithine beginning 7 days 
prior to the induetion of the CNS reaction, by sub curative diminazene aceturate treatment, 
compared to similarly infected and treated animals that did not receive eflornithine (Fig. 
5.3). The inflammatory changes seen in non-eflornithine treated animals were 
characterised by the presence of a few inflammatory cells in the meninges and ventricles, 
and occasional perivascular cuffing of the blood vessels. The inflammatory cells were 
mainly macrophages and lymphocytes. Sections prepared from the brains of uninfected 
animals treated with a course of eflornithine showed only very mild signs of inflammatory 
changes with a few inflammatory cells in the meninges and ventricles.
When the GFAP content of the seetions prepared from infected mice not treated with 
eflornithine was examined, activated astrocytes were detected mainly in area displaying 
signs of inflammatory cell infiltration such as close to the meninges and surrounding any 
small perivascular cuffs that were present. These cells stained intensely with GFAP and 
displayed numerous intricate cellular processes. In animals receiving eflornithine fewer 
astrocytes were detected and these stained less intensely and displayed a more simple 
morphology that the cells found in non-eflornithine treated mice (Fig. 5.3, GFAP positive 
cells show brown staining pattern).
A summary of the results of the statistical analyses of the data generated from the 
assessment of the severity of the neuroinflammation by applying the criteria outlined in the 
neuropathology grading scale (Table 2.1) is shown in Table 5.1. The results of a Wilcoxon 
signed rank test indicated that each individual assessor had applied the scale in a consistant 
manner. Therefore, an average of the two grading scores was used in the analyses. 
General linear model analysis of the combined data from tliree experiments showed no 
significant differences (p=0.066) between the results gained from each individual
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experiment. This indicates that the regimens used produced consistent neuropathological 
changes in each individual experimental run. A significant difference (p<0.001) was 
detected in the severity of the neuroinflammatory response between the three treatment 
regimens analysed. Here both the infected group receiving eflornithine and the infected 
mice that were not given eflornithine showed a significantly (p<0.0001) higher 
neuroinflammatory response than the uninfected drug treated animals. These groups 
returned a neuropathology grading score of 1.028 ± 0.118 (mean ± standard error) and 
1.375 + 0.110 respectively while the uninfected mice showed no pathological changes 
(0.00 ± 0.00). Although the severity of the response found in the eflornithine treated group 
was slightly lower than that seen in non-eflornithine treated mice this reduction was not 
statistically significant (p=0.100).
5.3.1.2. Amelioration of an established 
meningoencephalitis
A severe meningoencephalitis was found in sections prepared from the brains of mice 
infected with eflornithine resistant T.b.brucei and killed following a second diminazene 
acetiu'ate treatment (Fig. 5.4). The inflammatory reaction seen in these animals was 
characterised by the presence of a severe meningitis, perivasculai* cuffing of most blood 
vessels, large numbers of inflammatory cells in the ventricles and a moderate to severe 
encephalitis. The inflammatory cells were composed of macrophages, lymphocytes and 
plasma cells. A 7-day course of eflornithine resulted in only a slight reduction in the 
severity of the neuroinflammation compared to mice that did not receive eflornithine while 
a 14-day course of the drug produced a more marked decrease in the neuroinflammatory 
response (Fig. 5.4). Animals receiving this 14-day eflornithine treatment showed only a 
moderate meningitis, with perivascular cuffing of some blood vessels. Inflammatory cells 
were not seen in the neuropil of mice treated in this manner. No inflaimnatory changes 
were found in the brains of the uninfected drug treated animals.
Numerous intensely staining and highly stellate astrocytes were detected in the sections 
prepared from infected animals following the induction of a severe meningoencephalitic 
reaction. The astrocytes were particularly prominent in the hippocampus and surrounding 
the ventricles and perivascular cuffs. Following 14 days of eflornithine treatment there 
was a reduction in the number of astrocytes detected and the staining pattern displayed was 
less intense. The astrocytes seen following eflornithine treatment appeared smaller and
249
showed fewer cellular processes (Fig. 5.4, GFAP positive cells show brown staining 
pattern).
Analysis of variance using a randomised block design was carried out on the data 
generated from assessing the severity of the neuroinflammatory reaction. A summary of 
the results of this analysis is shown in Table 5.2. Since a Wilcoxon signed rank test 
showed no difference in the grading method employed by the individual assessors the 
average of the two scores was used in the analysis procedures. The results of the statistical 
testing showed that the severity of the response seen in infected animals following a 7-day 
course of eflornithine (2.950 + 0.130) was only slightly reduced compared with identically 
treated mice that were not given eflornithine (3.156 ± 0.170). This reduction was not 
statistically significant (p=0.873). In contrast the severity of the neuropathological 
response seen in animals given a 14-day eflornithine course (2.271 + 0.129) was 
significantly reduced (p<0.0001) compared with infected animals given a similar course of 
treatment but no eflornithine (3.348 + 0.066). The extension of the eflornithine treatment 
period to 14 days also resulted in a significant reduction (p=0.0004) in the 
nem'opathological reaction compared with that seen in mice given only a 7-day course of 
the drug.
5.3.2. The effect of eflornithine on cytokine 
expression
To determine whether eflornithine altered the transcription of the cytokines IL-la, IL-6, 
TNF-a or the chemokines MCP-1, M IP-la or RANTES, RT-PCR analyses were 
performed on the RNA extracted from the brain tissue of T.b.brucei GVR35/C1.3 DFMO 
5.2 -infected mice in the presence or absence of eflornithine treatment. mRNA from 
uninfected mice and uninfected drug treated mice was also analysed for the expression of 
these mediators.
5.3.2.1. Prevention of the neuroinflammatory response
The effect of eflornithine treatment on the development of a CNS inflammatory reaction 
was investigated by treating infected mice with eflornithine before the induction of the 
inflammatory reaction, by subcurative drug treatment with diminazene aceturate, and 
analysing the cytokine response. This was compared with infected non-eflornithine treated 
miee, uninfected mice and uninfected drug treated animals.
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Before any comparisons were made regarding the levels of cytokine expression between 
the various treatment groups the quality of the mRNA from each group was assessed by 
the amplification of mRNA of the housekeeping gene p-actin. The banding pattern, seen 
on a 2% agarose gel stained with ethidium bromide, resulting from the amplification of 
pooled mRNA samples from animals in each treatment group is shown in Figure 5.5. All 
subsequent PCR photographs in this Chapter have been prepared using the PCR products 
resulting from this amalgamated mRNA sample. The intensity of the PCR bands found 
following p-actin amplification was similar in each group indicating that the quality of the 
starting material was comparable and therefore differences in the resulting PCR band 
intensities would reflect differences in the levels of expression of the target sequence in 
subsequent cytokine analyses rather than poor quality mRNA.
The banding pattern of IL -la expression, resulting from amplification of pooled mRNA 
from the individual animals forming each treatment group, shows that mice constitutively 
express this cytokine within the CNS. Infection with trypanosomes appears to increase this 
expression level and eflornithine treatment produces a reduction in the levels of IL -la 
compared to non-eflornithine treated infected mice (Figure 5.6). When IL-6 was 
investigated no expression was found in the CNS of uninfected miee but was detected both 
eflornithine treated and non-treated infected animals. The expression of IL-6 following 
eflornithine was reduced compared to non-treated mice and the band, although present, 
was not captured efficiently on the gel photograph (Figine 5.7). Analysis of TNF-a 
expression showed that TNF-a mRNA was present following infection and induction of 
the CNS inflammatory response and this level did not appear to be altered by eflornithine 
treatment. No expression of TNF-a was detected in either uninfected or uninfected drug 
treated groups (Figure 5.8).
The banding pattern fi'om MCP-1 RT-PCR analyses showed only a very low level of 
expression in both uninfected groups of mice. This was again difficult to capture in a 
photographic image. The expression level of this chemokine was increased in the infected 
groups and was not further altered by eflornithine treatment (Figure 5.9). All groups of 
mice showed M IP-la expression. The strongest band resulted from amplification of 
material from infected, non-eflornithine treated mice and a slight reduction in this 
expression level was found following eflornithine treatment. Uninfected mice produced 
much lower levels of M IP-la (Figure 5.10). RANTES mRNA was detected in the brains 
of mice from all treatment groups although both the infected non-eflornithine treated and
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the infected eflornithine treated regimens resulted in much higher levels of RANTES 
expression (Figure 5.11).
No significant change in the levels of cytokine or chemokine expression were found 
between uninfected mice and uninfected animals treated with diminazene aceturate and 
eflornithine suggesting that these drugs do not alter the transcription of these mediators 
under normal conditions.
5.3 .2 .1f. Statistical analysis
Alterations in the expression of the cytokines IL-la, IL-6 and TNF-a and the chemokines 
MCP-1, M IP-la and RANTES were detected in mouse brain, between eflornithine treated 
animals, non-eflornithine treated animals and control mice. To allow statistical analyses to 
be performed on the RT-PCR findings the intensity of the band resulting from the 
amplification of these mediators, from mRNA extracted from each individual animal, was 
assigned a numerical score as described in Chapter 2. In all cases, analyses resulting in p- 
values of less than 0.05 were considered to indieate a significant alteration in the 
expression levels of the specified cytokine or chemokine. Treatment groups where 
significant alterations in the expression of these inflammatory mediators were detected are 
detailed in Table 5.3. Summary data for each cytokine and treatment regimen, together 
with graphs depicting trends in their expression levels are described in Figures 5.12-5.17.
Animals infected with T.b.brucei GVR35/C1.3 DFMO 5.2 and treated subcuratively with 
diminazene aceturate gave an IL -la  median value of 2.5. This was significantly higher 
than that found in either uninfected control mice (median 1.50) or infeeted animals treated 
with eflornithine (median 1.50). The levels of IL -la were not different between 
uninfected mice and infected animals treated with eflornithine (Figure 5.12). A reduction 
in the expression of IL-6 was also found in infected mice treated with eflornithine (median 
0.25). This level of expression was significantly lower than that seen in infected mice that 
were not given eflornithine (median 0.5), but was not altered from the uninfected mice 
(median 0.00). IL-6 expression in the non-eflornithine treated mice was significantly 
higher than in uninfected mice (Figure 5.13). No difference was found in the expression of 
TNF-a in eflornithine treated mice (median LOO) when compared to infected animals that 
did not receive the drug (median 1.00) and both of these treatment groups showed 
significantly higher levels of TNF-a expression than uninfected mice (median 0.00) 
(Figure 5.14). The same pattern was found in the expression of MCP-1 where both groups
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of infected mice retmned a median value of 1,5. This was significantly higher than that 
seen in uninfected animals (median 0.125) (Figure 5.15). No significant differences were 
detected between any of the treatment groups in the expression of M IP-la. Here the 
lowest levels of expression were found in the uninfected mice (median 0.50) and the 
highest was detected in the infected, non-eflornithine treated animals (median 1.50). The 
infected eflornithine treated group showed a median PCR value of 1.00. In the case of 
RANTES the highest levels of expression were found in infected eflornithine treated mice 
(median 3.00) with a lower level seen in non-eflornithine treated infected animals (median 
2.00). Although a higher level was found in the eflornithine treated mice the difference 
between the two groups was not significant. Both of the infected groups of mice showed 
significantly higher levels of RANTES expression than that seen in uninfected mice 
(median 0.75) (Figure 5.17).
S.3.2.2. Amelioration of an existing meningoencephalitis
The effect of eflornithine treatment on cytokine expression in the amelioration of a 
meningoencephalitis was investigated using the RT-PCR teelinique. Infected animals, 
treated with two doses of diminazene aceturate to induce a severe meningoencephalitis, 
were treated with either a 7 or 14-day course 2% eflornithine in their drinking water 
beginning 7 days after the second diminazene aceturate dose. The cytokine response in 
these mice was compared to those found in infected animals treated with an identical 
diminazene aceturate regimen but given no eflornithine, uninfected animals given both 
diminazene aceturate and eflornithine and normal iminfected animals.
Prior to RT-PCR analyses for assessing cytokine and chemokine expression the mRNA 
extracted from each group of mice was checked for quality by amplification of p-actin 
transcripts. The resulting PCR products produced bands of a similar intensity when seen 
on an ethidium bromide stained, 2% agarose gel. A photograph of the gel resulting from 
amplification of the pooled mRNA from individual animals in each treatment group is 
shown in Figure 5.18. This indicated that any alteration in the intensity of the bands 
present following cytokine or chemokine RT-PCR would be the result of differences in the 
levels of the specific mRNA in the extracted sample.
As previously seen in chapter 4 of this thesis, RT-PCR analyses revealed that IL -la was 
constitutively expressed in uninfected mice. This expression was upregulated in all groups 
of infected animals irrespective of eflornithine treatment (Figure 5.19). As before no IL-6
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bands were detected following amplification of mRNA from uninfected mice but were 
found in all infected groups with the infected non-eflornithine treated animals showing a 
slightly more intense PCR band than the eflornithine treated group (Figure 5.20). TNF-a 
mRNA was found in all groups of animals with weaker bands present in the uninfected 
groups and more intense PCR bands in the infected animals (Figuie 5.21).
When the expression of MCP-1 was examined an increase in band intensity was noted in
the infected mice compared to the uninfected animals (Figure 5.22). RT-PCR analyses for 
M IP-la detected weak PCR bands in uninfected mice. The strongest expression of MIP- 
l a  was found in infected non-eflornithine treated mice while 7 or 14 days of eflornithine 
treatment appeared to result in a slight reduction in the strength of this band (Figure 5.23). 
Expression of the chemokine RANTES was detected by the presence of PCR bands in 
material amplified from all groups of mice. The intensity of the bands was higher in the
infected groups of mice compare to the uninfected animals.
No appreciable alterations in the expression of the cytokines and chemokines examined 
were detected between uninfected mice and uninfected animals treated with diminazene 
aceturate and eflornithine. This suggests that the these drugs have no effect on cytokine or 
chemokine transcription in the normal CNS.
5.3.2.2.1. Statistical analysis
The effect of eflornithine treatment on cytokine and chemokine expression when 
administered after a severe post-treatment reactive encephalopathy (PTRE) had been 
induced was analysed in a similar manner to that described above. Treatment groups 
where significant differences were detected are listed in Table 5.4. Summary statistics for 
the expression of each cytokine and chemokine, in all experimental regimens, as well as 
plots of the median expression levels are detailed in Figures 5.25-5.30.
When the levels of IL -la  expression were studied in the amelioration of a severe 
meningoencephalitis no differences were detected between any of the treatment groups. 
Infected animals treated with a double diminazene aceturate treatment to induce the PTRE 
prior to a 7-day course of eflornithine showed a median PCR value of 2.75. The same 
expression level (median 2.75) was seen in identically treated mice that were not given 
eflornithine. A slightly higher level of IL -la  expression (median 3.00) was seen after a 
14-day course of eflornithine while the median remained at 2.75 in infected animals given 
a similar course of treatment but no eflornithine. No treatment regimens resulted in a
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significant alteration, to level of IL -la  expression, from that found in uninfected control 
mice (median 2.00) (Figure 5.25).
No IL-6 expression was detected in the uninfected group of animals (median 0.00) whereas 
both groups infected mice, treated with two diminazene aceturate treatments, showed a 
significant elevation in IL-6 levels, compared with uninfected animals, with median values 
of 1.00 and 1.25. Eflornithine treatment of these infected mice did not result in any 
significant changes in IL-6 expression and animals receiving either a 7 or 14-day course of 
the drug returned a median PCR value of 1.00 (Figure 5.26).
Both groups of infected non-eflornithine treated mice expressed TNF-a. The level of 
TNF-a found in these mice (median 1.25, 1.75 respectively) was not statistically different 
to that seen in the uninfected group of animals (median 0.125). The administration of 
either a 7 or 14-day eflornithine course to infected, diminazene aceturate treated mice 
resulted in an increase in the expression of TNF-a (median 2.00, 2.00 respectively). 
Although this was not statistically higher than the expression seen in the infected non- 
eflornithine treated mice it was significantly higher that of the uninfected animals (Figure 
5.27).
No significant differences were deteeted, between any of the treatment groups, in the 
expression levels of MCP-1. Infected animals given a 7-day course of eflornithine showed 
a median PCR value of 1.75 this was slightly higher when the course of treatment was 
extended to 14 days (median 2.00). Uninfected mice gave the lowest levels of expression 
(median 1.00) while the infected groups of animals that were not given eflornithine showed 
only a small increase in MCP-1 expression (median 1.25, 1.50 respectively) (Figure 5.28).
Uninfected mice expressed low levels of M IP-la (median 0.375) this was significantly 
increased in infected non-eflornithine treated groups (median 2.75, 2.00 respectively). 
There a slight decrease in the level of this chemokine following a 7 days eflornithine 
course (median 1.00) and a 14-day eflornithine treatment period (median 1.50). The levels 
found in the eflornithine treated mice were not significantly reduced from those seen in 
animals that were not given eflornithine. However the reduction in the expression level 
resulted in no significant difference being detected between the eflornithine treated groups 
and the uninfected controls (Figure 5.29).
Infected animals given 7-days of eflornithine showed the highest levels of RANTES 
expression (median 3.00). This was significantly different to the expression of RANTES
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found in the uninfected miee (median 1.50). When the eflornithine treatment was extended 
to 14-days a slightly lowered expression level was seen (median 1.50). The infected 
groups of animals not given eflornithine gave intermediated median PCR values of 1.75 
and 2.00 respectively. The expression seen in these groups was not significantly altered 
from the levels found in any of the other treatment regimens (Figure 5.30).
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Figure 5.3. Prevention of the CNS-inflammatory reaction by eflornithine 
treatment.
Coronal sections through the hippocampal region of the brain prepared from 
trypanosome-infected mice treated on day 21 post-infection with diminazene aceturate. 
The mice were either treated (A&B) or not treated (C&D) with a 14 day course of 
eflornithine beginning on day 14 post-infection. The figure demonstrates the reduction 
in inflammatory cell infiltration, characterised by fewer cells in the ventricle and 
perivascular cuffs (A) and the down-regulation of astrocyte activation (B) that results 
from eflornithine treatment compared with non-eflomithine treated mice (C&D).
Panels A&C, H&E, X I50; panels B&D, GFAP, X300.
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Figure 5.4. Amélioration of an established m eningoencephalitis by 
eflornithine treatment.
Coronal sections through the hippocampal region o f  the brain prepared from 
trypanosome-infected m ice treated on day 21 post-infection with diminazene 
aceturate and given a second dose o f  the drug following relapse to parasitaemia. 
M ice were given a course o f  eflornithine, beginning 7 days after administration o f  
the second diminazene aceturate treatment, for a period o f  7 (A&B) or 14 (C&D) 
days. Additional animals did not receive eflornithine treatment (E&F). The figure 
shows the dose dependent anti-inflammatory effect o f  eflornithine treatment. 
Animals given a 7 day course o f  the drug show a reduction in inflammatory cell 
infiltration (A) and astrocyte activation (B) compared with non-eflom ithine treated 
mice (E&F). Following a 14 day course o f  eflornithine the inflammatory reaction 
in further reduced with fewer cells in the perivascular cuffs, a resolution o f  the 
encephalitis (C) and a dramatic reduction in astrocyte activation (D). Panels A, C 
& E, H&E, X I 50; panels B, D & F, GFAP, X300.
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Figure 5.5. p-actin check gel for groups of animals used to study the 
development of a CNS inflammatory reaction.
To ensure that the mRNA extracted from each group o f animals was o f  a similar quality, 
amplification o f the mRNA o f housekeeping gene P-actin was carried out. RT-PCR was 
performed on the mRNA extracted from; mice infected with T.b.brucei GVR35/C1.3 
DFMO 5.2 and treated on day 21 post-infection with diminazene aceturate (40mg/kg i.p.) 
to induce a CNS inflammatory reaction (lane 1); infected animals given a 14-day course o f  
2% eflornithine in their drinking water beginning at day 14 post-infection and treated with 
diminazene aceturate on day 21 post-infection (lane 2); normal uninfected mice (lane 3); 
and uninfected mice treated with diminazene aceturate and eflornithine (lane 4). All 
animals were killed on day 28 o f  the experimental procedure. A known positive control 
(lane 5) and negative control consisting o f  water in place o f template (lane 6) were also 
included in the RT-PCR reaction. All band are o f  a similar intensity thus allowing 
comparisons to be made with regard to the expression levels o f the cytokines and 
chemokines using RT-PCR analyses.
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Figure 5.6. The effect of eflornithine on lL-1a expression in the development 
of a CNS inflammatory reaction.
RT-PCR was performed to detect IL -la  expression, on the mRNA extracted from; mice 
infected with T.b.brucei GVR35/C1.3 DFMO 5.2 and treated on day 21 post-infection with 
diminazene aceturate (40mg/kg i.p.) to induce a CNS inflammatory reaction (lane 1); 
infected animals given a 14-day course o f  2% eflornithine in their drinking water 
beginning at day 14 post-infection and treated with diminazene aceturate on day 21 post­
infection (lane 2); normal uninfected mice (lane 3); and uninfected mice treated with 
diminazene aceturate and eflornithine (lane 4). All animals were killed on day 28 o f  the 
experimental procedure. A known positive control (lane 5) and negative control consisting 
o f water in place o f template (lane 6) were also included in the RT-PCR reaction. IL-a 
expression was detected in all groups o f  mice. Lane 1 shows the strongest PCR band and 
results from the amplification o f mRNA from infected, non-eflomithine treated mice. 
Uninfected animals express IL -la  (lanes 3 & 4) at a much lower level. While infected 
eflornithine treated mice express IL -la  at an intermediated level (lane 2).
t -"1
600bp < •
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Figure 5.7. The effect of eflornithine on IL-6 expression in the development 
of a CNS inflammatory reaction.
RT-PCR was performed to detect IL-6 expression, on the mRNA extracted from; mice 
infected with T.b.brucei GVR35/C1.3 DFMO 5.2 and treated on day 21 post-infection with 
diminazene aceturate (40mg/kg i.p.) to induce a CNS inflammatory reaction (lane 1); 
infected animals given a 14-day course o f  2% eflornithine in their drinking water 
beginning at day 14 post-infection and treated with diminazene aceturate on day 21 post­
infection (lane 2); normal uninfected mice (lane 3); and uninfected mice treated with 
diminazene aceturate and eflornithine (lane 4). All animals were killed on day 28 o f the 
experimental procedure. A known positive control (lane 5) and negative control consisting 
o f water in place o f template (lane 6) were also included in the RT-PCR reaction. The 
PCR bands resulting from the amplification o f mRNA from infected, non-eflomithine 
treated mice can be seen in lane 1. A much weaker band, was present in the animals 
treated with eflomithine, although this image was difficult to capture (lane 2). No IL-6 
expression was seen in uninfected mice (lanes 3 & 4).
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Figure 5.8. The effect of eflornithine on TNF-a expression in the 
development of a CNS inflammatory reaction.
RT-PCR was performed to detect TNF-a expression, on the mRNA extracted from; mice 
infected with T.b.brucei GVR35/C1.3 DFMO 5.2 and treated on day 21 post-infection with 
diminazene aceturate (40mg/kg i.p.) to induce a CNS inflammatory reaction (lane 1); 
infected animals given a 14-day course o f 2% eflomithine in their drinking water 
beginning at day 14 post-infection and treated with diminazene aceturate on day 21 post­
infection (lane 2); normal uninfected mice (lane 3); and uninfected mice treated with 
diminazene aceturate and eflomithine (lane 4). All animals were killed on day 28 o f  the 
experimental procedure. A known positive control (lane 5) and negative control consisting 
o f water in place o f  template (lane 6) were also included in the RT-PCR reaction. The 
PCR bands resulting from the amplification o f mRNA from infected, non-eflomithine 
treated mice and infected animals given eflomithine are o f similar intensity (lanes 1 & 2 
respectively). While, uninfected animals show no TNF-a (lanes 3 & 4) expression.
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Figure 5.9. The effect of eflornithine on MCP-1 expression in the 
development of a CNS inflammatory reaction.
RT-PCR was performed to detect MCP-1 expression, on the mRNA extracted from; mice 
infected with T.b.brucei GVR35/C1.3 DFMO 5.2 and treated on day 21 post-infection with 
diminazene aceturate (40mg/kg i.p.) to induce a CNS inflammatory reaction (lane 1); 
infected animals given a 14-day course o f  2% eflomithine in their drinking water 
beginning at day 14 post-infection and treated with diminazene aceturate on day 21 post­
infection (lane 2); normal uninfected mice (lane 3); and uninfected mice treated with 
diminazene aceturate and eflomithine (lane 4). All animals were killed on day 28 o f  the 
experimental procedure. A known positive control (lane 5) and negative control consisting 
of water in place o f  template (lane 6) were also included in the RT-PCR reaction. MCP-1 
expression was detected in all groups o f mice. The PCR bands resulting from the 
amplification o f mRNA from infected, non-eflomithine treated mice and infected animals 
given eflomithine are o f  similar intensity (lanes 1 & 2 respectively). While, uninfected 
animals showed only an extremely low level o f MCP-1 expression, that was difficult to 
capture on film (lanes 3 & 4).
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Figure 5.10. The effect of eflornithine on MIP-1a expression in the 
development of a CNS inflammatory reaction.
RT-PCR was performed to detect M IP-la expression, on the mRNA extracted from; mice 
infected with T.b.brucei GVR35/C1.3 DFMO 5.2 and treated on day 21 post-infection with 
diminazene aceturate (40mg/kg i.p.) to induce a CNS inflammatory reaction (lane 1); 
infected animals given a 14-day course o f 2% eflomithine in their drinking water 
beginning at day 14 post-infection and treated with diminazene aceturate on day 21 post­
infection (lane 2); normal uninfected mice (lane 3); and uninfected mice treated with 
diminazene aceturate and eflomithine (lane 4). All animals were killed on day 28 o f  the 
experimental procedure. A known positive control (lane 5) and negative control consisting 
of water in place o f  template (lane 6) were also included in the RT-PCR reaction. M IP-la  
expression was detected in all groups o f  mice. The PCR band resulting from the 
amplification o f mRNA from infected, non-eflomithine treated mice was o f  the strongest 
intensity (lane 1). Eflomithine treatment o f uninfected mice resulted in a less intense PCR 
band (lane 2) while uninfected animals expressed M IP-la at a much lower level (lanes 3 &
4).
268
eoobp
R A N T E S
Figure 5.11. The effect of eflornithine on RANTES expression in the 
development of a CNS inflammatory reaction.
RT-PCR was performed to detect RANTES expression, on the mRNA extracted from; 
mice infected with T.b.brucei GVR35/C1.3 DFMO 5.2 and treated on day 21 post­
infection with diminazene aceturate (40mg/kg i.p.) to induce a CNS inflammatory reaction 
(lane 1); infected animals given a 14-day course o f  2% eflomithine in their drinking water 
beginning at day 14 post-infection and treated with diminazene aceturate on day 21 post­
infection (lane 2); normal uninfected mice (lane 3); and uninfected mice treated with 
diminazene aceturate and eflomithine (lane 4). All animals were killed on day 28 o f  the 
experimental procedure. A known positive control (lane 5) and negative control consisting 
o f water in place o f  template (lane 6) were also included in the RT-PCR reaction. 
RANTES expression was detected in all groups o f mice. Both the infected non- 
eflomithine treated (lane 1) and the infected eflomithine treated (lane 2) group o f  mice 
show much higher levels o f RANTES expression than the uninfected animals (lane 3 & 4).
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Infected + eflom ithine
Treatment Groups 
Infected - eflom ithine Uninfected, dm g treated
Experiment 1
M edian 1.75 3.00 1.50
U pper quartile 3.00 3.00 1.50
Lower quartile 1.00 3.00 1.50
M aximum 3.00 3.00 1.50
Minimum 1.00 1.50 1.50
Number 6 3 3
Experiment 2
M edian 1.00 2.50 1.00
Upper quartile 1.50 2.625 *
Lower quartile 1.00 2.00 *
M aximum 1.50 3.00 1.00
M inimum 1.00 2.00 1.00
Number 5 6 1
Experiments 1 & 2
M edian 1.50 2.50 1.50
Upper quartile 2.00 3.00 1.50
Lower quartile 1.00 2.25 1.125
Maximum 3.00 3.00 1.50
Minimum 1.00 2.00 1.00
Number 11 9 4
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Figure 5.12. Summary statistics for iL-1a
The expression level o f  IL-1 a  in mouse brain was assessed in 3 groups o f  mice; infected 
with T.b.brucei GVR35/C1.3 DFMO 5.2 given a 14-day course o f  2% eflomithine in their 
drinking water beginning on day 14 post-infection and treated with diminazene aceturate 
(40mg/kg i.p.) on day 21 post-infection (I+E); infected with T.b.brucei GVR35/C1.3 DFMO
5.2 and treated on day 21 post-infection with diminazene aceturate (40mg/kg i.p.) (I-E); and 
uninfected animals given a 14-day course o f  2% eflomithine in their drinking water 
beginning on day 14 o f the experiment and treated with diminazene aceturate (40mg/kg i.p.) 
on day 21 o f the procedure (UIC). All animals were killed on day 28 o f  the experiment. 
Following RT-PCR analyses the intensity o f the resulting PCR band, as seen on a 2% 
agarose gel stained with ethidium bromide, was taken as an indication o f  the quantity o f IL- 
l a  mRNA present in the initial sample. This was graded on a scale o f  0 to 4 where 0 
indicated no band and 4 indicated an extremely intense PCR band. The analyses o f the data 
from experiment 1 and 2 as well as the combined data from both experiments are shown. 
Summary statistics are given for each group o f animals and the medians o f the combined 
results from experiments 1 and 2 are plotted to indicate any expression trends. * too few 
data points.
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Infected + eflom ithine
Treatment Groups 
Infected - eflom ithine Uninfected, dm g treated
Experiment 1
M edian 0.125 0.50 0.00
Upper quartile 0.25 0.50 0.00
Lower quartile 0.00 0.50 0.00
M aximum 0.25 0.50 0.00
M inimum 0.00 0.50 0.00
Number 6 3 3
Experiment 2
M edian 0.50 1.00 0.00
Upper quartile 0.50 2.25 *
Lower quartile 0.25 0.50 *
M aximum 0.50 3.00 0.00
Minimum 0.25 0.50 0.00
Number 5 6 1
Experiments 1 & 2
Median 0.25 0.50 0.00
Upper quartile 0.50 1.50 0.00
Lower quartile 0.00 0.50 0.00
Maximum 0.50 3.00 0.00
M inimum 0.00 0.50 0.00
Number 11 9 4
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Figure 5.13. Summary statistics for IL-6
The expression level o f IL-6 in mouse brain was assessed in 3 groups o f  mice; infected with 
T.b.brucei GVR35/C1.3 DFMO 5.2 given a 14-day course o f  2% eflomithine in their 
drinking water beginning on day 14 post-infection and treated with diminazene aceturate 
(40mg/kg i.p.) on day 21 post-infection (I+E); infected with T.b.brucei GVR35/C1.3 DFMO
5.2 and treated on day 21 post-infection with diminazene aceturate (40mg/kg i.p.) (I-E); and 
uninfected animals given a 14-day course o f  2% eflomithine in their drinking water 
beginning on day 14 o f  the experiment and treated with diminazene aceturate (40mg/kg i.p.) 
on day 21 o f the procedure (UIC). All animals were killed on day 28 o f the experiment. 
Following RT-PCR analyses the intensity o f  the resulting PCR band, as seen on a 2% 
agarose gel stained with ethidium bromide, was taken as an indication o f  the quantity o f IL- 
6 mRNA present in the initial sample. This was graded on a scale o f 0 to 4 where 0 
indicated no band and 4 indicated an extremely intense PCR band. The analyses o f the data 
from experiment 1 and 2 as well as the combined data from both experiments are shown. 
Summary statistics are given for each group o f animals and the medians o f  the combined 
results from experiments 1 and 2 are plotted to indicate any expression trends. * too few 
data points.
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Infected + eflom ithine
Treatment Groups 
Infected - eflom ithine Uninfected, drug treated
Experiment 1
M edian 1.50 0.50 0.00
Upper quartile 2.00 1.00 0.00
Lower quartile 0.875 0.50 0.00
M aximum 2.00 1.00 0.00
Minimum 0.50 0.00 0.00
Number 6 3 3
Experiment 2
Median 0.50 1.75 0.00
Upper quartile 0.75 3.00 *
Lower quartile 0.375 1.00 *
Maximum 1.00 3.00 0
Minimum 0.25 1.00 0
Number 5 6 I
Experiments 1 & 2
Median 1.00 1.00 0.00
Upper quartile 2.00 2.50 0.00
Lower quartile 0.50 0.75 0.00
Maximum 2.00 3.00 0.00
Minimum 0.25 0.50 3.00
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Figure 5.14. Summary statistics for TNF-a
The expression level o f TNF-a in mouse brain was assessed in 3 groups o f mice; infected 
with T.b.brucei GVR35/C1.3 DFMO 5.2 given a 14-day course o f  2% eflomithine in their 
drinking water beginning on day 14 post-infection and treated with diminazene aceturate 
(40mg/kg i.p.) on day 21 post-infection (I+E); infected with T.b.brucei GVR35/C1.3 DFMO
5.2 and treated on day 21 post-infection with diminazene aceturate (40mg/kg i.p.) (I-E); and 
uninfected animals given a 14-day course o f 2% eflomithine in their drinking water 
beginning on day 14 o f the experiment and treated with diminazene aceturate (40mg/kg i.p.) 
on day 21 o f  the procedure (UIC). All animals were killed on day 28 o f the experiment. 
Following RT-PCR analyses the intensity o f  the resulting PCR band, as seen on a 2% 
agarose gel stained with ethidium bromide, was taken as an indication o f the quantity o f  
TNF-a mRNA present in the initial sample. This was graded on a scale o f 0 to 4 where 0 
indicated no band and 4 indicated an extremely intense PCR band. The analyses o f  the data 
from experiment 1 and 2 as well as the combined data from both experiments are shown. 
Summary statistics are given for each group o f animals and the medians o f the combined 
results from experiments 1 and 2 are plotted to indicate any expression trends. * too few 
data points.
272
Infected + eflom ithine
Treatment Groups 
Infected - eflomitiiine Uninfected, drug treated
Experiment I
M edian 2.00 1.50 0.25
Upper quartile 2.625 2.00 0.50
Lower quartile 1.00 1.00 0.50
M aximum 3.00 2.00 0.50
Minimum 1.00 1.00 0.00
Number 6 3 3
Experiment 2
M edian 1.50 1.25 0
Upper quartile 1.50 1.625 *
Lower quartile 0.75 0.875 *
M aximum 1.50 2.00 0
Minimum 0.50 0.50 0
Number 5 6 I
Experiments I & 2
M edian 1.50 1.50 0.125
Upper quartile 2.00 1.75 0.438
Lower quartile 1.00 1.00 0.00
M aximum 3.00 2.00 0.50
M inimum 0.50 0.50 0.00
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Figure 5.15. Summary statistics for MCP-1
The expression level o f MCP-1 in mouse brain was assessed in 3 groups o f mice; infected 
with T.b.brucei GVR35/C1.3 DFMO 5.2 given a 14-day course o f 2% eflomithine in their 
drinking water beginning on day 14 post-infection and treated with diminazene aceturate 
(40mg/kg i.p.) on day 21 post-infection (I+E); infected with T.b.brucei GVR35/C1.3 DFMO
5.2 and treated on day 21 post-infection with diminazene aceturate (40mg/kg i.p.) (I-E); and 
uninfected animals given a 14-day course o f  2% eflomithine in their drinking water 
beginning on day 14 o f the experiment and treated with diminazene aceturate (40mg/kg i.p.) 
on day 21 o f the procedure (UIC). All animals were killed on day 28 o f the experiment. 
Following RT-PCR analyses the intensity o f the resulting PCR band, as seen on a 2% 
agarose gel stained with ethidium bromide, was taken as an indication o f the quantity o f  
MCP-1 mRNA present in the initial sample. This was graded on a scale o f 0 to 4 where 0 
indicated no band and 4 indicated an extremely intense PCR band. The analyses o f the data 
from experiment 1 and 2 as well as the combined data from both experiments are shown. 
Summary statistics are given for each group o f animals and the medians o f the combined 
results from experiments 1 and 2 are plotted to indicate any expression trends. * too few 
data points.
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Infected + eflom ithine
Treatment Groups 
Infected - eflom ithine Uninfected, drug treated
Experiment 1
M edian 1.00 1.50 1.00
U pper quartile 1.50 2.00 2.00
Lower quartile 0.875 1.50 0.00
M aximum 1.50 2.00 2.00
M inimum 0.50 1.50 0.00
N umber 6 3 3
Experiment 2
M edian 1.50 2.00 0.00
Upper quartile 1.75 3.00 *
Lower quartile 0.75 1.50 *
M aximum 2.00 3.00 0
Minimum 0.50 1.50 0
N um ber 5 6 I
Experiments 1 & 2
M edian 1.00 1.50 0.50
U pper quartile 1.50 2.75 1.75
Lower quartile 1.00 1.50 0.00
M aximum 2.00 3.00 2.00
M inimum 0.50 1.50 0.00
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Figure 5.16. Summary statistics for MIP-1 a
The expression level o f MIP-1 a  in mouse brain was assessed in 3 groups o f mice; infected 
with T.b.brucei GVR35/C1.3 DFMO 5.2 given a 14-day course o f  2% eflomithine in their 
drinking water beginning on day 14 post-infection and treated with diminazene aceturate 
(40mg/kg i.p.) on day 21 post-infection (I+E); infected with T.b.brucei GVR35/C1.3 
DFMO 5.2 and treated on day 21 post-infection with diminazene aceturate (40mg/kg i.p.) 
(I-E); and uninfected animals given a 14-day course o f 2% eflomithine in their drinking 
water beginning on day 14 o f  the experiment and treated with diminazene aceturate 
(40mg/kg i.p.) on day 21 o f  the procedure (UIC). All animals were killed on day 28 o f  the 
experiment. Following RT-PCR analyses the intensity o f  the resulting PCR band, as seen 
on a 2% agarose gel stained with ethidium bromide, was taken as an indication o f the 
quantity o f  M IP-la mRNA present in the initial sample. This was graded on a scale o f 0 
to 4 where 0 indicated no band and 4 indicated an extremely intense PCR band. The 
analyses o f the data from experiment 1 and 2 as well as the combined data from both 
experiments are shown. Summary statistics are given for each group o f animals and the 
medians o f the combined results from experiments 1 and 2 are plotted to indicate any 
expression trends. * too few data points.
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Infected + eflom ithine
Treatment Groups 
Infected - eflom ithine Uninfected, dm g treated
Experiment 1
M edian 1.50 2.5G LOG
Upper quartile 1.625 2.5G I.GG
Lower quartile I.GO I.5G G.GG
M aximum I.GO I.5G G.GG
M inimum LOG I.5G G.GG
N um ber 6 3 3
Experiment 2
M edian 3.GG 3.GG G.5G
Upper quartile 3.GG 3.GG *
Lower quartile 3.GG 2.875 *
Maximum 3.GG 3.GG G.5G
Minimum 3.GG 2.G5 G.5G
Number 5 6 I
Experiments 1 & 2
M edian 2.GG 3.GG G.75
U pper quartile 3.GG 3.GG I.GG
Lower quartile I.5G 2.5G G.I25
M aximum 3.GG 3.GG I.GG
Minimum LOG I.5G G.GG
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Figure 5.17. Summary statistics for RANTES
The expression level o f RANTES in mouse brain was assessed in 3 groups o f mice; 
infected with T.b.brucei GVR35/C1.3 DFMO 5.2 given a 14-day course o f  2% eflomithine 
in their drinking water beginning on day 14 post-infection and treated with diminazene 
aceturate (40mg/kg i.p.) on day 21 post-infection (I+E); infected with T.b.brucei 
GVR35/C1.3 DFMO 5,2 and treated on day 21 post-infection with diminazene aceturate 
(40mg/kg i.p.) (I-E); and uninfected animals given a 14-day course o f  2% eflomithine in 
their drinking water beginning on day 14 o f the experiment and treated with diminazene 
aceturate (40mg/kg i.p.) on day 21 o f the procedure (UIC). All animals were killed on day 
28 o f the experiment. Following RT-PCR analyses the intensity o f  the resulting PCR band, 
as seen on a 2% agarose gel stained with ethidium bromide, was taken as an indication o f  
the quantity o f RANTES mRNA present in the initial sample. This was graded on a scale 
o f 0 to 4 where 0 indicated no band and 4 indicated an extremely intense PCR band. The 
analyses o f  the data from experiment 1 and 2 as well as the combined data from both 
experiments are shown. Summary statistics are given for each group o f  animals and the 
medians o f the combined results from experiments 1 and 2 are plotted to indicate any 
expression trends. * too few data points.
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Figure 5.18. p-actln check gel for groups of animals used to study the effect 
of eflomithine in the amelioration of a meningoencephalitis.
To ensure the mRNA extracted from each group o f animals was o f similar quality, 
amplification o f the mRNA for housekeeping gene P-actin was carried out. RT-PCR 
analyses was performed on the mRNA extracted from; mice infected with T.b.brucei 
GVR35/C1.3 DFMO 5.2 treated with diminazene aceturate on day 21 post-infection and 
again on relapse to parasitaemia and killed either 14 or 21 days later (lane 1); infected 
animals treated with two diminazene aceturate doses and given a 7-day course o f 2% 
eflomithine in their drinking water beginning 7 days after the administration o f the second 
diminazene aceturate (lane 2); infected animals treated with two diminazene aceturate 
doses and given a 14-day course o f eflomithine beginning 7 days after the administration o f  
the second diminazene aceturate (lane 3); normal uninfected animals (lane 4); and 
uninfected animals treated with diminazene aceturate and eflomithine (lane 5). A known 
positive control (lane 6) and a negative control consisting o f  water in place o f  template 
(lane 7) were also included in the RT-PCR reaction. All bands are o f a similar intensity 
thus allowing comparisons to be made with regard to the levels o f  cytokine and chemkine 
expression using the RT-PCR technique.
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Figure 5.19. The effect of eflomithine treatment on the expression of IL-1 a  in 
the amelioration of a meningoencephalitic reaction.
RT-PCR was performed, to detect IL-1 a  expression, on the mRNA extracted from; mice 
infected with T.b.brucei GVR35/C1.3 DFMO 5.2 treated with diminazene aceturate on day 
21 post-infection and again on relapse to parasitaemia and killed either 14 or 21 days later 
(lane 1); infected animals treated with two diminazene aceturate doses and given a 7-day 
course o f 2% eflomithine in their drinking water beginning 7 days after the administration 
of the second diminazene aceturate (lane 2); infected animals treated with two diminazene 
aceturate doses and given a 14-day course o f eflomithine beginning 7 days after the 
administration o f the second diminazene aceturate (lane 3); normal uninfected animals 
(lane 4); and uninfected animals treated with diminazene aceturate and eflomithine (lane 
5). A known positive control (lane 6) and a negative control consisting o f water in place o f  
template (lane 7) were also included in the RT-PCR reaction. IL-1 a  expression was 
detected in all groups o f animals. The infected groups o f mice (lanes 1-3) showed similar 
expression levels regardless o f treatment regimen.
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Figure 5.20. The effect of eflomithine treatment on the expression of IL-6 in 
the amelioration of a meningoencephalitic reaction.
RT-PCR was performed, to detect IL-6 expression, on the mRNA extracted from; mice 
infected with T.b.brucei GVR35/C1.3 DFMO 5.2 treated with diminazene aceturate on day 
21 post-infection and again on relapse to parasitaemia and killed either 14 or 21 days later 
(lane 1); infected animals treated with two diminazene aceturate doses and given a 7-day 
course o f 2% eflomithine in their drinking water beginning 7 days after the administration 
of the second diminazene aceturate (lane 2); infected animals treated with two diminazene 
aceturate doses and given a 14-day course o f  eflomithine beginning 7 days after the 
administration o f  the second diminazene aceturate (lane 3); normal uninfected animals 
(lane 4); and uninfected animals treated with diminazene aceturate and eflomithine (lane 
5). A known positive control (lane 6) and a negative control consisting o f water in place o f  
template (lane 7) were also included in the RT-PCR reaction. No IL-6 expression was 
detected in uninfected animals (lanes 4 & 5). Infected non-eflomithine treated mice (lane 
1) show a slightly stronger PCR band than either o f the eflomithine treated groups o f  
animals (lanes 2 & 3).
600bp
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Figure 5.21. The effect of eflomithine treatment on the expression of TNF-a 
in the ameiioration of a meningoencephaiitic reaction.
RT-PCR was performed, to detect TNF-a expression, on the mRNA extracted from; mice 
infected with T.b.brucei GVR35/C1.3 DFMO 5.2 treated with diminazene aceturate on day 
21 post-infection and again on relapse to parasitaemia and killed either 14 or 21 days later 
(lane 1); infected animals treated with two diminazene aceturate doses and given a 7-day 
course o f 2% eflomithine in their drinking water beginning 7 days after the administration 
of the second diminazene aceturate (lane 2); infected animals treated with two diminazene 
aceturate doses and given a 14-day course o f  eflomithine beginning 7 days after the 
administration o f the second diminazene aceturate (lane 3); normal uninfected animals 
(lane 4); and uninfected animals treated with diminazene aceturate and eflomithine (lane 
5). A known positive control (lane 6) and a negative control consisting o f  water in place o f  
template (lane 7) were also included in the RT-PCR reaction. Similar levels o f TNF-a 
expression were seen in all groups o f  infected mice (lanes 1-3). TNF-a expression was 
detected in uninfected animals although at a much lower level (lanes 4 & 5).
600bp
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Figure 5.22. The effect of eflomithine treatment on the expression of MCP-1 
in the amelioration of a meningoencephalitic reaction.
RT-PCR was performed, to detect MCP-1 expression, on the mRNA extracted from; mice 
infected with T.b.brucei GVR35/C1.3 DFMO 5.2 treated with diminazene aceturate on day 
21 post-infection and again on relapse to parasitaemia and killed either 14 or 21 days later 
(lane 1); infected animals treated with two diminazene aceturate doses and given a 7-day 
course o f  2% eflomithine in their drinking water beginning 7 days after the administration 
o f the second diminazene aceturate (lane 2); infected animals treated with two diminazene 
aceturate doses and given a 14-day course o f  eflomithine beginning 7 days after the 
administration o f the second diminazene aceturate (lane 3); normal uninfected animals 
(lane 4); and uninfected animals treated with diminazene aceturate and eflomithine (lane 
5). A known positive control (lane 6) and a negative control consisting o f water in place o f  
template (lane 7) were also included in the RT-PCR reaction. MCP-1 expression was 
detected in all animals. No differences in the expression levels were seen between the 
infected non-eflomithine (lane 1) and the infected eflomithine treated groups (lanes 2 & 3). 
Uninfected animals showed the lowest levels o f  MCP-1 expression (lanes 4 & 5).
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Figure 5.23. The effect of eflomithine treatment on the expression of MIP-1 a  
in the amelioration of a meningoencephalitic reaction.
RT-PCR was performed, to detect M IP-la expression, on the mRNA extracted from; mice 
infected with T.b.brucei GVR35/C1.3 DFMO 5.2 treated with diminazene aceturate on day 
21 post-infection and again on relapse to parasitaemia and killed either 14 or 21 days later 
(lane 1); infected animals treated with two diminazene aceturate doses and given a 7-day 
course o f 2% eflomithine in their drinking water beginning 7 days after the administration 
o f the second diminazene aceturate (lane 2); infected animals treated with two diminazene 
aceturate doses and given a 14-day course o f eflomithine beginning 7 days after the 
administration o f the second diminazene aceturate (lane 3); normal uninfected animals 
(lane 4); and uninfected animals treated with diminazene aceturate and eflomithine (lane
5). A known positive control (lane 6) and a negative control consisting o f water in place o f  
template (lane 7) were also included in the RT-PCR reaction. M IP-la was detected in all 
groups o f mice. Uninfected animals (lanes 4 & 5) showed the weakest bands whereas 
infected non-eflomithine treated mice expressed higher levels o f  the chemokine (lane 1). 
Eflomithine treatment o f  infected mice resulted in a slight decrease in the intensity o f  MIP- 
l a  expression (lanes 2 & 3).
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Figure 5.24. The effect of eflomithine treatment on the expression of 
RANTES in the amelioration of a meningoencephalitic reaction.
RT-PCR was performed, to detect RANTES expression, on the mRNA extracted from; 
mice infected with T.b.brucei GVR35/C1.3 DFMO 5.2 treated with diminazene aceturate 
on day 21 post-infection and again on relapse to parasitaemia and killed either 14 or 21 
days later (lane 1); infected animals treated with two diminazene aceturate doses and given 
a 7-day course o f  2% eflomithine in their drinking water beginning 7 days after the 
administration o f  the second diminazene aceturate (lane 2); infected animals treated with 
two diminazene aceturate doses and given a 14-day course o f  eflomithine beginning 7 days 
after the administration o f  the second diminazene aceturate (lane 3); normal uninfected 
animals (lane 4); and uninfected animals treated with diminazene aceturate and eflomithine 
(lane 5). A known positive control (lane 6) and a negative control consisting o f  water in 
place o f template (lane 7) were also included in the RT-PCR reaction. RANTES was 
expressed in samples from all groups o f  mice. Higher levels o f  RANTES mRNA were 
found in infected mice (lanes 1-3) compared with uninfected animals (lanes 4 & 5).
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Experiment 1
I+E7 I+E 14 I-E I I-E2 UIC
M edian 3.00 2.00 2.00 2.25 2.75
U pper quartile 3.00 3.00 * * 3.00
Lower quartile 1.25 1.75 * * 1.75
Maximum 3.00 3.00 2.00 3.00 3.00
Minimum 1.00 1.50 2.00 1.50 1.00
Number 5 5 1 2 6
Experiment 2
M edian 2.25 3.00 2.50 2.75 1.75
Upper quartile 2.875 3.00 * * 2.00
Lower quartile 2.00 2.25 * * 1.50
M aximum 3.00 3.00 3.00 3.00 2.00
Minimum 2.00 2.00 2.00 2.50 1.50
Number 4 4 2 2 4
Experiment 3
M edian 3.00 3.00 3.00 2.75 NA
Upper quartile 3.00 3.00 3.00 3.00 NA
Lower quartile 2.50 2.00 2.50 2.125 NA
M aximum 3.00 3.00 3.00 3.00 NA
M inimum 2.50 2.00 2.50 2.00 NA
Number 3 3 3 4 NA
Experiments 1, 2 & 3
M edian 2.75 3.00 2.75 2.75 2.00
Upper quartile 3.00 3.00 3.00 3.00 3.00
Lower quartile 2.00 2.00 2.00 2.125 1.50
M aximum 3.00 3.00 3.00 3.00 3.00
M inimum 1.00 1.50 2.00 1.50 1.00
Number 12 12 6 8 10
IL-1 EXPRESSION PATTERN
i i i i i
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Figure 5.25. Summary statistics for IL-1 a
The expression level o f  IL-1 a  in mouse brain was assessed in 5 groups o f mice; infected 
with T.b.brucei GVR 35/C 1.3 DFMO 5.2 and treated on day 21 post-infection with 
diminazene aceturate (40mg/kg i.p.) and again on relapse to parasitaemia given, a 7 (I+E7) 
or 14 (I+E 14) day course o f 2% eflomithine in their drinking water beginning 7-days after 
the second diminazene aceturate treatment; infected animals treated with both doses o f  
diminazene aceturate and killed 14 (I-El) or 21 (I-E2) days later; and uninfected animals 
treated with diminazene aceturate and eflomithine (UIC). Following RT-PCR analyses the 
intensity o f  the resultant PCR band was graded on a scale o f  0 to 4 where 0 indicated no 
band and 4 indicated an extremely intense band. The analyses o f  the data from the 3 
individual experiments as well as the combined results are shown. Summary statistics are 
given for each group o f animals and the medians o f the combined results plotted to indicate 
any expression trends. NA; not assessed, * too few data points.
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Experiment 1
I+E7 I+E 14 I-E l I-E2 UIC
M edian 1.00 1.00 1.00 0.625 0.00
U pper quartile 1.00 1.00 * * 0.00
Lower quartile 0.25 0.375 * * 0.00
M aximum 1.00 1.00 1.00 1.00 0.00
Minimum 0.00 0.25 1.00 0.25 0.00
Num ber 5 5 1 2 6
Experiment 2
M edian 2.00 1.75 1.50 2.00 0.00
U pper quartile 2.00 2.00 * * 0.00
Lower quartile 1.625 1.50 * * 0.00
Maximum 2.00 2.00 2.00 2.50 0.00
M inimum 1.50 1.50 1.00 1.50 0.00
Number 4 4 2 2 4
Experiment 3
M edian 1.00 1.00 0.50 1,50 NA
U pper quartile 2.50 2.00 2.50 2.75 NA
Lower quartile 0.50 0.50 0.50 0.625 NA
M aximum 2.50 2.00 2.50 3.00 NA
M inimum 0.50 0.50 0.50 0.50 NA
Number 3 3 3 4 NA
Experiments 1, 2 & 3
M edian 1.00 1.00 1.00 1.25 0.00
U pper quartile 2.00 1.875 2.125 2.375 0.00
Lower quartile 0.625 0.625 0.50 0.625 0.00
M aximum 2.50 2.00 2.50 3.00 0.00
Minimum 0.00 0.25 0.50 0.25 0.00
Number 12 12 6 8 10
1.4
1.201 ^a: 0.8 Ü^ 0.6 
% 0.4
2  0.2
0
IL-6 EXPRESSION PATTERN
I+E7 I+E 14 I-E1 I-E2
Treatment Group
UIC
Figure 5.26. Summary statistics for IL-6
The expression level o f IL-6 in mouse brain was assessed in 5 groups o f mice; infected 
with T.b.brucei GVR 35/C 1.3 DFMO 5.2 and treated on day 21 post-infection with 
diminazene aceturate (40mg/kg i.p.) and again on relapse to parasitaemia given, a 7 (I+E7) 
or 14 (I+E 14) day course o f 2% eflomithine in their drinking water beginning 7-days after 
the second diminazene aceturate treatment; infected animals treated with both doses o f  
diminazene aceturate and killed 14 (I-El) or 21 (I-E2) days later; and uninfected animals 
treated with diminazene aceturate and eflomithine (UIC). Following RT-PCR analyses the 
intensity o f the resultant PCR band was graded on a scale o f 0 to 4 where 0 indicated no 
band and 4 indicated an extremely intense band. The analyses o f  the data from the 3 
individual experiments as well as the combined results are shown. Summary statistics are 
given for each group o f animals and the medians o f the combined results plotted to indicate 
any expression trends. NA; not assessed, * too few data points.
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Experiment 1
I+E7 I+E 14 I-E l I-E2 UIC
M edian 1.50 2.00 3.00 1.00 0.00
U pper quartile 3.00 2.250 * * 0.125
Lower quartile 0.50 1.25 * * 0.00
M aximum 3.00 2.50 3.00 2.00 0.50
Minimum 0.00 0.50 3.00 0.00 0.00
Number 5 5 1 2 6
Experiment 2
M edian 2.00 2.00 1.25 1.75 0.50
Upper quartile 2.375 2.00 * * 0.50
Lower quartile 2.00 1.625 * * 0.3125
Maximum 2.50 2.00 1.50 2.00 0.50
Minimum 2.00 1.50 1.00 1.50 0.25
Number 4 4 2 2 4
Experiment 3
Median 1.00 1.00 1.00 1.50 NA
Upper quartile 2.00 3.00 2.00 3.00 NA
Lower quartile 1.00 1.00 0.00 0.00 NA
Maximum 2.00 3.00 2.00 3.00 NA
Minimum 1.00 1.00 0.00 0.00 NA
Number 3 3 3 4 NA
Experiments 1, 2 & 3
M edian 2.00 2.00 1.250 1.75 0.125
Upper quartile 2.375 2.00 2.25 2.75 0.50
Lower quartile 1.00 1.125 0.75 0.00 0.00
Maximum 3.00 3.00 3.00 3.00 0.50
Minimum 0.00 0.50 0.00 0.00 0.00
Number 12 12 6 8 10
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Figure 5.27. Summary statistics for TNF-a
The expression level o f IL-6 in mouse brain was assessed in 5 groups o f mice; infected 
with T.b.brucei GVR 35/C l.3 DFMO 5.2 and treated on day 21 post-infection with 
diminazene aceturate (40mg/kg i.p.) and again on relapse to parasitaemia given, a 7 (I+E7) 
or 14 (I+E 14) day course o f 2% eflomithine in their drinking water beginning 7-days after 
the second diminazene aceturate treatment; infected animals treated with both doses o f  
diminazene aceturate and killed 14 (I-El) or 21 (I-E2) days later; and uninfected animals 
treated with diminazene aceturate and eflomithine (UIC). Following RT-PCR analyses the 
intensity o f  the resultant PCR band was graded on a scale o f  0 to 4 where 0 indicated no 
band and 4 indicated an extremely intense band. The analyses o f  the data from the 3 
individual experiments as well as the combined results are shown. Summary statistics are 
given for each group o f animals and the medians o f  the combined results plotted to indicate 
any expression trends. NA; not assessed, * too few data points.
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Experiment 1
I+E7 I+E 14 I-E l I-E2 UIC
M edian 2.00 2.00 3.00 0.875 0.625
Upper quartile 2.50 2.25 * * 1.25
Lower quartile 1.00 1.75 * * 0.00
M aximum 3.00 2.50 3.00 1.50 2.00
M inimum 0.00 1.50 3.00 0.25 0.00
Number 5 5 1 2 6
Experiment 2
M edian 1.25 2.25 1.25 1.50 1.50
U pper quartile 1.50 2.875 * * 2.00
Lower quartile 1.00 2.00 * * 1.00
M aximum 1.50 3.00 1.50 1.50 2.00
M inimum 1.00 2.00 1.00 1.50 1.00
Number 4 4 2 2 4
Experiment 3
M edian 2.00 1.00 0.25 1.25 NA
Upper quartile 2.00 2.50 3.00 2.875 NA
Lower quartile 1.00 1.00 0.00 0.00 NA
M aximum 2.00 2.50 3.00 3.00 NA
Minimum 1.00 1.00 0.00 0.00 NA
Number 3 3 3 4 NA
Experiments 1, 2 & 3
M edian 1.75 2.00 1.25 1.50 1.00
Upper quartile 2.00 2.50 3.00 2.25 2.00
Lower quartile 1.00 1.625 1.888 0.063 0.188
Maximum 3.00 3.00 3.00 3.00 2.00
Minimum 0.00 1.00 0.00 0.00 0.00
Number 12 12 6 8 10
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Figure 5.28. Summary statistics for MCP-1
The expression level o f MCP-1 in mouse brain was assessed in 5 groups o f mice; infected 
with T.b.brucei GVR 35/C l.3 DFMO 5.2 and treated on day 21 post-infection with 
diminazene aceturate (40mg/kg i.p.) and again on relapse to parasitaemia given, a 7 (I+E7) 
or 14 (I+E 14) day course o f 2% eflomithine in their drinking water beginning 7-days after 
the second diminazene aceturate treatment; infected animals treated with both doses o f 
diminazene aceturate and killed 14 (I-El) or 21 (I-E2) days later; and uninfected animals 
treated with diminazene aceturate and eflomithine (UIC). Following RT-PCR analyses the 
intensity o f  the resultant PCR band was graded on a scale o f 0 to 4 where 0 indicated no 
band and 4 indicated an extremely intense band. The analyses o f  the data from the 3 
individual experiments as well as the combined results are shown. Summary statistics are 
given for each group o f  animals and the medians o f the combined results plotted to indicate 
any expression trends. NA; not assessed, * too few data points.
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Experiment 1
I+E7 I+E14 I-E l I-E2 UIC
M edian 1.00 0.50 3.00 1.75 0.125
U pper quartile 1.00 1.50 * * *
Lower quartile 0.50 0.25 * * *
Maximum 1.00 2.00 3.00 2.00 0.25
Minimum 0.00 0.00 3.00 1.50 0.00
Number 5 5 1 2 2
Experiment 2
M edian 1.25 2.00 3.00 3.00 0.75
Upper quartile 1.875 2.50 * * 1.375
Lower quartile 0.625 0.75 * * 0.313
Maximum 2.00 2.50 3.00 3.00 1.50
Minimum 0.50 0.50 3.00 3.00 0.25
Number 4 4 2 2 4
Experiment 3
M edian 3.00 1.50 2.00 2.00 NA
Upper quartile 3.00 2.50 2.50 2.375 NA
Lower quartile 2.50 1.50 1.50 1.625 NA
M aximum 3.00 2.50 2.50 2.50 NA
M inimum 2.50 1.50 1.50 1.50 NA
Number 3 3 3 4 NA
Experiments 1, 2 & 3
M edian 1.00 1.50 2.75 2.00 0.375
Upper quartile 2.375 2.375 3.00 2.875 1.125
Lower quartile 1.00 0.50 1.875 1.625 0.188
M aximum 3.00 2.50 3.00 3.00 1.50
M inimum 0.00 0.00 1.50 1.50 0.00
Num ber 12 12 6 8 6
MIP-1 EXPRESSION PATTERN
3
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Figure 5.29. Summary statistics for MIP-a
The expression level o f M IP-la in mouse brain was assessed in 5 groups o f mice; infected 
with T.b.brucei GVR 35/C l.3 DFMO 5.2 and treated on day 21 post-infection with 
diminazene aceturate (40mg/kg i.p.) and again on relapse to parasitaemia given, a 7 (I+E7) 
or 14 (I+E 14) day course o f  2% eflomithine in their drinking water beginning 7-days after 
the second diminazene aceturate treatment; infected animals treated with both doses o f  
diminazene aceturate and killed 14 (I-El) or 21 (I-E2) days later; and uninfected animals 
treated with diminazene aceturate and eflomithine (UIC). Following RT-PCR analyses the 
intensity o f the resultant PCR band was graded on a scale o f  0 to 4 where 0 indicated no 
band and 4 indicated an extremely intense band. The analyses o f  the data from the 3 
individual experiments as well as the combined results are shown. Summary statistics are 
given for each group o f animals and the medians o f the combined results plotted to indicate 
any expression trends. NA; not assessed, * too few data points.
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Experiment 1
I+E7 I+E 14 I-E l I-E2 UIC
M edian 3.00 3.00 2.00 2.00 1.50
Upper quartile 3.00 3.00 * * 1.75
Lower quartile 2.25 2.25 * * 1.00
M aximum 3.00 3.00 2.00 3.00 2.50
Minimum 2.00 2.00 2.00 1.00 1.00
Number 5 5 1 2 6
Experiment 2
M edian 2.50 1.50 1.25 1.50 1.50
Upper quartile 2.875 2.00 * * 2.00
Lower quartile 2.50 1.00 * * 1.00
M aximum 3.00 2.00 1.50 1.50 2.00
Minimum 2.50 1.00 1.00 1.50 1.00
Number 4 4 2 2 4
Experiment 3
M edian 3.00 2.00 3.00 1.50 NA
U pper quartile 3.00 2.50 3.00 2.75 NA
Lower quartile 3.00 2.00 1.00 0.625 NA
Maximum 3.00 2.50 3.00 3.00 NA
M inimum 3.00 2.00 1.00 0.50 NA
Number 3 3 3 4 NA
Experiments 1, 2 & 3
M edian 3.00 2.00 1.75 1.50 1.50
Upper quartile 3.00 3.00 3.00 2.75 2.00
Lower quartile 2.50 2.00 1.00 1.00 1.00
Maximum 3.00 3.00 3.00 3.00 2.50
Minimum 2.00 1.00 1.00 0.50 1.00
Number 12 12 6 8 10
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Figure 5.30. Summary statistics for RANTES
The expression level o f RANTES in mouse brain was assessed in 5 groups o f mice; 
infected with T.b.brucei GVR 35/C l.3 DFMO 5.2 and treated on day 21 post-infection 
with diminazene aceturate (40mg/kg i.p.) and again on relapse to parasitaemia given, a 7 
(I+E7) or 14 (I+E 14) day course o f 2% eflomithine in their drinking water beginning 7- 
days after the second diminazene aceturate treatment; infected animals treated with both 
doses o f diminazene aceturate and killed 14 (I-El) or 21 (I-E2) days later; and uninfected 
animals treated with diminazene aceturate and eflomithine (UIC). Following RT-PCR 
analyses the intensity o f the resultant PCR band was graded on a scale o f  0 to 4 where 0 
indicated no band and 4 indicated an extremely intense band. The analyses o f  the data 
from the 3 individual experiments as well as the combined results are shown. Summary 
statistics are given for each ^oup o f animals and the medians o f  the combined results 
plotted to indicate any expression trends. NA; not assessed, * too few data points.
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5.4. Discussion
5.4.1. Eflomithine in the prevention of CNS 
infiammation
In the current study histological assessment of brain sections prepared from mice infected 
with eflornithine-resistant T.b.brucei showed the presence of mild inflammatory changes 
characterised by the infiltration of the meninges and ventricle with a few lymphocytes and 
macrophages and the development of perivascular cuffing around the occasional blood 
vessel. A reduction in the level of this inflammatory reaction was seen in the brains of 
mice treated with a course of 2 % eflomithine in their drinking water, beginning 7-days 
prior to the induction of the CNS inflammatory response by subcurative diminazene 
aceturate treatment. In these animals only a few infiltrating cells were seen and no cuffs 
were found. A reduction in the degree of astrogliosis was also observed in the mice 
receiving eflomithine treatment. These findings confirm those published previously 
(Jennings et al, 1997). In this study eflomithine treatment, when given prior to the 
exacerbation of the CNS response was shown to reduce the severity of the resultant 
neuroinflammatory reaction and associated astrogliosis. The findings of both 
investigations suggest that eflomithine has an anti-inflammatory action that can help to 
prevent the progress of a CNS inflammatory response irrespective of the effect of the dmg 
on the parasite.
Although this reduction in pathology could be gauged by histological examination, the 
anti-inflammatory effect was not found to be significant when analysed using statistical 
methods. This finding could reflect insufficient sensitivity in the grading scale used to 
score the slides when applied to assess sections displaying only mild inflammatory 
changes. The changes associated with a very early CNS reaction can be easily identified 
and a grade of 1 assigned to the section. The point at which this score rises to an 
intermediate grade 1.5 or a grade 2 is more subjective. This variation would enlarge the 
standard error of the mean score for these mice and make significant differences harder to 
detect. Increasing the number of animals included in this investigation and the statistical 
power of the study may have helped to clarify this point.
Since trypanosome infection can stimulate the production of IL-1 a , IL- 6  and TNF-a as 
well as MCP-1, M IP-la and RANTES, within the CNS (Hunter et al, 1991; Sharafeldin et
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al, 2 0 0 0 ) it would be logical to assume that one possible mechanism by which eflomithine 
could achieve its anti-inflammatory effect would be through inhibition of the production of 
these pro-inflammatory agents. In this study a semi-quantitative method of assessing the 
expression of these cytokines and chemokines, involving the use of RT-PCR analyses to 
detect specific mRNA transcripts, was employed. The results showed that following 
eflomithine treatment the transcription of IL-1 a  and IL- 6  was lowered significantly 
compared with non-eflornithine treated trypanosome infected groups of mice. M IP-la and 
RANTES expression was also decreased, but this reduction could not be considered 
significant. No change in the production of either TNF-a or MCP-1 was detected 
following eflomithine administration.
IL-1 a  is a cytokine that is commonly produced in response to injury and immunological 
challenge. Its plays a primarily pro-inflammatory role in the immune response and its 
local expression can lead to the migration of inflammatory cells to the site of its 
production. It is unclear whether this chemotactic action is a direct effect of the cytokine 
or a secondary effect brought about by the ability of IL-a to stimulate the synthesis of 
chemokines. The corresponding reduction in the levels of the chemokines M IP-la and 
RANTES found in the CNS following eflomithine administration could therefore be a 
reflection of the alteration in IE -la  expression. Treatment of experimental allergic 
encephalomyelitis (EAE), the animal model of multiple sclerosis (MS), with anti-MIP-la 
antibodies has been shown to shown to inhibit the development of the acute stage of the 
disease and it has been suggested that this chemokine controls monocyte recmitment 
during the developmental phase of EAE (Bajetto et al, 2001; Glabinski and Ransohoff, 
1999b). Similarly, RANTES is known to attract lymphocytes and monocytes to sites of 
inflammation (Vaddi et a l, 1997) and has been implicated in the pathogenesis of a range 
of CNS inflammatory disorders including, MS, Alzheimer’s disease, stroke and cerebral 
lupus (Appay and Rowland-Jones, 2001; De Groot and Woodroofe, 2001). Therefore, the 
reduction in IE -la levels precipitated by eflomithine treatment could help to diminish the 
CNS inflammatory response, resulting from trypanosome infection and subcurative drug 
treatment, by reducing the chemoattractant signal that initiates inflammatory cell migration 
and infiltration.
The pro-inflammatory properties of IL-1 within the CNS have been demonstrated by 
investigations administrating the IL-1 receptor antagonist (IE-Ira), a naturally occurring 
antagonist that blocks the actions of IL-1 by binding non-productively with IL-1 receptors, 
to mice following induction of cerebral ischaemic injury. Treatment of these animals with
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IL-Ira was shown to reduce the levels of oedema and glial cell activation associated with 
this type of CNS damage. The reduction in astrocyte activation that occurs following 
eflomithine treatment of trypanosome infected mice, could therefore result from the ability 
of eflomithine to significantly reduce the production of IL-1 a  as seen in this study.
IL-1 a  often controls the synthesis of IL- 6  (Dinarello, 1998); it is therefore possible that the 
reduction in the expression level of IL- 6  precipitated by eflomithine treatment is a direct 
effect of the lowered IL-1 a  production. On the other hand, since lymphocytes, 
macrophages and astrocytes are all capable of synthesising IL- 6  (Oppenlieim and 
Saklatvala, 1993), the reduction in IL- 6  levels seen in the CNS following eflomithine 
treatment could be the result of the lowered neur oinflammatory reaction. The converse of 
the above situation has also been dociunented and under some circumstances IL-a 
production is mediated by the presence of IL-6 . In transgenic mice expressing IL- 6  under 
the control of the GFAP promoter, elevated levels of IL-1 a  have been detected (Wang, 
Asensio, and Campbell, 2002). Therefore, the reduction in the synthesis of IL- 6  seen 
following eflomithine treatment could precipitate a corresponding drop in the expression 
of IL-1 a  leading to an overall reduction in the severity of the CNS inflammatory reaction. 
The exact interplay between these two cytokines following eflomithine treatment, resulting 
in a reduction in the levels of both mediators remains unclear.
Although a significant increase in the expression of the cytokine TNF-a and the 
chemokine MCP-1 was detected in trypanosome infected animals when compared to 
uninfected mice no alteration in the production of these mediators was detected following 
eflomithine treatment. This finding suggests that eflomithine does not mediate the 
production of either TNF-a or MCP-1 during the development of a CNS-inflammatory 
response and that in this situation the levels of these inflammatory agents are not directly 
linked to the expression of IL-1 a, IL-6 , M IP-la or RANTES.
5.4.2. Eflomithine in the amelioration of CNS 
inflammation
In the present study the anti-inflammatory effect of eflomithine treatment was assessed in a 
semi-quantitative fashion. When the severity of the neuropathological response was 
graded, following the induction of a severe meningoencephalitis in mice infected with 
eflomithine resistant trypanosomes, significant differences were found between the groups
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given various treatment regimens. Since no gross inflammatory changes were seen in the 
uninfected groups of animals, all infected groups, including those receiving eflomithine, 
showed a significantly higher neuropathological response score when compared with these 
uninfected mice. In the infected groups of mice a 7-day course of eflomithine only slightly 
reduced the severity of the inflammatory reaction when compared to mice that were not 
given eflomithine. However, when tins course was extended to 14 days, a significant 
reduction in the severity of the CNS response was found in comparison with all the other 
infected groups of animals. The reduction in the severity of the neuroinflammatory 
response was accompanied by a dramatic reduction in the level of astrocyte activation 
which was more pronounced following the extended treatment schedule. This suggests 
that the ability of eflomithine to ameliorate the severe meningoencephalitis is a dose 
dependent response. The findings of this study confirm those previously observed in this 
model system (Jennings et al., 1997) and measure the efficacy of the anti-inflammatory 
action of eflomithine in the resolution of a severe neuroinflammatory response in a semi- 
quantitative manner.
When the expression of IL-a, IL-6 , TNF-a, MCP-1, M IP-la and RANTES was examined 
no significant differences in the transcript levels in eflornithine-treated verses non- 
eflomithine treated groups were noted, despite the dramatic decrease in the severity of the 
CNS inflammation. Unlike the previous experiments, where the preventative effect of 
eflomithine on the generation of CNS inflammation was examined, IE -la  levels in 
infected animals appeared to remain only slightly elevated in comparison to those found in 
the uninfected mice regardless of the drug regimen administered. In a similar fashion, IL- 6  
expression was not altered by eflomithine treatment dur ing this phase of the disease.
Again in contrast to the effects seen during the developmental phase of the CNS reaction, 
TNF-a expression seems to increase following eflomithine administration. The expression 
levels of TNF-a in the eflomithine treated animals were not significantly higher than those 
seen in the infected non-eflornithine treated mice. However, the increase in the production 
of this cytokine was substantial enough to make the levels in eflornithine-treated animals 
significantly higher than those seen in the uninfected mice. Infected mice that were not 
given eflomithine did not show TNF-a levels that were significantly higher than the 
uninfected groups. The apparent rise in TNF-a transcription in animals that show a 
dramatically reduced level of CNS inflammation is anomalous to findings using transgenic 
mice that over express TNF-a. In these transgenic animals severe neuroinflammatory 
reactions were seen, characterised by the widespread infiltration of the brain by numerous
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inflammatory cells (Wang et al, 2002). However, a dichotomous effect of TNF-a in 
traumatic CNS damage has been suggested as the initial production of this cytokine 
following injury appears to have detrimental consequences, whereas, the presence of the 
cytokine later in the reaction seems to be advantageous and leads to a more rapid recovery 
(Lenzlinger et al, 2001). Although the meningoencephalitis that develops following 
trypanosome infection is not the result of traumatic damage, it is possible that the TNF-a 
production seen following eflomithine administration could have a beneficial effect in 
these animals.
A minor increase in MCP-1 and RANTES expression was found in infected animals that 
had received eflomithine treatment. This finding is rather enigmatic since following 
increased production of these chemotactic mediators a corresponding increase in the 
numbers of lymphocytes and monocytes into the locale would be expected due to their 
chemotactic influence on these cells. This would result in an increase in the overall 
severity of the inflammatory reaction and not a decrease as found in this scenario. When 
transcripts for M IP-la were examined a slight drop in the expression of this chemokine 
was found in infected eflomithine treated mice compared to infected animals not given 
eflomithine. This drop in expression was not significant and was more marked in mice 
receiving 7 days of eflomithine rather than the 14-day course.
5.4.3. Potential mechanism of action of 
efiornithine
As a whole the findings from this investigation indicate that, when eflomithine is 
administered during the prevention of the development of a neur oinflammatory reaction, 
the mechanism by which the drug exerts its anti-inflammatory effect is likely to involve the 
down-regulation of the transcription of IE -la and IL-6 . This could trigger a reduction in 
the synthesis of M IP-la and RANTES and instigate an overall dampening of the 
inflammatory cell infiltration into the CNS. These findings are in contrast to those seen 
when eflomithine treatment was given to resolve an established meningoencephalitis. 
Under these circumstances no significant alteration to the level of cytokine or chemokine 
transcription was detected, indicating that eflomithine treatment does not interfere with the 
transcription of these inflammatory mediators when given after a CNS inflammatory 
reaction has become established. However, eflomithine treatment during this stage of the 
infection still results in a dramatic decrease in the severity of the neuroinflammatory
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response. This suggests that a pathway other that inhibition of cytokine or chemokine 
transcription is altered by efiornithine to resolve the inflammatory CNS lesions at this 
point.
The temporal expression of cytokine and chemokine species within the CNS has been 
shown to have differential effects on the development of the disease. In EAE, it is possible 
to inhibit the acute stages of the disease by treatment with anti-MIP-la antibodies, 
whereas, the severity of the relapsing stage of the disease can be reduced by administration 
of anti-MCP-1 antibodies (Karpus and Kemiedy, 1997). Further to these findings it has 
been suggested that M IP-la controls monocyte recruitment during the acute stage of the 
disease but this role is adopted by MCP-1 during the relapsing stage of the condition 
(Kennedy et al, 1998). It is conceivable that this temporal demarcation of roles also exists 
in trypanosome-induced CNS inflammation. In this instance IE -la  and IL- 6  would be the 
major initiators of the early CNS reaction; however their roles in the later stages of the 
disease may have become superseded by other mediators. This situation would not be 
entirely unexpected due to the increased variety and numbers of additional cells infiltrating 
the CNS, together with higher levels of cellular activation foimd in a meningoencephalitic 
reaction compared with the mild inflammatory situation seen in the early stages. During 
the developmental phase of the CNS reaction only a few T-lymphocytes and macrophages 
have entered the brain. These cells are generally confined to the perivascular regions, 
ventricles and the meninges and no B-lymphocytes or plasma cells are present the CNS at 
this stage (Chapter 3).
Astrocytes are one of the first cell types to show morphological changes, indicating that 
they have become activated, during the development of the CNS response. However, these 
cells become more numerous and display phenotypic changes that indicate an intense state 
of activation during the meningoencephalitic reaction. In agreement with the findings 
from this study, a dramatic reduction in the level of astrocyte activation has previously 
been reported following efiornithine treatment of trypanosome-infected mice when 
administered prior to the development of the CNS-stage of the disease and following the 
induction of the PTRE (Jennings et al, 1997). Since IL-1, IL-6 , TNF-a, MCP-1, MIP-1 
and RANTES can each be synthesised by astrocytic cells (Asensio and Campbell, 2001; 
Sharafeldin et al, 2000; Szelenyi, 2001) it is possible, particularly during the development 
of the CNS reaction, that efiornithine acts directly on these cell to down-regulate the 
synthesis of these agents. This could result in the reduction in the severity of the 
inflammatory response seen following efiornithine therapy as well as inhibit any autocrine
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actions exerted by the cytokines and chemokines that would further exacerbate the 
astrocytic reaction.
A down-regulation of astrocyte activation has been reported following eflornithine 
treatment of mechanically induced brain injury in rats (Jeglinski et al, 1996; Zini et al, 
1990). This dampening of the astrocytic response was not found following eflornithine 
treatment when the astrogliosis was induced by administration of the neurotoxicant 
methyl-phenyl-tetrahydropyridine (MTPT) (O'Callaghan and Seidler, 1992). Following 
mechanical brain injury, the integrity of the blood-brain barrier (BBB) is compromised 
allowing the entry of inflammatory cells and other inflammatory mediators that could 
exacerbate the reactive astrocytosis (Norton, Aquino, Flozumi, Chiu et a l, 1992). This is 
not the case in neui'otoxicant injury as the BBB remains intact and therefore inflammatory 
cells and pro-inflammatory agents do no have free access to the CNS. The contrasting 
findings of these studies suggest that the astrocytic response may be induced and 
maintained thi'ough different mechanisms depending on the form of the initial insult. The 
results imply that astrocytic activation follows a pathway that is not directly affected by the 
presence eflornithine in situations where the BBB remains intact whereas eflornithine 
appears to play a major role in the dampening of the response in situations where damage 
to the BBB has occurred.
The extent of any damage caused to the BBB following trypanosome infection remains 
equivocal at the present time. Several studies have indicated that the integrity of the BBB 
becomes progressively weakened following trypanosome infection (Pentreath et al, 1994; 
Philip et al, 1994) while no deterioration of the tight-junctions that form the bander was 
detected in another investigation (Mulenga et al, 2001). If the BBB is impaired during the 
development of the meningoencephalitis the dramatic reduction in astrocyte activation 
could follow a similar course to that described for mechanical brain injury. This would not 
be the case during the early developmental stages of the CNS inflammation as the BBB 
would still be intact. This scenario would be more comparable to that seen following 
neurotoxicant damage. However, a dampening of the astrocytic response was found dur ing 
this stage of the inflammatory reaction. This provides further evidence that the reduction 
in IL -la and IL- 6  expression found in eflornithine-treated mice may have a direct effect on 
the development of the astrogliosis seen in the early CNS inflammatory response and 
suggests that this cell type may play a major role in the induction of the CNS response.
Since this investigation was performed using eflornithine-resistant trypanosomes, the 
parasitaemia within the CNS would not be affected by the eflornithine treatment.
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Therefore, the reduction in the severity of the neuroinflammation and the effects seen on 
cytokine and chemokine transcription are independent of any changes that would be 
initiated by clearance of the trypanosomes from the CNS. This indicates that eflornithine 
may be extremely useful as an anti-inflammatory adjunct therapy in the treatment of 
human disease even in T.h.rhodesiense infections where the parasites have shown primary 
resistance to the drug. The effects of eflornithine treatment on the production of IL -la  and 
IL- 6  may also help to explain the dramatic clinical improvement found in patients treated 
with the drug. If the production of these two cytokines is lowered within the CNS then the 
non-specific indications of infection, including, depression, fever, lassitude and appetite 
suppression, which are induced by these cytokines in conjunction with TNF-a, could be 
alleviated.
Overall the results from this investigation indicate that there is an urgent requirement to 
ensure the continued availability of eflornithine for the treatment of trypanosome 
infections. Further studies are pivotal to determine the exact effect of the drug at each 
stage in the disease development. The feasibility of using eflornithine as an adjunct 
therapy for T.b.rhodesiense-miQoXiom has been demonstrated and field trials, together with 
additional animal model studies, utilising combination therapy approaches, are now 
required to determine the most favourable treatment regimens thereby ensuring optimal 
drug efficacy, economy and safety of the chemotherapy.
C h a p t e r  6 
S u b s ta n c e  P a n d  h u m a n  A fr ic a n
TRYPANOSOMIASIS
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6.1. Introduction
6.1.1. Background
6.1.1.1. What is substance P?
Substance P (SP) is an 11-amino acid neuropeptide that is found widely distributed in both 
the central nervous system and peripheral tissues. Described in 1931 by von Euler and 
Gaddum, SP was the first neuropeptide to be identified in mammals and was originally 
extracted from equine brain and intestine (von Euler and Gaddum, 1931). In the early 
1970’s the amino acid sequence of SP was reported as Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe- 
Gly-Leu-Met-NHi (Chang, Leeman, and Niall, 1971). It is a member of the tachykinin 
family of peptides, that also includes neurokinin A (NKA) and neurokinin B (NKB). The 
tachykinin family is characterised by the carboxy-terminal amino acid sequence Phe-X- 
Gly-Leu-Met-NHz where X is an aromatic or hydrophobic amino acid (McGillis, Organist, 
and Payan, 1987). In addition to structural similarity, they also exliibit overlapping 
biological activities, including, contraction of smooth muscle and induction of sub-normal 
arterial blood pressure. Indeed, the name Tachykinin’ was employed to describe these 
peptides due to their ability to induce relatively fast smooth muscle contractions (Erspamer 
and Melchiorri, 1973).
6.1.1.2. Tachykinin nomenclature
At the International Union of Physiological Sciences Satellite Symposium, entitled 
Substance P and Neurokinins, a new nomenclature system was proposed for the tachykinin 
family and their receptors (Hemy, 1987). As the meeting was conducted in Montreal the 
system was designated the ‘Montreal Nomenclature’. In this classification the three 
endogenous mammalian tachykinins were designated as substance P; neurokinin A, 
previously referred to as neurokinin a, neuiomedin L or substance K; and neurokinin B, 
previously named neurokinin p or neuromedin K. The receptors were designated as the 
tachykinin NKl receptor; previously named SP-P; the tachykinin NK2 receptor, previously 
called SP-E, SP-K, or NK-A; and the tachykinin NK3 receptor, previously designated SP- 
E, SP-N, or NK-B. SP is the most potent ligand for the NKl receptor; NKA shows the 
highest affinity for the NK2 receptor while NKB prefers the NK3 receptor (Saria, 1999). 
However, this concept is currently under revision as NKA and NKB also bind to and
2 9 8
Stimulate the NKl receptor with appreciable affinity (Hastrup and Schwartz, 1996). This 
finding has led to speculation about exact binding mechanism of the ligands to the NKl 
receptor. It has been suggested that either the individual ligands bind to differential 
binding sites on the receptor or that there are two distinct conformations of this receptor. 
One conformation would act as a general tachykinin receptor and the second would display 
preferential binding for SP (Maggi and Schwartz, 1997),
6.1.2. Substance P biosynthesis
6.1.2.1. Preprotachykinin A gene
The sequence of the preprotachykinin-A (PPT-A) gene that encodes both SP and 
neurokinin-A was elucidated in 1984 (Nawa, Kotani, and Nakanishi, 1984). This gene is 
organised into 7 exons and 3 introns. The coding sequences of exons 2-6 are well 
conserved between species while there is more variation in the remaining two exons, 1 and 
7 (Bonner, Young, and Affolter, 1987). The promoter region that lies immediately in front 
of exon 1 is also highly conserved. The length of the introns remains similar between 
species however there is little correlation in the sequence of the bases. The RNA 
transcribed from the PPT-A gene undergoes differential splicing that results in different 
mRNAs, an a  PPT mRNA that is missing nucleotide regions in exon 6 , a p PPT mRNA 
that includes all 7 exons, and a y PPT mRNA with nucleotide regions missing from exon 4 
(Krause, Chirgwin, Carter, Xu et a l, 1987). Exon 3 of the PPT-A gene designates the 
transcript as capable of producing SP while if exon 6  is included the transcript also codes 
for NKA (Bonner et al, 1987). Therefore, SP and NKA can be produced from p and y 
PPT mRNAs while only SP can be produced from a  PPT mRNA (Krause et al, 1987). A 
fourth splicing variant, ô PPT, has also been identified in the rat (Harmar, Hyde, and 
Chapman, 1990). A second PPT gene, PPT-B, is responsible for the production of NKB 
(Pompei, Severini, Costa, Mas si et a l, 1999)
6.1.2.2. Post-translational processing
The existence of various different mRNA transcripts suggests that the production of 
tachykinins is controlled at the level of precursor processing. It appears that p PPT mRNA 
can either produce both SP and NKA in equal amounts or in some cases an N-terminally 
extended NKA molecule may result through differential proteolytic processing. This
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larger than normal NKA molecule is designated as NPK and includes sequence 
information contained in exons 4 and 5 of the PPT-A gene in addition to exon 6 . y PPT 
can produce SP, NKA or a shortened form of NPK designated neuropeptide-y. This 
attenuated form of NPK is produced from y PPT since this configuration of the transcript 
lacks the information encoded by exon 4 that specifies a protein with a potential a-helical 
conformation whose function remains unknown (Hayes, Shaw, Chakravarthy, and 
Buchanan, 1993).
SP is synthesised as a biologically inactive, glycine extended, precursor peptide that 
requires a post-translational carboxy-terminal amidation to produce the active moleeule. 
This process is a two-step procedure involving the sequential action of two sepai’ate 
enzymes. The first enzyme, peptidylglycine a-monooxygenase (PAM), catalyses the 
formation of a peptidyl-a-hydroxyglycine intermediate molecule. This intermediate is 
subsequently converted into the a-amidated, biologically active, form of SP by a second 
enzyme, peptidylamidoglycolate lyase (PGL) (Ogonowski, May, Moore, Barrett et a l, 
1997). As this amidation process appears to be the rate-limiting step in the production of 
the active SP molecule the enzymes involved have become prime candidates as 
pharmacological targets for reducing SP production thiough the development of specific 
enzyme inhibitors. One such molecule, 4-phenyl-3-butenoic acid (PBA), a turnover- 
dependent inactivator of PAM, has been shown to inliibit a-amidation in both cultured 
bovine epithelial cells (Oldham, Li, Girard, Nerem et a l, 1992) and cultured rat thyroid 
carcinoma cells (Bradbury, Mistry, Roos, and Smyth, 1990). More recently, Ogonowski 
and colleagues demonstrated that systemic administration of PBA inhibited the acute 
inflammatory response produced by injection of cairageenan into the hind paws of rats 
(Ogonowski et al, 1997)
6.1.3. Tachykinin receptors
Binding of tachykinin receptors by ligands or agonists is regulated by guanine nucleotides 
indicating that the receptors are coupled to G-proteins. In cultures of spinal neurones, it 
was found that the NKl-agonist complex became internalised following this binding 
(Mantyh, DeMaster, Malhotra, Ghilardi et a l, 1995; Maiityh, Rogers, Honore, Allen et a l, 
1997). Rapid endocytosis of this receptor was also demonstrated following injection of SP 
in the rat striatum in vivo (Mantyh, Allen, Ghilardi, Rogers et a l, 1995). This 
internalisation of the receptor-ligand complex is characteristic of G-protein coupled 
receptors (Hunt, 2000). G-protein coupled receptors form a superfamily of proteins
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characterised by the presence of seven, transmembrane a-helices. Signalling occurs 
thiough interactions with a family of heterotrimeric GTP-binding proteins, referred to as 
G-proteins (Edwai’ds, Tan, and Limbird, 2000). There appears to be pai’ticular amino acids 
that lie in specific positions within the molecule that are pivotal to the function of the 
receptor. One example of this can be seen in the positioning of the tyrosine amino acid, 
located in the inner part of the transmembrane 5 portion of the human NKl receptor. This 
molecule appears to be in a crucial position in the G-protein coupling of the receptor. If 
the amino acid is substituted with an alanine molecule, the binding affinity of the receptor 
for its ligand remains unaffected; however, the receptor is unable to generate any second 
messenger response (Quartara and Maggi, 1997).
Stimulation of the NKl receptor by the binding of SP or a SP agonist leads to the induction 
of various second messenger systems that can subsequently trigger effector mechanisms 
that control cellular excitability and function. To date three apparently independent second 
messenger systems have been reported to be induced following NKl stimulation. These 
pathways include; the stimulation of phosphatidyl inositol turnover, via phospholipase C, 
resulting in both intra- and extra-cellular calcium mobilisation; stimulation of adenylate 
cyclase leading to cyclic adenosine monophosphate accumulation; and mobilisation of 
arachidonic acid via phospholipase A2 (Quartara and Maggi, 1997).
There is some evidence to suggest that the upregulation in expression of NKl mRNA in 
the dorsal horn of the spinal cord induced by peripheral noxious stimulation is the result of 
a positive feedback loop involving the activation of the original NKl receptors (McCarson 
and Krause, 1996).
6-1.4. Substance P and the NKl receptor in 
nervous tissues
6.1.4.1. Distribution in the CNS
Investigations using autoradiography, mapping of NKl mRNA expression and 
immunocytochemistry have demonstrated that the NKl receptor is widely distributed 
throughout the CNS and the peripheral nervous system.
Within the brain NKl receptors have been shown in the striatum, the nucleus accumbens, 
the hippocampus, the lateral nucleus of the hypothalamus, the habenula, the
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interpeduncular nucleus, the nucleus of the tractus solitarius, the raphe nuclei and the 
medulla oblongata (Saria, 1999). Some apparently conflicting information with regard to 
the distribution of the NKl receptor and SP itself has also been generated. In the 
substantia nigra pars retieulata SP immunoreactive nerves have been deteeted with no 
apparent receptor presence (Nakaya, Kaneko, Shigemoto, Nakanishi et a l, 1994). In the 
hilus of the dentate gyrus the opposite situation is encountered. Here NKl receptors are 
present but the area is apparently devoid of SP-positive fibres (Nakaya et al, 1994). 
However, it remains unclear whether these mismatches are authentic or artefactual. The 
possibility also exists that NKA or NKB are the physiological ligands in preference to SP 
within these mismatched areas (Saria, 1999), or that SP acts at sites distal to its production 
(Bowden, Baluk, Lefevre, Vigna et a l, 1996).
6.1.4.2. SP and NKl receptors in spinal cord
Substance P is considered to be one of the major mediators of pain and neurogenic 
inflammation in peripheral tissues, although the precise contribution of SP to this process 
remains equivocal. SP is synthesised by primary afferent fibres that have their cell bodies 
in the dorsal root ganglion (DRG). These small diameter, mostly unmyelinated, fibres 
transport the SP from the DRG to their central and peripheral terminals where it is stored in 
dense core vesicles. On noxious stimulation SP is thought to be released from these 
terminals; however, the mechanisms evoking pain behaviour following SP release remain 
unclear (Basbaum, 1999). The fibres responsible for the synthesis and transport of SP are 
also responsible for the synthesis of the excitatory amino acid glutamate. On noxious 
stimulation glutamate is known to be released from these fibres and activate second order 
neurones in the spinal cord. Some researchers believe that the co-synthesis and release of 
these two molecules leads to a synergistic effect that enhances the glutamatergic 
transmission increasing nociceptive processing and pain (Dougherty, Palecek, Zorn, and 
Willis, 1993; Randic, Hecimovic, and Ryu, 1990). Others refute this hypothesis and claim 
that SP has little relevance to the production of pain (Bossut, Frenk, and Mayer, 1988). 
However, the evidence presented in this section strongly supports a role for the tachykinins 
in pain perception and transmission and provides a framework in which to speculate about 
the significance and mechanism of action of SP and the tachykinin receptors in this 
response.
Areas of the spinal cord that express the highest levels of NKl receptors include the dorsal 
horns, the intermediolateral nucleus of the thoracic spinal cord and discrete nuclei in the
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ventral horns (Nakaya et al, 1994). The surgical loss of sensory fibres has been shown to 
cause an upregulation of NKl receptors at discrete sites in the spinal cord. This may 
indicate that these sites are innervated by primai'y afferent neurones suggesting that SP and 
NKl play a major role in pain perception (Croul, Sverstiuk, Radzievsky, and Murray, 
1995; Yashpal, Dam, and Quirion, 1991). Furthermore, there is a distinct biphasic 
modulation in NKl receptor expression in the dorsal horns of the spinal cord following 
adjuvant-induced inflammation of the hind paw in rats as measured by the binding of 
Bolton Hunter SP (Stucky, Galeazza, and Seybold, 1993). Acute painful stimuli have been 
shown to produce a rapid decrease in NKl receptor binding. This is presumably due to the 
internalisation of the NKl receptor-endogenous ligand complex within the neurones of the 
rat dorsal spinal cord that is associated with the acute pain response (Mantyh et al., 1995). 
However after 48 hours, the initial decrease in NKl receptor binding was followed by a 
widespread increase in Bolton Hunter SP binding (Stucky et al, 1993). By 
employing Scatchard analysis the increased level of binding was found to be the result of a 
10 fold increase in the affinity of the NKl receptor for Bolton Hunter SP and the 
presence of a low affinity binding site.
Evidence suggesting a significant role for the NKl receptor in the hyperalgesia that 
accompanies persistent peripheral inflammation and tissue damage originates from studies 
employing specific non-peptide NKl receptor antagonists in decerebrated rats. In these 
experiments it was found that footpad administration of complete Freund’s adjuvant 
resulted in an increase in the excitability of the flexor reflex in rats. This rise in 
excitability decreased significantly following administration of the NKl receptor 
antagonist RP-67,580 but was unaffected by the inactive enantiomer RP-68,651 (Ma and 
Woolf, 1997; Parsons, Honda, Jia, Budai et a l, 1996).
Further evidence supporting a role for SP in persistent pain became available from 
additional studies employing the CNS penetrating, non-peptide, non-neurotoxic, NKl 
receptor antagonist L-733,060 (Rupniak, Carlson, Boyce, Webb et a l, 1996). Injection of 
formalin into the footpad of conscious gerbils produces a two-phase nociceptive response. 
The response entails a vigorous licking of the affected paw which peaked during the first 
15 minutes immediately following the formalin injection and subsided to a relatively low 
constant level 20 to 40 minutes after stimulation. The NKl receptor antagonist was 
administered by injection into the jugular vein of anaesthetised animals 3 hours prior to the 
formalin injection. This permitted the entrance of the maximal concentration of the 
antagonist into the CNS. The treatment was found to inliibit the late phase of the response 
in a dose dependent manner and block the response completely at a dose of 1 Omg/kg. No
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effect was seen during the early stage, except a minimal reduction in the response in 
animals that had been given the high dose of antagonist.
The co-administration of a NKl receptor antagonist and a N-methyl D-aspartate (NMDA) 
receptor antagonist produces a more potent inhibition of the nociceptive reflex in rats than 
that seen following administration of the individual antagonists. This suggests a co­
operative action between the two receptors in the production of the nociceptive response 
(Xu, Dalsgaard, and Wiesenfeld-Hallin, 1992). These findings strengthen the theory that 
the message resulting from activation of the NKl receptor is a slowly developing long 
lasting depolarisation while the initial response is the result of the fast synaptic input by 
excitatory amino acids such as glutamate to second order sensory neurones. Experiments 
employing NKl receptor knockout mice have shown that these animals respond normally 
to acute chemical, thermal and mechanical pain. However, on intraplantar administration 
of formalin a reduction in the paw licking reaction was noted during the second phase of 
the response (de Felipe, Herrero, O'Brien, Palmer et a l, 1998; Giffin et al, 1986; Wang, 
1988). Also a lack of the wind up response whereby increasing the intensity of the 
stimulus results in a progressive increase in response was absent in the knockout animals 
(de Felipe et al, 1998; Herrero, Laird, de Felipe, Smith et al., 1997) These data are in 
agreement with that previously generated from the antagonist administration experiments 
referred to above.
6.1.4.3. SP and NKl receptors in astrocytes
Astrocytes are the most numerous glial cell type found in the brain and among other 
functions play a pivotal role in the brain’s reaction to injury. Upon stimulation the 
astrocytes become activated and participate in immunologic and inflammatory events 
through the expression of adhesion molecules and the secretion of various cytokines. The 
human astrocytoma cell lines U-373 MG (Heuillet, Menager, Fardin, Flamand et a l, 1993; 
Lee et al, 1989) and U C ll (Johnson and Johnson, 1992) are known to express functional 
NKl receptors. Studies have also demonstrated SP receptors localised to 0-2A progenitor 
cells and type-2 astrocytes in vitro (Marriott and Wilkin, 1993). As astrocytes undergo 
phenotypical changes in response to injury the phenotypical status of astrocytes in culture 
remains unclear. It is therefore not knovwi whether normal imstimulated astrocytes in vivo 
express the receptor.
In normal optic nerve, in vivo, the astrocytes express very few NKl receptors but this 
number increases dramatically in the glial scar formed following transection of the nerve
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(Mantyh, Johnson, Boehmer, Catton et a l, 1989). A correlation between the extent of 
NKl expression in astrocytomas and glioblastomas and the malignancy of the tumour has 
also been demonstrated (Heimig, Laissue, Horisberger, and Reubi, 1995). Further, it has 
been suggested that the presence of NKl receptors may infer an increased gi'owth 
advantage when present in brain tumours and may be an effective and legitimate 
chemotherapeutic target in these tumour types (Luo, Sharif, and Sharif, 1996).
In vitro studies employing the human astrocytoma cell line U373 MG cells have shown 
that SP can induce the production of the proinflammatory cytokine interleukin (IL) ~ 6  
(Cadman, Witte, and Lee, 1994; Gitter, Regoli, Howbert, Glasebrook et a l, 1994). This 
induction was inhibited by the simultaneous addition of NKl receptor antagonists to the 
culture system. The production of IL- 6  is often mediated by the presence of IL-l. To 
determine if this was the case in this scenario neutralising antibodies were added to remove 
any endogenous IL-l; however, no change in the production of IL- 6  was seen (Gitter et al, 
1994). Therefore, the secretion of IL- 6  by cultured U373 MG cells appears to be 
independent of IL-l induction. In contrast to these findings, the addition of SP alone to rat 
astrocyte enriched primary cultures was unable to stimulate TNF-a production but caused 
a dose dependent increase in TNF-a production when added in conjrmction with LPS. 
When IL-l neutralising antibodies were added the enhanced production returned to the 
levels observed following stimulation with LPS alone (Luber-Narod, Kage, and Leeman, 
1994). This suggests that TNF production by astrocytes may be controlled in part by the 
presence of IL-l. The apparent discrepancy between the two studies could be the result of 
primary versus transformed cell lines and the different cytokines being investigated.
Reactive astrocytes, in vivo, not only express the NKl receptor but can also be induced to 
express SP and SP-immunoreactive astrocytes have been found in post-mortem white 
matter specimens from 5 patients with multiple sclerosis (MS) (Kostyk, Kowall, and 
Hauser, 1989). These SP immunoreactive astrocytes were seen around the edges of both 
inflammatory (active) and non-inflammatory (inactive) MS lesions. Astrocytes expressing 
SP have also been found in gerbil forebrain following ischaemic, thermal and mechanical 
injury (Lin, 1995),
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6.1.5. SP and NKl receptors in peripherai tissues
6.1.5.1. The cardiovascular system
SP and NKl receptors can be found not only in nervous tissue but also on many different 
cell types in the peripheral tissues.
In the vascular system, immunocytochemistry and autoradiography studies have shown 
that endothelial cells in lai'ge blood vessels and post-capillary venules express NKl 
receptors in vivo (Greeno, Mantyh, Vercellotti, and Moldow, 1993; Saito, Konishi, Takano, 
Nonaka et a l, 1990). In tissue culture, stimulation of the endothelial cell NKl receptors 
induces cellular proliferation and migration. These two processes are central to the 
development of blood and lymph vessels. In an avascular rabbit cornea, application of SP 
or NKl receptor agonists, results in the generation of new vascular tissue (Ziche, 
Morbidelli, Pacini, Geppetti et a l, 1990). This phenomenon has been further demonstrated 
following co-administration of SP and IL-la. Doses of these mediators, that do not elicit a 
response individually, when applied in tandem, result in an intense neovascularisation of 
implanted sponge material in rats (Fan, Hu, Guard, Gresham et a l, 1993; Walsh, Hu, 
Mapp, Polak et a l , 1996). A possible role for the NKl receptor in tumom* growth was also 
suggested following the discovery of the receptors on the blood vessels in human primary 
neoplasms (Hennig et al, 1995).
Vasodilation (Maggi, Patacchini, Perretti, Tramontana et a l, 1990) and vasoconstriction 
(Shirahase, Kanda, Kurahashi, Nakamura et a l, 1995) of rabbit pulmonary artery and 
isolated veins (Patacchini and Maggi, 1995) can be induced through stimulation of the 
NKl receptors. This ability to control vascular tone indicates that NKl receptors may be 
involved not only with the normal regulation of blood pressure but also the early 
generation of stress induced hypertension. In various salt-dependent hypertensive rat 
models an increase in blood pressure occurs when the animals are treated with NKl 
receptor antagonists. Since the hypertensive effect of the NKl receptor antagonist was 
only found in salt-dependent models of hypertension, this suggests that SP could exert an 
effect on the sodium regulatory mechanisms in the rat (Kohlmann, Jr., Cesaretti, Ginoza, 
Tavares et a l, 1997). The question of whether the blood vessel, endothelial cell NKl 
receptors are imiervated or stimulated directly by circulating tachykinins remains equivocal 
(Ferrell, Lockhart, and Karimian, 1997; Maggi et al, 1990).
3 0 6
Another important process that appears to be mediated through the NKl receptors is the 
increase in post capillary venular permeability that permits plasma protein extravasion. 
The use of selective NKl receptor agonists and antagonists has shown that the NKl 
receptor is the major, and perhaps the exclusive, mediator of tachykinin induced plasma 
protein extravasion. (Eglezos, Giuliani, Viti, and Maggi, 1991). Again this process appears 
to result from stimulation of the NKl receptor on endothelial cells. Following stimulation 
gap formation between the endothelial cells occurs allowing the passage of the plasma 
proteins (Baluk, Nadel, and McDonald, 1992). However, although the arteries are 
innervated by many SP-positive fibres this is not true of the post capillary venules; 
therefore, the reaction seen in these venules may be the result of SP release at distant rather 
than local sites (Bowden et al, 1996).
In a rat model of cardiomyopathy, induced by magnesium deficiency, increased levels of 
SP were found in the plasma during the first week of reduced magnesium intake. The 
resulting elevation of SP levels was followed by increases in the presence of various 
inflammatory mediators. If the magnesium deficient rats were treated with a NKl receptor 
antagonist the increase in SP still occurred, though, there was no concurrent increase in the 
levels of the inflammatory mediators and no cardiac lesions developed. These findings 
have been extended to include NKl receptor activation in the aggravation of cardiac 
damage resulting from ischaemia-reperfusion injury (Kramer, Phillips, and Weglicki, 
1997; Walsh, Weglicki, and Correa-de-Ai'aujo, 1996). However, the results are in 
contention with those previously reported (Ustinova, Bergren, and Schultz, 1995). These 
workers foimd that blockade of the NKl receptors by administration of a selective 
antagonist aggravated the post-ischaemic response implying a protective role for the NKl 
receptor in the pathogenesis of ischaemic heart disease.
6.1.5.2. The respiratory system
NKl receptors are found throughout the respiratory system (Walsh, Salmon, Featherstone, 
Wharton et a l, 1994). In the airways of various species, NKl receptors mediate the 
tachykinin-induced secretion of mucus by seromucous glands and goblet cells (Rogers, 
Aursudkij, and Barnes, 1989; Webber, 1989) and the involvement of NKl receptors in 
asthma and bronchial hypersensitivity has been demonstrated by employing selective 
antagonists. Following the inhalation of cigarette smoke, plasma protein extravasion is 
induced in the guinea-pig trachea and bronchi. This process can be blocked by the 
administration of a NKl receptor antagonist (Delay-Goyet and Lundberg, 1991). A
3 0 7
recruitment of leucocytes into the airways was found to occur in parallel with the plasma 
protein extravasion induced by challenge with hypertonic saline (Baluk, Bertrand, 
Geppetti, McDonald et a l, 1995) or antigen (Kaltreider, Ichikawa, Byrd, Ingram et a l,
1997). Again, this inflammatory cell infiltration could be inhibited by administration of a 
NKl receptor antagonist. A potentially therapeutic use for NKl receptor antagonists can 
be demonstrated from research employing models of astlima. When previously sensitised 
‘asthmatic’ mice were pre-treated with RP-67,580, a NKl receptor antagonist, before 
challenge with toluene di-isocyanate, a known cause of occupational asthma, the 
development of the bronchial hyper-reactivity was inhibited (Scheerens, Buckley, Muis, 
Van Loveren et a l, 1996). The exact cell types involved in this response remain unknown 
and further research into the role of SP and the NKl receptor in the pathogenesis of asthma 
is urgently required.
6.1.5.3. The gastrointestinal system
One of the first properties of SP to be discovered was its ability to cause the smooth 
muscle of the intestine to contract. NKl receptors are found at high concentrations in the 
smooth muscle layers, sub-mucosa, intestinal epithelium and in the ganglia of the enteric 
plexuses (Sternini, Su, Gamp, and Bumiett, 1995). Definitive evidence that tachykinins, 
acting tlii'ough NKl receptors, are responsible for the non-adrenergic non-cholinergic 
(NANC) excitation of the circular muscle of the gut has been established by employing 
selective antagonists (Zagorodnyuk, Santicioli, Turini, and Maggi, 1997). This suggests a 
key role for NKl receptors in gut motility. Indeed the activation of NKl receptors appears 
to be involved in such processes tluoughout the intestinal tract including inhibition of 
colonic motility in response to rectal distension (Julia, Morteau, and Bueno, 1994), stress 
induced defecation (Ikeda, Miyata, Orita, Kubota et a l, 1995) and inhibition of gastric 
emptying induced by peritoneal irritation (Julia and Bueno, 1997). Various studies, 
investigating several different species and gut areas including porcine jejunum (Brown, 
Parsons, and O'Grady, 1992), cat small intestine (Brunsson, Fahrenkrug, Jodal, Sjoqvist et 
a l, 1995) and guinea-pig ileum and colon (Reddix and Cooke, 1992), have also 
demonstrated the involvement of tachykinins in mediating epithelial ion and water 
transport (Cooke, Sidhu, Fox, Wang et a l, 1997).
The varied roles of SP and the NKl receptor, ranging from pain and inflammation to gut 
motility and ion/water regulation, and their wide distribution within the intestine resulted 
in a number of investigations to determine their role in the pathophysiology of intestinal
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inflammatory conditions. In colon specimens taken from human patients with ulcerative 
colitis and Crohn’s disease, a dramatic increase in the expression of NKl receptors, 
together with aberrant NKl receptor expression in areas where it is not usually present, 
was found (Mantyh, Vigna, Bollinger, Mantyh et a l, 1995; Mantyh, Gates, Zimmerman, 
Welton et a l, 1988). In rat intestine SP plays a role in the inflammatory response to 
Clostridium difficile toxin A. This was elucidated by demonstrating that the inflammatory 
response to toxin A could be inliibited by pre-treating the rats with the NKl receptor 
antagonist CP-96,345 (Pothoulakis, Castagliuolo, LaMont, Jaffer et a l, 1994). The 
phenomenon has been further investigated and it appears that the intestinal macrophages in 
the lamina propria are induced to express and release SP on stimulation with Clostridium 
difficile toxin A instigating an inflammatory reaction in the gut (Castagliuolo, Keates, Qiu, 
Kelly gfaZ., 1997).
6.1.6. NKl receptors and SP in infiammatory ceiis
As a result of the vast quantity of evidence implicating NKl receptors and SP in the 
inflammatory response extensive research to elucidate the mechanisms involved in this 
process has been carried out. It appears that SP has many actions on various cells from the 
immune system including the stimulation of proliferative responses and the induction of 
cytokine production. These functions are discussed below.
6.1.6.1. Monocytes
Analysis of normal human monocytes, using flow cytometry, has shown that they contain 
SP (De Giorgio, Tazzari, Barbara, Stanghellini et a l, 1998). These findings were 
supported by the demonstration of mRNA transcripts for SP in human peripheral blood 
monocytes (Lai, Douglas, Rappaport, Wu et a l, 1998). It appears that monocytes not only 
produce SP but also respond to its presence. In a study employing cultured human 
monocyte-derived macrophages the addition of SP to the culture system resulted in an 
increase in the production of tumour necrosis factor (TNF). If lipopolysaccharide (LPS) 
was added in conjunction with the SP a synergistic effect was seen and TNF production 
occurred at higher levels than with either stimulant individually. The stimulatory activity 
of SP was inhibited by the addition of NKl receptor antagonists (Lee, Ho, and Douglas,
1994). This potentiation of TNF production by monocytes had been described previously 
by Lotz and co-workers who had also demonstrated that SP could induce interleukin (IL)~ 
1 and IL- 6  production by these cells (Lotz, Vaughan, and Carson, 1988). These findings
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were further corroborated when it was shown that preincubation of murine peritoneal 
macrophages with SP, prior to stimulation with LPS, results in a significant augmentation 
of the production of the proinflammatory cytokines IL-l, TNF-a and IL- 6  (Berman, 
Chancellor-Freeland, Zhu, and Black, 1996). Further work has shown that a fragment of 
SP containing the amino acids lying in positions 4-11 can induce TNF production by 
cultured human peripheral blood derived monocytes or aliquots of whole human blood 
(Nair and Schwartz, 1995). In addition, the production of the cytokine interferon-y (IFN-y) 
can be induced if monocytes are stimulated with pokeweed mitogen, this stimulation is 
significantly enhanced by the concurrent addition of SP (Wagner, Fink, Hart, and 
Dancygier, 1987). These findings suggest that SP could act as a priming agent or primary 
activation signal in the induction of the cascade of responses that occur during macrophage 
stimulation
Despite overwhelming evidence that SP elicits many monocyte responses, the ability of SP 
to bind with high affinity and specificity to human peripheral blood monocytes and 
macrophages was not reported until 1994 (Lucey, Novak, Polonis, Liu et a l, 1994). This 
group determined that ^^ I^-SP bound to a specific receptor on the monocytes and that this 
binding occurred within 6  hours of introduction of the labelled SP to the culture system.
6.1.6.2. Polymorphonuclear leucocytes
Flow cytometry has demonstrated that normal human gianulocytes contain SP (De Giorgio 
et al, 1998). Furthermore, SP has been shown to have an effect on polymorphonuclear 
leucocytes (PMNL). Pre-treatment of cultured human PMNL’s with SP resulted in an 
increase in the respiratory burst produced by these cells in response to stimuli including 
formyl-methionyl-leucyl-phenylalanine (FMLP), concavalin A (conA) and opsinized 
zymosan (STZ). However the oxygen burst induced by TNF-a was strongly inhibited by 
pre-treatment with SP (Serra, Calzetti, Ceska, and Cassatella, 1994). The eosinophils in 
the liver granulomas that develop in schistosmiasis have been shown, by means of in situ 
hybridisation, to produce SP (Weinstock, Blum, Walder, and Walder, 1988). By 
employing NKl receptor antagonists, SP was shown to induce maturation of the B-cells 
within the schistosome granuloma into antigen secreting cells and also to increase the 
capacity of the granuloma to produce IFN-y, ÎL-4, IL-5 and IL- 6  (Blum, Metwali, Cook, 
Mathew et a l, 1993; Blum, Metwali, Elliott, Sandor et a l, 1996).
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SP and the NKl receptor have been shown to mediate the adhesion of neutrophils and 
eosinophils to the endothelial cells of inflamed blood vessels. This adhesion process, 
controlled by the expression of adhesion molecules on endothelial cells and their 
complementary ligands on leucocytes, is a necessary step in the transmigration of 
leucocytes into tissues during an inflammatory reaction. Blockade of the NKl receptor by 
administration of the antagonist, CP-96,345 to anaesthetised rats reduced the adherence of 
both eosinophils and neutrophils in the blood vessels of the tracheal mucosa (Baluk et al,
1995). As SP has been shown to induce the expression of ICAM-1 by cultured human 
umbilical vein endothelial cells (Nakagawa, Sano, and Iwamoto, 1995) blockade of the 
NK-1 receptor could prevent this upregulation causing a reduction in cellular adhesiveness.
SP has also been shown to regulate a number of neutrophil functions. The cytotoxic 
activity of human neutrophils against antibody coated target cells is increased by SP in a 
dose dependent manner. In addition, pre-treatment of neutrophils with SP results in a rapid 
increase in FMLP-stimulated superoxide anion production (Wozniak, McLennan, Betts, 
Murphy et a l , 1989). Therefore, SP may play a key role in the control of the cell-mediated 
immune response to infection by bacteria or parasites.
6.1.6.3. Lymphocytes
Normal lymphocytes have been shown generally to be negative or only weakly positive for 
SP, with only 10-20% of the cells forming the weakly positive subsets (De Giorgio et al,
1998). However, activated CD4 and CD8  T-cell subsets, and T-cells from leukaemic 
patients, are strongly labelled with antibodies against SP when analysed using flow 
cytometry (De Giorgio et al, 1998). The ability of lymphocytes to produce SP has been 
corroborated in a study employing human peripheral blood isolated lymphocytes 
stimulated with phytohaemagglutanin (PHA) and IL-2. These cells were shown to contain 
SP mRNA by nested RT-PCR and SP protein using an enzyme immunoassay method (Lai 
eta l, 1998).
Lymphocytes not only produce SP but also express the SP receptor. This was 
demonstrated by the ability of T-cells, prepared from murine spleen and Peyers patches, to 
bind fluorescein labelled SP (Stanisz, Scicchitano, Danzin, Bienenstock et a l, 1987). In 
addition, T-cell functions have been shown to be entranced by SP. ConA induced 
proliferation of both spleen and peripheral blood lymphocytes is enhanced by 
administration of SP. This augmentation was completely inhibited when a NKl receptor 
antagonist was added to the tissue culture system at the same time as the SP (Santoni,
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Perfumi, Spreghini, Romagnoli et a l, 1999). Evidence from a separate study also suggests 
that T-cells show a chemotactic response to SP that is mediated not only through the NKl 
receptor but also tlirough the NK2 receptor (Hood, Cruwys, Urban, and Kidd, 2000). 
There is also evidence indicating that the adhesiveness of T-cells to endothelial cells is 
enhanced by SP. This appears to occur through an increased expression of ICAM-1 by the 
endothelial cells in conjunction with a corresponding increase in the avidity of the LFA-I 
ligand on lymphocytes (Vishwanath and Muklieijee, 1996).
SP receptors have also been demonstrated on B-cell populations. Flow cytometry 
experiments using fluorescein labelled SP and studies using ^^ I^-SP show SP binding to 
murine B-cells (Stanisz et al, 1987). Immunoglobin secretion by B-cells can be 
modulated by SP. Laurenzi and co-workers found that the number of IgG secreting cells in 
cultures of enriched human B-cells stimulated with the polyclonal activator Staphylococcus 
aureus protein A was significantly increased when SP was added to the culture system 
(Laurenzi, Persson, Dalsgaard, and Ringden, 1989). An in vivo experiment investigating 
the effect of SP in chronic granulomatous inflammation associated with schistosome 
infection has shown that blockade of the SP receptor leads to a reduction in antibody 
production by inhibiting the maturation of intragranuloma B-cells, This reduction in IgM 
production was accompanied by a decrease in IFN-y, IL-4, IL-5 and IL- 6  production by the 
granuloma and suggests that SP could be affecting a variety of cytokine pathways resulting 
in B-cell maturation (Blum et al, 1996).
Overall, the effects of SP on lymphocytes appear to be lai’gely stimulatory. Protein, DNA 
and immunoglobin synthesis by mature T and B-cells is significantly enlianced on 
stimulation by SP (McGillis et al, 1987). These findings suggests a largely 
proinflammatory action SP in inflammatory responses.
6.1.7. Substance P and trypanosomiasis
Accumulating evidence implicates SP in the pathogenesis of a wide range of inflammatory 
conditions. These conditions range from neurological disorders including multiple 
sclerosis, where SP immunoreactive astrocytes have been demonstrated in the CNS lesions 
(Barker and Lamer, 1992), to systemic diseases such as rheumatoid arthritis, where 
significantly higher levels of SP were found in serum froiu arthritic patients compared to 
healthy controls (Anichini et al, 1997). The involvement of SP has also been 
demonstrated in parasitic diseases. Sera from patients with Falciparum malaria can induce
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the production of SP by cultured human brain microvascular endothelial cells (Chiwakata 
et al, 1996) and B-cell maturation in schistosome granulomas appears to be controlled by 
SP produced by granuloma eosinophils (Blum et al, 1996; Weinstock et al, 1988). Mice 
treated with a SP antagonist show an increased susceptibility to infection with Salmonella 
suggesting a role for SP in possible resistance to bacterial infections. Further evidence for 
the involvement of SP in bacterial conditions comes from studies investigating the 
enterotoxic responses of rats to Clostridium difficile toxin A. In these experiments pre­
treatment of rats with the SP antagonist, CP-96,345, resulted in a reduction in the intestinal 
response to the enterotoxin (Pothoulakis et al, 1994). In the case of viral infections SP has 
been shown to modulate the replication of human immunodeficiency virus (HIV). In these 
studies, treatment of peripheral blood monocyte derived macrophages, infected with HIV 
in vitro, with SP resulted in a 2 to 8  fold increase in the expression of HIV as determined 
by reverse transcriptase activity (Ho, Cnaan, Li, Zhao et a l , 1996)
The ability of SP to modulate this vast range of inflammatory responses of both infectious 
and non-infectious aetiologies led us to postulate that SP may be involved in the 
pathogenesis of the meningoencephalitis associated with human African trypanosomiasis. 
The development of this condition encompasses many of the features of the inflammatory 
reactions mentioned above. This CNS invasive parasite evokes an elaborate cascade of 
events, including, astrocyte activation, inflammatory cell infiltration and polyclonal B-cell 
activation in conjunction with the production of a complex milieu of cytokines and 
chemokines. SP has previously been implicated in the regulation and control of all of these 
events. The following chapter will investigate the role of SP in the induction and 
development of the trypanosome-induced CNS inflammatory reaction found in our mouse 
model of human African trypanosomiasis.
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6.2. Materials and methods
The involvement of SP in the neuropathogenesis of human African trypanosomiasis was 
investigated using two complementary systems. Initial studies employed the NKl receptor 
antagonist RP-67,580 to block the action of SP and the latter experiments used mice in 
which the NKl receptor had been genetically ablated. Due to the possible usage of 
alternative neurokinin receptors by SP in NKl knockout mice, the neuropathological 
response was also studied following administration of the NK2 and NK3 receptor 
antagonists, SR48968 and SRI42801 respectively, in these animals. Each of the 
experimental rationales is detailed individually below.
6.2.1. Administration of the NKl receptor 
antagonist
6.2.1.1. RP-67,580 and RP-68,651
The highly selective, non-peptide NKl receptor antagonist RP-67,580 (2-[l-amino-2-(2- 
methoxyphenyl)ethyl]-7,7-diphenyl-4-perhydroisoindolone (3aR, 7aR) } was employed in 
this study. The antagonist was dissolved in isotonic saline and administered to the mice by 
intraperitoneal injection (i.p.) at a dose rate of 2mg/kg. This treatment inliibits the action 
of SP by blocking the NKl receptor. To ensure that any differences found between 
experimental and control animals were a result of NKl receptor blockade and not a 
secondary factor caused by the drug but unrelated to SP, the inactive enantiomer RP- 
68,651 {3aS, 7aS} was employed in infected control animals. Both the antagonist and the 
enantiomer were donated by Rhone-Poulenc Rorer (Vitry sur Eine, France)
6.2.1.2. Animals, Infections and treatments
6.2.1.2.1. Experiments 1, 2 & 3
Female CD-I mice (Charles River Breeding Laboratories) weighing 28-35g were infected 
i.p. with 4 X 10"^  T.b.hrucei parasites. These parasites belonged to cloned stabilate 
GVR35/C1.5 previously described in the ‘General materials and methods’ chapter of this 
thesis. Parasitaemia was confirmed by weekly examination of blood taken by a tail snip. 
The infection was allowed to progress until day 28 post-infection when the mice were
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treated with the trypanocidal drug diminazene aceturate (Berenil®; Hoechst 
Pharmaceuticals) at 40mg/kg i.p. to induce a CNS inflammatory reaction. On day 35 post­
infection the antagonist was administered. A dose of 2mg/kg i.p. was given to each mouse 
twice daily. This regimen was continued for a period of 10 days. The animals were 
sacrificed at the end of this period, their brains excised and processed for histopathology. 
A total of 26 infected mice were treated with diminazene aceturate and antagonist in these 
experiments. Experiment 1 involved 6  mice, 11 animals were used in experiment 2 and 
experiment 3 contained 9 mice.
In parallel with this protocol various control regimens were followed. Control groups 
included infected mice given diminazene aceturate followed by saline in place of RP- 
67,580; uninfected mice treated with diminazene aceturate; and uninfected mice given RP- 
67,580. In experiment 3 the infected saline treated controls were replaced by infected mice 
treated with the inactive enantiomer RP-68,651.
6.2.1.2.2. Experiment 4
A  slightly modified forth experiment was also performed utilising the same basic regimen. 
In this experiment the animals were infected as before; however, the antagonist therapy 
was initiated on day 27 post-infection, 1 day prior to the diminazene aceturate treatment. 
The RP-67,580 was administered as previously described and the treatment continued for 
21 days. At the end of this period, on day 49 post-infection the animals were killed and the 
brains removed for histopathological examination. A total of 9 mice were infected and 
treated with the antagonist and diminazene aceturate in this experiment. Control groups 
were included as described above.
6.2.2. Use of NK1 receptor knockout mice
6.2.2.1. Generation of the knockout animals
The genetically altered knockout mice employed in the following experiments were 
generated using embryonic stem (ES) cells prepared from the inbred 129/Sv mouse strain 
in which exon 1 of the NKl receptor gene had been disrupted by targeted homologous 
recombination using a replacement vector and ultimately re-implanted in a C57BL/6 
mouse (de Felipe et al, 1998).
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Briefly the procedure involved transfecting the ES cells with a linearised, genetically 
manipulated genomic DNA fragment known as the targeting vector. In this case the 
targeting vector consisted of a clone of exon 1 from the NKl receptor gene, with a cassette 
containing an internal ribosome entiy site and the lacZ coding sequence, together with a 
neomycin resistance gene, inserted into the unique Stul restriction enzyme site. Two 
copies of the thymidine kinase gene from herpes simplex virus (HSV-TK) were also 
introduced outside of the homologous region of interest. As the neomycin resistance gene 
confers resistance to geneticin and the HSV-TK gene confers resistance to gancyclovir, a 
positive and negative selection strategy could then be employed to detect appropriately 
transfected clones. Clones resistant to geneticin (positive selection) but sensitive to 
gancyclovir (negative selection) were selected as successfully transfected cells.
ES cell lines are derived from the inner cell mass of pre-implantation blastocysts. These 
cells are uncommitted and pluiipotent and can therefore form either somatic or germ-line 
tissues when reintroduced into the blastocyst. The selected ES cell clones were injected 
into C57BL/6 blastocysts and subsequently reimplanted into the uterus of pseudopregnant 
foster mothers. The use of ES cells derived from 129/Sv mice facilitates the identification 
of chimeric animals by the presence of the dominant Agouti coat colour in the offspring. 
Chimeric males were then mated with C57BL/6 females and transmission of the mutant 
allele to the pups was determined by Southern blot analysis of DNA extracted from 
samples of tail tissue. Mice homozygous for the mutation were generated from subsequent 
matings of animals heterozygous for the disrupted allele. The resultant homozygous mice 
were healthy, bred normally and did not show impaired maternal behaviour and were 
therefore used to found the knockout colony (de Felipe et al., 1998).
6.2.2.2. Animals, infections and treatments
Professor Stephen Hunt, gifted the animals used in experiments 1 and 2 below as adult 
mice, from the MRC Molecular Biology Laboratory, University of Cambridge. Following 
these initial experiments Prof. Hunt took up a new position at University College London 
and it became necessary to establish breeding colonies of both knockout and wild-type 
mice in the Parasitology animal unit at Glasgow University Veterinary School. Following 
the required quarantine period and prerequisite health screen of pups from the first litters, 
the breeding animals were transferred to the Parasitology animal unit and the mice used in 
all subsequent experiments were bred ‘in-house’. All animals weighed between 25-35g at 
the beginning of the experimental procedures.
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6.2.2.2.1. Neuroinflammation in NK1 knockout animais
6.2.2.2.1.1. Experim ent 1
A total of 14 NKl receptor knockout mice (NKl'^") and 13 wild-type animals (NKl^^^) 
were infected i.p. with 3 x 10"^  Tb.brucei cloned stabilate GVR35/C1.6 as previously 
described. Parasitaemia was monitored by examination of fresh blood smears. On day 28 
post-infection the mice were treated with diminazene aceturate (40mg/kg i.p.) to induce a 
CNS inflammatory reaction. The experiment was continued until day 40 post-infection 
when the animals were sacrificed and their brains extracted and processed for 
histopathology.
In parallel with this regimen uninfected control groups consisting of 5 NKl'^' animals and 
6  NKk^ "^^  were included in the design. These mice were treated with diminazene aceturate 
in the same manner and sacrificed on the same day as the experimental animals. This 
procedure excludes the possibility of an independent clinical or pathological effect of the 
drug on the mice in the absence of a trypanosome-infection.
6.2.2.2.1.2. Experim ent 2
In experiment 2, 15 NKT'^’ and 15 NKl'^ '^ '^  animals were infected as previously described. 
The infection was allowed to progress naturally until day 21 post-infection when the mice 
were given diminazene aceturate (40mg/kg i.p). This time point is 7 days eai'lier than that 
used in experiment 1. The experiment was terminated at 40 days post-infection when the 
mice were killed and processed as described above. Again uninfected, diminazene 
acetui'ate treated control groups that consisted of 5 NKl'^' and 4 NKl^^^ animals were 
included in the experimental protocol.
The change to the experimental protocol was necessary due to the severity of the reaction 
encountered in some animals in experiment one. This extreme response necessitated their 
culling prior to the end point of the experimental regimen.
6.2.2.2.1.3. Experim ent 3
This experiment contained 15 NKl"''" and 18 NKl’^'^ '^  mice. An identical infection and 
treatment protocol to that outlined in experiment 2 above was followed. However, these 
animals were maintained under a cycling 2 hours light followed by 4 hours dark regimen.
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The control groups in this experiment consisted of 4 NK1'^‘ and 5 uninfected,
diminazene aceturate treated animals. In addition to these mice 5 NK1‘^~ and 3 N K l’^'"’^ 
animals were included as normal controls. These mice were not infected and did not 
receive any drug treatments.
6.2.2.2.1.4, Experiment 4
An identical protocol to that detailed for experiment 2 was followed in this experiment. 14 
NKl'^' and 15 N K l’*’^’*’ animals were infected, diminazene aceturate treated and sacrificed at 
the end of the procedure as described above. Uninfected, diminazene aceturate treated 
animals were again included as controls. On this occasion 2 NKl'^' and 2 N K l’*'^"** mice 
were used.
6.2.2.2 2. NK2 and NK3 receptor antagonists
The highly selective, non-peptide NK2 (SR489968) and NK3 (SRI42801) receptor 
antagonists used in this study were kindly gifted by Sanofi Recherche, Montpellier, France. 
These compounds are currently under clinical trial for the treatment of human CNS 
disease. The antagonists were dissolved in 0.5ml of DMSG and diluted to 250pg/ml with 
0.9% sterile saline. A combined solution containing 250pg/ml NK2 receptor antagonist 
and 250fig/ml NK3 receptor antagonist was also prepared.
6.2.2.2.2.I. Experiment 5
In this experiment groups of NKl'^' and N K l’^'^  ^ mice were treated with 25pg of NK2 
receptor antagonist, 25 pg of NK3 receptor antagonist or a combination containing 25pg of 
NK2 and 25pg NK3 receptor antagonist. This was administered i.p. in a volume of 0.1ml. 
The treatment was begun three days prior to trypanosome infection and then daily until 
sacrifice. The trypanosome-infected groups comprised 7 NKF^' and 10 NKF^ "^^  animals 
given NK2 receptor antagonist, 8 NKF^" and 10 NKl'^ '^*’ mice treated with NK3 receptor 
antagonist, 8 NKU' '^ and 9 NKl"^^  ^ mice given a combination of both antagonists while 6 
NKU'" and 8 NKl'*'^ '^  mice received no antagonist treatment. All mice were treated with 
diminazene aceturate (4Omg/kg i.p.) on day 21 post-infection. The experiment was 
concluded on day 40 post-infection when the animals were killed and their brains 
processed for histopathology.
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Control groups of uninfected mice were included in the experimental design. These groups 
comprised 5 NKl"^" and 4 treated with the NK2 and NK3 receptor antagonist
combination followed by diminazene aceturate on day 21 post-infection and 6 NKl"^' and 6 
Nk i +^+ given no antagonist or diminazene aceturate treatment.
6.2.2 3. Clinical Assessment
Throughout the course of the experimental procedures described above the mice were 
examined independently and the degree of clinical impairment resulting from the treatment 
regimens assessed. This was determined using a visual assessment scale of 0-6 where 0 
indicated a normal healthy mouse and 6 indicated death or euthanasia due to the severity of 
the reaction. A complete description of this scale is detailed in Table 6.1. As an indicator 
of the overall clinical performance of the animal tluoughout the experimental regimens 
average values were calculated for each mouse over the series of repeat observations. The 
resulting data was then analysed statistically.
6.2.3. Histopathology
6.2.3.1. Assessing the inflammatory reaction
At necropsy, the brains were removed and fixed in 5% neutral buffered formalin. The 
tissue was then processed and paraffin wax embedded. Sections were cut from each block 
at a thickness of 3 pm and stained with haematoxylin and eosin for examination by light 
microscopy. The severity of the neuropathology was graded in a blinded fashion using the 
grading system detailed in chapter 2. Using this system the severity of the inflammatory 
reaction is graded on a scale of 0 to 4, where 0 indicates a normal pathology and 4 
indicates a severe meningoencephalitis. A detailed account of the criteria used in this 
assessment scale can be found in Chapter 2, Table 2.1. The inflammatory score for each 
section was assessed independently by two individuals in a blinded fashion.
The assignation a numerical value to a particular degree of inflammation allowed the 
results of the pathological assessment to be analysed using appropriate statistical methods.
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Animal appearance Numerical Score
Noimal, healthy 0
Slow, sluggish, stary coat 1
Altered gait, reduced co-ordination of hind limbs 2
Flaccid paralysis of one hind limb 3
Atrophy of muscles and hind quarters, complete flaccid 
paralysis of both hind limbs
4
Moribund 5
Dead / ethanased 6
Table 6.1. Parameters defining the visual assessment scale for the clinical 
grading scores
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6.2.3 2. Assessing astrocyte activation
The level of astrocyte activation in the brain sections was assessed using the indirect 
immunocytochemistry (ICC) protocol to identify glial fibrillary acidic protein (GFAP). 
GFAP is a major intermediate filament protein present in differentiated astrocytes. The 
protocol is detailed in Chapter 2. Briefly, sections were stained using a polyclonal anti- 
GFAP primary antibody. This was followed by a biotin labelled anti-rabbit IgG and a final 
addition of a streptavidin-biotin complex labelled with a horseradish peroxidase enzyme. 
The GFAP positive cells were visualised using the chromogen diaminobenzidine tetra- 
hydrochloride. This results in the deposition of a brown end product that can be assessed 
microscopically.
The number of astrocytes stained was determined in a random sample of animals from both 
experimental approaches. A total of 32 mice, 8 infected mice from both the NKl receptor 
antagonist treated and untreated groups and 8 mice from the NKl'^' and NKl^^^ groups 
were assessed. The assessment was caiiied out by counting the number of astrocytes in 5 
random fields in the hippocampal area. An eyepiece graticule was used to standardise the 
area of the brain counted and each section was assessed on two occasions. Astrocyte 
activation was not investigated in the NK2 and NK3 receptor antagonist experiment.
6.2.4. Statistical analyses
Comparisons between appropriate groups of animals were undertaken to assess the 
neurological response, the level of astrocyte activation and the clinical appearance of the 
mice following infection and induction of a CNS inflammatory reaction by sub-curative 
drug treatment of trypanosome-infection. The severities of the neuropathological reactions 
were analysed in both the NKl receptor antagonist experiments and the experiments 
employing the NKl receptor knockout animals. Clinical response scores were analysed in 
the knockout experiments only. The neuropathological scores for the individual mice were 
based on the average of the independent assessor scores measured at the end of the 
experiment. A Wilcoxon signed rank test was employed to ensure that uniformity existed 
between the assessors scoring methods thus preventing bias results. Clinical response 
scores were determined using the average score over a series of repeat observations taken 
during the course of the experiment. Analyses were possible using parametric statistical 
tests. Comparisons between individual groups in a single experiment were carried out 
using a two sample t-test while comparisons across experiments were performed using
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general linear model procedures and the randomised block analysis of variance. Means 
and standard errors (S.E.) are shown as summary statistics. The tests were imdertaken 
using a proprietary statistical software package, Minitab version 13, and p-values of less 
that 0.05 were considered significant.
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6.3. Results
6.3.1. The effect of the NK1 receptor antagonist
6.3.1.1. Severity of the meningoencephalitis
The histopathological examination of brain sections prepared from T.b.brucei-mfected, 
diminazene aceturate treated, mice from each experiment, showed a severe meningitis and 
prominent perivascular cuffing associated with most of the blood vessels. In addition, 
there was a moderate encephalitis with inflammatory cells present in the parenchyma. The 
inflammatory cell infiltrate comprised mainly lymphocytes, plasma cells and macrophages 
(Fig. 6.1).
Sections from T.b.bmcei -infected, diminazene aceturate treated, mice given a course of 
RP-67,580 showed an overall marked reduction in the severity of the CNS inflammatory 
reaction compared with saline treated animals. These mice exhibited a moderate 
meningitis with perivascular cuffing of some vessels and no encephalitis (Fig. 6.1).
A summary of the results of the statistical analyses of the neuropathology grading data is 
shown in Table 6.2. The results of a Wilcoxon signed rank test demonstrated that the mean 
of the difference between the pathology scores allocated to each section by the individual 
assessor was zero. This indicates that the grading scale used to score the sections was 
uniformly applied by the individual assessors. As the procedures used in experiment 4 
were slightly modified from the initial 3 experiments the resulting data were analysed 
using three different combinations of the data sets. When the results of the initial tluee 
identical experiments were combined a significant reduction (p<0.001) in the severity of 
the inflammatory reaction was detected with the antagonist treated mice exhibiting a lower 
pathology score (2.442 + 0.176) than the non-treated animals (3.405 + 0.164). There was 
no significant difference between the data sets generated form each of the individual 
experiments (p<0.252) and no interaction between the experiment and the scores for each 
group (p<0.583). The neuropathological grades from the antagonist treated animals (2.167 
+ 0.441) compared with non-antagonist treated mice (3.0 + 0.289) in the fourth experiment 
showed no significant difference (p=0.14) when analysed individually. However when this 
data set was combined with the 3 initial experiments the reduction in the pathological 
response in the antagonist treated mice (2.371 ± 0.171) remained highly significant 
(p<0.001) when compared to the scores in the non-treated mice (3.283 + 0.145). Again the
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analyses did not detect any difference between the results generated between the 
experiments (p<0.275) and no interaction was found between the experiments and the 
groups (p<0.806).
The inactive enantiomer RP-68,651 had no effect on the severity of the 
meningoencephalitis induced by subcurative drug treatment following T.b.brucei -  
infection. No significant difference (p=0.38) was found between the neuropathology 
scores of the enantiomer treated group (3.5 + 0.22) and the saline treated animals (3.3 ± 
0.17). This indicates that the reduction in the pathology found following RP-67,580 
treatment is a result of the blockade of the NKl receptor and not attributable to an 
unrelated secondary action of the antagonist. These data were therefore combined with 
that from the saline treated animals to form the composite non-antagonist treated control 
data set represented in Tables 6.2 and 6.3. No pathological changes were found in any of 
the uninfected control animals given similar drug regimens to the infected animals.
6.3.1.2. Astrocyte activation
A diffuse astrocytosis was seen throughout the brain of infected, diminazene aceturate 
treated, animals that received saline in place of RP-67,580. Numerous (188.03 ± 5.42), 
intensely GFAP stained, large reactive astrocytes were evident. These activated astrocytes 
displayed long and elaborately branched processes and were present particularly in areas of 
high inflammation (Fig. 6.2, GFAP positive cells show brown staining pattern).
A reduction in this astrocyte activation was seen in infected, diminazene aceturate treated 
mice following RP-67,580 therapy. In these animals the astrocytes were significantly 
(p<0.001) fewer in number (99.89 ± 3.01) and stained more weakly with GFAP. There 
was also a reduction in the degree of stellation exhibited by these cells (Fig. 6.2). In 
addition, the distribution of the activated cells was more limited and appeared to be 
confined to the corpus callosum, the hippocampus, along the choroid fissure and around 
the ventricles. The results of statistical analysis of these data are shown in Table 6.3.
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6.3,2. The effect of genetic abiation of the NK1 
receptor
6.3.2.1. Severity of the meningoencephalitis
The histopathological examination of brain sections from both knockout and wild-type 
mice showed inflammatory changes characteristic of the post-treatment reactive 
encephalopathy (PTRE). In general a moderate to severe meningitis was found and 
perivascular cuffs were apparent. The sections also exhibited a moderate to severe 
encephalitis with inflammatory cells present in the brain parenchyma. The inflammatory 
cell infiltrate consisted mainly of lymphocytes, plasma cells and macrophages (Fig. 6.3).
Table 6.4 shows a summary of the statistical analyses of the data generated from 
assessment of the severity of the neurological response of wild-type and knockout mice to 
trypanosome-infection. The results of a Wilcoxon signed rank test demonstrated that the 
mean of the difference between the pathology scores allocated to each section by the 
individual assessor was zero indicating that the grading scale was uniformly applied. Data 
from experiments 1 and 3 were analysed individually as the regimen differed slightly to 
that employed in experiments 2 and 4. Experiments 2 and 4 followed identical protocols 
and therefore the data were analysed in a combined form. A significant (p=0.019) increase 
in severity of the inflammatory reaction was seen in the brains of the knockout mice (3.173 
+ 0.140) compared with wild-type animals (2.538 ±_0.208) in experiment one. This pattern 
was also found in the pooled data set from experiments 2 and 4 with the NKT^' animals 
again showing a significantly (p=0.003) higher pathology (3.565 + 0.092) than the 
mice (3.008 ± 0.145). When the data set from experiment 1 was combined with that of 
experiments 2 and 4 a fui'ther increase in the level of significance was seen (p<0.001) and 
the inflammatory response in knockout animals remained higher (3.438 + 0.081) than that 
seen in wild-type animals (2.866 ± 0.122).
The data generated from experiment 3 however did not match this trend. In this 
experiment, no significant difference (p=0.52) was detected between the CNS grading 
scores of the NKT'^ " mice (2.850 + 0.204) and the animals (3.028 + 0.178). In
contrast to the other experiments, although the difference is not statistically significant, the 
pathology grades assigned to the wild-type animals were in fact higher than those seen in 
the knockout mice. One factor not constant between this and the remaining experiments 
was the introduction of a 2-hour light and 4 hour dark regimen. Due to the difference in
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the environmental conditions during this experiment and the resultant reversal of the 
pathological findings no analyses were performed on the combined data from all 4 
experiments.
Overall, these data indicate that genetic ablation of the NKl receptor gene results in an 
increase in the neuropathological response to trypanosome-infection when compared to 
wild-type mice. An apparent influence on the inflammatory reaction by the photoperiod 
was also suggested by the result gained from mice maintained under a set light dark 
regimen.
6.3.2.2. Astrocyte activation
Diffuse astrocyte activation was found throughout the brain sections of both loiockout and 
wild-type animals. When the number of astrocytes present in each group was analysed the 
resulting counts were not significantly different (p=0.699) between the NKl'^' mice 
(106.322 + 5.62) and the NKl"^ "^^  animals (103.38 + 4.47). A summary of these statistics is 
given in Table 6.5. No morphological differences were detected in the appearance of the 
astrocytes between the two groups of animals and the cells stained intensely with GFAP 
and displayed long elaborately branched processes (Fig. 6.4, GFAP positive cells show 
brown staining pattern). This result indicated that any further investigation of astrocyte 
activation in subsequent experiments using these knockout mice would be of little value.
6.3.2 3. Severity of the clinical response
A summary of the results of statistical analyses of the clinical data is presented in Table 
6.6. No significant difference (p=0.230) was detected between the degree of the clinical 
impairment in wild-type (3.500 + 0.384) and knockout (2.792 ± 0.427) animals from 
experiment 1. The severity of this reaction was much higher than that found in mice from 
the other experiments and may reflect the later timing of the diminazene aceturate 
treatment in this regimen. Analyses of the data from experiments 2 and 4 show that 
trypanosome-infection in the knockout mice results in a significantly (p=0.047) lower 
(0.400 + 0.113) degree of clinical impairment to that found in the wild-type animals (0.964 
+ 0.270). When the results from experiment 1 were combined with those from 
experiments 2 and 4 this trend was continued. The NK1'^‘ animals again showed a 
significant (p=0.023) reduction in clinical reaction (1.179 ± 0.232) when compared with 
NKT^ '"'^  mice (1.731 ± 0.283). The results of the general linear model analysis indicated
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that there was a significant difference (p<0.001) in the clinical outcomes between the 
experiment, however there was no significant interaction (p==0.173) between the 
experiment and the genetic status of the animals. This indicates that although the clinical 
grades do vary between the experiments this has no impact on the differences found 
between the knockout and wild-type mice. Due to the influence of the later administration 
of the diminazene aceturate in experiment 1, this finding was in fact to be expected when 
the pooled data set was analysed.
Analysis of the data generated from experiment 3 did not detect a significant difference 
(p=0.28) between the clinical reaction of the knockout mice (1.856 ± 0.478) when 
compared to wild-type animals (1.224 ± 0.330). Although the difference between the two 
means is not significant a reversal of the trend demonstrated in experiments 1, 2 and 4 is 
suggested. In contrast to the other experiments the knockout animals show a higher level 
of clinical impairment than that found in the wild-type animals. Again this may reflect the 
difference in enviromnental factors during this investigation.
These analyses indicate that dismpting the gene encoding the NKl receptor results in a 
significant reduction in the degree of clinical impairment found in these mice following 
trypanosome challenge and induction of the PTRE. Again the photoperiod appears to be 
an important enviroimiental factor influencing the clinical outcome of the infection in these 
animals.
Taken together, the overall results from this series of experiments show that when the 
knockout animals exhibit a more severe neuropathological response than the wild-type 
mice they have a healthier clinical appearance. This suggests that these NKE^" animals 
demonstrate a disease phenotype where there is an apparent dissociation between the 
clinical and neuropathological responses.
6.3.3. The effect of NK2 and NK3 receptor 
antagonists
6.3.3.1. Severity of the meningoencephalitis
Histopathological examination of brain sections prepared from infected wild-type and 
knockout mice showed inflammatory changes. A moderate to severe meningitis was 
present and perivascular cuffs were apparent. In some groups a severe
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meningoencephalitis was seen with the presence of inflammatory cells in the neuropil. The 
inflammatory cell infiltrate was characterised by the presence of lymphocytes, plasma cells 
and macrophages (Fig. 6.5)
As before the severity of the neuroinflammatory response was graded by two independent 
assessors in a blinded fashion. The results of a Wilcoxon signed rank test on the data 
generated from this analysis showed that the mean difference between the severity scores 
allocated by each assessor was zero. This indicated that the grading scale used to assign 
the neuropathology score had been applied in a uniform manner. During the course of the 
experimental regimen two mice and one NKf^" mouse died. Therefore no
neuropathology data are available for these animals. Factorial statistical analyses of the 
data sets indicated a highly significant (p<0.001) interaction between the factors examined 
in the wild-type and laiockout groups. Therefore, individual group comparisons were 
undertaken using a one-factor analysis of variance separately for NKF'^" and mice.
The initial results of these tests indicated that the uninfected control groups of mice 
showed a lower neuropathology score that than the remaining infected groups. This result 
was to be expected since the animals had not been challenged with trypanosomes and 
therefore showed normal CNS histology on examination. Consequently, the analyses were 
repeated comparing only those groups of mice that were infected. The results of these 
analyses are detailed in Tables 6,7-6.8. Table 6.9 shows a summary of the results of one 
factor analysis of vaiiance between the wild-type and laiockout groups for each treatment 
regimen.
Statistical analyses of the results in the wild-type animals (Table 6.7) showed that mice 
treated with the NK3 receptor antagonist developed a significantly (p=0.0495) lower 
neuropathological response (2.950 ± 0.252) than mice given either the NK2 receptor 
antagonist (3.650 ± 0.113) or those treated with the NK2 and NK3 receptor antagonist 
combination (p=0.006, 3.889 ± 0.060). No treatment regimens significantly altered the 
severity of the CNS inflammatory reaction from that seen in the untreated wild-type mice 
(3.250 ±0.263).
In the knockout animals the data indicate that infected NK1'^‘ treated with a combination of 
NK2 and NK3 receptor antagonists displayed a significant (p=0.035) reduction in the 
neuropathological response (2.438 ± 0.290) compared to NKl'^" infected animals that had 
received no antagonist treatment (3.708 ± 0.187) (Table 6.8). No other significant 
differences were found between the NKl'" '^ treatment groups (Table 6.8). NKl'^' animals 
treated with NK2 receptor antagonist and NK3 receptor antagonist monotherapies also
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showed a reduction in the severity of the neuropathological response (2.607 ± 0.308 and 
2.688 + 0.343, respectively) compared to non-treated mice. Although these results follow 
the downward trend they camiot be considered significant (p>0.05).
In comparisons of treatment regimens between the wild-type and knockout mice (Table 
6.9) a significantly (p=0.016) lower neuropathology score (2.60 + 0.308) was found in the 
knockout mice receiving the NK2 receptor antagonist treatment when compared to wild- 
type animals (3.650 +0.113) following a similar treatment regimen. No significant 
difference was found between the response of NKT^ '^  ^ and NKl'^' animals following NK3 
receptor antagonist treatment. However, a significant reduction (p=0.002) in the CNS 
inflammation was found in NKl'^' mice receiving a combination of NK2 and NK3 receptor 
antagonists (2.438 + 0.290) compared to NKl^^^ animals treated in an identical manner 
(3.889 ±0.060).
6.3.3 2. Severity of the clinical response
The factorial design analysis of the clinical data from all groups of animals found no 
significant (p=0.298) interaction between the factors examined in the wild-type and 
knockout groups. The analysis of all animals indicated a significant (p=0.009) difference 
in the clinical response scores generated by the wild-type and knockout mice. The analysis 
determined that NKl'^’ animals showed a less severe clinical response (0.025j t  0.01) than 
their NKl '^^  ^ counterparts (0.144 ± 0.032). When the uninfected animals were removed 
from the analyses the differences between the two groups remained significant (p=0.002) 
with the NKl'^' mice generating a lower clinical response score (0.034 ± 0.013) than the 
NKl^^*" animals (0.180 ± 0.038) (Table 6.10).
One factor analysis of variance was undertaken separately in wild-type and knockout data 
sets. This confirmed that the treatment regimens had no effect on the clinical responses of 
the animals in either group (p=0.122, p=0.405, respectively). In addition, individual 
regimens were compared for differences in the clinical response between the wild-type and 
knockout mice. These analyses indicated that NKf^’ mice treated with a combination of 
NK2 and NK3 receptor antagonists showed a significantly (p=0.024) improved clinical 
response (0.003 ± 0.003) compared to NKf^ "^^  animals (0.224 ± 0.078) receiving a similar 
treatment regimen (Table 6.11).
Overall these data indicate significant differences in the clinical and neuropathological 
response of NKl'^' and NKT^ "^^  animals to trypanosome infection and selective NK receptor
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antagonist treatments. The results also suggest that alternative receptor usage may 
influence the neuropathological response in N K l’^" mice since blockade of the NK2 and 
NK3 receptors resulted in a significant reduction in the neuropathological reaction. 
However, this phenomenon does not seem to play a role in the development of the clinical 
picture as this pattern of improvement was not found within the NKT^' group.
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Figure 6.1. The effect of RP-67,580 treatment on the severity of the 
neuroinfiammatory response.
Coronal section through the hippocampal brain region of trypansome-infected 
mice. Animals treated with the NKl receptor antagonist for 10 days, beginning 
7 days following diminazene aceturate treatment (A) show a reduction in the severit 
of the neuroinflammation. Fewer inflammatory cells are found in the perivascular 
cuffs and the degree of encephalitis is reduced compared with mice that did not 
receive treatment with the antagonist (B). H&E, XI50.
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Figure 6.2. The effect of RP-67,580 treatment on astrocyte activation.
Comonal sections through the hippocampal brain region of trypansome-infected 
mice. Animals treated with the NKl receptor antagonist for 10 days beginning 
7 days following diminazene aceturate treatment (A) show fewer activated astrocytes 
than mice that were not given RP-67,580 (B). GFAP, X300.
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Figure 6.3. The neuroinflammatory reaction In NK1 receptor knockout 
and wild-type mice.
Coronal sections through the hippocampal brain region of trypanosome-infected 
mice. NKl receptor knockout animals (A) show a more severe neuroinflammatory 
reaction to trypanosome infection and subcurative diminazene aceturate treatment 
than wild-type mice with functional NKl receptors (B). The degree of perivascular 
cuffing and inflammatory cell infiltration of the neuropil is increased in the knockout 
mice (A) compared to that found in the wild-type animals (B). H&E, XI50.
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Figure 6.4. The astrocytic reaction in NK1 receptor knockout and 
wild-type mice.
Coronal sections throuogh the hippocampal brain region of trypanosome-infected 
mice. NKl receptor knockout animals (A) and wild-type mice (B) show a similar 
degree of astrocyte activation following trypansome infection and subcurative 
drug treatment with diminazene aceturate. GFAP, X300.
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Figure 6.5. The effect of treatment with NK2 and NK3 receptor 
antagonists on the severity of the neuroinflammatory reaction.
Coronal sections through the hippocampal region of NK1+/+ (A-D) and 
NKl-/- (E-H) mice following various treatment schedules. The figure 
demonstrates the differences in the neuroinflammatory response between wild- 
type and knockout animals when treated with the various receptor antagonists. 
H&E stained sections prepared from NK2 receptor antagonist treated mice (A 
and E); NK3 receptor antagonist treated mice (B and F); mice treated with a 
combination of NK2 and NK3 receptor antagonists (C and G); and animals 
receiving no antagonist treatment (D and H) are shown. The antagonist treatment 
has resulted in amelioration of the neuroinflammatory response in the NKl-/- 
mice (E-G) compared with NK1+/+ mice (A-C) following the same antagonist 
regimen. However, the neuroinflammatory response is more severe in the NKl-/- 
mice receiving no antagonist treatment (H) than that encountered in similarly 
treated wild-type animals (D). H&E, X I50.
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Astrocyte count
Trypanosome -  antagonist 188.03 + 5.42 (» = 8)
Trypanosome + antagonist 99.89 + 3.01 (» = S)
p-value <0.001
Table 6.3. A ssessm ent of the astrocytic response to trypanosome-infection 
in the presence or absence of SP antagonist treatment.
Astrocytes were counted in 5 random fields from the hippocampal region of each animal 
using a graticule to define the area. Each section was assessed on 2 occasions and the 
average count per animal utilised. Data are expressed as mean + S.E. for each group, », 
number of animals in each gi'oup. Figures detailed in red highlight groups showing 
significant differences.
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Astrocyte count
103.38 ±4.47 (« = 8)
N tcr '‘ 106.32 ±5.62 (« = 8)
p-value 0.699
Table 6.5. A ssessm ent of the astrocytic response to trypanosome-infection 
in NK1*'* and NKT' animals.
Astrocytes were counted in 5 random fields from the hippocampal region of each animal 
using a graticule to define the area. Each section was assessed on 2 occasions and the 
average count per animal utilised. Data are expressed as mean + S.E. for each group, n, 
number of animals in each group.
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Neuropathology scores o f  mice
NK2-RA NK3-RA NK2&3-RA No antagonist
NK3-RA
(-1.380, -0.0003)
p=0.006p=0.805
NK2&3-RA
(-0.480,0.958) (0.220, 1.658)
p=0.473 p=0.695 p=0.124
No antagonist
(-1.142, 0.342) (-0.442, 1.042) (-1.399, 0.121)
Mean + SE 3.650 + 0.113 2.950 + 0.252 3.889 + 0.060 3.250 + 0.263
Number 10 10 8
Table 6.7. Neuroinfiammatory response scores of mice following
treatment with specific NK receptor antagonists
Neuropathology response scores were measured in trypanosome infected NKl^ *^  ^ mice 
following administration o f NK2-receptor antagonist (RA), NK3-RA, a combination o f  
both NK2 & 3-RA’s or no antagonist treatment. The mean score and standard error (mean 
+ SB) are shown, together with the number o f animals are listed for each group. The 95% 
confidence intervals for the differences between group means are shown along with the p- 
values. The figures in the body o f  the table demonstrate the comparisons, in terms o f  
statistical significance, between the groups shown in the row and column headings. 
Figures detailed in red highlight groups showing significant differences.
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Neuropathology scores o f NKl'^' mice
NK3-RA
NK2&3-RA
No antagonist
Mean + SE
NK3-RA NK2&3-RA No antagonistNK2-RA 
p=0.997 
(-1.071, 1.232) 
p=0.977 
(-1.321,0.982) 
p=0.094
(-0.136, 2.338) (-0.180, 2.222)
2.607 + 0.308 2.688 + 0.343 2.438 + 0.290 3.708 + 0.187
Number 8 8
Table 6.8. Neuropathology response scores of NK1'^ ‘ mice following 
treatment with specific NK receptor antagonists
Neuroinflammatory response scores were measured in trypanosome-infected NKl'^' mice 
following administration o f NK2-receptor antagonist (RA), NK3-RA, a combination o f  
both NK2 & 3-RA’s or no antagonist treatment. The mean score and standard error (mean 
+ SE) are shown, together with the number o f animals are listed for each group. The 95% 
confidence intervals for the differences between group means are shown along with the p- 
values. The figures in the body o f the table demonstrate the comparisons, in terms o f  
statistical significance, between the groups shown in the row and column headings. 
Figures detailed in red highlight groups showing significant differences.
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6.4. Discussion
6.4.1. Neuropathology
The data from this series of experiments show that blockade of the NKl receptor by 
administration of RP-67,580 in trypanosome-infected mice, sub-curatively treated with the 
trypanocidal drug diminazene aceturate, reduces the severity of the resultant CNS 
inflammatory reaction. In contrast to these findings, animals in which the NKl receptor 
had been genetically ablated exhibited a heightened inflammatory CNS reaction compared 
to wild-type mice with functional NKl receptors. Although these results are apparently 
contradictory they both suggest a role for SP in the generation of the CNS inflammation 
associated with trypanosome-infection. Further investigations blocking the NK2 and NK3 
receptors in the NKl"^' mice suggested that alternative receptor usage may be an important 
mechanism in the development of the neuropathological changes seen in these animals.
Within the CNS various cells types including endothelial cells, neurones, microglia and 
astrocytes have been shown to express the NKl receptor (Kostyk et al, 1989; Lai, Zhan, 
Campbell, Douglas et a l, 2000; Lambert, Lescoulie, Yassine-Diab, Enault et a l, 1998; 
Mantyh et al, 1997). In addition, the NKl receptor has been demonstrated on many of the 
cell types present in the inflammatory infiltrate including macrophages and lymphocytes 
(Lucey et al, 1994; Stanisz et al, 1987). The NK2 receptor is widely distributed in the 
peripheral nervous system and has also been described in the CNS (Hagan, Beresford, 
Stables, Dupere et a l, 1993; Maggi, 1995). These receptors are especially prevalent in 
some thalamic nuclei, discrete layers of the frontal cortex and in the hippocampus (Hagan 
et al, 1993). The CNS is the main, but not exclusive, site of NK3 receptor expression, and 
these can be found in the cerebral cortex, the solitary nucleus, the interpeduncular nucleus, 
the habenula and the ventral tegmental area (Maggi, 1995). SP itself can be produced by 
numerous cell types such as neurones, microglia, astrocytes and endothelial cells within the 
brain (Kostyk et al, 1989; Lai et al, 2000; Linnik and Moskowitz, 1989; Nakaya et al, 
1994) as well as the infiltrating macrophages and lymphocytes (De Giorgio et al, 1998). 
Therefore, due to the abundance of cell types present in the meningoencephalitic reaction, 
that can both produce SP and react to its presence, SP could potentially play a central role 
in the control of this neuroinflammation acting in both an autocrine and paracrine fashion.
It is possible that following activation the astrocytes and microglia within the brain 
produce SP. This could have a direct chemotactic effect on peripheral T-cells and
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monocytes (Hood et al, 2000). In addition, SP could stimulate the brain micro vascular 
endothelial cells to up-regulate adhesion molecule expression (Vishwanath and Mukherjee,
1996). The enlianced expression of ICAM-1 by the endothelial cells together with a 
corresponding increase in the avidity of the LFA-1 ligand on the lymphocytes, also 
induced by SP, could facilitate the transmigration of the leucocytes into the brain 
(Vishwanath and Muldierjee, 1996). In addition to direct effects, SP may elicit the 
production of pro-inflammatory cytokines by both resident CNS cells and inflammatory 
cells leading to a cascade of events that result in further exacerbation of the reaction. 
Indeed the addition of SP in conjunction with LPS to cultui’es of rat microglia has been 
shown to induce a fourfold increase in the production of IL-1 by these cells in comparison 
to LPS stimulation alone (Martin, Anton, Gornbein, Shanahan et a l, 1993). However, this 
enliancement was not found in an earlier study investigating the production of TNF~a by 
rat microglial cultures. Moreover, tlirough [^ ^^ I] Bolton Hunter SP binding experiments 
these investigations indicated that neither resting nor stimulated microglia express 
detectable SP binding sites (Luber-Narod et al., 1994). In contrast, these receptors have 
been demonstrated on human foetal microglia (Lai et al, 2000).
Blockade of the NKl receptor by administration of RP-67,580 could therefore inhibit these 
inflammatory pathways and subsequently down regulate the intensity of the immune 
response, suggesting a pro-inflammatory role for SP. As the antagonist was administered 
by intraperitoneal injection (i.p.) in these experiments this dampening of the inflammation 
could occur not only within the brain but also in the peripheral systems. It is possible that 
this overall reduction in the inflammatory response may then be reflected in the CNS as a 
secondary effect. However, cytokine levels and leucocyte activation states would need to 
be investigated to confirm this hypothesis.
The reduction in the severity of the inflammatory reaction seen following SP antagonist 
treatment was not echoed in mice where the action of the NKl receptor had been blocked 
by genetic manipulation. In fact, mice that did not express the receptor showed a higher 
degree of inflammation than the wild-type animals. This finding, although somewhat 
enigmatic, nevertheless continues to indicate a key role for SP in the control of CNS 
inflammatory reactions. The level of SP mRNA is known to be increased in these NKl'^' 
mice and the expression and distribution of the NK2 and NK3 receptors is comparable to 
the wild-type animals (de Felipe, O'Brien, Palmer, Doyle et al, 1997). It is possible that 
the heightened SP levels in the knockout mice lead to alternative receptor usage by the 
neuropeptide in the control of inflammation. A degree of promiscuity between the ligands 
and their ‘preferred’ receptor has been suggested by studies investigating discrepancies in
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the distribution of the ligands and their receptor. These ‘mismatches’ between the 
expression of SP and its receptor in the rat CNS have been demonstrated using 
immunocytochemistry in both light and electron microscopy studies (Liu, Brown, Jasmin, 
Maggio et a l, 1994). In the guinea pig intestine NK3 receptors are present on specific 
neurones (Laufer, Wormser, Friedman, Gilon et a l, 1985) even though NKB cannot be 
detected in this area (Too, Cordova, and Maggio, 1989). Since SP and NKA are present in 
this area it is thought that these tachykinins stimulate the NK3 receptors on these neurones 
in this scenario, (Too et al, 1989). Moreover, SP has also been shown to induce 
endothelium-independent contraction of the intrapulmonary arteries in excised rabbit lungs 
by stimulation of the NK2 receptor rather than via its preferred NKl receptor (Shirahase et 
al, 1995).
The investigation utilising specific NK2 and NK3 receptor antagonists in the NKl'^' mice 
seems to suggest that alternative receptor usage plays and important role in the induction of 
the neuroinflammatory response in the knockout animals. In NKl*^’ mice SP mRNA 
expression is known to be upregulated (de Felipe et al, 1997), It is possible that, due to 
this increased production in knockout animals, SP displaces NKA and NKB from the NK2 
and NK3 receptors, respectively. Subsequent signalling by SP thi'ough these alternative 
receptors may induce pro-inflammatory mechanisms within the CNS. This would 
culminate in the increase in the severity of the neuropathological response seen in the 
knockout mice. The finding that treatment of NKl'^" mice, with specific NK2 and NK3 
receptor antagonists, results in a reduction in the severity of the neui'opathological reaction 
substantiates this hypothesis. When a treatment regimen comprising a combination of 
these NK2 and NK3 receptor antagonists was administered to the knockout animals a 
statistically significant reduction in the severity of the CNS inflammation was found 
indicating a synergistic effect of the two antagonists.
The importance of the NK2 receptor in this phenomenon was further highlighted by the 
results found in the NKL^^  ^ mice. Although none of the antagonist treatment regimens 
resulted in a significant change in the neuropathological response compared with non­
treated mice in the wild-type group, both the NK2 receptor antagonist and combined NK2 
and NK3 receptor antagonist treated groups showed a significantly higher 
neuro inflammatory reaction than the NK3 receptor antagonist treated animals. These 
findings suggest that in the wild-type mice, the stimulation of the NK2 receptor, normally 
triggered by NKA, has an anti-inflammatory action, possibly counteracting that of SP 
signalling thi’ough the NKl receptor. When the NK2 receptor is blocked tliis counter- 
regulatory mechanism is inliibited leading to the increase in the severity of the reaction
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found in the NK2 receptor antagonist treated and NK2 and NK3 receptor antagonist 
combination therapy treated mice. Furthermore, both NK2 receptor antagonist and
NK2 and NK3 receptor antagonist combination treated groups in the knockout animals 
showed a significantly lower neuropathological response when compared with their 
identically treated wild-type counterparts. The role of the NK3 receptor in this reaction 
remains equivocal since only a slight, non-significant, reduction in the severity of the 
response was found in NK3 receptor antagonist treated wild-type mice compared to non­
treated controls. However, this small difference in the response was enough to highlight 
the effects of both of the treatments that included the NK2 receptor antagonist.
The existence of non-classical neurokinin receptors in NKl receptor knockout mice is also 
conceivable. Such non-classical receptors have been demonstrated in the induction of IL-1 
production by microglia in response to SP (Martin et al., 1993). Human monocytes have 
also been shown to express a non-neurokinin SP receptor that leads to stimulation of MAP 
kinase on activation (Kavelaars, Broeke, Jeurissen, Kardux et a l, 1994). Also, in the 
bovine adrenal medulla, the N-terminal sequence of SP has been shown to binds to a non- 
NKl receptor site (Geraghty, Livett, Rogerson, and Burcher, 1990). It is possible that 
these non-classical pathways are enhanced in the knockout mice and therefore the 
inflammatory response would not mimic that found in animals in which the NKl receptor 
had been blocked by a specific antagonist especially since the SP mRNA levels are known 
to be higher in these mice.
The possibility of receptor independent activation is also feasible. There is evidence 
indicating that SP can integrate itself directly into cell membranes without the presence of 
a receptor. SP is an amphiphilic molecule with a hydrophilic N-terminus and a 
hydrophobic tail. The ability of this type of molecule to bind to negatively charged 
membranes and subsequently insert itself has been demonstrated (Mousli, Bronner, 
Landry, Bockaert et a l, 1990a; Mousli, Bueb, Bronner, Rouot et a l, 1990b). Once 
inserted the molecule adopts a membrane spanning conformation and can activate proteins I
on the inner side of the membrane. The receptor independent activation of G-proteins by 
SP has been demonstrated in vitro. In this artificial system the addition of SP to the j
membranes resulted in an increase in the GTPase activity indicating that the G-protein |
coupled receptor had been successfully stimulated (Mousli et al, 1990a; Mousli et al, \
1990b). I
The technique used in the production of the NKl receptor knockout mice employed in 
these experiments generates animals that lack the gene from the beginning of their |
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development through to adulthood. This ‘permanent’ mutation may result in the 
development of alternative mechanisms in these animals that, in complex systems, allow 
the blocked pathways to be by-passed. This developmental plasticity may occur tlirough a 
variety of routes, related proteins may functionally compensate for the absent molecule or 
differential genetic pathways may be induced. It is also possible that the presence of the 
defective pathway during the early developmental stages may subsequently compromise 
functions in the adult animal (Muller, 1999). These theories are substantiated by the 
indications of alternative receptor usage in the NK2 and NK3 receptor antagonist 
investigation in the knockout animals and may help to explain the enigmatic results found 
when the NKl receptor knockout mice were employed in place of the GDI animals used in 
the NKl receptor antagonist studies.
Recent advances in the field of genetic manipulation have led to the production of 
transgenic animal with specific mutations whose expression can be controlled in a time or 
tissue dependent manner. Inactivation of a gene in adulthood could prevent the evolution 
of the adaptive changes resulting from developmental plasticity witnessed in conventional 
knockout animals, whereas tissue specific knockout animals would allow the role of genes 
that exhibit wide spread expression to be defined in individual tissues (Muller, 1999). 
Either of these conditional gene targeting approaches would be highly applicable to the 
study of the SP in the induction of CNS inflammation.
6.4.1.1. Astrocytosis
As previously stated astrocytes can be induced to express both the NKl receptor and its 
ligand, SP. A significant drop in the number of astrocytes was found in our model 
following blockade of the NKl receptor with RP-67,580. This suggests that, during the 
inflammatory response, there could be an interaction between SP and the astrocytes which 
culminates in an increase in astrocyte number. The possibility exists that a positive 
feedback mechanism develops where the astrocytes produce SP that subsequently 
augments the inflammatory response in these cells by inducing the expression of 
inflammatory cytokines. Astrocytes in vitro have been shown to produce ÏL-6 when 
stimulated with SP, and TNF-a production can be upregulated if SP is added to the culture 
system in conjunction with LPS (Cadman et al, 1994; Gitter et al, 1994; Luber-Narod et 
al, 1994). Moreover, SP-immunoreactive astrocytes have been demonstrated around the 
edges of MS lesions suggesting that these cells do produce SP in response to inflammatory 
situations in vivo (Kostyk et al, 1989). However, neither the primary source of the SP nor
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the target cells can be determined from these experiments. The resulting down regulation 
of the astrocyte activation may therefore be due to an indirect effect of the antagonist 
causing a reduction in cytokine production by other cell types in the inflammatory infiltrate 
rather than a primary effect on the astrocytes.
When astrocyte numbers were analysed in the NKl receptor knockout experiments no 
significant difference was found between the NKT^' and the NKl"^^  ^mice. Again there are 
several explanations for this finding including alternative receptor usage or developmental 
plasticity. However, since the knockout animals develop a more severe CNS inflammatory 
reaction than the wild-type mice it would be logical to assume that there would be a similar 
increase in the level of astrocyte activation. Yet this augmentation of the astrocytic 
response was not seen. It is therefore still possible that the knockout mice do exhibit a 
reduction in the level of astrocyte activation that is being masked by the coiTesponding 
increase in the severity of the neuropathology. If this is in fact the case it would imply that 
different pathways are being utilised by SP in the induction of inflammatory cell 
infiltration and the initiation of the activation of the resident CNS astrocytes in these 
knockout animals.
6.4.2. Clinical Response
The clinical impairment of NKl mice following trypanosome-infection and sub-curative
drug treatment was less severe than that seen in wild-type mice. This finding again 
suggests a role for SP in the development of the pathology associated with trypanosome- 
infection. However, this clinical improvement was not accompanied by a corresponding 
decrease in the severity of the neuropathological response, as would be expected, but was 
associated with a heightened neuroinflammatory reaction in the knockout animals. Thus 
the NKl receptor laiockout mice exhibit a dissociation between the neuropathological and 
the clinical response to trypanosome-infection.
This type of dissociation has been reported in inflammatory reactions in the human CNS of 
patients who have died of HIV infection. Here up to one-third of the patients that 
exhibited the clinical neurological response of dementia show mild pathological changes 
within the brain whereas 50% of non-demented cases exhibit these changes (Kennedy,
1993). Several explanations may exist for the paradox. The separation of the clinical from 
the neuropathological outcome could indicate that independent pathways mediate the 
induction of each response. In this scenario one of the pathways may be partially inhibited
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in the knockout animals while the other remains frmctional leading to the apparent 
dissociation of the responses. The differential usage of alternative receptors to induce 
specific reactions has been suggested by experiments investigating smooth muscle tone 
and mucus secretion in ferret trachea. In this study the contraction of the smooth muscle in 
the trachea was attributed to the action of SP and NKA on NK2 or NK3 receptors where as 
the induction of mucus secretion, lysozyme output and transport of albumin across the 
tracheal wall was via NKl receptor stimulation (Webber, 1989). This implies that SP can 
act thi'ough the NK2 and NK3 receptors and that the stimulation of particular neurokinin 
receptors by the same ligand can induce different outcomes.
As previously stated SP mRNA levels are upregulated in the NKT^" mice (de Felipe et al,
1997) and a corresponding increase in SP protein could conceivably result in a switch to 
alternative or non-classical receptor usage by the neuropeptide that may induce the 
inflammatory reaction in isolation from the clinical response. This hypothesis is further 
substantiated by the results of NK2 receptor and NK3 receptor blockade in NKl receptor 
knockout and wild-type mice. In these studies there were no significant changes to the 
clinical picture see between the treatment regimens within the two groups of animals. This 
suggests that alternative receptor usage does not play a role in the development of the 
clinical response even though this phenomenon was strongly suggested by the results of 
the neuropathological investigation. When the overall clinical response between the wild- 
type and knockout groups was examined the NKT^" mice showed a signiflcantly better 
clinical response than the NKl^^^ animals. This agrees with our initial studies using these 
animals. While it is reasonable to imagine that any increase in the CNS inflammatory 
reaction would be detrimental to the mice the possibility that this reaction may be in part 
beneficial camiot be excluded. This theory of a positive effect of CNS inflammation has 
been described previously in experiments involving aspirin treatment of T.b.brucei- 
iiifected rats (Quan et al, 2000). In these studies infected animals given aspirin showed a 
reduction in the level of CNS inflammation; however, this amelioration of the 
inflammatory reaction was accompanied by an exacerbation of the neurodegenerative 
response. Results from the analyses comparing individual treatment regimens between the 
NKl'^" and NKl '^"^ mice showed that treatment with a combination of the NK2 and NK3 
receptor antagonists induced a significant improvement in the knockout animals. This 
corresponds with the finding that this treatment regimen significantly reduces the severity 
of the neuropathological response in the knockout mice compared with both non­
antagonist treated knockout mice and identically treated wild-type animals and suggests a 
beneficial action of reduced CNS inflammation.
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Recently, a dissociation between the analgesic effects and the motivational ‘reward’ effects 
of opiate administration has been described in the N K l’^ ' mice (Murtra, Sheasby, Hunt, and 
de Felipe, 2000). The motivational properties of morphine administration were 
investigated using a conditioned place preference procedure. In this regimen mice learn to 
associate the reward of morphine with one of two visually and texturally different 
compartments. Wild-type mice developed a strong predilection for the compartment where 
they received morphine yet this preference was not seen in the knockout animals. In 
addition, these NKT' '^ mice showed a significant reduction in the avoidance of naloxone- 
induced withdrawal from morphine. These findings suggest that the knockout animals 
have a reduced capacity to detect both the rewards of morphine and the symptoms of its 
withdrawal. It is unlikely that these behavioural changes are due to a secondary loss of the 
mu opiate receptor as the animals exhibit classical signs of drug withdrawal and the central 
analgesic actions of morphine are still present. Therefore, there is an apparent divergence 
between the opiate-induced motivational and the analgesic pathways in these mice.
6.4.3. Influence of the photoperiod
When trypanosome-infected, sub-curatively drug treated, NKl receptor knockout mice 
were maintained under a 2 hour light 4 hour dark regimen the clinical and 
neuropathological responses were not significantly altered from the wild-type mice. 
Moreover, the results suggested a reversal of the trend exhibited when the mice were 
housed under normal 12 hour light 12 hour dark diurnal conditions. These apparently 
‘aberrant’ findings may be the result of the altered light dark ratio under which the mice 
were maintained.
The eye, as well as the brain, has been described as an ‘iimnuno-privileged’ site where 
under typical conditions a suppression of the normal immune response to antigens occurs. 
This protects these areas from unwanted, and potentially deleterious, effects of 
immunological activity. If antigen is introduced into the anterior chamber of the eye an 
antibody response is induced together with a T-cell mediated suppression of delayed-type 
hypersensitivity. This altered immune reaction is termed ‘anterior chamber-associated 
immune deviation’ (ACAID) and can be modulated by the exposure of the eye to light and 
dark (Ferguson, Fletcher, Herndon, and Griffith, 1995). A study investigating the role of 
neuropeptides in this reaction demonstrated that SP was absent or expressed only at very 
low levels in the eye under normal 12 hour diurnal conditions. However, when mice were 
housed under a continuous dark regimen the levels of SP increased substantially. This SP
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was rapidly released into the aqueous humor of the eye when the mice were reintroduced 
to light. In the same study the ACAID, in diurnal mice, was inhibited by inoculation of the 
anterior chamber of the eye with SP at similar concentrations to those detected in the dark 
reared animals. Following challenge of, SP-treated, immunised animals with antigen the 
delayed-type hypersensitivity response was not suppressed (Ferguson et al, 1995).
The results from this investigation clearly demonstrate a direct effect of the photoperiod on 
the levels of SP produced in the eye and a consequential alteration in the immune response. 
It is possible that a similar mechanism is present within the brain and this would help to 
explain the anomaly in the experimental results gained following alteration of the 
photoperiod. If this is the case the raised levels of SP in the wild-type mice may result in 
an increase in the neui'opathological reaction. Furthermore, this subtle change in SP 
concentrations may not be detected in the knockout animals due to the already high SP 
levels and the absence of the NKl receptor. The increased severity of the reaction in the 
wild-type but not the knockout mice would result in the abolition of any significant 
difference between the animals and reflect the irregular findings of the anomalous 
experiment.
6.4.4. SP and human African trypanosomiasis
The results of this study strongly suggest a role for the neuropeptide SP in the induction 
and control of the CNS inflammatory response associated with sub-curative drug treatment 
of trypanosome-infection. Flowever, neither the specific cell types involved nor the exact 
mechanism of action can be ascertained from these experiments. The prevalent expression 
of this neuropeptide and its receptors, in conjunction with the vast array of possible 
responses make dissecting the specific mechanisms involved an extremely complex task. 
The combined results of the experiments utilising the NKl receptor knockout mice and 
NKl receptor knockout mice in conjunction with NK2 and NK3 receptor antagonists 
strongly suggest an important role for the NK receptors in the development of the 
neuroinflammatory reaction. Due to the fact that blockade of the individual receptors 
induces conflicting effects on the neuroinflammation associated with trypanosome 
infection these experiments indicate that further detailed studies are required to fully 
investigate the roles of these receptors before any therapeutic regimen employing NK 
antagonists can be instigated.
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Several of the clinical and biochemical features exhibited during the late-stage of sleeping 
sickness could also result from aberrant SP activity. The increased levels of prostaglandins 
found in the CSF of late-stage patients could be a consequence of the action of SP as the 
neuropeptide has been shown to induce the expression of eicosanoids by spinal astrocytes 
(Marriott, Wilkin, and Wood, 1991). As stated previously, SP plays a central role in the 
body’s response to pain (Basbaum, 1999). Changes in the patients’ perception of sensory 
stimuli occur frequently in sleeping sickness and hyperaesthesia is a commonly reported 
manifestation in trypanosomiasis cases (Apted, 1970). Another symptom that occurs 
frequently following trypanosome-infection is an intense generalised pruritus and a role for 
SP in the pathophysiology of itching has also been suggested (Greaves and Wall, 1996). 
The combined information regarding the properties of SP and the clinical manifestations 
present in the late-stage of the disease, together with the results from this series of 
experiments indicate a central action for the nemopeptide in the pathology of African 
sleeping sickness.
SP has been implicated as a mediator in a diverse variety of conditions ranging from 
depression (Kramer, Cutler, Feiglmer, Shrivastava et a l, 1998) and multiple sclerosis 
(Barker and Lamer, 1992) to inflammatory bowel disease (Pothoulakis et al, 1994), 
emesis (Saria, 1999) and arthritis (Anichini et al, 1997). In the case of depression and 
emesis compounds have been developed that are currently in clinical trials for the 
treatment of these conditions (Saria, 1999). It would appear from these studies that 
administration of NKl receptor antagonists would be advantageous in treatment of the 
neuroinflammatory reaction associated with trypanosome infections while NK2 receptor 
antagonists may prove detrimental to the outcome of the chemotherapy. The role of the 
NK3 receptor in the development of the neuropathological and clinical response remains 
unclear. Further detailed studies, to elucidate the exact role of SP in human African 
trypanosomiasis, are therefore required due to the increasing availability of novel SP 
related compounds that could potentially be employed in the development of safer and 
more efficacious treatment regimens for the chemotherapy of this devastating parasitic 
infection.
C h a p t e r  7
G e n e r a l  D is c u s s io n  a n d  C o n c l u s io n s
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7.1. Development of CNS inflammation
The results of the current investigation show that following trypanosome infection an 
inflammatory reaction develops within the CNS. This inflammatory response is initiated 
before the parasites have crossed the blood-brain barrier (BBB) and may be the result of 
inter-related mechanisms involving astrocyte activation, T-cell infiltration and the 
production of cytokines and chemokines within the CNS (Figure 7.1).
Astrocytes are found in close apposition to the BBB and it is possible that soluble factors 
present in the blood, produced either directly by the trypanosome or as a result of the 
developing inflammatory response to the infection outwith the CNS, stimulate the early 
activation of the astrocyte population. Following activation, astrocytes can produce 
cytokines and chemokines, as well as cellular adhesion molecules that would enhance the 
transmigration of T-cells tlirough the BBB to survey the brain tissue for the presence of the 
parasites. Increased levels of IL-6, TNF-a, MCP-1, M IP-la and RANTES mRNA were 
found within the CNS of mice killed at 7 days post-infection. These increases occurred 
before any influx of inflammatory cells was detected and this suggests that the 
inflammatory mediators are produced by cells resident within the brain. Activated 
astrocytes were identified, by increased staining with anti-glial fibrillary acidic protein, on 
day 14 post-infection, it is therefore possible that activation of this cell population was 
initiated at an earlier time-point in the course of the disease but was not detected using the 
staining teclmique employed. If this is the case the astrocytes could be the cellular source 
of the cytokines and chemokines. This hypothesis is not inconceivable as production of 
these inflammatory mediators by astrocytes following trypanosome infection in rats has 
been demonstrated previously using an immunocytochemistry double-labelling teclmique 
(Sharafeldin et al, 2000). It is important to remember that a few macrophages were 
present in the meninges and blood vessels of both uninfected mice and animals killed at 7 
days post-infection. These inflammatory cells could also be the source of the cytokines 
and chemokines (Fitzgerald et a l, 2001; Vaddi et a l, 1997). By day 14 post-infection both 
CD4'*’ and CD8^ cells were found in the meninges and a few CD4^ cells were seen in the 
corpus callosum. It is feasible that these cells were initially activated by the presence of 
trypanosomes in the peripheral tissues and were subsequently attracted to the CNS by the 
increased levels of chemokines within the brain tissue. MCP-1, M IP-la and RANTES all 
have T-cell chemoattractant properties (Vaddi et a l, 1997) and their upregulation within 
the CNS during the acute stage of the infection may explain the early appearance of this 
cell type in the brain tissue.
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Figure 7.1. Schematic representation of possible inflammatory mechanisms 
involved in the generation of the post-treatment reactive encephalopathy (PTRE).
Following trypanosome infection, astrocytes, in close apposition to the blood-brain barrier, are 
activated by the presence of parasite derived material or inflammatory mediators in the periphery, 
inducing the production of cytokines, chemokines and Substance P within the CNS. Many positive 
feed-back pathways are possible, encouraging the infiltration of T-cells, activated out-with the CNS 
parenchyma, and macrophages. The majority of infiltrating T-cells belong to the CD4 subset and 
their effector functions can only be induced by antigen presented in conjunction with major histo- 
compatability (MHC) class II molecules. These molecules can be expressed by astrocytes, 
macrophages and B-cells. Once the trypanosomes enter the CNS, the inflammatory reaction is 
exacerbated as the parasites provide a source of antigen to stimulate the T-cell response. In addition, 
the parasite antigen induces B-cell activation. The subsequent development of Plasma cells is 
controlled by the T-cells and the presence of cytokines including IL-6. The cascade of events 
culminates in the generation of the severe meningoencephalitis associated with the PTRE.
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During the early-CNS stage of the infection a significant rise in the severity of the 
neuroinflammatory reaction within the brain was found, characterised by an increase in the 
number and spatial distribution of T-cells and macrophages. Astrocyte activation also 
became more pronounced at this time-point. The worsening of the CNS inflammation was 
accompanied by an upregulation in the expression of IL-1 a, IL-6, TNF-a, MCP-1, and 
M IP-la mRNA. An increase in the expression of these cytokines and chemokines could 
induce enhanced expression of cellular adhesion molecules on the CNS endothelial cells, 
attract monocytes to the brain from the periphery, and facilitate their subsequent 
transmigration across the BBB. In the mouse model of human African trypanosomiasis 
employed in this study the parasites enter the brain between 14 and 21 days post-infection 
(Jennings et al, 1979). This implies that parasite antigen would be present within the CNS 
of animals killed at day 21 post-infection. It is possible that the increase in the severity of 
the overall reaction seen during this stage of the infection results from secondary activation 
of the infiltrating T-cell population by re-stimulation with the particular parasite antigen 
specified by their T-cell receptors. This could result in a positive feedback mechanism 
with the production of additional cytokines and further transmigration of inflammatory 
cells into the brain. In the case of CD8^ cells the parasite antigen would have to be 
presented in combination with MHC class I molecules, whereas CD4^ cells only recognise 
antigen when displayed in conjunction with MHC class II molecules. Resident brain cells 
such as astrocytes (Wong et al, 1984) and microglia (Nakajima and Kohsaka, 2001) as 
well as the infiltrating macrophage population can be induced to express both MHC class I 
and class II molecules. These cell types could therefore play a major role in the 
exacerbation of the inflammatory reaction ultimately generating the severe 
meningoencephalitis seen in the post-treatment reactive encephalopathy.
Following subcurative trypanocidal drug treatment with diminazene aceturate, the parasites 
are cleared from the peripheral tissue, but since the drug does not cross the BBB efficiently 
parasites can remain sequestered within the CNS. It would be logical to assume that the 
clearance of the trypanosomes from non-CNS tissue would result in a reduction in the 
numbers of circulating T-cells activated against specific parasite antigen during the 
apparently aparasitaemic period. A concurrent decrease in the severity of the reaction 
within the CNS may also be expected as a consequence of the reduction in T-cell 
activation. This, however, does not occur and an exacerbation of the neuroinflammatory 
response, with further astrocyte activation and increased T-cell numbers, is seen following 
this treatment regimen. Dendritic cells, specialised antigen presenting cells, have been 
identified in the meninges and choroid plexus of the brain (McMenamin, 1999). It is
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possible that during the period of aparasitaemia, the dendritic cells in these regions take up 
parasite antigen from the trypanosomes in the CNS and transport this to the cervical lymph 
node to initiate fmther T-cell activation and CNS infiltration. In addition, it is possible that 
parasite antigen is carried from the CNS to the lymphatic system in the circulating CSF 
instigating further immune reactivity (Hickey, 2001). To substantiate this hypothesis the 
levels of circulating activated T-cells following diminazene aceturate would have to be 
investigated. Although a rise in the severity of the CNS inflammation was found in the 
mice at this stage this was not accompanied by a simultaneous rise in the expression of the 
inflammatory mediators in the brain tissue. Levels of IL-1 a, IL-6, TNF-a and M IP-la 
expression were reduced immediately following diminazene aceturate treatment compared 
to mice killed at 28 days post-infection, and MCP-1 expression remained relatively 
constant. In contrast higher levels of RANTES were detected at this point. RANTES can 
be produced by a wide variety of cell types, including, T-cells, macrophages, microglia and 
astrocytes (Vaddi et a l, 1997), all of which are present in the CNS by this stage in the 
neuro inflammatory reaction. RANTES has many target cells and can recruit T-cells, 
macrophages and dendritic cells to sites of inflammation (Appay and Rowland-Jones, 
2001). This could augment the inflammatory response in the brain and result in the 
exacerbation of the CNS inflammation. Also at this stage in the disease process, B-cells 
were detected in the CNS. The reduction in the expression of M IP-la found in the CNS at 
this point in the infection is surprising, as this chemokine has been shown to attract B-cells 
to participate in the immune reaction (Schall et al., 1993).
A slight increase in the severity of the CNS inflammation was found in mice exhibiting the 
PTRE compared to those killed during the late-CNS stage of the infection, and larger 
numbers of T-cells and B-cells were present in the infiltrate. This was accompanied by an 
initial increase in the expression of IL-6, TNF-a, MCP-1 and M IP-la. The expression of 
IL-1 a  was only marginally increased and RANTES levels dropped compared to mice 
killed dui'ing the late-CNS stage of the disease. Levels of IL-1 a  and IL-6 expression 
continued to rise as the PTRE developed, whereas TNF-a, MCP-1 and M IP-la expression 
declined. Following the initial drop in RANTES expression the levels increased to a 
similar intensity to those found during the late-CNS-stage of the infection, as the PTRE 
progressed. As well as an increase in the numbers of T-cells present at this time many B- 
cells and plasma cells were present in the inflammatory infiltrate although these tended to 
be confined to the meninges, perivascular cuffs and ventricles. The presence of specific 
antibody is not in general enough to result in the activation of naïve B-cells. B-cells 
interact with native antigen, recognised by their B-cell surface receptor, which they
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internalise and process to display in conjunction with MHC class II molecules. CD4^ cells 
then interact with the MHC class II moleculeipeptide complex, displayed by the B-cell. 
The presence of co-stimulatory molecules, including ICAM-1, ICAM-3, and CD40 and 
their respective ligands on each cell enhances this interaction and stimulates the B-cell to 
enter the cell cycle and proliferate (Roitt et a l, 2001). The differentiation of antigen 
primed B-cells into antibody producing plasma cells occurs under the direction of a range 
of cytokines including IL-6 (Hirano, 1998). This cytokine was expressed in mice 
exhibiting the PTRE. This is not always the mechanism used in the activation of B-cells, 
as there are a few antigens that will cause expansion of the B-cell population with no T-cell 
intervention. However, the predominance of CD4^ cells in the inflammatory infiltrate, 
together with the complex cytokine and chemokine milieu, and the subsequent appearance 
of numerous B-cells and plasma cells suggests that the B-cell activation found at this point 
in the disease process is controlled in a T-cell dependent manner.
7.2. Substance P in the CNS response
A role for the neuropeptide Substance P (SP), in the generation of the CNS reaction, has 
also been suggested from the investigations performed in this study. It would appear that 
this neuropeptide has a largely pro-inflammatory effect since a reduced neuroinflammatory 
response was found in trypanosome-infected mice following blockade of the NKl receptor, 
the preferred receptor for SP, using a specific non-peptide antagonist RP-67,580. 
Contradictory results were found when transgenic mice, lacking a functional NKl receptor, 
were infected with the parasite. These animals showed an increased pathology compared 
to mice of the same genetic background with normal NKl receptor function. Further 
investigations employing the NKl receptor knockout mice in conjunction with NK2 and 
NK3 receptor antagonists suggested that these divergent results could be the consequence 
of alternative receptor usage by SP in the transgenic animals. In addition, in normal wild- 
type mice, an anti-inflammatory role for usage of the NK2 receptor by its favoured ligand 
NKA, was indicated by the discovery that inhibition of this receptor by a specific non­
peptide NK2 receptor antagonist increased the severity of the neuropathological reaction 
compared to wild-type mice not treated with the antagonist. This finding suggests that 
blockade of neuiopeptide receptors should be employed with caution in the treatment of 
neuroinflammatory reactions and NKl inhibition may be beneficial as an adjunct therapy 
to the treatment regimens employed in cases of human African trypanosomiasis whereas 
blockade of the NK2 receptor may have adverse consequences.
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SP is known to effect the migration of T-cells (Hood et al, 2000), and can be produced by 
astrocytes, lymphocytes and macrophages (De Giorgio et al, 1998). These are the main 
cell types implicated by the current investigation in the generation of the CNS 
inflammatory reaction associated with trypanosome infection. In addition, SP can induce 
or enliance the expression of IL-6 by astrocytes (Gitter et al, 1994; Luber-Narod et al,
1994) and IL-1, TNF-a and IL-6 by inflammatory cells (Berman et al, 1996). The ability 
of this neuropeptide to provoke IL-6 production by astrocytes is of particular interest in 
this case since expression of this cytokine appears to be upregulated within 7 days of the 
onset of the infection. The results of this study suggest that the astrocyte population is 
responsible for the early development of the CNS reaction since activation of this cell type 
can be detected by 14 days post-infection. Taken together these findings also imply that 
the astrocytes may be the cellular source of the IL-6 and that this cytokine production 
could be a consequence of upregulated SP expression. To investigate this hypothesis 
further it would be useful to determine whether the levels of SP production are enhanced 
within the CNS following trypanosome infection. Astrocytes not only react to SP but can 
also express this neuropeptide. It would also be of interest to ascertain the source of this 
neuropeptide in the CNS of trypanosome-infected mice.
Various theories have been suggested for the development of the PTRE including; par asite 
persistence within the CNS as a consequence of subcurative chemotherapy (Himter and 
Kemiedy, 1992; Jennings et al, 1989), the release of parasite antigen within the CNS 
following chemotherapy (Pepin and Milord, 1991), the toxic nature of the ar senical drugs 
used to treat late-stage human disease (Hurst, 1959), immune complex deposition (Lambert 
et al, 1981) and autoimmunity (Poltera, 1980). None of these hypotheses are mutually 
exclusive. This investigation moves some way towards elucidating the mechanisms 
generating the CNS inflammatory response by highlighting the prominent role of the 
astrocytes and CD4^ cells in the reaction. Unfortunately the cellular soiu'ce of the 
cytokines and chemokines expressed was not identified and this remains a matter for 
conjecture. Although, in a rat model of trypanosomiasis, astrocytes and microglia have 
been implicated as the cells producing these mediators (Sharafeldin et al, 2000). The 
development of the PTRE in this mouse model of HAT, in the absence of arsenical drug 
treatment, would suggest that this factor is not a prerequisite for the occurrence of the 
meningoencephalitis in the human situation. However, use of toxic arsenical-based 
chemotherapy may still exacerbate the CNS inflammatory reaction. Information from the 
current investigation indicates that the mechanisms resulting in the development of the 
severe meningoencephalitis are likely to involve immune-mediated pathways entailing a
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combination of the above theories. The pathogenesis of the CNS-inflammatory reaction 
following trypanosome infection and subcurative trypanocidal drug treatment is complex 
and involves an intricate interplay between the CNS cells, inflammatory cells, 
neuropeptides, cytokines and chemokines (Figure 7.1).
7.3 . Mechanism of action of efiornlthine
In the present investigation the ability of eflornithine to prevent the development of a 
neuroinflammatory reaction and to resolve an already established meningoencephalitis was 
demonstrated. This anti-inflammatory action of eflornithine in preventing and 
ameliorating the CNS inflammation associated with trypanosome infection and subcurative 
trypanocidal drug treatment has been reported previously (Jennings et al, 1997); in this 
study the effects of eflornithine treatment on the severity of the response were not 
quantified and were purely observational and cytokine and chemokine expression was not 
examined. The results of these experiments were in agreement with those seen in the 
present investigation and confirm the value of eflornithine as a prophylactic to preclude the 
development of the CNS inflammation and in the resolution of an already established 
meningoencephalitis. It would appear from the results of the current investigation that 
alteration in the production of cytokines and chemokines, particularily IL-1 a and IL-6, 
may be the mechanism utilised by eflornithine to prevent the development of CNS 
inflammation. However, this does not seem to be the case in the amelioration of the 
meningoencephalitis. If the theories raised by the current investigation, regarding the 
development of the PTRE and the involvement of clonal expansion of the T-cell and B-cell 
populations within the CNS are correct then the more traditional ornithine decarboxylase 
(ODC) inlribitory pathway associated with eflornithine treatment could prevent the 
proliferation of these inflammatory cells. This may play a major role in the resolution of 
an established CNS reaction. A partial restoration of this proliferative response, may well 
occur following eflornithine treatment and concurrent putrescine administration resulting 
in a limited reduction in the severity of the neuropathological reaction, as seen in the 
earlier study (Jennings et al, 1997).
It is important to remember that the approach used in the present investigation detects 
changes in the expression level of cytokine and chemokine mRNA. It is possible that 
eflornithine inliibits the translation of these mRNA transcripts and prevents the production 
of the active protein molecule. Therefore, alterations in the expression of mRNA may not 
reflect subsequent changes in the concentration of the cytokines and chemokines in the
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tissue studied. For more concrete evidence of the role of these mediators in the mechanism 
of action of eflornithine their concentrations in the CNS must be investigated.
7.4. Future investigations
The pathways studied and the techniques used in the present investigation are by no means 
exhaustive. The semi-quantitative method employed in determination of the cytokine and 
chemokine expression levels in this study has now been superseded by vastly improved 
tecliniques. The application of image analysis software to precisely measure the intensity 
of the PCR amplicons would allow a more accurate interpretation of cytokine and 
chemokine expression pattern to be made. In addition the data generated using this 
approach would be more amenable to statistical analysis and would, in all probability, 
allow the use of more powerful parametric statistical tests rather than the non-parametric 
procedures employed in the current study. Furthermore, the development of ‘real-time 
PCR’ techniques, such as Taqman® or SYBR® Green, provides a method to accurately 
quantify the level of mRNA in a starting sample. The rationale for these techniques relies 
on the detection and quantitation of a fluorescent reporter molecule. The signal detected 
from this reporter molecule increases in direct proportion to the amount of PCR product 
present in the reaction mix and therefore reflects the concentration of the target sequence in 
the original sample.
In recent years it has become apparent that cytokines and chemokines do not function as 
individual entities but instead act in complex cascades and networks. The importance of 
the balance of pro-inflammatory and counter-inflammatory cytokines as well as the 
relationship between those which provoke tissue damage and those which protect tissue 
elements is now appreciated. Within the CNS this situation is complicated further since 
many of these inflammatory mediators facilitate normal physiological functions, such as 
the control of sleeping patterns, thermoregulation and appetite control. Although an 
investigation of the expression profiles of specific cytokine and chemokine elements 
known to be present within the CNS following trypanosome infection does provide 
information with regard to the development of the neuroinflammation, it may be of more 
benefit to study the expression pattern of a much wider range of mediators that could 
influence the generation of the meningoencephalitic response. With the development of 
microarray technology this approach is now possible. Using microarrays, the expression of 
numerous genes can be examined and a snapshot of the gene activity at a given time-point, 
or following a paiticular treatment regimen, can be profiled. In this instance valuable
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insight would be gained by studying the expression profiles of cytokines, chemokines and 
neuropeptides within the CNS of mice at various time-points after infection and 
subcurative trypanocidal drug treatment. By analysing the expression data generated from 
the microaiTays not only the presence or absence of particular mediators could be 
investigated but also the inter-relationships between the expression patterns of these 
molecules could be identified. It is possible that the switch from the eaiiy-CNS response 
seen following trypanosome infection to the development of the severe 
meningoencephalitis reflects an alteration in the balance of pro- and anti-inflammatory 
mediators rather than a change in an individual agent. The breadth of information gained 
from microarray studies would therefore substantially enhance the current understanding 
regarding the delicate equilibrium required to maintain the counter inflammatory profile 
within the CNS. In addition possible therapeutic strategies to prevent the exacerbation of 
the CNS inflammatory response, as well as the adverse reactions to melarsoprol 
chemotherapy, currently encountered in cases of human trypanosome infections, may be 
highlighted.
7.5. Conclusions
The results gained from the present investigation substantially enhance the currently 
available knowledge regar ding the development of the CNS inflammatory reaction found 
following trypanosome infection and subcurative drug treatment. The main findings 
gained from this study aie listed below.
• The importance of the astrocytes in the early CNS events that ultimately result 
in the development of the neuroinflammation has been shown.
• A time-course of inflammatory cell infiltration has been delineated with 
cellulai' infiltration of the CNS occurring prior to the detectable invasion of the 
brain tissue by the trypanosomes.
• The predominance of CD4^ cells in the inflammatory cell infiltrate and the 
possible mechanisms employed in the augmentation of the inflammatory 
reaction have been highlighted.
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• Alterations in the expression patterns of the cytokines IL-1 a, IL-6 and TNF-a 
as well as the chemokines M IP-la, MCP-1 and RANTES have been detected 
tluoughout the course of the infection.
• Inhibition of the transcription of IL-1 a  and IL-6 has been indicated as the 
possible pathway used by eflornithine in the preventing the development of the 
CNS inflammatory response. However, the mechanism of action of the drug in 
the amelioration of an established meningoencephalitis remains equivocal.
• A pro-inflammatory role for the neuropeptide Substance P, in the CNS 
inflammatory reaction has been discovered and the use of NKl receptor 
antagonists as an adjunct therapy to decrease the severity of the 
neuroinflammatory reaction has been suggested.
• In addition to the findings directly related to the development of CNS 
inflammation occurring as a result of trypanosomiasis, the difficulties of 
interpreting data gained from the use of transgenic animals in complex systems 
where redundancy and alternative pathways can be utilised has been 
highlighted.
In conclusion, it would appear that following trypansome infection an inflammatory 
reaction is instigated in the CNS quickly after the introduction of the parasite. The factor 
that initiates this CNS response remains unclear and may be parasite derived or an 
inflammatory agent produced in response to the infection outwith the CNS. It seems likely 
that the astrocytes, which are found in close apposition to the BBB, are the primary cell 
type within the CNS to react to this triggering factor. Once activated the astrocyte 
population produces an array of cytokines and chemokines, as well as SP, which augment 
the development of the inflammatory response by recruiting inflammatory cells to the CNS 
and stimulating further cellular activation. All the elements necessary to propagate the 
inflammatory reaction are present within the CNS following invasion of the brain by the 
parasites. As the reaction becomes more severe CD4^ cells become the predominant cell 
type in the inflammatory infiltrate and may succeed the astocytes in the further 
development of the inflammation. B-cells and plasma cells increase in number as the 
response matures. It is probable that these cells are activated and encouraged to proliferate 
and differentiate within the CNS in response to specific parasite antigen, CD4"^  cell 
stimulation and the provision of the appropriate cytokines in the immediate environment. 
The complete cascade of events results in the development of the severe
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meningoencephalitic response that is characteristic of the PTRE. The trypanostatic drug 
eflornithine prevents the development of this inflammatory cascade by inliibiting the 
transcription of IL-1 a and IL-6, however, its mechanisim of action in the amelioration of 
an established meningoecephaltis has yet to be fully elucidated.
As hmnan CNS tissue is accessible only from patients that have died during the late-stage 
of trypanosome infection or following the development of the PTRE, information 
regarding the subtle CNS changes that occur early after infection cannot be ascertained 
from the human population. The availability of the highly reproducible and well- 
documented murine model of human African trypanosomiasis has therefore provided a 
means to investigate the events that initiate the inflammatory response and control the 
development of the subsequent meningoencephalitis. Additional pharmacological actions 
of the trypanostatic drug eflornithine have been highlighted and the value of the use of this 
drug in treatment of infections that are not directly susceptible to eflornithine therapy has 
been demonstrated through the use of this murine model. This information may facilitate 
the development of new therapeutic approaches to help prevent the devastating adverse 
effects that are associated with the late-stage of trypanosome infection and subcurative 
drug treatment. Without this model such knowledge would not be available.
A p p e n d ix  1
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20x SSC (Salt Sodium Citrate)
Sodium chloride 175.3g
Sodium citrate 88.2g
Dissolve the salts in 800ml of distilled water. Adjust the pH to 7.00 and make up the final 
volume to 1 litre with distilled water. Differing strengths of SSC can be prepared as 
required by dilution of the x20 stock with distilled water.
2M sodium acetate pH4.0
Sodium acetate (anliydrous) 16.42g
Glacial acetic acid 35 ml
Dissolve the sodium acetate in 40ml of distilled H2 O and add the 35ml of acetic acid. 
Adjust the pH to 4.0 with glacial acetic acid and the final volume to 100ml with distilled 
H2O.
0.1 M citrate buffer
Solution 1
Tri sodium citrate (di-hydrate) 44.1 g
Dissolve salt in 1.5 litres of distilled water
Solution 2
Citric acid (mono-hydrate) lOg
Dissolve salt in 500ml of distilled water
Working Solution
To prepare the buffer solution take 1275ml of tri-sodium citrate (solution 1) and add 
between 200 and 225 ml of citric acid (solution 2) to give a final pH of 6.0
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0.2M phosphate buffer
Solution A
Sodium dihydrogen phosphate 6.24g
Dissolve ill 100ml of distilled water
Solution B
Disodium hydrogen phosphate 5.66g
Dissolve in 100ml of distilled water
Working solution
Mix 9,5ml of solution A with 40.5ml of solution B and make to lOOmls with distilled 
water, adjust the pH to 7.4.
4% paraformaldehyde
Paraformaldehyde 1 g
Dissolve paraformaldehyde in 10ml of distilled water at 60  ^C with constant stirring. Once 
dissolved, cool the solution and 12.5ml 0.2M phosphate buffer (see above). Adjust the pH 
to 7.3 and the total volume to 25ml with distilled water. Store at 4® C for up to 24 hours or 
at —20^ C for longer periods.
Bouin’s fixative
Saturated aqueous picric acid solution 150ml
40% formaldehyde 50ml
Glacial acetic acid 10ml
Mix solutions and store at room temperature
Denaturing Solution
Gaunidium thiocyanate 47.5g
Sodium citrate 0.74g
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Sarcosyl (N-lauryl-sarcosine) 0.5g
p-mercaptoethanol 0.7ml
Place 50ml sterile H2 O onto a heated stirrer. Slowly add the salts listed above with 
constant stirring. The reaction is endothermie and requires constant heating to facilitate the 
dissolution of the salts. Once the salts have dissolved make the volume of the solution up 
to 90 ml with sterile H2 O and adjust the pPI to 7.0. Add the p-mercaptoethanol and adjust 
the final volume to 100ml with sterile H2 O. The denaturing solution can be stored at 4^C 
in the dark for approximately one month.
DEPC water
Di-ethyl-pyro-carbonate (DEPC) 1ml
Add 1ml of DEPC to 999ml of distilled water. This should be performed wearing
protective gloves and in the fume cupboard.
LANA’S fixative
Sorensen’s solution A
Dissolve 17.855g di-sodium hydrogen phosphate di-hydrate in 500ml of distilled water. 
Sorensen’s solution B
Dissolve 13.8g sodium di-hydrogen phosphate di-hydrate in 500ml of distilled water. 
Working fixative solution
Prepare 500 ml of complete Sorensen’s solution by adding 360 ml of Sorensen’s A and 
140ml of Sorensen’s B solutions. Add:
40% formaldehyde 108ml
Saturated aqueous picric acid 140ml
Distilled water 252ml
Mix solutions thoroughly and store a 4® C until required.
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Phosphate Buffered Saline (PBS) for ICC
Di-sodium hydrogen phosphate (anhydrous) 14.8g
Potassium di-hydrogen phosphate (anliydrous) 4.3g
Sodium Chloride 72g
Add salts to 8 litres of distilled water with constant stirring. Adjust the pH to 7.4 and make 
the total volume up to 10 litres with distilled water.
PCR loading buffer
Bromophenol blue 25mg (0.25%)
Glycerol 3ml (30%)
Distilled H2O 7ml (70%)
Mix the glycerol and distilled H2O. Weigh the dye and add to the solution. Mix 
thoroughly until the bromophenol blue has dissolved.
TBE electrophoresis buffer (x10 stock 
solution)
Tris base 545 g
Boric acid 278g
EDTA (di-sodium salt) 46.5g
Slowly added the salts to approximately 3 litres of distilled H2 O with heat and constant 
stirring. Once dissolved adjust the pH to 8.3 and the final volume to 5 litres with distilled 
H2O.
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